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Abstract 
Infiltration  of  inflammatory  cells  into  the  tissue  during  the  inflammatory 
response  is  beneficial  to  the  host.  Chemokines  and  their  receptors  are 
instrumental  in  this  process  by  influencing  the  migration  and  behaviour  of 
leukocytes in the tissue. However, prolonged inflammation is associated with 
many diseases. 
In recent years, a family of atypical receptors have emerged which do not seem 
to signal. One of these receptors, D6, is able to internalise and degrade 12 pro 
inflammatory  CC  chemokines  and  has  a  role  in  the  resolution  of  the 
inflammatory response. Here, using a murine transgenic approach, the potential 
therapeutic role of D6 in suppressing cutaneous inflammation in vivo has been 
investigated, using a well characterised model of skin inflammation. In addition, 
expression  of  D6  in  a  range  of  inflammatory  disorders  has  also  been 
characterised. 
Transgenic mice were generated (K14D6), using an epidermis specific transgene, 
in which expression of the D6 transgene was driven by the human keratin 14 
promoter in epidermal keratinocytes. K14D6 mice were validated and we have 
shown  that  D6  is  expressed  in  K14D6  but  not  in  wild type  epidermal 
keratinocytes. The K14D6 transgene was shown to be functional as only K14D6 
keratinocytes  were  able  to  bind  CCL2  and  progressively  deplete  extracellular 
CCL3. K14D6 mice can dampen down cutaneous inflammation in response to a 
topical  application  of  TPA.  In  addition,  K14D6  mice  displayed  reduced 
infiltration of epidermal T cells and mast cells compared to wild type mice.  
Using a microarray approach, we examined the transcriptional consequences of 
non ligated D6 and after ligand binding in primary murine keratinocytes from 
K14D6 and wild type mice. Although limited conclusions could be made from the 
microarray data, our results suggest the possibility that non ligated D6 in murine 
keratinocytes may have a negative impact on the transcription of some genes, 
such as chemokines.  
In a previous study, D6 null mice displayed a human psoriasis like pathology after 
chemical induced skin inflammation, suggesting a possible involvement of D6 Vicky King, 2010       3 
dysfunction as a contributing factor in the pathogenesis of psoriasis. We have 
investigated  the  possible  correlation  between  D6  expression  levels  and 
cutaneous disease development. Analysis of skin biopsies revealed that D6 mRNA 
levels  were  8 fold  higher  in  uninvolved  psoriatic  skin  compared  to  matching 
psoriatic lesional skin, atopic dermatitis and control skin. In PBMCs, there was no 
significant difference in D6 mRNA expression in psoriasis patients compared to 
control. A preliminary study examining surface D6 expression on leukocytes from 
control and rheumatoid arthritis patients revealed enhanced D6 expression on B 
cells and myeloid DCs.  
In this study, we have shown for the first time that increased expression of D6 in 
vivo  can  limit  cutaneous  inflammation,  therefore  providing  a  rationale  for 
exploring the therapeutic potential of D6 in human inflammatory diseases. In 
addition,  we  provide  evidence  that  D6  expression  is  dysregulated  in 
inflammatory disorders further suggesting an involvement of this receptor in the 
pathogenesis of these diseases. Vicky King, 2010       4 
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1  Introduction 
1.1 Haemopoiesis 
Within  the  body,  there  are  many  different  types  of  blood  cells  with  various 
functions. Haemopoiesis is the expansion and development of these blood cells 
from haemopoietic stem cells (HSCs). The principle site of haemopoiesis varies 
depending  on  the  developmental  stage  of  the  mammal.  In  the  fetus, 
haemopoiesis  initially  takes  place  in  the  yolk  sac  then  the 
aortic/gonad/mesonephrous  (AGM)  region,  and  finally  the  liver  (Cumano  and 
Godin,  2007).  After  birth,  the  major  location  for  haemopoiesis  is  within 
specialised  niches  in  the  bone  marrow  (Adams  and  Scadden,  2006). 
Haemopoietic stem cells are defined by two main properties, self renewal and 
multipotency (Bonnet, 2002). By having the capacity to renew, HSCs have the 
ability to proliferate and maintain their population. Multi potency refers to the 
potential of a single HSC to generate differentiated progenitor (also known as 
precursor) cells that can become various types of blood cell (Cumano and Godin, 
2007).  
Haemopoietic stem cells divide and give rise to two common progenitor cells, 
myeloid and lymphoid progenitors, which are specifically committed to generate 
myeloid  and  lymphoid  cells  respectively.  Under  normal  circumstances,  these 
progenitors do not generate cells belonging to the other pathway (Kondo et al., 
1997). A common myeloid progenitor cell (CMP) has the ability to differentiate 
into  a  granulocyte  monocyte  precursor  (GMP),  a  megakaryocyte  erythroid 
precursor  (MEP)  or  an  immature  precursor  that  is  positive  for  a  cell  surface 
protein known as cluster of differentiation (CD) 34. MEP can differentiate into a 
megakaryocyte,  which  gives  rise  to  platelets,  or  erythroblasts  from  which 
erythrocytes are derived. A GMP can differentiate and give rise to granulocytes 
(eosinophils, neutrophils and basophils), mast cells or monocytes (see 1.2.1.3). 
Macrophages,  osteoclasts  and  myeloid  dendritic  cells  (mDCs)  are  cell  types, 
which are differentiated from monocytes (Palucka et al., 1998, Schneider et al., 
1986).  Two  subsets  of  dendritic  cells  (DCs),  Langerhans  cells  and  interstitial 
dendritic  cells  (see  1.2.1.3)  are  derived  from  the  CD34
+  DC  precursor,  but 
Langerhans cells can also be derived from monocytes (Ginhoux et al., 2006). A 
third type of DC, plasmacytoid dendritic cells (pDCs; see 1.2.1.3) are derived Vicky King, 2010      Chapter 1, 23 
from common lymphoid progenitor cells that also give rise to either a T cell 
precursor or a B cell precursor. T lymphocytes (see 1.2.1.4) and natural killer 
cells are derived from T cell precursors whereas B lymphocytes (see.1.2.1.4) are 
derived from B cell precursors. The theory that haemopoiesis has two common 
progenitors cells feeding into distinct pathways is the classical model, however 
there is evidence that lineage pathways are sufficiently flexible to allow myelo 
lymphoid progenitors and myelo erythroid progenitors to exist (Arinobu et al., 
2007). A summary of the classical model of development of the different blood 
lineages is shown in Figure 1.1.   
 
 
 
Figure 1.1 The development of cell subsets during haemopoiesis. 
Haemopoietic stem cells (HSCs) can differentiate into common myeloid progenitor (CMP) or 
common  lymphoid  progenitor  (CLP)  which  give  rise  to  a  variety  of  distinct  cells.  (GMP) 
granulocyte monocyte precursor, (MEP) myeloid erythrocyte precursor, (CD34
+ im pre DC) 
cluster  of  differentiation  34
+  immature  dendritic  cell  precursor,  (pDC)  plasmacytoid  DC, 
(mDC) myeloid DC, (NK cell) natural killer cell, (Th lymphocyte) T helper lymphocyte, (Tc 
lymphocyte) cytotoxic T lymphocyte. 
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1.2 The immune system 
The immune system is composed of an organised network of specialised cells, 
molecules, tissues and organs that play a role in protecting the host from tissue 
damage or potentially harmful ‘foreign’ substances that are ‘non self’ material. 
The immune response (see 1.2.1) is the reaction of the immune system to tissue 
damage or ‘foreign’ material and consists of two components, the innate  and 
the adaptive response.   
Viruses, bacteria, fungi, protozoa and worms are foreign substances that can 
cause  infection  and  damage  to  the  host,  if  the  immune  system  is  unable  to 
detect and neutralise them. Potentially pathogenic material can invade the body 
through a variety of routes, including across the respiratory or gastrointestinal 
tracts, or through breaks in the skin. As a result, several lines of defence are in 
place within the body to prevent invasion and eliminate foreign matter. Areas of 
the body susceptible to the outside world contain ‘tools’ to augment physical 
barriers. For example, cilia and mucus, within the respiratory tract serve to trap 
and expel pathogens. Whereas chemical barriers, such as peptide antibiotics in 
the intestine (Ayabe et al., 2000), enzymes in the lungs, (Akinbi et al., 2000) 
and gastric acid within the stomach (Tennant et al., 2008) are all mechanisms 
that discourage microorganisms from surviving within the body. However, if a 
foreign  substance  does  manage  to  invade  or  tissue  damage  occurs,  the  body 
responds using specialised cells and proteins of the immune system to eliminate 
pathogens,  limit  tissue  damage  and  stimulate  tissue  repair.  A  sign  of  host 
response to infection or injury is acute inflammation (see 1.4) in which pain, 
heat, redness and swelling are all classical signals that the process is occurring. 
1.2.1  The immune response  
Present and functional from birth, the innate immune system is the first line of 
defence and responds immediately to pathogens or tissue damage.  However, 
the innate immune response has no immunological ‘memory’ and cannot ‘learn’ 
from previous encounters and upon repeat exposure to the same pathogen, the 
nature  and  strength  of  the  innate  immune  response  remains  the  same 
throughout life (Ptak and Szczepanik, 1998). In contrast, the adaptive immune 
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specific response  to a  previously  ‘seen’  molecule,  known  as an  antigen  (Ag). 
Therefore,  the  adaptive  immune  response  is  said  to  have  immunological 
‘memory’. This results in a quicker and more robust response to an antigen when 
detected the second or subsequent time. 
1.2.1.1  Recognition of pathogens in innate immunity 
The  innate  immune  system  can  respond  to  various  classes  of  microbes  by 
recognising highly conserved structures, known as Pathogen Associated Molecular 
Patterns (PAMPs). In bacteria and fungi, PAMPs tend to be components of the 
cell wall whereas the PAMP within viruses is viral nucleic acid (Medzhitov, 2007). 
The recognition of PAMPs is mediated by Pattern Recognition Receptors (PRRs), 
which are encoded within the germline, and are present either on the surface, 
within cells or may be secreted by them (Janeway and Medzhitov, 2002).  
Pathogen recognition receptors 
There  are  several  classes  of  pathogen  recognition  receptors and  the  Toll like 
receptors (TLRs) are the most well characterised class. TLRs are cell surface 
receptors  that  can  recognise  components  of  bacteria,  fungi,  viruses  and 
parasites (Akira et al., 2006). Discovery of the  family began when the Toll gene, 
encoding a transmembrane receptor within Drosophila (Hashimoto et al., 1988) 
was  also  found  to  exist  within  humans  (Medzhitov  et  al.,  1997).  Within 
mammals,  at  least  11  members  of  the  Toll like  receptor  family  have  been 
identified  and  the  stimuli  for  various  TLRs  are  known.  Recognition  of 
peptidoglycan and lipoteichoic acid from Gram positive bacteria is mediated by 
TLR2 (Schwandner et al., 1999) whilst TLR1 forms a heterodimer with TLR2 to 
recognise  triacylated  lipopeptides  (Takeuchi  et  al.,  2002).  TLR6  can  also 
heterodimerize  with  TLR2  to  recognise  diacylated  bacterial  lipoproteins 
(Takeuchi et al., 2001). TLR3 binds to double stranded RNA (Alexopoulou et al., 
2001)  while  TLR4  recognises  lipopolysaccharide  (LPS),  which  is  a  major 
component  of  the  outer  membrane  of  Gram  negative  bacteria  whereas  viral 
single stranded RNA is recognised by TLR7 and TLR8 (Heil et al., 2004, Lund et 
al., 2004). TLR9 binds bacterial DNA that contains CpG regions (Hemmi et al., 
2000)  and  no  endogenous  ligand  is  yet  known  for  TLR10.  A  ligand  known  for 
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In addition, murine TLR11 prevents infection by uropathogenic bacteria (Zhang 
et  al.,  2004)  however  the  specific  ligand  responsible  for  the  infection  is  not 
known. In addition to TLRs, there are other cell surface PRRs, for example, the 
C type  lectin  family.  These  receptors  can  bind  carbohydrate  structures 
associated with pathogens. One example is Dectin1, which can bind b glucans 
and is important in antifungal immunity (Taylor et al., 2007).  
In addition to cell surface PRRs, other PRRs are present within the cytoplasm of 
the  cell  and  detect  PAMPs  intracellularly.  This  includes  a  family  of  NOD like 
receptors  (NLRs),  so  called  because  they  contain  a  Nucleotide binding 
Oligomerization  Domain  (NOD)  at  the  carboxy  terminus  (Fritz  et  al.,  2006). 
There are two proteins established within the NOD subfamily, known as NOD1 
and NOD2, both are known to recognise bacterial lipopolysaccharide resulting in 
the activation of various genes (Inohara et al., 2001). Other NLRs such as NLRP1 
(Nod like  receptor,  pyrin  domain  containing  1)  and  NLRP3  form  multimeric 
protein  complexes  known  as  inflammasomes,  which  lead  to  the  activation  of 
enzymes involved in the cleavage of certain cytokines (Martinon and Tschopp, 
2007). Other types of cytosolic receptors are RNA helicases, such as retinoic 
acid inducible  gene  1  and  melanoma  differentiation associated  gene  5 
(Yoneyama  et  al.,  2004,  Andrejeva  et  al.,  2004),  which  detect  and  unwind 
double  stranded  RNA  prior  to  mediating  signalling  responses  important  for 
antiviral immunity. 
PRRs are expressed on a variety of immune cells and can influence functions 
within the innate and the adaptive immune response. Antigen presenting cells 
(see  1.2.1.3)  predominately  express  cell surface  PRRs,  in  particular  TLRs  
(Gordon, 2002). Direct interaction of a cell surface PRR and its ligand can result 
in the internalisation of the pathogen expressing the ligand (Medzhitov, 2001), in 
a process known as phagocytosis (see 1.2.1.3).  Internalisation of the pathogen is 
enhanced by the surface of the pathogen being coated in opsonins, which can be 
antibodies,  also  known  as  immunoglobulins  (Ig)  or  proteins  involved  in  the 
complement cascade. The first discovered complement pathway, so called the 
classical pathway, involves antibodies forming immune complexes and acting as 
opsonins. The detection of mannose binding lectin results in activation of the 
Lectin pathway (Fujita et al., 2004) whereas the alternative pathway is triggered 
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the complement protein C3, which can be cleaved to form active proteins C3a, 
C3b, C4a and C5a.  Another complement protein, C5b, induces the formation of 
a  multiple  protein  complex,  known  as  the  membrane  attack  complex,  which 
forms  a  pore  in  the  target  cell  membrane  resulting  in  lysis  of  the  cell  and 
consequently cell death (Walport, 2001).   
1.2.1.2  Immune response to endogenous danger signals 
In  addition,  the  immune  system  can  detect  endogenous  molecules  associated 
with  tissue  damage  or  stress,  therefore  act  as  ‘danger  signals’  and  elicit  an 
immune  response  (Gallucci  and  Matzinger,  2001).  Examples  of  endogenous 
‘danger  signals’,  known  as  Damage  Associated  Molecular  Patterns  (DAMPs), 
include  heat  shock  proteins,  high  mobility  group  box  1  and  hyaluronic  acid 
(Bianchi, 2007).  Some DAMPs can activate the immune response via TLRs, such 
as TLR4 (Termeer et al., 2002) or the inflammasome (Martinon et al., 2006). 
Both result in the transcription of many genes involved in the immune response. 
1.2.1.3  Cells of the innate immune system 
Leukocytes, also known as white blood cells, are involved in the innate immune 
response.  Leukocytes  are  derived  from  HSCs  (see  1.1)  and  leukocytes  of  the 
innate  immune  system  include  basophils,  eosinophils,  neutrophils,  mast  cells, 
monocytes, macrophages, dendritic cells and natural killer cells. All the cells 
have different morphology and distinct functions.  
Granulocytes; neutrophils, eosinophils and basophils 
Granulocytes are white blood cells characterised by the presence of granules 
within their cytoplasm. They are classified into three types by their histological 
appearance following staining. Eosinophilic granules stain pink with acidic stains, 
basophilic granules stain blue with basic reagent and neutrophils contain neutral 
staining granules.  
Neutrophils  are  the  most  abundant  leukocyte  within  the  human  body  and 
normally  circulate  within  the  blood.  Neutrophils  are  one  of  the  first  cells 
recruited in an immune response and are a hallmark of acute inflammation (see 
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cytoplasm  (known  as  degranulation),  which  are  toxic  and  help  destroy  the 
encountered  pathogen.  Two  main  types  of  granules  are  contained  within  the 
cytoplasm of neutrophils, azurophilic granules and specific granules. Azurophilic 
granules  contain  microbicidal  substances  such  as  defensins,  enzymes  such  as 
myeloperoxidase  and  the  proteases,  elastase,  proteinase 3  and  cathepsin  G 
(Faurschou and Borregaard, 2003). Specific granules contain enzymes including 
properdin,  which  induces  the  production  of  the  complement  molecule,  C5a 
(Schwaeble  and  Reid,  1999).  In  turn,  C5a  is  a  chemotactic  molecule,  which  
enhances the migration of macrophages, mast cells,  dendritic cells and more 
neutrophils to the site of infection or inflammation (Sozzani et al., 1995). 
Eosinophils  develop and  mature  in the  bone  marrow  making up  to  5%  of the 
leukocyte population. After maturation, eosinophils circulate in the blood ready 
to respond to chemokines (see 1.5) and migrate into inflammatory tissues or to 
the site of a parasitic helminth infection. Activation of eosinophils by interleukin 
(IL) 5, a cytokine released from Th2 cells (see 1.2.1.4), results in the release of 
contents from preformed granules containing major basic protein and eosinophil 
cationic protein (Kita et al., 1992). Upon activation, eosinophils also produce 
lipid mediators, including prostaglandins and leukotrienes (Bandeira Melo et al., 
2002) which are both instrumental in inflammation. Additionally, eosinophils are 
widely known for their role in allergic responses, such as atopic asthma, where 
the immune system overreacts to allergens (Hogan et al., 2008).  
Basophils are the least common type of granulocyte, constituting less than 1% of 
white  blood  cells  within  a  healthy  individual.  Basophils  are  found  within  the 
circulation and have the ability to move into tissues. Upon activation, basophils 
release  preformed  mediators  such  as  histamine  and  heparin  alongside  lipid 
mediators  and  cytokines  (Galli  et  al.,  1991).  Histamine  increases  vascular 
permeability,  smooth  muscle  contraction  and  mucous  secretion  (Maintz  and 
Novak,  2007)  and  these  effects  are  augmented  by  leukotrienes  and 
prostaglandins, which also mediate vasodilatation and increased permeability. 
All  of  these  substances  therefore  contribute  to  the  inflammatory  process. 
Notably,  basophils  are  major  producers  of  a  cytokine  called  IL 4  (Min  et  al., 
2004)  and  this  has  been  linked  to  their  role  in  chronic  allergic  inflammation 
(Mukai et al., 2005). Recent evidence has demonstrated that basophils can also 
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to protease allergens and helminth parasites (Perrigoue et al., 2009, Sokol et 
al., 2009). 
Monocytes and macrophages 
Monocytes constitute 10 15% of leukocytes in humans and enter the circulation 
from  the  bone  marrow  where  they  patrol  the  blood.  From  the  bloodstream, 
monocytes  can  undergo  migration  into  tissues  where  they  differentiate  into 
macrophages. Human monocytes express CD14 on their surface however they are 
a heterogeneous population as another subset of monocytes were discovered to 
be CD14
low CD16
+ (Passlick et al., 1989, Ziegler Heitbrock, 2000). A spontaneous 
null mutation in the coding region of the colony stimulating factor 1 gene in 
Csfm
op/Csfm
op  mice  has  demonstrated  a  key  role  for  macrophage colony 
stimulating factor in the development and differentiation of macrophages (Marks 
and Lane, 1976, Yoshida et al., 1990). Csfm
op/Csfm
op mice have excess bone 
formation  resulting  in  osteopetrosis  characterised  by  dense  and  brittle  bones 
(Marks  and  Lane,  1976).  Csfm
op/Csfm
op  mice  also  have  reduced  number  of 
osteoclasts,  which  are  bone  resorbing  cells,  and    macrophages  within  their 
tissues (Naito et al., 1991).   
The  presence  of  infection  or  inflammation  results  in  the  recruitment  of 
monocytes into the tissue, where they may differentiate into macrophages. In 
response  to  cytokines,  small  protein  molecules  that  act  as  extracellular 
messengers (see 1.4.1), macrophages are polarised functionally.  Macrophages 
are referred to as M1 (classically activated) if they are induced by cytokines, 
interferon g  (IFN g)  and  tumour  necrosis  factor  (TNF)  or  M2  (alternatively 
activated) macrophages if induced by IL 4 or IL 10 (Gordon, 2003). 
Like  neutrophils,  macrophages  are  also  known  as  professional  phagocytes. 
Phagocytes are cells that ingest and destroy solid particles by a process called 
phagocytosis (Allen and Aderem, 1996). Phagocytes express PRRs (see 1.2.1.1) 
which are able to bind PAMPs, and fragment crystalline g receptors (FcgR), which 
recognise  the  carboxy terminal  constant  region  of  immunoglobulin  isotype  G 
(IgG) on opsonin coated pathogens (Swanson and Hoppe, 2004). Upon recognition 
of PAMPs and opsonin coated pathogens, the cell plasma membrane elongates 
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known  as  a  phagosome.  The  phagosome  then  fuses  with  lysosomes,  which 
contain  destructive  enzymes.  Killing  of  the  microbe  is  mediated  by  the 
production  of  reactive  oxygen  intermediates  converted  from  oxygen  by 
nicotinamide  adenine  dinucleotide  phosphate  (NADPH)  oxidase  and  lysosomal 
proteases (Roos et al., 2003). Chronic granulomatous disease, caused by defects 
in  the  NADPH  oxidase  enzyme  within  phagocytic  cells,  leads  to  increased 
susceptibility to infections illustrating the importance of phagocytosis in innate 
immunity (Rosenzweig, 2008).  
Phagocytosis is also a mechanism to remove ‘self’ cells in the body that are 
undergoing  apoptosis  (programmed  cell  death).  Apoptosis  alters  membrane 
phospholipid  symmetry  resulting  in  exposure  of  phosphatidylserine,  which 
targets  the  cell  for  phagocytosis  (Fadok  et  al.,  2001).  This  mechanism 
distinguishes  healthy  ‘self’  cells  from  non healthy  ‘self’  cells  and  avoids 
phagocytosis  of  healthy  cells.  Phagocytosis  of  apoptotic  cells  prevents  the 
surrounding  cells  and  tissues  from  being  exposed  to  the  contents  of  the 
apoptotic cell, and in terms of phosphatidylserine  actually promotes an anti 
inflammatory response (Huynh et al., 2002). 
Mast cells 
Mast cells are long lived cells found in various locations. Mast cell precursors are 
present in the circulation and differentiate into mature mast cells within the 
tissue in which they reside (Metcalfe et al., 1997). Mast cells are present within 
the skin, mucosal tissues and in close proximity to the blood vessels ready to 
encounter  pathogens.  Activation  of  mast  cells  results  in  the  secretion  of 
contents,  which  is  similar  to  that  of  basophils.  Histamine  from  preformed 
granules  is  released,  as  is  newly  synthesised  lipid  mediators  and  cytokines 
(Marshall, 2004). Mast cells can function as effector cells in both the innate and 
the adaptive immune response. These effector functions include the degradation 
of toxins (Metz et al., 2006) and the killing of pathogens (Dawicki and Marshall, 
2007).  Mast  cells  are  considered  immunomodulatory  due  to  their  ability  to 
influence immune cells (Galli et al., 2008). Through the release of a soluble 
mediator known as tumour necrosis factor (see 1.4.1), mast cells can recruit 
innate immune cells, such as dendritic cells (Suto et al., 2006) and cells of the 
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also been described as being able to mediate a negative effect on the immune 
response by producing  IL 10 (Grimbaldeston et al., 2007) but the mechanism by 
which IL 10 produced by mast cells mediates this effect is unknown (Galli et al., 
2008).  Mast  cells  have  been  implicated  in  allergy,  inflammation  and 
autoimmunity (Lee et al., 2002, Nakae et al., 2007). 
Dendritic cells 
These cells were discovered and named by Steinman and Cohn in 1973, due to 
their appearance resulting from branched projections (dendrites) from the cell 
(Steinman and Cohn, 1973). DCs are a heterogeneous  population with several 
subsets,  including  plasmacytoid  DCs  (pDCs),  myeloid  DCs  (mDCs),  Langerhans 
cells  (see  1.3.2)  and  interstitial  DCs  (Shortman  and  Liu,  2002).  All  DCs  are 
capable  of  acting  as  antigen  presenting  cells  (see  below)  but  dendritic  cell 
subtypes reside in different locations. The differentiation of DCs is under the 
influence  of  FMS related  tyrosine  kinase  3 ligand  (Flt3 L).  Disruption  of 
haemopoiesis occurs in mice that lack Flt3 L and they consequently have low 
numbers of DCs (McKenna et al., 2000).  In vivo studies have shown increased 
numbers  of  myeloid  and  plasmacytoid  DCs  after  treatment  with  recombinant 
Flt3 L  (Karsunky  et  al.,  2003).  In  addition,  DCs  can  be  cultured  from  blood 
monocytes in the presence of granulocyte macrophage colony stimulating factor 
and the cytokine IL 4 (Sallusto and Lanzavecchia, 1994). However, Langerhans 
cells  are  dependent  on  transforming  growth  factor b  (TGF b)  for  their 
development as  mice lacking TGF b do not have Langerhans cells in their skin 
(Borkowski et al., 1996). DCs are characterised by specific cell surface markers, 
with different subsets mediating different functions. The main functions of DCs 
is  antigen  presentation  and  they  are  important  in  the  adaptive  response,  by 
providing signals to T lymphocytes which influence the development of T cell 
clones into distinct subsets (see 1.2.1.4). 
Antigen presenting cells; linking innate and adaptive immunity 
Antigen  presenting  cells  (APCs),  mainly  dendritic  cells  and  macrophages,  are 
capable  of  capturing,  processing  and  presenting  pathogen derived  particles 
known  as  antigens,  on  their  cell  surface  to  T  lymphocytes  (see  1.2.1.4). 
Dendritic cells are the ‘professional APC’ as these cells are capable of initiating 
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cells in peripheral tissues continuously sample the environment ready to detect 
pathogens or cell damage. Activation of PRRs results in phagocytosis by the DC 
which then begin to process the pathogenic molecule into peptides, which are 
presented  on  the  cell  surface,  by  major  histocompatibility  complex  class  II 
molecules  (Blander  and  Medzhitov,  2006).  Dendritic  cells  undergo  maturation 
where  they  begin  to  lose  the  ability  to  capture  antigen  and  increase  their 
expression of cell surface molecules, such as CD80 and CD86 (Banchereau and 
Steinman, 1998). At the same time, DCs migrate from their site of activation 
(i.e. a Langerhans cell in the epidermis) to lymph nodes, which is under the 
control  of  the  chemokine  receptor  CCR7.  This  is  discussed  in  more  detail  in 
section 1.5.4.  Once in the lymph nodes, DCs can present the antigenic peptide 
to  T  lymphocytes  (see  1.2.1.4)  and  generate  an  adaptive  immune  response 
(Jenkins et al., 2001). 
1.2.1.4  Cells of adaptive immunity 
Lymphocytes 
Lymphocytes are cells involved in the adaptive immune response and these too 
are derived from HSCs (see 1.1). Lymphocytes can be classified as T lymphocytes 
(T  cells)  or  B  lymphocytes  (B  cells)  and  the  functions  of  both  are  described 
below. B lymphocytes develop in the bone marrow and T lymphocytes do too but 
undergo  further  selection  and  development  in  the  thymus  (Boehm  and Bleul, 
2007). Both subsets of lymphocytes have very diverse repertoires of receptors on 
their surfaces that enable them to recognise specific motifs on any pathogenic 
material  they  may  encounter.  The diversity  of  these  lymphocyte  receptors  is 
formed by somatic recombination of V(D)J gene segments during development 
(Tonegawa, 1983, Bassing et al., 2002). Lymphocytes expressing receptors with 
high  affinity  for  ‘self’ molecules  are  usually  deleted,  whereas  lymphocytes 
expressing receptors with high affinity binding to pathogen associated molecules 
will survive (Boehm and Bleul, 2007). The antigen specific receptor present on T 
lymphocytes is known as the T cell receptor (TCR) whereas the antigen specific 
receptor on B lymphocytes is known as the B cell receptor (BCR). 
Naive  lymphocytes  (those  not  yet  engaged  by  an  antigen  for  their  receptor) 
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lymphatics, to search for antigens. The chemokine receptor, CCR7 (see 1.5.4) is 
expressed  on  naive  T  cells  and  is  important  in  mediating  their  migration 
(Britschgi et al., 2008).    
T Lymphocytes 
Naive T cells continuously search for antigens, being ‘presented’ on the surface 
of antigen presenting cells (see 1.2.1.3). The interaction between a TCR and the 
‘presenting’  major  histocompatibility  complex  (MHC)  is  restricted  by  the 
expression of a cell surface molecule on naive T cells. The expression of CD4 on 
one type of naive T cells restricts their interaction to being with MHC class II 
presented antigen whereas CD8 positive (CD4 null) expressing naive T cells may 
only  interact  with  MHC  class  I  presented  antigens,  which  are  generally 
intracellular pathogens. The interaction between T cells and APCs is focused at a 
specialised  cell cell  junction,  known  as  the  immunological  synapse  (Dustin, 
2002). Additionally, during T cell stimulation by APCs, the chemokine receptors 
CCR5 and CXCR4 (see 1.5.2) are recruited to the immunological synapse (Molon 
et  al.,  2005).  Recognition  of  the  presented  antigen  by  the  TCR  with  a 
simultaneous  second  signal,  provided  by  the  interaction  of  co stimulatory 
molecules,  results  in  the  proliferation  and  activation  of  T  cells.  The  best 
characterised  co stimulatory  pathway  is  the  B7 1/B7 2 CD28/CTLA4  pathway. 
For example, CD86 (B7 2), a co stimulatory molecule present on mature DCs, 
binds  CD28  on  the  surface  of  naive  T  lymphocytes  (Caux  et  al.,  1994).  This 
interaction between CD28 and B7 1 or B7 2 results in promotion of T cell survival 
and the induction of cytokine release, in particular IL 2, which in turn stimulates 
clonal expansion of the engaged T cell (Carreno and Collins, 2002). Naive T cells 
then differentiate into effector T cells that perform specific functions according 
to the type of antigen that activated them. The differentiation of naive T cells is 
regulated by transcription factors and the cytokine milieu in the environment. 
Upon activation and proliferation, CD4
+ naive T cells differentiate into various 
subsets of effector cells. One effector cell subset is defined as T helper cells due 
to  their  ability  to  help  B  cells  (see  below).  Upon  activation,  T  helper  cells 
secrete  a  variety  of  cytokine  combinations,  which  define  T  helper  cells  into 
three main subtypes. These are T helper cell type 1 (Th1), T helper cell type 2 
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described by the type of cell that primarily produces them and are classified as 
Th1  or Th2 associated. IL 1, IL 6, IL 12, tumour necrosis factor (TNF) and IFN 
g are Th1 associated cytokines whereas Th2 associated cytokines are IL 4, IL 5 
and IL 13 (Abbas et al., 1996).  
TCR activation induces low expression of a T box transcription factor, T bet, 
which in turn induces the expression of IL 12b2R and results in the T cell being 
responsive  to  IL 12  (Mullen  et  al.,  2001).  T bet  is  also  upregulated  by  signal 
transducer and activator 1 (STAT1), which is induced by IFN g (Afkarian et al., 
2002). IL 12 binding results in the upregulation of the transcription factor STAT4 
(Thierfelder et al., 1996). Both T bet expression and the activation of STAT4 
result in the production of IFNg. The secretion of IFNg by the T helper cell is very 
effective in activating macrophages in a classical manner and defines the cell as 
a Th1 cell.  
IL 4 is the predominant cytokine capable of inducing differentiation of naive T 
cells into Th2 cells by inducing the production of STAT6, which then activates 
the transcription factor GATA 3 (Kaplan et al., 1996). STAT6 activation induces 
high levels of GATA 3 (Zhu et al., 2001). As GATA 3 levels rise, this inhibits T bet 
and,  as  a  result,  this  attenuates  Th1  development  (Ouyang  et  al.,  1998). 
Moreover, GATA 3 results in the production of cytokines, IL 4, IL 5 and IL 13, 
which  characterise  these  cells  as  Th2  (Murphy  and  Reiner,  2002).  These 
cytokines activate B cells and help in the defence against parasites.  
Another subset of T helper cells has been discovered that are distinct from Th1 
and Th2. These cells produce IL 17 (Harrington et al., 2005) and are accordingly 
called Th17 cells. Th17 cells produce IL 17A, IL 17F, IL 6, IL 22 and TNF a. The 
differentiation of naive T cells into Th17 cells can be induced by IL 23 (Aggarwal 
et al., 2003) or IL 6 (see 1.4.1) along with TGF b (Kimura et al., 2007, Mangan et 
al., 2006). The expression of IL 17 by Th17 cells in response to IL 6 and TGF b 
requires an orphan nuclear receptor RORgt and is regulated by STAT3 (Ivanov et 
al., 2006, Yang et al., 2007). Th17 cells are shown to be present, and play a role 
in,  tissue  inflammation  and  autoimmunity  (Hirota  et  al.,  2007a,  Park  et  al., 
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Additionally, a new subset of T helper cells, known as Th9 cells, was recently 
discovered that produced high levels of IL 9 and IL 10 (Dardalhon et al., 2008, 
Veldhoen et al., 2008). These cells are similar to Th2 yet they are distinct from 
Th2 cells as they produce IL 9. However, it remains to be determined whether 
these cells are functionally different from Th2 cells. 
CD4
+  naive  T  cells  can  also  differentiate  into  a  subset  of  cells  known  as 
regulatory  T  cells  (Treg  cells).  These  cells  are  able  to  suppress  and  regulate 
effector T cell responses and  play a role in maintaining peripheral tolerance and 
prevent  autoimmune  diseases  (Sakaguchi  et  al.,  2006).  Treg  cells  are 
characterised  by  the  expression  of  the  transcription  factor,  forkhead  box  P3 
(Foxp3) which plays a role in the development of these cells (Hori et al., 2003). 
Two subsets of Foxp3
+ Treg cells have been identified, one subset is the naturally 
occurring CD4
+CD25
+ Treg (nTreg) cells and the second subset is known as inducible 
Treg (iTreg) cells. Natural occurring Treg cells are derived in the thymus whilst 
iTregs are derived from CD4
+ naive T cells induced to express Foxp3 by TGF b in 
the  periphery  (Chen  et  al.,  2003).  In  vivo,  Scurfy  mice  carry  a  spontaneous 
mutation  of  Foxp3,  which  results  in  the  development  of  a  fatal  autoimmune 
disease (Brunkow et al., 2001). Foxp3 has also been identified as the defective 
gene in humans with immunodysregulation polyendocrinopathy and enteropathy, 
X linked (IPEX) syndrome (Bennett et al., 2001). These conditions illustrate the 
importance of Treg cells. Although CD4
+ T cells can be classified into functional 
subsets,  there  is evidence  of  functional  plasticity in CD4
+  T  cell  subsets.  For 
example, there is evidence that Th17 cells can convert to Th1 cells (Lee et al., 
2009) and regulatory T cells can change to memory T cells (Zhou et al., 2009).  
After the activation and proliferation of T cells, these cells migrate to sites of 
inflammation,  a  process  regulated  by  many  factors  including  adhesion 
molecules,  chemokines  and  chemokine  receptors  (see  1.5.3.1).  After  the 
clearance of pathogen, some Ag specific T cells will remain in the body, known 
as  memory  T  cells.  These  cells  reside  in  peripheral  tissue  and  subsequent 
exposure  to  the  antigen  will  result  in a  more  rapid  response than  the initial 
exposure response  (Woodland and Kohlmeier, 2009). 
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B Lymphocytes 
Although B cells are primarily known as antibody producing cells, B cells can also 
act as antigen presenting cells (Chen and Jensen, 2008). Presentation of Ag on B 
cells and their recognition by T cells, involves co stimulatory molecules and the 
release  of  cytokines.  This  triggers  B  cell  proliferation  and  the  secretion  of 
antibodies  (Parker,  1993).  Cytokines  released  by  the  activated  T  helper  cells 
during this process, feedback to act in an autocrine manner inducing the T cell 
to proliferate. In addition, B cells also influence T cell differentiation through 
the secretion of polarising cytokines (Harris et al., 2000).  
1.3 Cutaneous immune system 
The skin is the largest organ in the body and one of its main functions is to act as 
a physical barrier to protect the internal organs and tissues within the body. 
Originally  thought  as  a  passive  barrier,  the  skin  is  highly  equipped  with 
immunological  mechanisms  to  be  the  body’s  first  line  of  defence  against 
infection and tissue injury (Elias, 2007). 
1.3.1  Structure of the skin 
The  skin  is  composed  of  many  epithelial  layers  and  is  divided  into  distinct 
compartments, which contain various cell types within it. In humans, the skin is 
composed  of  three  main  compartments,  the  epidermis,  the  dermis  and  the 
hypodermis whereas mice have two main compartments, the epidermis and the 
dermis. The epidermis is the outer layer of the skin, consisting of many layers of 
stratified squamous epithelial cells.  The epidermis is subdivided into five layers, 
from the deepest layer to outermost layer, stratum basale (basal cell layer), 
stratum spinosum (prickle cell layer), stratum granulosum (granular cell layer), 
stratum lucidum and finally the stratum corneum. It is of note that murine skin 
contains  less  cell  layers  of  keratinocytes  than  human  epidermis,  resulting  in 
murine skin having a thinner epidermis in comparison to human epidermis. The 
structure of murine skin is shown in Figure 1.2.  
The  epidermis  of  both  human  and  mouse  skin  constantly  renews  itself  in  a 
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driven  by  stem  cells,  which  replace  cells  that  are  lost  through  normal 
differentiation or cell death due to tissue injury (Blanpain et al., 2007). The 
major  cells  of  the  epidermis  are  keratinocytes,  which  undergo  terminal 
differentiation  regularly  to  maintain  homeostasis.  Keratinocytes  with  the 
stratum  basale,  known  as  basal  keratinocytes  undergo  differentiation  whilst 
gradually moving outwards through each layer, changing shape and the types of 
structural proteins they express. Within the basal layer, keratinocytes express 
keratin 5 and keratin 14  (K5 and K14) but as these cells differentiate and enter 
the spinosum layer, the expression of K5 and K14 is downregulated and other 
keratin proteins, K1 and K10 are expressed (Blanpain and Fuchs, 2009). Upon 
reaching  the  stratum  corneum,  the  cells  within  this  layer  are  known  as 
corneocytes, which are derived from dead keratinocytes, which begin to shed off 
the skin surface. The stratum corneum is an important layer as this prevents the 
skin from dehydration and prevents toxic agents from entering the skin (Proksch 
et al., 2008). Other cells within the epidermis are melanocytes, which produce 
melanin responsible for the pigmentation of skin, which are located within the 
basal layer of the epidermis. Langerhans cells are specialised dendritic cells that 
reside within the epidermis and merkel cells are associated with sensory nerve 
endings.  
Underneath the epidermis connected by the basement membrane (basal lamina), 
the dermis consists of connective tissue. The dermis contains many cell types 
alongside hair follicles, sweat glands, sebaceous glands, blood vessels, lymphatic 
vessels and sensory nerves. Underlying the dermis in humans is the hypodermis 
layer, consisting of a layer of subcutaneous fat, helping to insulate the body. 
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Figure 1-2. The structure and layers within murine skin.  
The skin is one of the largest organs within the body and contains many layers within it. The 
outer layer, known as the epidermis, contains cell layers composed of keratinocytes. The 
compartment underneath the epidermis is the dermis and contains connective tissues and 
blood vessels. 
 
1.3.2  Immune response within the skin 
Bos and Kapsenberg first proposed the concept of the ‘skin immune system’ in 
1986, in which both epithelial and immune cells were associated with a role in 
the cutaneous immune response. The main cells involved are keratinocytes and 
Langerhans  cells  within  the  epidermis,  whilst  within  the  dermis,  mast  cells, 
dermal dendritic cells and T cells are key players (Bos and Kapsenberg, 1986, 
Kupper and Fuhlbrigge, 2004). Their main function is to alert the innate immune 
system when the skin is disturbed by trauma, ultraviolet radiation or pathogens. 
Originally,  keratinocytes  were  considered  as  only  being  required  for  the 
structural component of the skin but are increasingly being considered important 
participants  in  the  cutaneous  immune  response.  Keratinocytes  constitutively 
produce  antibiotic  peptides  to  kill  microbial  pathogens  that  enter  the  skin 
(Wiedow et al., 1998). Additionally, injury or infection results in the production 
of  b defensins and cathelicidins, both antimicrobial peptides, by keratinocytes 
(Harder et al., 1997, Dorschner et al., 2001). Keratinocytes have the ability to 
recognise  PAMPs  (see  1.2.1.1)  due  to  their  expression  of  various  Toll like 
receptors (Kollisch et al., 2005). Keratinocyte TLRs binding to PAMPs results in 
the production of various immunological agents, including cytokines (see 1.4.1), 
chemokines  (see  1.5)  and  antimicrobial  peptides.  TLRs  confirmed  to  be 
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TLR5 as well as endosomal TLR3 and TLR9 (Lebre et al., 2007). Keratinocytes 
express NLRs, such as NLRP3, which can recognise PAMPs or DAMPs present in 
the  cytoplasm  (Feldmeyer  et  al.,  2007).  Various  cytokines  are  released  from 
keratinocytes  after  stimulation  with  endotoxin  and  ultraviolet  light,  notably 
TNFa, IL 1 and IL 6 (Kock et al., 1990, Petit Frere et al., 1998). Indeed, IL 1b 
secretion  from  human  keratinocytes  induced  by  ultraviolet  irradiation  is 
mediated by NLRP3 and activation of the inflammasome complex (Feldmeyer et 
al., 2007). These cytokines play a role in activating other resident immune cells 
and upregulate the expression of adhesion molecules on the endothelium, which 
in turn recruits more leukocytes from the vasculature into the skin (see 1.4.1). 
Additionally,  keratinocytes  are  capable  of  stimulating  Langerhans  cells  and  T 
cells of the adaptive immune system. In response to a TLR9 ligand, keratinocytes 
produce cytokines which enhance the antigen presenting ability of Langerhans 
cells (Sugita et al., 2007). Another study has suggested that keratinocytes can 
induce  functional  responses  in  memory  T  cells  by  processing  and  presenting 
peptides to antigen experienced T cells resulting in T cell cytokine production 
(Black et al., 2007).  
Langerhans  cells  are  the  subset  of  dendritic  cells  that  reside  within  the 
epidermis and are characterised by the presence of Birbeck granules (rod shaped 
organelles within their cytoplasm) and expression of Langerin in their membrane 
(Valladeau  et  al.,  2000).  Langerhans  cells  are  derived  from  CD34
+ 
haematopoietic  progenitor  cells  during  haemopoiesis  (see  1.1).  These  DC 
progenitors  then  differentiate  into  either  of  two  alternative  DC  subsets;  one 
expresses  cutaneous  lymphocyte associated  antigen  (CLA)  and  subsequently 
differentiates  into  a  CD11c
+CD1a
+  cell,  the  alternative  lacks  CLA  and 
differentiates into a CD11c
+ CD1a
   cell (Ito et al., 1999, Strunk et al., 1997). The 
CD11c
+CD1a
+ population migrate to the epidermis and become Langerhans cells 
whilst the CLA
  population become interstitial DCs, of which a subpopulation of 
these are dermal DCs found in the dermis of the skin. Langerhans cells express 
TLR2, TLR4 and TLR5 whereas dermal DCs express TLR3 and TLR4 and as a result 
they secrete different cytokines in response to specific stimulation (Rozis et al., 
2008).  Both  subsets  can  capture  and  process  antigen  (Nestle  et  al.,  1998). 
Recent data suggests that dermal DCs and Langerhans cells drain to the lymph 
nodes  but  only  dermal  DCs  induce  proliferation  of  T  cells  (Fukunaga  et  al., 
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skin draining lymph nodes is mediated by the surface expression of chemokine 
receptors  including  CCR7  (see  1.5.3.2).  In  the  lymph  nodes,  DCs  will  present 
antigen to T and B cells, which will then migrate to the skin and eliminate the 
trigger causing the response. 
Normal healthy skin contains twice as many T cells than there are in the blood 
and the majority are skin homing memory T cells (Clark et al., 2006). Within the 
population of T cells, a subset known as intraepithelial lymphocytes (IELs) are 
associated with epithelial and mucosal tissues. IELs express TCRs composed of g 
and d chains (gd T cells) whereas other T cells express an ab TCR (ab T cells) and 
these are predominately found in the blood and lymphatics (Girardi and Hayday, 
2005). In mice, a proportion of gd IELs are localised in the skin and are termed 
dendritic epidermal T cells (DETCs). These cells are the first T cells to develop 
in mice with limited diversity and they express a canonical Vg5Vd1 TCR (Asarnow 
et al., 1988). Although no equivalent population has been found in human skin, 
gd T  cells  with  limited  diversity  have  been  discovered  in  the  human  dermis, 
which are distinct from peripheral blood gd T cell populations (Holtmeier et al., 
2001).  DETCs  can  be  activated  by  stressed,  damaged  or  transformed 
keratinocytes (Havran et al., 1991). Studies have shown that DETCs play a role in 
keratinocyte  homeostasis.  DETCs  constitutively  express  insulin  like  growth 
factor 1 (IGF 1) but increased levels are released upon stimulation and this in 
turn promotes keratinocyte survival (Boismenu and Havran, 1994, Sharp et al., 
2005). In vivo, increased numbers of keratinocytes were found to be undergoing 
apoptosis in mice lacking DETCs (Sharp et al., 2005). Additionally, by culturing 
DETCs with skin from TCRd
-/-  mice (lack DETCs), Sharp et al., demonstrated that 
DETCs can promote keratinocyte survival by the production of IGF 1  (Sharp et 
al.,  2005).  A  role  for  IGF 1  in  skin  homeostasis  has  been  established  by  the 
overexpression of IGF 1 in vivo, which resulted in epidermal thickening (Bol et 
al., 1997) whilst mice lacking IGF 1R have a thinner, disrupted epidermis (Liu et 
al., 1993) as a consequence of decreased proliferation and accelerated rate of 
differentiation in keratinocytes (Sadagurski et al., 2006). In addition, DETCs play 
a  role  in  maintaining  epidermal  integrity  and  barrier  function  in  response  to 
environmental challenges (Girardi et al., 2006).  Other studies have shown that 
DETCs  play  a  role  in  promoting  wound  healing  and  protecting  against 
inflammatory responses. Wound healing was found to be delayed in TCRd /  mice 
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delay in wound closure was rescued by activated DETCs or keratinocyte growth 
factor 1  (Jameson  et  al.,  2002),  which  had  previously  been  shown  to  be 
produced  by  DETCs  in  vitro  upon  activation  (Boismenu  and  Havran,  1994). 
Girardi et al.,  demonstrated a role for DETCs in regulating the inflammatory 
response  by  showing  that  DETCs  can  downregulate  spontaneous  cutaneous 
inflammation in TCRd
-/-  mice (Girardi et al., 2002). Moreover, microarray data 
showed epidermal cells from TCRd
-/-  mice have increased expression of various 
inflammatory  genes,  such  as  IL 1b  and  chemokines  (Girardi  et  al.,  2006).  A 
mechanism  for  the  DETC  regulation  of  cutaneous  inflammation  is  that  DETCs 
induce protein expression of hyaluronan, which allows macrophage infiltration 
into the damaged tissue to facilitate wound repair (Jameson et al., 2005). 
1.4 Acute inflammation 
Acute inflammation is a normal physiological response triggered by infection or 
tissue  damage.  Resident  cells  within  the  tissue,  such  as  epithelial  cells, 
macrophages  or  mast  cells,  trigger  the  release  of  various  inflammatory 
mediators, including cytokines (see 1.4.1), chemokines (see 1.5) and vasodilative 
amines  upon  stimulation  by  agents  suggestive  of  infection  or  tissue  damage. 
Acute inflammation is characterised by the infiltration of leukocytes controlled 
by  chemokines  (discussed  in  detail  in  1.5.3.1),  in  which  initially  neutrophils, 
then  24  to  48hrs  later,  mononuclear  cells  dominate  (Medzhitov,  2008). 
Additionally,  increased  blood  flow  and  vascular  permeability,  mediated  by 
histamine results in the heat, redness and swelling associated with inflammation 
(Maintz and Novak, 2007). 
1.4.1  Cytokines in inflammation 
Cytokines  allow  one  cell  to  mediate  effects  on  cells  at  a  distance,  on 
neighbouring cells, or even on itself. When the immune system is insulted, cells 
of the innate and adaptive immune system can secrete and detect cytokines, 
which  are  involved  in  many  important  biological  processes,  including 
inflammation (Vilcek and Feldmann, 2004). 
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Tumour necrosis factor 
One family of cytokines, known as the tumour necrosis factor (TNF) superfamily 
can  mediate  various  biological  responses.  One  member,  TNFa,  is  mainly 
produced by activated macrophages but can also be released by other types of 
leukocytes  and  it  plays  an  important  role  in  host  defence  (Medzhitov  and 
Janeway,  2000).  TNFa is  produced  in  a  pro form  as  a  26kDa  transmembrane 
protein arranged as a homotrimer (Kriegler et al., 1988, Tang et al., 1996). This 
membrane form can be cleaved by TNF a converting enzyme (TACE) to release 
soluble TNF (Black et al., 1997). TNFa can bind two membrane receptors, TNFR1 
(p55)  or  TNFR2  (p75),  which  are  members  of  the  TNF  receptor  superfamily 
(Locksley  et  al.,  2001).  Signalling  through  TNFR1  and  TNFR2  can  lead  to  the 
activation of transcription factors, NF kB or activating protein 1 (AP 1), which 
can promote cell survival and inflammation, or caspase induced cell death (Baud 
and Karin, 2001). The inflammatory response is mainly coordinated through NF 
kB,  resulting  in  increased  transcription  of  various  genes,  including  those 
triggering the cytokine cascade by producing IL 1b, IL 6, more TNFa, chemokines 
(see 1.5) and adhesion molecules (Bonizzi and Karin, 2004). 
Tumour necrosis factor is a key mediator in inflammation and its overexpression 
can  result  in  many  chronic  inflammatory  diseases  and  autoimmune  diseases 
(Kollias et al., 1999). The interest in pro inflammatory cytokines started when 
pro inflammatory cytokines were detected in biopsy samples from rheumatoid 
arthritis (RA) patients, which illustrated their importance in joint inflammation 
(Feldmann and Maini, 1999). Studies using animal models of arthritis indicated 
TNFa as  a  key  mediator  of  the  disease,  as  anti TNF  treatment  ameliorated 
collagen induced arthritis (Piguet et al., 1992, Williams et al., 1992) which is an 
accepted murine model of RA (see 1.4.3.3). Additionally, it was discovered that 
overexpression  of  human  TNFa   (hTNFa)  in  mice  resulted  in  a  spontaneous 
arthritis (Keffer et al., 1991). Butler et al., backcrossed hTNFa  transgenic mice 
onto an arthritis susceptible DBA/1 background and the expected elevated levels 
of  human  TNFa   were  accompanied  by  increased  IL 1b  and  IL 6  levels  in  the 
joints of these mice (Butler et al., 1997). As a result, TNFa in particular and 
other  cytokines  have  been  targeted  for  therapeutic  use  in  RA  and  other 
inflammatory diseases. This is discussed in more detail in 1.4.4. Vicky King, 2010      Chapter 1, 43 
IL-1 family 
Members  of  the  interleukin 1  (IL 1)  family  are  produced  by  macrophages, 
activated Th1 cells, epithelial and endothelial cells. The IL 1 family is composed 
of 11 members including IL 1a, IL 1b, IL 1 receptor antagonist (IL 1Ra), IL 33 and 
several new members, resulting in the proposal of a new terminology, IL 1F1 
through  to  IL 1F11  (Sims  et  al.,  2001).  Like  TNF,  IL 1a  and  IL 1b exist  in 
precursor  forms  and  whilst   IL 1a  is  active  in  its  precursor  (Kaplanski  et  al., 
1994)  and  mature  form,  IL 1b  secretion  is  dependent  on  cleavage  by  IL 1b 
converting  enzyme  (ICE)  also  known  as  caspase  1  (Thornberry  et  al.,  1992). 
Notably,  for  the  secretion  of  IL 1b  from  monocytes  and  macrophages, 
stimulation by adenosine triphosphate (ATP) is required, which then activates 
the  P2x7  receptor  (Ferrari  et  al.,  2006)  and  this  subsequently  triggers  the 
formation of active caspase 1. Both IL 1a and IL 1b can bind IL 1 receptor type I 
(IL 1RI)  and  IL 1R  type  II,  however  only  IL 1RI  is  able  to  initiate  signal 
transduction (Sims et al., 1993) which requires IL 1R accessory protein in order 
to do so (Cullinan et al., 1998) whereas IL 1RII acts as a decoy receptor (Colotta 
et al., 1993). 
IL 1b  induces  endothelial  cells  to  upregulate  the  expression  of  adhesion 
molecules involved in leukocyte binding and so indirectly recruits leukocytes to 
sites of inflammation (Wang et al., 1995). IL 1b , like TNF, can induce fever by 
acting on the hypothalamus and it can also induce the synthesis of acute phase 
proteins,  a  response  impaired  in  IL 1b  deficient  mice  (Zheng  et  al.,  1995). 
Additionally, IL 1 results in the production of other cytokines such as IL 6 which 
is also involved in the inflammatory response (Dinarello, 1996). Membrane IL 1a 
has been shown to play a role in lipid mediated inflammation as IL 1a deficient 
mice demonstrated reduced lesion size in an atherogenesis model induced by 
high  cholesterol  (Kamari  et  al.,  2007).  Within  the  interleukin 1  family,  an 
endogenous antagonist exists, IL 1Ra can block the action of IL 1 by binding to 
IL 1RI, therefore preventing the activity of IL 1 (Arend, 1991). Mice deficient in 
IL 1Ra develop spontaneous diseases such as arthritis (Horai et al., 2000).  
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IL-6  
IL 6 was originally identified as a substance released by T lymphocytes which 
induced B lymphocytes to produce antibodies (Hirano et al., 1986). IL 6, is now 
known to mediate various biological functions including the activation of T and B 
cells, macrophages, osteoclasts (bone absorbing cells) and the proliferation of 
keratinocytes as well as having effects on haemopoiesis  (Kishimoto, 2005). IL 6 
exerts  it  effects  by  binding  to  the  IL 6  receptor  which  then  associates  with 
glycoprotein 130 (gp130), a signal transducer protein (Taga et al., 1989). As well 
as a membrane bound IL 6R, a natural soluble form of IL 6R (sIL 6R) can also be 
produced by shedding from the cell surface or alternatively from spliced mRNA 
(Lust  et  al.,  1992,  Matthews  et  al.,  2003).  Soluble  IL 6R  along  with  IL 6  can 
stimulate cells that express gp130 but do not express membrane bound IL 6R 
(Mackiewicz et al., 1992) and this process is known as trans signalling (Rose John 
and Heinrich, 1994).  
In the context of inflammation, IL 6 plays a role in stimulating endothelial cells 
to upregulate their expression of the chemokine, CCL2 (see 1.5) and it therefore 
plays a role in recruiting leukocytes to sites of inflammation (Romano et al., 
1997).  Illustrating  the  role  of  IL 6  in  inflammation,  IL 6  deficient  mice  were 
found  to  be  resistant  or  to  have  reduced  severity  to  experimental  induced 
arthritis and collagen induced arthritis respectively (Boe et al., 1999, Sasai et 
al.,  1999).  In  addition,  Nowell  et  al.,  demonstrated  that  in  an  experimental 
induced model of arthritis, it is sIL 6R which directs the IL 6 activity and this can 
be blocked by exogenous soluble glycoprotein 130 (Nowell et al., 2003). Indeed, 
elevated levels of IL 6 and sIL 6R have been documented in both rheumatoid 
arthritis and crohns disease  (Mitsuyama et al., 2006, Robak et al., 1998). This 
has subsequently led to the therapeutic targeting of IL 6, in which one antibody, 
Tocilizumab, is currently subject to clinical trials (see 1.4.4). 
1.4.2  Resolution of inflammation 
Normally  the  acute  inflammatory  response  is  followed  by  resolution  of 
inflammation and tissue repair, through the removal of leukocytes and debris at 
the inflamed site, resulting in tissue homeostasis. The mechanisms involved have 
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stimuli to fight and remove it 2) cell clearance occurs and 3) the site where the 
inflammatory response took place returns back to it normal state (Serhan et al., 
2007). The resolution of inflammation was thought to be a passive process but in 
recent years, new cellular and molecular mechanisms for the resolution phase of 
inflammation have been discovered. These mechanisms involve families of lipid 
mediators, known as lipoxins, resolvins and protectins. 
Lipoxins were the first to be discovered and are derived from Arachidonic Acid 
(AA)  present  within  the  cell  membrane.  It  was  discovered  that  during  acute 
inflammation  prostaglandins,  especially  prostaglandin  E2  (PGE2),  also  derived 
from  AA  can  encourage  the  conversion  of  a  class  of  molecules  known  as 
leukotrienes to lipoxins, which promote resolution (Levy et al., 2001). Resolvins 
and protectins are derived from omega 3 polyunsaturated fatty acid, known as 
Eicosapentanoic  Acid  and  Docosahexanoic  acid.  Resolvins  are  split  into  two 
groups; the Resolvin E series and Resolvin D series, named according to the fatty 
acid they are derived from. Resolvin E series are derived from Eicosapentanoic 
acid and the D series are generated from Docosahexanoic acid. Protectins are 
also derived from Docosahexanoic acid (Serhan et al., 2002). Lipoxins A4 and B4 
as  well  as  Resolvin  E1  mediate  the  first  mechanisms  involved  in  resolving 
inflammation. They are capable of preventing neutrophils from migrating across 
the vascular endothelium into the tissues (Colgan et al., 1993, Papayianni et al., 
1996,  Serhan  et  al.,  2000).  Lipoxin  A4  and  Resolvin  E1  can  inhibit  IL 12 
production  from  dendritic  cells  (Aliberti  et  al.,  2002,  Arita  et  al.,  2005) 
therefore preventing activation of T cells in the area. Protectin D1 inhibits the 
production of TNFa and IFNg from stimulated T cells and induces T cell apoptosis 
(Ariel  et  al.,  2005).  Consequently,  protectin  D1  limits  the  activation  of 
leukocytes and causes T cell death. Lipoxin A4, Resolvin E1 and Protectin D1 can 
stimulate macrophages to take up neutrophils by phagocytosis (Godson et al., 
2000, Schwab et al., 2007) therefore by removing apoptotic cells, cell clearance 
occurs. Macrophages then leave the site of inflammation via the draining lymph 
node allowing the tissue to return to normal (Bellingan et al., 1996). 
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1.4.3   Chronic inflammation 
When acute inflammation persists or complete resolution does not occur, the 
beneficial aspect of inflammation is lost and inflammation becomes chronic. This 
can last days, months or even years and can result in tissue damage. The cell 
infiltrate changes, leukocytes accumulate with increased numbers of adaptive 
immune cells. Chronic inflammation results in the development of a wide variety 
of  inflammatory  diseases,  influenced  by  both  genetic  predisposition  and 
environmental factors. 
1.4.3.1   Psoriasis 
Psoriasis  is  an  inflammatory  skin  disease  which  is  prevalent  worldwide  and 
affects 2 3% of the population in the UK (Smith and Barker, 2006). Psoriasis is a 
disease mediated by components of the immune system with evidence of genetic 
predisposition to the disease (Bowcock and Krueger, 2005). Clinical symptoms of 
psoriasis can appear in a variety of ways depending on location, severity and 
activity of the disease.  
Clinical spectrum of psoriasis 
Psoriasis  is  a  recurring  inflammatory  disease  with  a  wide  clinical  spectrum 
including five types of psoriasis, summarised in Table 1.1 (as reviewed by Naldi 
and  Gambini,  2007).  Psoriatic  lesions  are  generally  characterised  by 
erythematous  plaques  covered  with  silvery  scales  surrounded  by  a  distinct 
border, and the skin may itch or bleed more easily. The most common type of 
psoriasis is psoriasis vulgaris, also known as plaque psoriasis. Guttate psoriasis is 
common in children or young adults after streptococcal infection (Telfer et al., 
1992, Gudjonsson et al., 2003). Pustular types of psoriasis are rarer than the 
non pustular  forms  however,  both  can  progress  to  psoriatic  erythroderma,  in 
which active psoriasis involves the whole skin or near total involvement affecting 
the  whole  body.  In  some  psoriasis  patients,  physical  trauma  to  the  skin  can 
trigger psoriatic lesions, known as the Koebner phenomenon (Weiss et al., 2002). 
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Table 1-1. Clinical spectrum of psoriasis 
Five different types of psoriasis occur and the location and presentation of the psoriatic 
lesions vary in each type. 
 
Pathological changes in psoriasis 
Within  psoriatic  skin,  pathological  changes  occur  and  the  lesions  contain 
common histological hallmark features. Within fully developed plaques, hallmark 
features  are;  epidermal  hyperplasia  (increased  number  of  cells  within  the 
epidermal compartment), hyperkeratosis, (overgrowth of the corneous layer of 
the skin), infiltration of immune cells, angiogenesis and epidermal thickening 
caused by increased keratinocyte proliferation (Murphy et al., 2007).  
Immunopathogenesis of psoriasis 
Originally,  the  pathology  of  psoriasis  was  proposed  to  be  mediated  by 
keratinocytes, due to abnormalities in keratinocyte proliferation compared to 
normal skin (Weinstein et al., 1984). By the late 1970’s, T cells were assumed to 
be  the  main  mediators  driving  the  disease.  Consistent  with  this,  when 
cyclosporin A (a drug that inhibits T cell activation) was given to a transplant 
patient,  clearance  of  the  patients  psoriasis  occurred  (Mueller  and  Herrmann, 
1979). Further studies with targeted therapy against activated T cells confirmed 
the role of T cells in the pathogenesis of psoriasis (Nicolas et al., 1991). Studies 
examining clonality of the T cell receptor have shown that infiltrating T cells in 
psoriatic plaques express a highly restricted TCR repertoire indicating oligoclonal 
expansion (Lin et al., 2001b). This suggests that a common antigen is present 
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such example could be an antigen derived from streptococcal infection which 
can preceed type 1 psoriasis, which is characterised by early manifestation of 
the disease, i.e., under 40 years of age (Weisenseel et al., 2002). Additionally, a 
study  by  Vollmer  et  al.,  has  shown  that  the  same  T  cell  receptor  pattern 
dominates in repeated flares of psoriasis (Vollmer et al., 2001). Although it has 
also  been  suggested  that  regulatory  T  cells  are  dysfunctional  resulting  in 
uncontrolled T cell activation (Sugiyama et al., 2005). 
Characterisation of T cells within psoriatic lesions shows that they belong to the 
Th1 subset and produce type 1 cytokines including TNFa, IFNg and IL 2 (Austin et 
al., 1999, Schlaak et al., 1994). As a result, psoriasis has been classified as Th1 
mediated  disease  (Lew  et  al.,  2004).  TNFa,  in  particular  is  implicated  as  an 
important mediator as it is central to the presentation of spontaneous psoriasis 
in a murine model (Boyman et al., 2004). Additionally the study by Boyman et 
al., illustrated that resident populations of T cells and DCs are able to induce 
psoriasis, shown by grafting non lesional human skin from psoriasis patients to 
immunodeficient AGR129 mice (these mice are deficient in both type 1 and type 
II IFN receptors and for the recombinase activating gene 2). 
There  is  also  evidence  of  the  innate  immune  system  being  dysregulated  in 
psoriasis (Bos et al., 2005). IFNa  released from plasmacytoid DCs (see 1.2.1.3) is 
able to drive T cell proliferation and development of the disease (Nestle et al., 
2005).  Plasmacytoid  dendritic  cells  can  be  activated  by  environmental  TLR  
agonists  (see  1.2.1.1),  heat  shock  proteins  produced  by  damaged  cells  (see 
1.2.1.2) or even anti microbial peptides produced by keratinocytes (Buchau and 
Gallo, 2007). In addition, in vivo models have implicated macrophages as having 
a pathogenic role in the disease (Stratis et al., 2006, Wang et al., 2006). 
A central role for pro inflammatory cytokines within psoriasis was proposed over 
15 years ago (Nickoloff, 1991). Indeed the levels of IL 6 was discovered to be 
elevated  in  psoriatic  plaques  and  was  found  to  promote  keratinocyte 
proliferation  in  vitro  (Grossman  et  al.,  1989).  Therefore,  the  altered 
proliferation  of  keratinocytes  was  thought  to  be  a  consequence  of  the 
inflammatory response driven by cytokines. In vitro studies have shown exposure 
to  TNFa  and  IL 1b  induces  changes  to  keratinocytes,  which  are  observed  in 
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19  and  IL 20  are  present  in  psoriatic  lesions  and  play  a  role  in  promoting 
keratinocyte survival and inhibiting keratinocyte apoptosis (Ruckert et al., 2000, 
Wei et al., 2005). To determine the role of single cytokines, transgenic mice 
expressing cytokines in basal keratinocytes were studied. In mice overexpressing 
IL 6,  no  psoriasis  phenotype  was  seen  and  no  effect  on  keratinocyte 
differentiation or proliferation occurred (Turksen et al., 1992). However, when 
IL 1a  was  overexpressed  in  a  similar  manner,  inflammatory  lesions  were 
observed along with hyperkeratosis (Groves et al., 1995). Of the several new IL 1 
family members that have been described, one, IL 1F6, when overexpressed in 
the  mouse  skin  resulted  in  a  phenotype  of  hyperkeratosis,  accumulation  of 
inflammatory cell infiltrate and increased levels of cytokines and chemokines 
(Blumberg et al., 2007). The same study found that IL 1F5 was antagonistic of 
the effects and therefore the balance between IL 1F5 and IL 1F6 plays a role in 
regulating skin inflammation (Blumberg et al., 2007).    
Altered  signal  transduction  and  transcription  pathways  in  epidermal 
keratinocytes  have  been  suggested  as  an  explanation  for  dysregulation  of 
keratinocyte proliferation in psoriasis (McKenzie and Sabin, 2003). Indeed, mice 
with  specific  deletion  of  the  I  kappa  B  kinase  2  (IKK2),  which  is  a  protein 
involved  in  the  process  of  activating  NF kB,  in  the  epidermis  developed  a 
psoriasis like pathology mediated by TNFa, implicating a role for NF kB in the 
pathology  of  the  disease  (Pasparakis  et  al.,  2002).  A  study  by  Zenz  et  al., 
targeted in the skin the deletion of specific transcription factors (junB and c jun 
proteins)  involved  in  activating  transcription  factor  AP 1,  which  in  turn  is 
involved  in  the  regulation  of  genes  involved  in  keratinocyte  differentiation 
(Eckert  and  Welter,  1996).  Mice  deficient  of  jun  proteins  within  their 
keratinocytes  demonstrated  a  psoriasis like  pathology  (Zenz  et  al.,  2005). 
Additionally, when JunB and jun were deleted in keratinocytes of recombinase 
activating gene 2 deficient mice or TNFR1 deficient mice, it was discovered that 
involvement of T and B cells, as well as TNFa,  were required for development of 
a  psoriasis  phenotype  (Zenz  et al.,  2005).  Interestingly,  this  study  illustrated 
that changes within the epidermis can have consequences for distant sites such 
as joints, as these mice also developed arthritic like lesions (Zenz et al., 2005). 
Signal  transducers  and  activators  of  transcription  are  involved  in  conveying 
extracellular  signals  to  the  nucleus.  One  of  these,  STAT3  was  found  to  be 
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mice  with  constitutively  active  STAT3  expression  in  the  epidermis  developed 
spontaneous psoriatic lesions, which were dependent on activated T cells (Sano 
et al., 2005). These studies therefore indicate that the pathogenesis of psoriasis 
is mediated by cross talk between immune cells and keratinocytes. 
Recent emerging data has implicated IL 23 and Th17 cells (see 1.2.1.4) in the 
pathogenesis  of  psoriasis.  IL 23  was  implicated  when  it  was  shown  that  an 
injection of IL 23 into murine skin resulted in histopathological features similar 
to psoriasis (Chan et al., 2006). IL 23 is a heterodimeric protein composed of IL 
23p19 and a subunit of IL 12, IL 12p40 (Oppmann et al., 2000). IL 23 binds and 
signals through the IL 23 receptor complex which is composed of IL 12RB1 (IL 
12p40)  and  IL 23R  subunits  (Parham  et  al.,  2002).  In  human  psoriatic  skin 
lesions, it was discovered that there was elevated mRNA levels of IL 23p19 and 
IL 12p40  compared  to  uninvolved  skin  (Lee  et  al.,  2004).  Additionally,  it  has 
been shown that polymorphisms in the genes that encode for IL 23R or IL 12p40 
can contribute to the psoriasis phenotype and depending on the polymorphism in 
these  genes,  they  can  promote  susceptibility  or  protection  from  developing 
psoriasis (Capon et al., 2007, Cargill et al., 2007, Nair et al., 2008). It is of note 
that STAT3 is the main mediator involved in IL 23 signalling (Yang et al., 2007). 
IL 23 can induce Th17 cells to produce Th17 cytokines (Aggarwal et al., 2003). 
Indeed IL 17 mRNA was detected in lesional psoriatic skin but not in uninvolved 
skin (Teunissen et al., 1998) and cells producing IL 17 have been isolated from 
the  dermis  of  psoriatic  lesions  (Lowes  et  al.,  2008).  These  studies  therefore 
implicate Th17 and IL 17 (see 1.2.1.4) in the pathogenesis of psoriasis. Other 
Th17 type cytokines have also been implicated such as IL 22.  A study by Zheng 
et al., found that the inflammatory skin reaction induced by injections of IL 23 
was dependent on IL 22 (Zheng et al., 2007). Consistent with this, human studies 
have revealed elevated levels of IL 22 mRNA and protein levels in psoriatic skin 
(Boniface et al., 2007). It is of note that IL 12, a Th1 cytokine and IL 23, both 
signal using IL 12p40 subunit and the studies by Chan et al., and Zheng et al., 
both illustrated that the injection of IL 12 is able to mediate skin inflammation 
although not to the same extent. Therefore, the studies to date suggest that the 
pathogenesis of psoriasis seems to involve interactions between keratinocytes 
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1.4.3.2   Psoriatic arthritis  
Psoriatic  arthritis  (PsA)  is  an  inflammatory  joint  disease  (arthritis)  that  is 
associated  with  psoriasis.  As  with  all  types  of  arthritis,  inflammation  of  the 
joints results in swelling, redness and pain. Psoriatic arthritis is recognised as 
being distinct from rheumatoid arthritis (see 1.4.3.3) by clinical features such as 
involvement  of  distal  interphalangeal  joints,  asymmetrical  joint  distribution, 
dactylitis (inflammation of the whole digit) and inflammation at the site where 
the  tendon  enters  the  bone,  known  as  enthesitis  (Gladman  et  al.,  2005). 
Diagnosis depends on the presentation pattern of joints affected along with a 
history of psoriasis in the patient, or the patient’s family and can also involve 
radiographic imaging in which erosion of the joint and bony proliferations are 
characteristic of PsA (Kleinert et al., 2007). 
1.4.3.3  Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily causes 
swelling and destruction of joints and their surrounding tissue. RA is a disease 
where  complications  occur  away  from  the  joint  and  it  is  associated  with 
increased  mortality  (Gabriel,  2008).  RA  affects  approximately  1%  of  the 
population  in  the  UK  and  affects  more  women  than  men  in  a  ratio  of  3:1 
(Symmons et al., 2002). RA is described as an autoimmune condition because the 
immune  system  begins  to  attack  host  molecules.  In  many  cases  of  RA,  the 
immune  system  may  produce  antibodies  that  are  specific  for  immunoglobulin 
class G (IgG) or citrullinated peptides (Schellekens et al., 1998). However, these 
can  be  present  before  the  onset  of  disease.  The  trigger  of  clinical  onset  of 
disease is not entirely known, although genetic predisposition and environmental 
components are high risk factors. For example, RA is associated with certain 
alleles of HLA DR4 and smoking is implicated as an environmental risk factor in 
these individuals in the development of the disease (Klareskog et al., 2006).  
The clinical features of rheumatoid arthritis are presentation with stiffness and 
inflammation  in  several  joints  in  a  symmetrical  pattern.  Pathologically,  the 
lining  of  the  synovium  becomes  inflamed  (synovitis)  and  synovial  hyperplasia 
occurs  due  to  increased  numbers  of  leukocytes,  including  T  and  B  cells 
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(Sweeney and Firestein, 2004). The synovium begins to invade the cartilage and 
forms  a  mass  of  tissue  called  the  pannus.  As  disease  progresses,  the  pannus 
begins to cause damage to the cartilage and erosion of the bone which can lead 
to  joint  destruction  and  severe  disability  (Sweeney  and  Firestein,  2004). 
Increased understanding of the mechanisms involved has allowed therapeutics to 
be  developed.  The  most  successful  of  these  so  far  is  anti TNF  therapy 
(Feldmann, 2002).   
1.4.4  Treatment of inflammatory diseases 
Patients with chronic inflammatory diseases suffer a severely reduced quality of 
life. Fortunately research into understanding the pathogenesis of the diseases, 
and  in  particular,  how  the  various  immune  mechanisms  involved  in  the 
inflammatory  response  can  cause  damage  has  revealed  several  therapeutic 
targets  for  treatment.  New  therapies  have  targeted  cytokines  as  these  are 
thought  to  be  the  principle  mediators  involved  in  inflammation  (see  1.4.1). 
Therapies that block TNF include Etanercept (a fusion protein), Infliximab (an 
anti TNFa  chimeric  monoclonal  antibody)  and  Adalimumab  (a  humanised 
monoclonal antibody against TNF). Targeting IL 1, Anakinra is an IL 1 receptor 
antagonist.  Etanercept, Infliximab and Adalimumab have all been approved for 
use in psoriasis (Tzu and Kerdel, 2008) and RA. Infliximab is also used to treat 
Crohns disease (Mouser and Hyams, 1999) whilst use of Anakinra is restricted to 
treating RA (Bresnihan et al., 1998). A new emerging therapy is Tocilizumab, an 
anti IL 6 receptor antibody which, in clinical trials has reduced disease activity 
in  rheumatoid  arthritis  patients  (Genovese  et  al.,  2008).  Although  these 
therapies do improve clinical symptoms, one problem is that some patients do 
not respond well to these treatments. However, increased understanding of how 
the  inflammatory  process  is  mediated  has  led  to  targeting  small  molecules 
known as chemokines for alternative treatments (Pease and Williams, 2006). 
1.5 Chemokines 
Chemokines  are  small  peptide  molecules  (8 12kDa)  that  belong  to  a  larger 
family, known as cytokines. This subset of cytokines have the ability to regulate 
cell  migration either  for  homeostasis  (see 1.5.3.2)  or  to  direct leukocytes  to 
sites  of  inflammation  or  infection  (see  1.5.3.1)  and  are  also  known  as Vicky King, 2010      Chapter 1, 53 
‘chemotactic cytokines’. Due to their ability to guide the directional movement 
of leukocytes, chemokines are involved in multiple biological processes including 
lymphoid  organ  development,  lymphocyte  trafficking,  angiogenesis  and 
inflammation (Rot and von Andrian, 2004). The functional role of chemokines is 
discussed in detail in 1.5.3.  
To  date,  approximately  50  chemokines  have  been  discovered  with  a  shared 
homology of between 20 and 80% in amino acid sequences (Borish and Steinke, 
2003). To be classified as a chemokine, the molecule must have a characteristic 
biochemical hallmark (see 1.5.1) as well as the ability to regulate chemotaxis. 
Chemokines  mediate  their  biological  effects  through  their  own  family  of 
chemokine receptors (see 1.5.2), which are part of a larger family of G Protein 
Coupled Receptors (Murphy et al., 2000). Chemokine ligands are often described 
as being ‘promiscous’ because many bind to multiple different receptors. Usually 
a  member  of  a  certain  chemokine  family  will  only  bind  to  members  of  the 
relevant chemokine receptor family (i.e., CCLs mostly bind CCRs).  
1.5.1  Nomenclature 
Originally,  upon  identification,  chemokines  were  given  names  reflecting  their 
assumed function. However, due to the large number of chemokines discovered, 
and  to  prevent  molecules  being  given  multiple  names,  a  systematic 
nomenclature system was established (Zlotnik and Yoshie, 2000).  
The  structural  motif  required  to  be  classified  as  a  chemokine,  is  a  series  of 
cysteine residues. Chemokines are named according to the precise nature of this 
cysteine sequence, followed by L (for ligand) and a number. The spacing and 
positioning  of  the  first  two  N terminal  cysteine  residues  determines  their 
chemokine classification. Following this classification, chemokines are divided 
into  four  subfamilies.  A  summary  of  the  systematic  classification  is  shown  in 
Table 1 2. 
CC chemokine family 
Chemokines assigned to the CC family have the first two N terminal cysteine 
residues adjacent to each other (CC). Twenty eight members, CCL1 to CCL28, 
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subgroups. The majority of the CC chemokines are regarded as being important 
in controlling the movement of cells to sites of inflammation. Examples of CC 
chemokines in this role include CCL3 and CCL5, which are involved in eosinophil, 
macrophage  and  mast  cell  recruitment  to  sites  of  inflammation  (Conti  and 
DiGioacchino, 2001) whereas CCL2, CCL7, CCL8 and CCL13 are all involved in 
controlling the migration of monocytes. Other CC chemokines, such as CCL19 
and  CCL21  function  under  homeostatic  conditions  and  are  important  in 
coordinating the innate and the adaptive immune responses (see 1.5.3.2). CC 
chemokines tend to bind a subgroup of chemokine receptors referred to as CC 
chemokine receptors (CCRs; see 1.5.2) 
CXC chemokine family 
The CXC subfamily, where any amino acid (X) separates the first two adjacent 
cysteine residues, is the second largest family with 16 members. CXCL8 (IL 8) is 
an important chemokine that recruits polymorphonuclear cells and is the most 
potent chemokine for neutrophils. Additionally, CXCL8 can trigger firm adhesion 
of  monocytes  to  vascular  endothelium  in  vitro  (Gerszten  et  al.,  1999).  Mice 
however do not express CXCL8 but MIP 2 and KC are homologues of human CXC 
chemokines  and  both  bind  murine  CXCR2  (Bozic  et  al.,  1994).  Another  CXC 
chemokine,  CXCL12,  was  discovered  to  have  an  important  role  in  embryonic 
development and haemopoiesis (see 1.5.3.3). 
Additionally,  CXC  chemokines  can  be  further  subdivided  by  the  presence  or 
absence of a specific motif, known as the ELR motif (see 1.5.3.4). The presence 
of  the  motif correlates  with  the ability  of  the chemokine  to  stimulate  blood 
vessel formation, a process known as angiogenesis (see 1.5.3.4).  
 
XC and CX3C chemokine family 
The XC subfamily contains the second and fourth conserved cysteine residues 
whilst in the CX3C subfamily, chemokines contain three amino acids between 
the first and second cysteine residue. Two members form the XC subfamily (XCL1 
and XCL2) whilst the CX3C chemokine family only has one member, CX3CL1, also 
known as fractalkine (Bazan et al., 1997, Ono et al., 2003). CX3CL1 is one of two Vicky King, 2010      Chapter 1, 55 
chemokines that is membrane bound, the other is CXCL16 (Matloubian et al., 
2000) whereas all the others are secreted.  
Constitutive versus inflammatory chemokines 
Additionally,  chemokines  and  their  receptors  can  be  broadly  divided  into 
constitutive or inflammatory subgroups. Homeostatic (constitutive) chemokines 
are  present  under  normal  conditions  and  have  a  role  in  basal  leukocyte 
trafficking  and  lymphoid  organ  structure.  CCL19,  CCL21  and  CCL25  are 
considered constitutive chemokines. Mice which are homozygous for the paucity 
of lymph node T cell (plt) mutation do not express CCL19 or CCL21 and this 
consequently results in T lymphocytes and dendritic cells being unable to home 
to the secondary lymphoid organs (Gunn et al., 1999). CXCR5 is a receptor which 
only binds one ligand, CXCL13 (Legler et al., 1998). CXCR5 deficient mice have 
defects in the development of B cell follicles within the spleen (Voigt et al., 
2000).  
In contrast, inflammatory (inducible) chemokines can be produced at very high 
levels  upon  stimulation  with  inflammatory  agents.  The  genes  for  human 
inflammatory  chemokines  are  mostly  found  on  chromosome  17  for  CC 
chemokines  and  inflammatory  CXC  chemokines  are  typically  found  on 
chromosome 4 (Murphy et al., 2000). Inflammatory chemokines, such as CCL2, 
CCL3  and  CCL5,  are  produced  by  many  different  cell  types  and  recruit 
leukocytes to sites of infection, inflammation or tissue injury. The chemokine 
receptor,  CCR2,  is  regarded  as  an  inflammatory  receptor,  which  binds  a 
subgroup  of  chemokines,  previously  named  monocyte  chemotactic  proteins 
(MCPs 1 4), now known as CCL2, CCL7, CCL8 and CCL13 (Murphy et al., 2000). 
Inflammatory chemokines and their receptors tend to be more promiscuous than 
chemokines involved in basal trafficking and homing. However, some chemokines 
cannot be strictly classified as inflammatory or constitutive as they have the 
ability to function as both (Moser et al., 2004). A summary of inflammatory and 
constitutive chemokines is shown in Table 1 2. 
1.5.2  Chemokine receptors 
Chemokine receptors are seven transmembrane spanning receptors, which are 
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varies between 340 and 370 amino acid and most contain a DRYLAIV motif in the 
second intracellular loop, which is highly conserved (Murphy et al., 2000). The 
three dimensional structure of chemokine receptors is not known and current 
models  are  based  on  the  three  dimensional  structure  of  another  G protein 
coupled receptor (GPCR) known as rhodopsin (Palczewski et al., 2000). 
The chemokine receptors have a systematic classification system (Murphy et al., 
2000), in which receptors are named according to the subfamily of chemokines 
they bind, followed by R (for receptor) and a number. This is summarised in 
Table 1 2. 
CC chemokine receptors 
Currently the CCR subfamily consists of 10 receptors and all bind chemokines 
within  the  CC  subfamily.  CCR1  was  the  first  CC  chemokine  receptor  to  be 
identified  and  is  the  receptor  for  multiple  chemokines,  which  include  CCL3, 
CCL5,  CCL7  and  CCL14  (Gao  et  al.,  1997).  CCR1  is  expressed  on  monocytes, 
basophils, eosinophils, T and B lymphocytes. In mice lacking CCR1, neutrophils 
failed to migrate in response to CCL3 (Gao et al., 1997). Additionally, using a 
model of granuloma formation induced with Schistosoma mansoni eggs, the size 
of lung granuloma formation was reduced in CCR1 deficient mice and was also 
associated  with  an  imbalance  in  Th1/Th2  cytokines  (Gao  et  al.,  1997).  CCR1 
knockout mice have also been shown to prolong allograft survival in corneal  and 
cardiac  transplants (Gao et al., 2000, Hamrah et al., 2007) as well as showing 
partial  resistance  to  development  of  experimental  autoimmune 
encephalomyelitis (Rottman et al., 2000). 
CCR2 is predominantly expressed on monocytes but is also expressed on T cells 
and dendritic cells. Based on chemokine receptor expression, monocytes can be 
subdivided  into  two  subsets,  CCR2
hi  CX3CR1
lo  which  migrate  to  sites  of 
inflammation  and  a  CCR2
lo  CX3CR1
hi  homeostatic  subset  (Geissmann  et  al., 
2003). In a model of experimental peritoneal inflammation, mice lacking CCR2 
were unable to recruit monocytes and macrophages to the peritoneum (Kurihara 
et al., 1997). It was also discovered, when mice deficient in CCR2 were crossed 
with apolipoprotein E (ApoE) null mice, that lack of CCR2 resulted in reduction 
of atherosclerotic lesions (Boring et al., 1998). In contrast, CCR2 is thought to be 
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accelerated disease progression and  reduced accumulation of microglia within 
the brain  (El Khoury et al., 2007). 
CCR3 is a chemokine receptor predominately expressed on eosinophils and its 
ligand CCL11 is a potent chemo attractant and activator of this cell type (Elsner 
et al., 1998). Basophils, mast cells and Th2 cell subsets express CCR3 to a lesser 
extent and other ligands of CCR3 are CCL5, CCL7, CCL13, and CCL26 (Murphy et 
al., 2000). Due to the expression profile of CCR3 and the association of these 
cells with allergic disease, in particular asthma, CCR3 was thought to play a key 
role in these diseases. A study by Humbles et al., showed that after allergen 
challenge, eosinophils were unable to migrate to the lungs in CCR3 deficient 
mice (Humbles et al., 2002). It was discovered that large numbers of eosinophils 
had accumulated beneath the blood vessels in the subendothelial space in  CCR3 
deficient mice (Humbles et al., 2002). Additionally, in a model of allergic skin 
inflammation, eosinophils failed to migrate to the skin in CCR3 knockout mice 
(Ma et al., 2002). Together these data suggest that CCR3 plays a key role in 
mediating eosinophil migration and subsequently allergic disease. 
CCR4 is expressed on distinct subsets of T cells, such as Th2 and skin homing T 
cells (Bonecchi et al., 1998, Campbell et al., 1999). CCL17 and CCL22 are ligands 
which bind with high affinity to CCR4 (Imai et al., 1997, Imai et al., 1998). The 
contribution  that  CCR4  makes  towards  Th2  responses  in  the  lung  requires 
clarification since in a model of airway inflammation, which was Th2 dependent, 
no disrupted effects were seen in mice lacking CCR4 (Chvatchko et al., 2000). 
CCR4 is required in the homing of T cells to the skin (see 1.5.3.2). 
CCL3,  CCL4,  CCL5  and  CCL8  are  all  ligands  for  CCR5,  which  is  a  major  co 
receptor for HIV (see 1.5.4.1). Expression of CCR5 can be found on macrophages, 
dendritic cells  and  certain  T  cell  subsets.  CCR5  knockout  mice  infected  with 
Listeria monocytogenes had reduced efficiency in clearing the infection and had 
impaired macrophage function (Zhou et al., 1998). CCR5 is also involved in T cell 
stimulation  within  the  immunological  synapse  (Contento  et  al.,  2008)  and  is 
thought to be protective against West Nile virus (see 1.5.4.1). 
To date, only one ligand, CCL20, has been identified, which is able to bind CCR6 
(Baba  et  al.,  1997).  Various  subsets  of  T  cells,  in  particular  Th17  cells  and 
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discovered to be involved in the localisation of DCs, homeostasis of lymphocytes 
and the immune response within the gut (Cook et al., 2000). CCR6 is involved in 
controlling the migration of Th17 cells to the intestine and the regulation of 
effector  T  cell  subsets  (Wang  et  al.,  2009).  CCR6  has  a  pathological  role  in 
experimental  autoimmune  encephalomyelitis  (EAE)  in  which  CCR6  has  been 
shown to be involved in the initiation of EAE by regulating the entry of Th17 
cells into the central nervous system (Reboldi et al., 2009) and by controlling 
regulatory CD4
+ T cells (Villares et al., 2009).  
Studies  using  CCR7  knockout  mice  confirmed  the  importance  of  CCR7  in 
lymphoid organ development as well as involvement in co ordinating the innate 
and the adaptive immune response (see 1.5.3.2). CCR7 is a receptor for CCL19 
and  CCL21  and  is  constitutively  expressed  on  T  cells  and  mature  DCs  in  the 
lymphoid organs (Forster et al., 1999). CCR7 plays a key role in mediating the 
trafficking of mature dendritic cells from peripheral tissues to the lymph node 
and the role of CCR7 is discussed in more detail in 1.5.3.2.  
The  role  of  CCR8  is  not  well defined  as  studies  involving  this  receptor  are 
conflicting. CCR8 is the receptor for CCL1 and CCL16 and expression of CCR8 is 
predominantly on Th2 cells (Roos et al., 1997). A role for CCR8 in the functional 
Th2 response was implicated in the first study on CCR8 knockout mice. In the 
study, CCR8 knockout mice displayed a dysfunctional Th2 immune response, in 
which  there  was  defective  Th2  cytokine  production  and  reduced  eosinophil 
recruitment in an ovalbumin induced model of airway inflammation (Chensue et 
al., 2001). However, other studies have shown that absence of CCR8 did not 
affect Th2 cytokine response or eosinophilia in a murine model of allergic airway 
inflammation  (Chung  et  al.,  2003).  In  a  model  of  ovalbumin  induced  allergic 
airway disease, CCR8 knockout mice developed pathological disease similar to 
wild type mice and the absence of CCR8 did not affect the Th2 response in this 
model  (Goya  et  al.,  2003).  Other  studies  have  shown  that  CCR8  may  have  a 
negative impact on the immune response. In septic peritonitis, CCR8 knockout 
mice  displayed  an  enhanced  innate  immune  response  to  clear  bacteria 
(Matsukawa et al., 2006). Additionally, in a model of asthma induced by fungal 
allergens, CCR8 knockout mice were able to clear the fungal material from the 
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may reflect the complexity of utilising distinct in vivo models to define the role 
of individual receptors. 
CCR9  binds  CCL25  which  is  expressed  in  the  small  intestine  (Zaballos  et  al., 
1999). Studies utilizing CCR9 deficient mice have demonstrated a role for CCR9 
in regulating T cell development within the thymus and migration of gd T cells to 
the small intestine (Uehara et al., 2002). As a homing receptor for the gut, CCR9 
has been implicated in crohns disease (Papadakis et al., 2001) and also cancer 
(see 1.5.4.2). 
Another CC chemokine receptor to which CCL27 and CCL28, have been shown to 
bind is CCR10 (Homey et al., 2000b, Wang et al., 2000). CCR10 is expressed on a 
subset of T cells, which home in a CCL27 dependent manner to the skin (see 
1.5.3.2) and has been implicated in cutaneous diseases such as psoriasis (see 
1.5.4.3) and cancer (see 1.5.4.2). Additionally, CCR10 is involved in directing 
the migration of IgA producing plasma cells towards CCL28 expressed in mucosal 
tissue (Kunkel et al., 2003). 
CXC chemokine receptors 
To date, there are six chemokine receptors which belong to the CXC subfamily 
and  are  accordingly  named  CXCR1  through  to  CXCR6  (although  see  1.6.3  for 
CXCR7). CXCR1 and CXCR2 are two closely related receptors with 77% homology 
and  bind  to  CXCL8  in  humans  with  high  affinity.  Both  receptors  are 
predominately expressed on human neutrophils (Doroshenko et al., 2002). CXCR1 
can  also  bind  CXCL6  whereas  CXCL1  to  CXCL7  can  all  bind  to  CXCR2.  CXCR1 
expression on human neutrophils is thought to be important for the clearance of 
urinary tract infection. Indeed, disease associated polymorphisms in CXCR1 have 
been  identified  in  children  prone  to  the  most  severe  form  of  urinary  tract 
infection known as acute pyelonephritis (Lundstedt et al., 2007). In the same 
study, reduced expression of CXCR1 was found in the children prone to acute 
pyelonephritis (Lundstedt et al., 2007). Murine CXCR1 has been identified and 
shown  to  be  a  functional  receptor  but  the  exact  role  of  murine  CXCR1  is 
unknown (Fan et al., 2007). CXCR2 deficient mice displayed impaired neutrophil 
migration and CXCR2 is protective against Toxoplasma gondii infection (Del Rio 
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of  CXCR2  slowed  the  progression  of  atherosclerosis  in  mice  (Boisvert  et  al., 
2000). 
CXCR3  is  highly  expressed  on  activated  lymphocytes,  predominantly  Th1 
lymphocytes and CXCL9, CXCL10 and CXCL11 are ligands for CXCR3. In a model 
of acute cardiac allograft rejection, CXCR3 deficient mice were resistant to the 
development  of  rejection  (Hancock  et  al.,  2000)  and  CXCR3  has  also  been 
implicated in atherosclerosis, glomerulonephritis and multiple sclerosis (Lazzeri 
and Romagnani, 2005).  
CXCR4 binds one ligand, CXCL12 (Nagasawa et al., 1999) and in mice, targeted 
deletion of CXCR4 is perinatally lethal showing an important role for CXCR4 in 
embryonic development and haemopoiesis (see 1.5.3.3). CXCR4, expressed on T 
lymphocytes,  plays  a  role  in  the  immunological  synapse  and  is  a  major  co 
receptor for human immunodeficiency virus (see 1.5.4.1).  
CXCR5, to date, only has one ligand which is CXCL13 (Legler et al., 1998). CXCR5 
is  expressed  on  B  lymphocytes  and  plays  a  role  in  B  cell  migration  and 
organisation of secondary lymphoid organs (see 1.5.3.2). The last of the CXC 
chemokine receptors discovered to date is CXCR6. One ligand, CXCL16, is known 
to bind CXCR6 which is expressed on T lymphocytes and has been shown to have 
a  minor  role  in  the  entry  of  human  immunodeficiency  virus  (HIV)  to  T 
lymphocytes (Matloubian et al., 2000). 
CX3CR1 and XCR1 
CX3CR1  facilitates  peripheral  blood  leukocyte  migration  and  adhesion.  In  a 
model  of  atherosclerosis,  reduced  lesion  size  in  ApoE  and  CX3CR1  double 
deficient mice was reported and thought to be mediated by CX3CR1 expression 
on  macrophages  (Combadiere  et  al.,  2003)  however  impaired  dendritic  cell 
migration has also been reported (Liu et al., 2008). 
Neutrophils and B cells express XCR1 which supports chemotaxis towards XCL1 
(Huang et al., 2001). XCR1 has been implicated in rheumatoid arthritis as the 
receptor  was  found  to  be  upregulated  on  mononuclear  cells  infiltrating  the 
synovial tissue from joints of RA patients (Wang et al., 2004a). Within the RA 
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Cell specific chemokine receptors 
Each  cell  type  expresses  a  certain  ‘set’  of  chemokine  receptors,  whose 
expression can be modulated over time by environmental stimuli. Additionally, 
chemokine receptors can distinguish between cell subsets, such as T cells. Naive 
T cells express CCR7 and, depending on the conditions during activation, CD4
+ 
naive T cells can differentiate into various effector subsets each with their own 
pattern of receptors. Th1 cells tend to express CXCR3, CXCR6 and CCR5 whilst 
CCR4 and CCR8 are typically expressed on Th2 cells (Syrbe et al., 1999). Th17 
cells  express  CCR6  (Hirota  et  al.,  2007b).  Expression  of  CCR7  can  also 
differentiate  the  subsets  of  memory  T  cells  (Sallusto  et  al.,  1999).  Receptor 
expression can also change on cells under inflammatory conditions, for example 
on  antigen  presenting  cells.    This  allows  the  cells  to  move  from  the  site  of 
inflammation  to  the  lymph  nodes  (see  1.5.3.2).  In  addition,  patterns  of 
chemokine receptors also allow cells to home to certain tissues (see 1.5.3.2).   
Cells  can  express  various  chemokine  receptors  and  chemokines  may  have 
multiple  target  receptors  (Mantovani,  1999).  This  means  a  single  chemokine 
could enhance the infiltration of multiple cell types whilst other chemokines in 
the local environment affect different subsets of cells. Additionally, cells may be 
‘pulled’ in opposing directions when surrounded by multiple chemokines. Also by 
having  multiple  receptors  on  cells,  if  one  chemokine  receptor  or  ligand  is 
defective  then  the  biological  function  can  be  achieved  by  other  chemokine 
receptors, therefore creating redundancy within the system. 
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  Systematic name  Chemokine receptor 
CCL1  CCR8 
CCL2  CCR2 
CCL3  CCR1, CCR5 
CCL3L1  CCR5 
CCL4  CCR5 
CCL5  CCR1, CCR3, CCR5 
CCL6   
CCL7    CCR1, CCR2, CCR3 
CCL8  CCR2, CCR3, CCR5 
CCL9   
CCL10   
CCL11  CCR3 
CCL12  CCR2 
CCL13  CCR2, CCR3 
CCL14  CCR1 
CCL15  CCR1, CCR3 
CCL16  CCR1 
CCL17  CCR4 
CCL18   
CCL19  CCR7 
CCL20  CCR6 
CCL21  CCR7 
CCL22  CCR4 
CCL23  CCR1 
CCL24  CCR3 
CCL25  CCR9 
CCL26  CCR3 
CCL27  CCR10 
CCL28  CCR3, CCR10 
CXCL1  CXCR1, CXCR2 
CXCL2  CXCR2 
CXCL3  CXCR2 
CXCL4  CXCR3 
CXCL5  CXCR2 
CXCL6  CXCR1, CXCR2 
CXCL7  CXCR2 
CXCL8  CXCR1, CXCR2 
CXCL9  CXCR3 
CXCL10  CXCR3 
CXCL11  CXCR3 
CXCL12  CXCR4 
CXCL13  CXCR5 
CXCL14   
CXCL15   
CXCL16  CXCR6 
CX3CL1  CX3CR1 
XCL1  XCR1 
XCL2  XCR1   
Table 1-2. Classification of chemokines and their receptors 
Chemokines  are  classified  according  to  their  subfamily,  CC,  CXC,  CX3C  or  C  and  the 
receptors  are  classified  according  to  the  subfamily  of  chemokines  that  they  bind. 
Chemokines can also be classified as inflammatory (red), constitutive (blue) or function as 
both  (yellow).  The  receptors  for  some  chemokines  are  not  known  (left  blank)  or  the 
functions for chemokines are not known (white). Table is adapted from (Moser et al., 2004, 
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1.5.2.1  Chemokine receptor signalling 
Ligand binding to GPCRs catalyses the exchange of bound guanosine diphosphate 
(GDP)  for  guanosine  triphosphate  (GTP)  in  the  a subunit  of  the  G protein.  
Consequently, the G protein dissociates into active  a and bg subunits. The  a 
and bg  subunits  can  subsequently  activate  downstream  intracellular  signalling 
pathways or directly affect functional proteins depending on the Ga subtype, 
which has four main classes Gs, Gi, Gq/11, Ga12/13 and a recently discovered 
fifth  class,  known  as  Gv  (Oka  et  al.,  2009).  Chemokine  receptors  are 
predominantly thought to couple to Gi proteins for chemotaxis as ligand induced 
signalling  was  suppressed  with  pertussis  toxin,  an  inhibitor  of  Gi  proteins 
(Thelen, 2001). However, an alternative signalling pathway which is dependent 
on Gi proteins and also Gq proteins is required for dendritic cell migration in 
response  to  inflammatory  agents  (Shi  et  al.,  2007).  Additionally,  CXCR4  and 
CCR5  recruited  to  the  immunological  synapse  of  T  cells  were  coupled  to  Gq 
and/or G11 protein and lost their ability to initiate chemotaxis (Molon et al., 
2005).  An essential step for cell migration is the release of the subunits and the 
regulation of cell migration is mediated by the bg subunit (Neptune et al., 1999). 
The bg subunits activate the membrane associated enzymes phospholipase Cb2 
and phospholipase Cb3 (Barr et al., 2000, Sankaran et al., 1998), which catalyse 
the cleavage of phosphatidylinositol 4, 5 bisphosphate leading to the formation 
of inositol 1, 4, 5 trisphosphate (IP3) and diacylglycerol (DAG). Increased levels 
of IP3 induce the release of calcium from intracellular vesicles resulting in a 
transient rise in the levels of free calcium within the cell. DAG activates protein 
kinase C. The bg subunit also activates phosphatidylinositol 3 kinase g (Stephens 
et al., 1994) leading to the activation of protein kinase B (Didichenko et al., 
1996),  which  is  important  in  inducing  changes  within  the  cell  required  for 
chemotaxis (Li et al., 2000). Signalling is terminated by GTP hydrolysis, allowing 
re association of a  with the bg subunit. Signalling results in a variety of cellular 
responses  such  as  chemotaxis,  adhesion,  respiratory  burst  and  degranulation 
depending on the cell type, ligand and the receptor present. 
1.5.2.2  Chemokine receptor internalisation 
Upon ligand binding, chemokine receptors may internalise into the cell in two 
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dependent  internalisation  (Venkatesan  et  al.,  2003).  Internalisation  of  a 
chemokine receptor can affect the response by the cell to chemokines. 
In  clathrin mediated  endocytosis,  ligand  binding  results  in  G protein  coupled 
receptor  kinases  phosphorylating  residues  of  the  carboxy  terminus  and 
intracellular loops on chemokine receptors, resulting in the G protein becoming 
uncoupled  from  the  receptor  (Ferguson,  2001).  Phosphorylation  allows  two 
adapter  molecules,  adaptin 2  and  b arrestin  to  associate  with  the  receptor, 
recruit clathrin, and form clathrin coated pits (Laporte et al., 1999). These pits 
form from the cell membrane wrapping round the receptor and pinch off from 
the membrane. The chemokine receptor is targeted for recycling back to the 
cell surface (to be exposed to ligand) or for degradation in the late endosomal 
compartment.  Studies  have  shown  that  CXCR1  requires  both  b arrestins  and 
dynamin for endocytosis (Barlic et al., 1999) while CXCR4 also requires b arrestin 
but not dynamin (Cheng et al., 2000). 
There are reports that chemokine receptors can mediate receptor internalisation 
in a mechanism that does not involve clathrin; instead, they use lipid rafts or 
caveolae, which are cholesterol rich structures. Receptors enter a compartment 
known  as  a  caveosome  upon  internalisation  and  fuse  with  endosomes  which 
merge  with  the  clathrin  coated  pathway  (Sharma  et  al.,  2003).  Studies  have 
shown that CCR5 uses the caveolae pathway by showing its colocalisation with a 
protein, known as caveolin 1, which is thought to be involved in stabilising the 
caveolae  structure  (Nguyen  and  Taub,  2002).  However,  CCR5  has  also  been 
shown to be dependent on clathrin mediated endocytosis (Signoret et al., 2005). 
Regulation of receptor internalisation is controlled by a family of small GTPases, 
known as Rabs, which cycle between the inactive GDP bound and active GTP 
bound states. Rab GTPases localise to specific compartments within the cell. 
Rab4,  Rab5  and  Rab11  are  known  to  associate  with  the  early  endosomal 
compartment (van der Sluijs et al., 1992, Sonnichsen et al., 2000). Rab11 also 
associates with the recycling compartment (Ullrich et al., 1996). In vitro studies 
examining  internalisation  of  CXCR2  after  stimulation  using  overexpression  of 
dominant  negative  mutants  of  Rab5  and  Rab11  prevented  receptor 
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type  and  the  regulation  process  may  determine  how  a  cell  can  respond  to 
subsequent ligand. 
1.5.3  Functions of chemokines and their receptors 
Chemokines  are  described  as  chemotactic  because  they  are  able  to  elicit 
directional  cell  movement,  known  as  chemotaxis.  Due  to  the  ability  of 
chemokines to influence cell migration, chemokines are involved in many roles 
within the immune system. 
1.5.3.1  Leukocyte migration 
Leukocyte  extravasation  is  the  movement  of  leukocytes  from  the  circulation 
through  the  blood  vessel  walls  into  the  tissues,  which  is  regulated  by  the 
endothelium. In particular, chemokines trigger the arrest of leukocytes whilst 
rolling along the endothelium (Campbell et al., 1998).  Leukocyte extravasation 
was initially characterised as a three step cascade, involving leukocyte rolling, 
activation and arrest (Butcher, 1991) but is now viewed to have the additional 
steps of adhesion strengthening, intravascular crawling and transmigration (Ley 
et al., 2007).  
The  expression  of  adhesion  molecules  on  endothelial  cells,  which  play  an 
important  role  in  the  rolling  and  arrest  of  leukocytes,  are  upregulated  by 
inflammatory  stimuli.  A  family  of  adhesion  molecules  known  as  selectins  are 
involved  in  the  process  of  leukocyte  rolling  along  the  endothelium.  Resting 
endothelial  cells  store  P selectin  within  specialised  secretory  vesicles  and 
activation of endothelial cells by histamine or cytokines results in the expression 
of P selectin on the cell surface (Jones et al., 1993, Ley and Reutershan, 2006). 
In response to inflammatory cytokine binding, such as TNFa or IL 1, transcription 
occurs within the endothelial cell resulting in the expression of E selectin (Ley 
and Reutershan, 2006, Gotsch et al., 1994). The interaction of selectins with 
their  ligands  present  on  leukocytes  allows  leukocytes  to  adhere  to  the 
endothelium. The speed of leukocyte rolling along the endothelium was found to 
be faster in mice deficient in E selectin compared to the speed of leukocytes 
rolling in wild type mice and demonstrated that E selectin was required for slow 
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and L selectin require shear stress and ‘catch’ bonds to make the interactions 
stronger (Lawrence et al., 1997, Yago et al., 2004). A second class of molecules, 
known as integrins, present on leukocytes also participate in rolling and firm 
adhesion of leukocytes to the endothelium. Slow rolling in vivo was shown to 
require b2 integrins as well as E selectin. A study by Dunne et al., revealed that 
slow  rolling  of  leukocytes  required  lymphocyte  function  associated  antigen 1 
(LFA 1) and macrophage antigen 1 (Dunne et al., 2002). Slow leukocyte rolling 
mediated  by  macrophage  antigen 1  (MAC 1)  was  shown  to  bind  intracellular 
adhesion  molecule 1  (ICAM 1)  present  on  the  endothelium  in  order  to  do  so 
(Dunne et al., 2003). Additionally recent evidence suggests E selectin can induce 
LFA 1 on neutrophils into a structural conformation which has an intermediate 
affinity (Salas et al., 2004) for its ligand ICAM 1 on endothelial cells and allows 
for  transient  binding  (Chesnutt  et  al.,  2006).  However,  chemokines  are  the 
dominant activators of integrin mediated adhesion between leukocytes and the 
endothelium.  
Inflammatory  cytokines  stimulate  endothelial  cells  to  express  chemokines  on 
their surface.  Additionally, platelets can also deposit CCL5 on the endothelium 
which then triggers the arrest of monocytes (von Hundelshausen et al., 2001). 
Most circulating leukocytes express their integrins in a low affinity state (Carman 
and Springer, 2003) and chemokines are capable of activating integrins into a 
high affinity state (Laudanna et al., 2002). Evidence from T cells suggest that 
chemokines, such as CXCL12 and CCL21, can increase the affinity of the LFA 1 
integrin (Constantin et al., 2000) by inducing ‘inside out’ signalling  resulting in 
conformational changes  (Shamri et al., 2005). In human monocytes, increased 
affinity in very late antigen 4 (VLA 4) binding of vascular cell adhesion molecule 
1  involves  conformational  changes  (Chan  et  al.,  2001)  and  requires 
phospholipase  C  mediated  calcium  signalling  to  facilitate  monocyte  arrest 
(Hyduk et al., 2007).  Once firm adhesion of these cells occurs, transmigration 
can then take place. 
Transmigration  (diapedesis)  is  a  process  where  leukocytes  cross  the  vascular 
wall, which is composed of endothelial cells connected by adhesive junctions, 
and the endothelial cell basement membrane. Transmigration can be initiated 
by chemoattractants and shear stress signals (Cinamon et al., 2004). There is 
evidence  that  crawling  along  the  endothelium  is  required  for  transmigration. Vicky King, 2010      Chapter 1, 67 
This  has  been  shown  for  monocytes  and  neutrophils  which  are  dependent  on 
ICAM1 and MAC 1 present on the leukocyte (Schenkel et al., 2004, Phillipson et 
al., 2006). Diapedesis can occur in two ways, the paracellular route, which is the 
route most commonly used where the cells migrate between endothelial cells at 
their  junctions,  or  transcellular  where  leukocytes  go  directly  through  a  cell 
(Engelhardt and Wolburg, 2004).  
Leukocytes  transmigrating  by  the  paracellular  route  require  an  increase  in 
intracellular calcium levels within endothelial cells which has been proposed to 
be  activated  by  crosslinking  signals,  such  as  ICAM 1  or  soluble  proteins  from 
activated leukocytes (Etienne Manneville et al., 2000, Muller, 2003). Increased 
intracellular  levels  of  calcium  results  in  the  activation  of  myosin  light  chain 
kinase resulting in a conformational change in myosin II regulatory light chain 
and  subsequently  leading  to  the  retraction  of  endothelial  cells  that  might 
facilitate leukocyte passage (Hixenbaugh et al., 1997). Myosin light chain kinase 
mediates vascular permeability and was required for neutrophil transmigration 
in  the  lung  (Xu  et  al.,  2008).  Proteins  involved  in  the  transmigration  of 
leukocytes  are  platelet  endothelial  cell  adhesion  molecule  1  (Muller  et  al., 
1993), CD99 (Schenkel et al., 2002), and a family of proteins known as junction 
adhesion  molecules  (JAMs),  which  are  also  members  of  the  immunoglobulin 
superfamily  (Bazzoni,  2003).  Platelet  endothelial  cell  adhesion  molecule  1 
(PECAM 1), CD99 and JAMs have homophilic interactions but additionally JAMs 
can  also  interact  with  integrins  to  facilitate  leukocyte  transmigration 
(Ostermann et al., 2002). PECAM 1 can translocate from intracellular vesicles 
within  endothelial  cells  to  endothelial  junctions  (Mamdouh  et  al.,  2003). 
Blocking PECAM 1 with a soluble form of PECAM 1, which acts as a competitive 
inhibitor, has been shown to reduce transmigration by 90%, in vivo (Liao et al., 
1997). To add to this, PECAM 1 deficient mice are still able to recruit leukocytes 
to  sites  of  inflammation  and  additionally  demonstrate  there  are  PECAM 1 
independent  mechanisms  for  leukocyte  transmigration  (Duncan  et  al.,  1999). 
Blocking CD99 reduced diapedesis of monocytes and neutrophils whilst blocking 
both  CD99  and  PECAM 1  resulted  in  an  additive  effect  on  monocytes  and 
leukocyte migration (Lou et al., 2007, Schenkel et al., 2002). Junction adhesion 
molecules are present on epithelial cells and endothelial cells localised in the 
tight junction of cells and are present on various leukocytes. The first evidence 
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inflammation (Martin Padura et al., 1998). By blocking JAM A with a monoclonal 
antibody, monocytes and neutrophil transmigration was reduced (Martin Padura 
et al., 1998). Subsequent studies have found that JAM A can bind in a homophilic 
manner  between  JAM A  on  leukocytes  and  endothelial  cells  (Bazzoni  et  al., 
2000). Additionally, JAM A  is also able to bind leukocyte integrin LFA 1 and this 
interaction was required for diapedesis of T cells and neutrophils (Ostermann et 
al.,  2002).  In  vitro  studies  have  revealed  JAM A  is  able  to  relocate  from 
intracellular  junctions  to  the  surface  of  endothelial  cells  in  response  to 
stimulation with TNFa and IFNg (Ozaki et al., 1999). In addition to this, it has 
been  shown  at  endothelial  junctions  that  JAM A  co localises  with  LFA 1  on 
projections  of  the  neutrophil  membrane,  known  as  pseuopods  (Shaw  et  al., 
2004). JAM B is able to bind VLA 4 but in order to do so, JAM B has to bind to 
JAM C present on the leukocyte first (Cunningham et al., 2002). JAM B has been 
implicated in lymphocyte transmigration across high endothelial venules (HEV) 
where it is highly expressed (Johnson Leger et al., 2002). As well as binding to 
JAM B,  JAM C  can  bind  leukocyte  integrin  MAC1  (Santoso  et  al.,  2002). 
Overexpression  of  JAM C  in  endothelial  cells  in  vivo  resulted  in  an  influx  of 
monocytes and granulocytes in a lung inflammation model and a specific JAM C 
antibody blocked the increase in recruitment of cells (Aurrand Lions et al., 2005) 
illustrating a role for JAM C in the transmigration process. 
The ability of leukocytes to penetrate endothelial cells by the transcellular route 
was first shown by neutrophils (Feng et al., 1998). Leukocytes travelling by the 
transcellular  route  also  extend  protrusive  structures,  termed  podosomes,  to 
break  and  invade  the  endothelial  surface  (Carman  et  al.,  2007).  The 
transcellular pathway is mediated by caveolin, a protein involved in endocytosis, 
and F actin, a structural filament protein. It has been proposed that ligation of 
ICAM 1 leads to the translocation of ICAM 1 to caveolin and F actin rich areas 
(Millan et al., 2006). Other endothelial membrane structures such as vesiculo 
vacuolar organelles (Dvorak and Feng, 2001) may also be involved in forming a 
transmembrane pore and allowing leukocytes to migrate through the cell. 
Upon  migration  into  the  surrounding  tissues,  leukocytes  are  guided  by  local 
sources of chemokines to move towards the area of infection or inflammation. 
Leukocytes  are  then  activated  either  by  cytokines  released  by  resident  cells 
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1.5.3.2  Cell trafficking and surveillance 
During homeostasis, naive T lymphocytes (see 1.2.1.4) search for antigens by 
recirculating between the blood and the secondary lymphoid organs. In doing so, 
naive  T  cells  exit  the  blood  and  enter  the  lymph  nodes  via  high  endothelial 
venules (von Andrian and Mempel, 2003). Two homeostatic chemokines, CCL19 
and CCL21 and the shared receptor for these chemokines, CCR7, are required for 
the migration of lymphocytes across the high endothelial venules (HEVs) into the 
lymph nodes. Naive lymphocytes, Tregs and a subpopulation of memory T cells, 
known as central memory T cells (TCM cells), all express CCR7 (Reif et al., 2002, 
Sallusto et al., 1999, Szanya et al., 2002). CCR7 expressing cells home towards 
the  ligands,  CCL19  and  CCL21,  which  are  displayed  on  HEVs.  CCL21  is 
constitutively  expressed  by  HEVs  (Gunn  et  al.,  1998)  whereas  CCL19  is 
transcytosed across the endothelial barrier and displayed on the lumen of HEV 
(Baekkevold et al., 2001). The importance of CCR7 and its ligands in mediating T 
cell entry into the lymph nodes was demonstrated in mice deficient in CCR7 
(Forster et al., 1999) and in mice unable to produce CCL19 and CCL21 due to a 
spontaneous plt mutation (Gunn et al., 1999). In both strains of mice, there are 
reduced numbers of naive T cells present in the lymph nodes. Once in the lymph 
node,  and  in  the  absence  of  antigen  stimulation,  T  cells  resensitise  to 
sphingosine 1 phosphate (S1P), which binds the S1P receptor 1 expressed on T 
cells  and  mediates  lymph  node  egress  to  the  bloodstream  via  the  efferent 
lymphatics (Schwab and Cyster, 2007). 
Antigen  presenting  cells  (see  1.2.1.3),  such  as  monocytes  and  dendritic  cells 
patrol the blood and migrate to the tissues to scavenge for pathogens. During 
this  process,  monocytes  and  immature  DCs  express  inflammatory  chemokine 
receptors such as CCR1, CCR2 and CCR5 (MartIn Fontecha et al., 2003). After 
antigen capture and maturation, macrophages and dendritic cells downregulate 
the inflammatory receptors and upregulate the expression of CCR7 (Yanagihara 
et al., 1998). CCR7 on ‘mature’ DCs mediates their exit from the tissues, such as 
the  skin  and  intestine,  into  the  draining  and  mesenteric  lymph  nodes 
respectively (Jang et al., 2006, MartIn Fontecha et al., 2003).  
Once in the lymph nodes, DCs can activate naive lymphocytes to form effector T 
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area  (the  paracortex)  which  expresses  CCL19  (Gunn  et  al.,  1998)  whereas 
CXCL13 is produced in the follicular compartment enriched with B cells (Schaerli 
et  al.,  2000).  Indeed,  (as  mentioned  above  in  1.5.1)  the  structure  of  the 
follicular  compartments  within  the  spleen  and  lymph  nodes  are  disrupted  in 
CXCR5  deficient  mice  (Gunn  et  al.,  1999).  CXCR5  deficient  mice  displayed 
disorganisation of B cell follicles, and lymphocytes lacking CXCR5 were unable to 
migrate  to  B  cell  follicles  (Forster  et  al.,  1996).  Additionally,  CCR7  is  also 
involved in secondary lymphoid organ development in coordination with CXCR5, 
as  shown  using  mice  double  deficient  in  CXCR5  and  CCR7  which  lacked 
peripheral  lymph  nodes  (Ohl  et  al.,  2003).  Following  activation  in  the  lymph 
node, follicular B cells upregulate CCR7 and downregulate CXCR5 which directs 
them to the T cell zone to receive help from CD4
+ T helper cells (Reif et al., 
2002).  Additionally,  activated  CD4
+  T  cells  transiently  express  CXCR5  upon 
stimulation (Schaerli et al., 2000). During this process, a subset of T helper cells 
are  generated,  known  as  follicular  Th  cells,  which  express  CD4  and  stable 
expression of CXCR5 along with low levels of CCR7. These cells migrate towards 
the  B  cell  area  and  co localise  with  B  cells  providing  help  for  antibody 
production (Hardtke et al., 2005). 
Upon  encounter  with  antigen,  lymphocytes  upregulate  their  expression  of 
adhesion  molecules  and  chemokine  receptors  during  differentiation,  which 
allows them to migrate into distinct peripheral tissues, such as the skin or the 
intestine.  The  mechanism  that  drives  the  pattern  of  molecule  expression  is 
known  as  ‘imprinting’,  which  is  mediated  by  DCs  and  the  lymph  node 
environment (Sigmundsdottir and Butcher, 2008). There is evidence that naive T 
lymphocytes  are  ‘reprogrammed’  during  activation  and  the  lymph  node 
environment can influence this process. This was demonstrated in mice using 
naive  transgenic  T  cells.  Molecules  important  in  intestinal  homing  were 
upregulated on the T cells when activated in the mesenteric lymph nodes yet 
when  the  cells  were  activated  in  the  skin  draining  lymph  nodes,  molecules 
associated with trafficking to the peripheral tissues were upregulated (Campbell 
and Butcher, 2002). 
Indeed, environmental stimuli have been implicated in influencing the homing 
properties  of  antigen  experienced  memory  or  effector  T  cells,  in  which  DCs 
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present them to T cells in the lymph node. For example, vitamin D3 which can 
be generated in the skin after exposure to sunlight, can increase the expression 
of CCR10 on proliferating T cells (Sigmundsdottir et al., 2007). Keratinocytes and 
DCs  also  express  enzymes  which  are  involved  in  vitamin  D3  metabolism 
(Sigmundsdottir et al., 2007). Another example is retinoic acid, which is derived 
from the diet in the form of vitamin A. Retinoic acid has been shown in vitro to 
upregulate a4b7 integrin and  CCR9 on T cells, which are both homing receptors 
for the gut and bind mucosal vascular addressin cell adhesion molecule 1 and 
CCL25 respectively (Iwata et al., 2004). 
A  subset  of  T  lymphocytes  express  cutaneous  lymphocyte associated  antigen 
(CLA) and are capable of homing to the skin (Sigmundsdottir and Butcher, 2008). 
CLA
+ T lymphocytes are able to transmigrate through the blood vessel into the 
skin  by  binding  E  selectin  (Fuhlbrigge  et  al.,  1997).  Chemokine  receptors 
implicated in T cell homing to the skin are CCR4 and CCR10. Circulating CLA
+ 
CD4
+ T cells express CCR4 (Campbell et al., 1999) and a subset of these cells also 
express CCR10 (Hudak et al., 2002). Both have been shown to be important in 
recruiting T cells to inflamed skin (Reiss et al.,  2001). Cells expressing CCR4 
migrate  towards  its  ligand,  CCL17,  which  is  produced  by  keratinocytes  and 
dendritic cells within the skin (Campbell et al., 1999). Epidermal keratinocytes 
constitutively and inducibly express CCL27, a ligand for CCR10 (Morales et al., 
1999).  
1.5.3.3  Haemopoiesis 
Chemokines not only play a role within the immune system but also play a role in 
development and migration of stem cells and haemopoiesis (see 1.1). CXCL12, 
also known as stromal derived factor 1, is a constitutive chemokine, which binds 
CXCR4 (Nagasawa et al., 1999). Mice deficient in either CXCR4 or CXCL12 show 
problems  with  heart,  brain  and  blood  cell  development  and  ultimately  the 
deletions are perinatally lethal (Nagasawa et al., 1996, Zou et al., 1998). The 
phenotype of the CXCR4 and CXCL12 deficient mice are very similar and this was 
thought to be due to the monogamous relationship between the ligand and its 
receptor. However, it is of note that another chemokine receptor, CXCR7 (see 
1.6.3) was recently shown to bind CXCL12 (Balabanian et al., 2005). Additional 
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myelopoiesis and B lymphocyte development (Nagasawa et al., 1996, Zou et al., 
1998). 
A  role  for  CXCL12  and  CXCR4  was  demonstrated  in  the  movement  of 
haemopoietic stem cells (HSCs). HSC in CXCR4 deficient mice were able to move 
to the fetal liver but not from the liver to the bone marrow (Ma et al., 1999, Zou 
et al., 1998). CXCR4 has been found to be expressed on various tissue progenitor 
cells (Ratajczak et al., 2006) as well as haemopoietic stem cells (Rosu Myles et 
al., 2000). Similarly, CXCL12 is expressed in many different tissues and organs 
within  the  body,  such  as  within  the  bone  marrow,  lymph  node  and  muscle 
derived fibroblasts (Ratajczak et al., 2003, Zou et al., 1998). HSCs are retained 
within  the  bone  marrow  of  adult  mice,  and  this  is  mediated  by  CXCL12.  
Inactivation of CXCL12 by neutrophil derived proteases allows  mobilisation of 
HSCs  into  the  blood (McQuibban  et al.,  2001).  Indeed,  this  process  has  been 
targeted for stem cell mobilisation to increase numbers of HSC in the blood to 
harvest for use in stem cell transplants. In addition, engraftment of HSCs after 
transplantation induced homing to the bone marrow also requires CXCL12 and 
CXCR4. CXCL12 can stimulate the arrest of CD34
+ cells mediated by integrins 
(Peled et al., 1999) and proteoglycans can present immobilised CXCL12 on bone 
marrow endothelial cells which can induce CD34
+ cell adhesion (Netelenbos et 
al., 2002). The CXCR4 antagonist, AMD3100 can also stimulate rapid mobilisation 
of HSCs from the bone marrow (Broxmeyer et al., 2005). Evidence suggests that 
mobilisation  and  homing  of  HSCs  depend  on  opposing  expression  levels  of 
chemokine receptors and adhesion molecules on HSCs and it is the balance that 
determines whether stem cells home to the bone marrow or are mobilised into 
the bloodstream (Gazitt, 2004). 
1.5.3.4  Angiogenesis 
The  formation  of  new  blood  vessels,  known  as  angiogenesis,  is  an  important 
physiological mechanism required after tissue damage for wound repair and has 
been  implicated  in  tumour  growth  and  many  chronic  inflammatory  diseases 
(Carmeliet,  2005).  Angiogenesis  is  a  process  balanced  by  angiogenic  and 
angiostatic factors, which promote or inhibit the formation of new blood vessels 
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endothelial cells are required. Chemokines regulate this process by recruiting 
endothelial progenitor cells (EPCs) and inducing their proliferation. 
EPCs are a subtype of progenitor cells present within the bone marrow, which 
are able to migrate to the circulation and differentiate into mature endothelial 
cells. EPCs were initially isolated from adult peripheral blood (Asahara et al., 
1997) and subsequent characterisation of the phenotype of these cells revealed 
the expression of CD133, CD34 and vascular endothelial growth factor receptor 2 
(Peichev et al., 2000). One of the markers, CD133 (originally termed AC133) is a 
marker for haemopoietic stem and progenitor cells from human bone marrow 
and peripheral blood (Yin et al., 1997). Subsequently, it was discovered that a 
bone marrow derived population of CD133
+ cells could also be differentiated and 
expanded into endothelial progenitor cells (Quirici et al., 2001). Additionally, a 
CD34 negative population of cells isolated from peripheral blood can also give 
rise to EPCs and this population of cells is a subset of CD14
+ monocytes that are 
able to transdifferentiate into endothelial cells (Harraz et al., 2001). As a result, 
the  exact  definitions  of  EPCs  remain  controversial  due  to  the  different 
populations of cells within the blood that can acquire an endothelial phenotype.  
Like haemopoietic stem cells, EPCs are mobilised from the bone marrow stromal 
niche  to  the  vascular  compartment  of  the  bone  marrow  and  this  process  is 
initiated by the matrix metalloproteinase 9 (Heissig et al., 2002). An important 
trigger  for  the  mobilisation  of  EPCs  is  the  interaction  between  CXCL12  and 
CXCR4. Not only is CXCL12 expressed on bone marrow stromal cells but also on 
endothelial cells (Petit et al., 2007). CXCL12 gene expression is regulated by the 
transcription factor, hypoxia inducible factor 1a which is upregulated in hypoxic 
tissue (Ceradini et al., 2004) and in damaged arteries (Karshovska et al., 2007) 
which in turn recruits CXCR4
+ progenitor cells. Once mobilised, EPCs can then 
home  to  sites  of  endothelial  injury  and  ischaemia,  a  process  regulated  by 
chemokines, and contribute to endothelial regeneration and repair. 
The  CXC  subfamily  of  chemokines  can  regulate  angiogenesis  and  within  this 
family there are angiogenic and angiostatic members (Strieter et al., 2005). The 
CXC chemokines have an additional structural motif near the first N  terminal 
cysteine residue that determines their angiogenic or angiostatic properties. This 
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arginine, known as the ELR motif (Strieter et al., 1995).  Members that contain 
this motif tend to be angiogenic whereas members that lack the ELR motif tend 
to be angiostatic. CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 are all 
angiogenic  factors  that  mediate  their  effects  through  CXCR2  (Addison  et  al., 
2000).  Moreover,  by  mutating  the  ELR  motif  in  CXCL8,  it  was  no  longer 
angiogenic  but  in  fact  angiostatic  (Strieter  et  al.,  1995).  Angiostatic  factors 
include CXCL9 and CXCL10 (Angiolillo et al., 1995, Arenberg et al., 1996). There 
is an exception to the rule of ELR correlation within the CXC subfamily and that 
is CXCL12 which lacks the ELR motif but is angiogenic (Strieter et al., 2005). 
However, angiogenic properties are not just restricted to the CXC chemokines or 
the presence of an ELR motif. CCL11 and CX3CL1 are examples of chemokines 
outwith the CXC subfamily that are angiogenic (Lee et al., 2006, Salcedo et al., 
2001) and evidence has shown that CCL21 is angiostatic (Vicari et al., 2000).  
All  of  the  ELR
+  CXC  chemokines  bind  to  CXCR2,  which  is  expressed  on  EPCs 
(Addison  et  al.,  2000).  Mice  lacking  CXCR2  displayed  delayed  wound  healing 
(Devalaraja et al., 2000), illustrating that CXCR2 is a key receptor to the process 
of angiogenesis. In another study, blocking keratinocyte derived chemokine (KC/ 
CXCL1), a ligand of CXCR2, after arterial injury in ApoE deficient mice, resulted 
in inhibition of endothelial recovery (Liehn et al., 2004). The receptor through 
which CXC chemokines are thought to mediate their angiostatic effect is CXCR3. 
Ligands that can bind CXCR3 present on endothelial cells were found to mediate 
angiostatic activity (Romagnani et al., 2001). CXCR3 exists as two splice variants 
and one variant, CXCR3B was found to mediate the angiostatic activity of CXCL4, 
CXCL9 and CXCL10 (Lasagni et al., 2003) and binding to CXCR3B by CXCL4 and 
CXCL10  has  been  shown  to  activate  the  p38  (MAPK)  pathway  (Petrai  et  al., 
2008). A role for CCR2 and CCL2 in the homing of EPCs after endothelial injury 
has  also  been  shown.  Inflamed endothelial  cells  have  been  shown  to  express 
CCR2  (Weber  et  al.,  1999).  Indeed,  bone  marrow  derived  myeloid  cells 
overexpressing CCL2 were infused in vivo after arterial injury and resulted in 
accelerated healing of the endothelium (Fujiyama et al., 2003). 
1.5.4  Role of chemokines and their receptors in disease 
The process of inflammation is a delicate balancing act. Acute inflammation is 
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inflammation persists and does not resolve, this leads to chronic inflammation 
(see  1.4.3).  Central  in  many  inflammatory  diseases  is  the  infiltration  and 
recruitment of leukocytes mediated by chemokines. As a result, chemokines and 
their receptors have been implicated in the pathogenesis of a wide range of 
diseases  from  autoimmune  diseases,  for  example  multiple  sclerosis,  to 
inflammatory and vascular diseases such as atherosclerosis, and even tumours 
(Gerard and Rollins, 2001). 
1.5.4.1  Human immunodeficiency virus 
Human  immunodeficiency  virus  (HIV)  was  identified  in  1983  as  a  retrovirus, 
which  caused  acquired  immunodeficiency  syndrome  (Gallo  and  Montagnier, 
2003). A clinical characteristic of advanced HIV mediated disease is a fall in the 
number  of  circulating  CD4
+  T  cells.  It  was  later  discovered  that  envelope 
proteins, mainly glycoprotein 120 (gp120) present on the surface of HIV could 
bind to  CD4  (Dalgleish  et  al.,  1984).  This  explained  why  the  virus  tended  to 
infect cells expressing CD4, predominately CD4
+ T cells. The entry of HIV into 
cells  was  demonstrated  to  be  facilitated  by  chemokine  receptors,  CCR5  and 
CXCR4 (Deng et al., 1996, Dragic et al., 1996). Binding of gp120 to CD4 results in 
conformation  changes  in  gp120,  which  in  turn  is  then  able  to  bind  to  the 
chemokine receptor (Wu et al., 1996). This subsequently results in membrane 
fusion and expulsion of viral contents into the cell. 
Originally, HIV strains were classified according to the target cellular tropism.  
M tropic strains of HIV replicated in macrophages whilst T tropic strains infected 
T cells. T tropic strains preferentially use CXCR4 and M tropic use CCR5 to gain 
entry to the cells (Lusso, 2006). Subsequently, the HIV strains were designated 
according to the coreceptor used. For example X4 strains are CXCR4 specific, R5 
strains are CCR5 specific and R5/X4 strains are dual tropic and can use either 
CXCR4  and  CCR5  to  enter  their  target  cells  (Berger  et  al.,  1998).  Other 
chemokine receptors, such as CCR2B, CCR3, CCR8 and CX3CR1 have been shown 
to  be  used  by  certain  HIV  strains  for  cell  entry  in  vitro  (Lusso,  2006). 
Chemokines  also  play  a  role  in  HIV  pathogenesis.  CD8
+  T  cells  produced 
chemokines which were able to suppress replication of HIV in CD4
+ T cells (Levy 
et  al.,  1996).  These  chemokines  were  CCL3,  CCL4  and  CCL5,  which  are  all 
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bind  to  CCR5  (Cocchi  et  al.,  1995).  Indeed  high  levels  of  CCR5  binding 
chemokines are associated with slower disease progression (Ullum et al., 1998). 
Additionally, CCL3L1, a potent ligand for CCR5, has variable copy numbers in 
individuals due to duplicated isoforms of the gene which encodes CCL3 (Townson 
et  al.,  2002).  Subsequently,  low  CCL3L1  copy  numbers  was  discovered  to  be 
associated with increased susceptibility to HIV (Gonzalez et al., 2005).  
Interest in targeting chemokine receptors in HIV has arisen from evidence of a 
genetic polymorphism associated with the disease. A 32 base pair deletion in the 
gene  encoding  CCR5  results  in  a  loss  of  function  receptor  and  individuals 
homozygous for this deletion (known as CCR5D32), which occurs in 1% of the 
Caucasian population, are resistant to HIV infection (Liu et al., 1996). However, 
20% of the Caucasian population are heterozygous for the CCR5D32  mutation 
and in those that do get HIV, the rate of progression is slower (de Roda Husman 
et al., 1997). Other polymorphisms in CCR2, CX3CR1, CXCL12, CCL5 and CCL3 
genes have been discovered and have been associated with host resistance or  
susceptibility to HIV and disease progression (Reiche et al., 2007). 
Since individuals with the CCR5D32 mutation developed normally and seemed 
healthy, this lead to targeting CCR5 for HIV therapy. Indeed, one drug known as 
Maraviroc  has  been  approved  for  clinical  use  in  HIV.  Maraviroc  is  a  CCR5 
antagonist,  which  blocks  the  entry  of  HIV  into  CCR5  expressing  cells  by 
preventing the interaction between CCR5 and gp120 (Dorr et al., 2005). Another 
drug, AMD3100 was also able to inhibit HIV activity, in particular T tropic strains 
by acting as a CXCR4 antagonist (Schols et al., 1997). During clinical trials for 
AMD3100, it was discovered that AMD3100 resulted in an increase in circulating 
CD34
+ haemopoietic stem cells (Liles et al., 2003). As a result, AMD3100, is a 
drug currently approved for use to enhance the mobilisation of stem cells into 
the blood for collection and use in autologous transplantation in patients with 
haematological malignancies (Devine et al., 2004). 
Recent evidence suggests that CCR5 does play a role within host defence. CCR5 
has been shown to play a key role in the survival of mice infected with West Nile 
virus (Glass et al., 2005). West Nile virus is a virus transmitted by mosquitoes 
which  can  infect  humans  and  manifests  clinically  with  fever  and  sometimes 
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2006).  Mice  infected  with  West  Nile  virus  showed  increased  expression  of 
chemokines, in particular CCR5 ligands such as CCL3, CCL4 and CCL5, within the 
brain  (Shirato  et  al.,  2004).  CCR5  was  shown  to  be  involved  in  mediating 
leukocyte trafficking to the brain and was crucial in eliminating the virus form 
the brain (Glass et al., 2005). Subsequently, a role for CCR5 was examined in 
humans displaying symptoms of West Nile virus infection and the frequency of 
CCR5D32 within the cohort. It was concluded that individuals homozygous for  
CCR5D32 were at increased risk of West Nile virus infection and that CCR5 was 
indeed protective (Glass et al., 2006). 
1.5.4.2  Cancer 
Uncontrollable cell growth can ultimately result in cancer, which involves many 
steps. Primary tumour development requires signals which allow the tumour to 
grow and escape detection from the immune system (Hanahan and Weinberg, 
2000). The formation of secondary tumours in organs at a distant site from the 
original tumour is known as metastasis. For metastasis to occur, tumours must 
invade vascular or lymphatic vessels, home to other organs, promote growth and 
survival  in  the  new  environment  (Gupta  and  Massague,  2006).  Roles  for 
chemokines and their receptors in cancer have been established and play a role 
in directing cells during metastasis as well as tumour cell growth, survival and 
angiogenesis (Balkwill, 2003). 
Tumours do not only consist of cancerous cells but also contain leukocytes which 
influence the tumour microenvironment (Balkwill and Mantovani, 2001). There is 
evidence  that  chemokines  associated  with  tumour  cells  can  help  evade  the 
immune  response  and  prevent  rejection  of  the  tumour  (Coussens  and  Werb, 
2002). For example, ovarian cancer produces CCL2 and CCL5 (Negus et al., 1995, 
Negus et al., 1997) and their levels of expression were found to correlate with 
the  numbers  of  macrophages  and  lymphocytes  localised  within  the  area  of 
chemokine production respectively (Negus et al., 1997). Tumour cells can also 
promote an environment that helps them to survive by producing chemokines 
that  preferentially  select  Th2  lymphocytes  and  evade  the  immune  response 
against  tumours  (Balkwill  and  Mantovani,  2001).  In  Kaposi  sarcoma,  three 
chemokines,  which can attract Th2 cells, are encoded by the human kaposi 
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tumour  associated  macrophages  (TAMs)  are  M2  polarised  macrophages 
(Mantovani et al., 2004) and can release IL 10 which is immunosuppressive (Sica 
et  al.,  2000).  TAMs  also  play  a  role  in  tumour  progression,  metastasis  and 
angiogenesis (Bingle et al., 2002, Lin and Pollard, 2007). Additionally infiltrating 
leukocytes  and  stromal  cells  are  thought  to  promote  tumour  progression  by 
producing matrix metalloproteinases (Giraudo et al., 2004). Indeed, CCL2, CCL4 
and CCL5 can induce MMP 9 in macrophages (Robinson et al., 2002). 
Chemokines  also  contribute  to  tumour  growth  and  the  best characterised 
chemokines for this role are CXCL1, CXCL2 and CXCL3 (also known as the growth 
related  oncogene  (GRO)  family  of  chemokines).  These  chemokines  act  as 
autocrine growth factors in various cancers (Luan et al., 1997). CXCL1, CXCL2, 
CXCL3  and  CXCL12  can  all  activate  the  phosphatidylinositol  3 kinase  AKT 
pathway (Curnock et al., 2002) which promotes cell proliferation and survival in 
cancerous  cells  (Vivanco  and  Sawyers,  2002).  Additionally,  chemokines  can 
either promote or inhibit angiogenesis (see 1.5.3.4). The expansion of a solid 
tumour mass requires angiogenesis as new blood vessels are required to supply 
the  cancerous  tissue  with  oxygen  and  nutrients  from  the  blood  to  survive  
(Hanahan and Weinberg, 2000).  
Metastasis  is  not  a  random  process  but  is  actually  an  ordered  and  specific 
process  (Gupta  and  Massague,  2006).  For  example,  secondary  tumours  that 
metastasize from breast cancer tend to be found in bone marrow, lymph nodes, 
lung and liver directed by chemokines and their receptors (Muller et al., 2001). 
Indeed,  in  many  types  of  cancer,  malignant  cells  express  increased  levels  of 
chemokine receptors,  with  the  most  widely  expressed  receptors  being  CXCR4 
and CCR7, although CCR9 and CCR10 are also expressed. Human breast cancer 
and melanoma cell lines were discovered to express chemokine receptors that 
may  be  characteristic  for  each  type  of  cancer.  CXCR4  was  found  to  be  the 
dominant chemokine receptor on metastasising breast cancer cells whilst CCR10 
was  typically  the  highest  expressed  on  the  metastatic  melanoma  cell  lines 
(Muller et al., 2001). Therefore, tumour cells expressing chemokine receptors 
may  migrate  and  metastasise  to  sites  where  the  ligands  are  expressed. 
Expression of CCR7 has been found in various cancers, including breast cancer 
(Muller et al., 2001), non small lung cancer (Takanami, 2003) and oesophageal 
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with  lymph  node  metastasis  and  correlated  with  poor  clinical  outcome. 
Transfection of B16 murine melanoma cells with CCR7, which resulted in CCR7 
being expressed higher than CCR10, resulted in the melanoma cell metastasising 
more  efficiently  to  the  lymph  nodes  (Wiley  et  al.,  2001).  Furthermore, 
metastasis to the lymph nodes was blocked with anti CCL21 antibody (Wiley et 
al., 2001). The skin is a common site of metastasis for melanoma cancer cells, 
which highly express CCR10 and bind CCL27, which is also highly expressed in the 
skin (Murakami et al., 2003). Moreover, a form of T cell lymphoma known as 
cutaneous T cell lymphoma, forms tumours within the skin and also expresses 
CCR10  (Notohamiprodjo  et  al.,  2005).  Another  chemokine  receptor,  CCR9  is 
expressed in melanoma and prostate cancer cells (Hwang, 2004, Singh et al., 
2004) and CCR9 expression is correlated with metastasis to the small intestine 
(Letsch  et  al.,  2004)  where  it’s  ligand,  CCL25  is  expressed  (Zaballos  et  al., 
1999). 
1.5.4.3  Psoriasis 
As well as dysregulation in keratinocyte proliferation, altered activity of immune 
cells within the skin also occurs in psoriasis (see 1.4.3.1). There is increasing 
evidence  of  the  involvement  of  chemokines  and  their  receptors  in  this 
dysregulation of immune cells.  
CXCL8 was one of the first chemokines to be associated with psoriasis (Schroder 
and Christophers, 1986), however CXCL1 is another chemokine that is increased 
in the lesions of psoriatic skin, interestingly it colocalises with CXCL8 (Gillitzer 
et al., 1996). Both CXCL1 and CXCL8 can bind CXCR1 and CXCR2, which are both 
predominantly expressed on neutrophils (Morohashi et al., 1995). Indeed, within 
the epidermis of psoriatic skin, overexpression of CXCR2 has been attributed to 
infiltrating neutrophils, but also keratinocytes (Kulke et al., 1998).  
Keratinocytes are capable of producing CCL2 and CCL5 upon stimulation with 
TNFa  and  IFNg  (Li  et  al.,  1996).  Expression  of  CCL2  mRNA  is  present  within 
psoriatic lesions (Gillitzer et al., 1993) and CCL2 protein expression has been 
located to cells within the epidermis of normal and psoriatic skin (Deleuran et 
al., 1996). CCL2 can bind CCR2, a receptor that is expressed on monocytes and 
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to  have  elevated  levels  of  CCR2  expression  compared  to  controls  and  CCR2 
positive cells were present in psoriatic skin biopsies (Vestergaard et al., 2004).  
T lymphocytes have been implicated in the pathogenesis of psoriasis and studies 
indicate  that  CCL27,  CCL20,  CCR10  and  CCR6  play  a  role  in  recruiting  T 
lymphocytes to the skin.  In inflammatory skin diseases such as psoriasis and 
atopic dermatitis, the majority of T lymphocytes infiltrating the skin express 
CCR10  (Homey  et  al.,  2002).  As  mentioned  in  1.5.3.2,  CCL27  is  produced  by 
epidermal  keratinocytes  (Morales  et  al.,  1999).  Consistent  with  this,  the 
interaction between CCL27 and CCR10 regulates T cell recruitment to normal 
skin as well as inflamed skin (Homey et al., 2002). Additionally skin homing T 
cells also express CCR4 (Campbell et al., 1999). Blocking CCR4 or CCL27 in mice 
prevented the migration of lymphocytes to inflamed skin (Reiss et al., 2001). 
CCL20 is another chemokine that has been shown to be associated with psoriasis. 
Homey et al., have shown that CCL20 and its receptor, CCR6 are upregulated in 
psoriatic  skin  (Homey  et  al.,  2000a).  In  addition,  this  study  showed  that 
keratinocytes expressing CCL20 colocalised with skin infiltrating T lymphocytes 
and high levels of CCR6 were expressed on skin homing T lymphocytes (Homey et 
al., 2000a). Another receptor with a potential role in psoriasis is CXCR3, which is 
expressed on dermal lymphocytes and the ligands for CXCR3, CXCL9 and CXCL10, 
were upregulated in lesions of psoriatic skin (Rottman et al., 2001).  
1.5.4.4  Rheumatoid arthritis 
Rheumatoid  arthritis  (RA)  is  a  debilitating  chronic  inflammatory  disease  (see 
1.4.3.3). Within the synovium of rheumatoid arthritis patients, the inflammatory 
infiltrate consists of a mixture of cells including macrophages, T cells, B cells, 
neutrophils,  mast  cells  and  dendritic  cells.  The  recruitment  of  inflammatory 
cells to the synovial tissue is mediated by chemokines and their receptors, of 
which  several  have  been  identified  in  situ.  The  cellular  infiltrate  within  the 
synovial  tissue  of  rheumatic  joints  expresses  chemokine  receptors  including 
CCR5, CCR2, CCR3, CXCR3 and CXCR2 (Szekanecz et al., 2003). 
Studies  have  shown  that  synovial  fluid  and  tissues  from  rheumatoid  arthritis 
patients express high levels of CCL2 (Koch et al., 1992). CCL2 is a chemokine 
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stimulate cells within cartilage (chondrocytes) to produce MMP 3 which degrades 
the  extracellular  matrix  (Borzi  et  al.,  2000).  Additionally,  CCL2  and  other 
chemokines such as CXCL10 and CCL13 are able to increase the proliferation of 
fibroblast like synoviocytes resulting in synovial  hyperplasia (Garcia Vicuna et 
al.,  2004).  Targeting  CCL2  in  mice  resulted  in  a  reduction  in  macrophage 
infiltration and reduced disease severity of arthritis (Gong et al., 1997). In a 
collagen  induced  arthritis  model,  CCR2  null  mice  displayed  enhanced  T  cell 
production  and accumulation of macrophages within the joint (Quinones et al., 
2004). 
Additionally, CCL5 is another chemokine implicated in the pathogenesis of the 
disease. Expression of CCL5 is seen in the synovial lining of rheumatoid joints 
and  is  produced  by  synovial  T  cells  (Robinson  et  al.,  1995).  In  an  adjuvant 
induced  arthritis  model  in  rats,  blocking  CCL5  was  shown  to  ameliorate  the 
disease  (Barnes  et  al.,  1998).  Small  molecule  antagonist  blocking  CCR5,  a 
receptor for CCL5, in a collagen induced arthritis model resulted in inhibition of 
T cell migration and reduction in disease severity (Yang et al., 2002).    
Elevated levels of CCL20 were discovered in the rheumatoid joint along with 
expression of its receptor CCR6. It was found that expression of CCL20 in the 
joint resulted in the recruitment of cells expressing CCR6 (Matsui et al., 2001).  
Th17 cells express CCR6 and have been shown to be recruited to the joint in a 
murine model of arthritis (Hirota et al., 2007b). 
In addition, synovial fluid from RA patients contains elevated levels of CXCL8 
and  the  production  of  CXCL8  in  synovial  tissues  is  mediated  by  macrophages 
(Koch et al., 1991). Ligands of CXCR3, CXCL9 and CXCL10 are both upregulated 
in RA synovial tissue and synovial fluid (Patel et al., 2001). As well as being 
involved  in  the  recruitment  of  macrophages,  both  are  able  to  enhance 
proliferation  of  fibroblast like  synoviocytes  (Garcia Vicuna  et  al.,  2004). 
Increased levels of XCL1 and CX3CL1 are also present within synovial fluid of 
rheumatoid arthritis patients (Volin et al., 2001, Wang et al., 2004a) as well as 
increased expression of XCR1 on mononuclear cells in synovial tissue (Wang et 
al.,  2004a).  CX3CL1  is  thought  to  be  one  chemokine  involved  in  mediating 
angiogenesis in rheumatoid arthritis (Volin et al., 2001). Vicky King, 2010      Chapter 1, 82 
These studies show chemokines and their receptors play a pathological role in 
chronic  inflammatory  diseases  such  as  psoriasis  and  rheumatoid  arthritis. 
Targeting  chemokines  and  their  receptors  within  these  diseases  may  provide 
potential therapies. 
1.6 Atypical chemokine receptors 
In recent years, there has been the discovery of atypical chemokine receptors 
(Nibbs et al., 2003), which are officially chemokine binding proteins according to 
the international union of pharmacology (IUPHAR) classification system (Murphy 
et  al.,  2000).  These  seven  transmembrane  spanning  proteins  share  homology 
with true chemokine receptors and bind chemokines, but these receptors do not 
seem to signal upon ligand binding, at least not using the classical signalling 
pathways  used  by  GPCRs  (see  1.5.2.1).  With  no  evidence  of  signalling,  the 
atypical receptors do not receive a classical chemokine receptor name and are 
classified as chemokine binding proteins. Within this group, is the Duffy Antigen 
Receptor  for  Chemokines  (DARC),  D6  and  CCX CKR,  which  are  alternatively 
labelled  as  ‘silent’  receptors  (Graham,  2009).  Another  receptor  beginning  to 
emerge as a silent receptor is CXCR7. Although DARC, D6 and CCX CKR may not 
be able to signal and induce chemotaxis, studies show that these receptors have 
an important role within immunity and inflammation (Graham, 2009). 
1.6.1  DARC 
DARC was originally known as the Duffy blood group antigen, which was found to 
be  present  on  red  blood  cells  and  forms  a  blood  group  system  (Hadley  and 
Peiper, 1997). However, it was later discovered that the Duffy antigen allowed 
entry of parasites responsible for malaria, such as Plasmodium vivax (Horuk et 
al., 1993). Individuals who lack DARC on red blood cells, due to a polymorphism 
in the promoter which prevents the transcription factor GATA 1 from binding 
thus blocking expression of DARC on red blood cells, are resistant to malaria  
(Tournamille et al., 1995). It is thought that this mutation may have emerged 
due to selective pressure to prevent malaria infection.  
Following  cloning,  DARC  was  originally  thought  to  be  a  nine  transmembrane 
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transmembrane  spanning  structure  similar  to  the  chemokine  receptor  family. 
DARC lacks the conserved DRYLAIV motif and shows no increase in intracellular 
calcium subsequent to ligand binding (Neote et al., 1994). However, DARC can 
bind 11 ligands, including those from the CC and CXC family with preference for 
the inflammatory subset within both families (Gardner et al., 2004). Chemokine 
binding to DARC is localised to the amino terminal domain of the receptor (Lu et 
al., 1995) and requires a disulphide bridge between the first and fourth cysteine 
suggesting that sequences within the pocket caused by the disulphide bond are 
important  (Tournamille  et  al.,  1997).  As  well  as  being  expressed  on 
erythrocytes,  DARC  is  also  expressed  on  vascular  endothelial  cells  in  various 
organs  and  within  the  cerebellum  (Hadley  et  al.,  1994,  Horuk  et  al.,  1996). 
Individuals  who  lack  DARC  on  red  blood  cells  still  express  DARC  on  vascular 
endothelial cells (Peiper et al., 1995) leading to suggestions that DARC may play 
an important role within this location.  
DARC  on  erythrocytes,  may  function  as  a  ‘chemokine  sink’  (Darbonne  et  al., 
1991) and as a result may prevent activation of circulating leukocytes. Indeed, 
DARC deficient mice also show an exaggerated response to LPS and within the 
lungs  and  liver  of  these  mice,  increased numbers  of  polymorphonuclear cells 
were  found  (Dawson  et  al.,  2000).  It  has  been  suggested  that  DARC  on 
erythrocytes  plays  a  role  in  maintaining  the  concentration  of  chemokines  in 
plasma. Chemokines injected intravenously were more rapidly removed from the 
circulation in DARC deficient mice compared with wild type mice (Fukuma et 
al., 2003). In another study, DARC deficient mice displayed larger tumours in a 
model of prostate cancer compared to the tumours in wild type mice (Shen et 
al., 2006). Individuals lacking DARC on erythrocytes are at increased risk and 
mortality  of  various  malignant  diseases,  including  prostate  cancer  (Lentsch, 
2002). 
DARC is also expressed on endothelial cells and is proposed to play a role in 
transporting  chemokines  across  the  endothelium,  a  process  known  as 
transcytosis. CXCL8 transportation across the endothelium occurs through DARC 
(Middleton et al., 2002, Lee et al., 2003b) and DARC has been found associated 
with  caveolae  (see  1.5.2.2)  within endothelial  cells  (Chaudhuri et  al.,  1997). 
DARC has also been shown to play a role in chemokine induced angiogenesis in 
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endothelial cells within these mice resulted in a reduced angiogenic response 
(Du et al., 2002). To contrast this, endothelial DARC was able to transcytose 
chemokines  in  vitro and  using a  model of  contact  hypersensitivity,  leukocyte 
migration  across  the  endothelium  was  enhanced  in  DARC  transgenic  mice 
compared to wild type (Pruenster et al., 2009). 
Expression  of  DARC  has  been  found  to  be  present  in  a  variety  of  diseases 
including  renal  disease  and  within  rheumatoid  arthritis  synovium  (Liu  et  al., 
1999, Patterson et al., 2002). Indeed, upregulation of DARC on the endothelium 
has been found to take place during renal transplant rejection, pneumonia and 
in the early stages of rheumatoid arthritis (Gardner et al., 2006, Lee et al., 
2003a,  Segerer  et  al.,  2000).  The  role  of  DARC  in  acute  renal  injury  was 
investigated  using  two  neutrophil  dependent  models.  In  both  models,  DARC 
deficient  mice  were  protected  from  renal  injury.  In  the  ischaemic  perfusion 
model, the number of neutrophils recruited to the kidney was reduced (Zarbock 
et al., 2007). However, in a chronic model of renal inflammation characterised 
by  the  accumulation  of  macrophages  and  T  cells,  renal  recruitment  of 
macrophages and T cells still occurred in DARC deficient mice (Vielhauer et al., 
2009). These studies suggest that DARC does not play a role in monocyte and T 
cell recruitment in prolonged renal inflammation. In an LPS induced acute lung 
injury  model,  erythrocyte  DARC  was  shown  to  limit  polymorphonuclear  cell 
infiltration into the lung by acting as a chemokine sink and endothelial DARC was 
shown to play a minor role in promoting leukocyte transmigration through the 
pulmonary endothelium (Reutershan et al., 2009). 
1.6.2  CCX-CKR 
CCX CKR  (ChemoCentryx  chemokine  receptor)  has  previously  been  named  as 
CCR11 and CCRL1 (Gosling et al., 2000, Khoja et al., 2000, Schweickart et al., 
2000). Human CCX CKR can bind CCL19, CCL21 and CCL25 (Gosling et al., 2000) 
with  high  affinity.  These  chemokines  are  regarded  as  homeostatic  and  are 
involved  in  directing  cells  to  tissues  and  secondary  lymphoid  compartments. 
CCL19 and CCL21 are ligands for CCR7 and CCL25 was previously thought to bind 
only CCR9. CCX CKR has structural similarities to CCR7 and CCR9 and displays 29 
35% amino acid homology with the general chemokine receptor family (Gosling 
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chemokine receptor name because there was no evidence of signalling (Murphy, 
2002). This was later confirmed following characterisation of mouse CCX CKR 
which showed that murine CCX CKR in transfected cells could bind CCL19, CCL21 
and CCL25 yet did not give any signs of signalling as calcium flux did not occur 
(Townson  and  Nibbs,  2002).  This  has  led  to  the  inclusion  of  CCX CKR  in  the 
atypical chemokine receptor family. 
Mouse CCX CKR is highly expressed in the heart and lungs and is expressed at 
lower levels in all tissues (Townson and Nibbs, 2002). However human CCX CKR 
was found to be highly expressed in the heart, lung and small intestine as well as 
weak expression in the brain and skeletal muscles (Gosling et al., 2000, Townson 
and Nibbs, 2002).  Although CCX CKR does not seem to signal, the biochemical 
and trafficking properties of the receptor have been defined (Comerford et al., 
2006).  This  study  showed  that  human  CCX CKR  was  able  to  internalise  and 
degrade ligand more efficiently than CCR7 and was able to continue internalising 
CCL19 when CCR7 was not. Internalisation of chemokine and receptor did not 
require components of the clathrin coated mediated endocytosis pathway, such 
as  b arrestin  and  clathrin  coated  vesicles  but  did  require  dynamin  and  is 
suggested to require caveolae (Comerford et al., 2006).  
CCX CKR has been proposed to act as a scavenging receptor (Comerford et al., 
2006). In a study by Heinzel et al., CCX CKR was shown to be involved DC homing 
via the afferent lymphatics under homeostatic conditions. Reduced numbers of 
CD11c
+ MHCII
high DCs were found in the skin draining lymph nodes of CCX CKR 
deficient mice (Heinzel et al., 2007). Additionally, overexpression of CCX CKR in 
thymic epithelial cells resulted in impaired migration of haemopoietic thymic 
precursors  to  the  embryonic  analage  therefore  further  implicating  a  role  for 
CCX CKR in leukocyte migration under homeostatic conditions (Heinzel et al., 
2007).   
In  pulmonary  sarcoidosis,  CCX CKR  transcripts  are  upregulated  in 
bronchoalveolar  cells  and  transcript  levels  correlated  with  disease  severity 
alongside an increase in CCL19 levels in pulmonary sarcoidosis (lKriegova et al., 
2006).  However,  the  exact  role  of  CCX CKR  in  this  disease  has  not  yet  been 
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1.6.3  CXCR7 
Formally known as RDC1, this receptor was cloned and characterised from mouse 
genomic DNA where it was found to show 88% amino acid similarity to the human 
RDC1 receptor. Mouse RDC1 was discovered to share 43% amino acid similarity to 
mouse  CXCR2  and  the  RDC1  gene  was  localised  to  chromosome  1  where  the 
genes for CXCR2 and CXCR4 are also located (Heesen et al., 1998). This led to 
the suggestion that RDC1 was an orphan CXC chemokine receptor. 
It was then reported that RDC1 binds to CXCL12 and CXCL11 (Balabanian et al., 
2005, Burns et al., 2006). CXCL12 binding to RDC1 in transfected cells resulted in 
calcium mobilisation and cell migration therefore it was proposed to rename it 
CXCR7 (Balabanian et al., 2005). However, another study reported that there 
was no calcium flux or cell migration after ligand binding to CXCR7/RDC1 yet 
CXCR7/RDC1 expression increased cell survival and adhesion (Burns et al., 2006). 
More recently CXCR7/RDC1 has been implicated in promoting tumour growth in 
breast, lung and prostate cancer (Miao et al., 2007, Wang et al., 2008). In the 
study  by  Wang  et  al,  CXCR7/RDC1  was  shown  to  signal  via  a  downstream 
signalling  pathway,  known  as  the  AKT  pathway,  which  contradicted  previous 
results.  However,  the  contrasting results may  be  due to the  use  of different 
tumour  cell  lines  and  it  was  not  ruled  out  that  CXCL12  may  have  mediated 
signalling  though  CXCR4  heterodimerisation  with  CXCR7/RDC1  (Sierro  et  al., 
2007).  Indeed,  when  CXCR7  and  CXCR4  are  coexpressed,  CXCR7/CXCR4 
heterodimer  formed  as  efficiently  as  receptor  homodimers  and  it  has  been 
suggested  that  CXCR4/CXCR7  heterodimers  in  T  cells  may  regulate  CXCL12 
mediated  chemotaxis  (Levoye  et  al.,  2009).  Therefore,  more  studies  are 
required before this chemokine receptor is either officially designated into the 
CXCR subfamily or to confirm its membership in the atypical chemokine family.  
CXCR7 was found to be highly expressed on monocytes and B cells (Infantino et 
al., 2006). Indeed the ability of B cells to differentiate into plasma cells capable 
of secreting antibodies correlated with CXCR7 expression levels (Infantino et al., 
2006). Additionally, a ligand produced from mature plasmacytoid dendritic cells, 
was  found  to  be  different  from  CXCL12  and  CXCL11  but  was  able  to  induce 
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Disruption of CXCR7 in mice was lethal which illustrated a role for the receptor 
in vascular development (Sierro et al., 2007). The defects in CXCR7 null mice 
were due to defects in the heart and not due to haemopoietic problems (Sierro 
et al., 2007). Additionally expression of CXCR7 has been shown in the neurons of 
developing, and adult, rat brains although the exact role for CXCR7 at this site is 
not known (Schonemeier et al., 2008). 
In zebrafish, the migration of primordial germ cells (PGCs) was primarily known 
to be guided by CXCL12 and its receptor CXCR4 (Doitsidou et al., 2002, Knaut et 
al.,  2003).  Initial  studies  suggested  that  there  was  regulated  expression  of 
chemokine receptors CXCR4 and CXCR7 at the leading and trailing edge of the 
migrating primordium (Dambly Chaudiere et al., 2007). A recent study has shown 
that  CXCR7  is  expressed  in  the  somatic  environment  and  plays  a  role  in  the 
migration of PGCs (Boldajipour et al., 2008). The authors conclude that CXCR7 
acts as a decoy receptor and is involved in PGC migration by controlling the 
levels of the chemokine CXCL12 (Boldajipour et al., 2008). 
1.6.4  D6 
The  atypical  chemokine  receptor,  D6,  was  originally  identified  in  the  mouse 
(Nibbs et al., 1997a). It encodes a protein of 378 amino acids containing seven 
transmembrane spanning domains with 30% identity and 60% homology to the 
murine  CCR  family.  However,  the  amino  acid  sequence  in  the  second 
intracellular domain, which is highly conserved among chemokine receptors, was 
found to contain the sequence DKYLEIV and not DRYLAIV. The DRYLAIV motif is 
important for G protein coupling and chemokine receptor signalling. Human D6 
was also cloned and was discovered to be 71% identical to murine D6 and also 
contained the DKYLEIV motif (Nibbs et al., 1997b). Purification of the human D6 
protein revealed that D6 has a molecular mass of 49kDa and was sulphated and 
glycosylated at the N terminus (Blackburn et al., 2004). 
Mouse expression of D6 is high in lung, liver and spleen and is expressed in the 
heart, brain, thymus, ovary, muscle, liver and kidney as well as the skin (Nibbs 
et al., 1997a). D6 is present on astrocytes within the brain (Neil et al., 2005). 
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endothelial cells lining the lymphatics within humans (Nibbs et al., 2001) and 
leukocytes,  in particular, B cells and dendritic cells (McKimmie et al., 2008). 
D6 displays high affinity binding to a large number of inflammatory chemokines 
within the CC chemokine subfamily including CCL2, CCL3, CCL4, CCL5, CCL7, 
CCL8, CCL11, CCL13, CCL14 (Nibbs et al., 1997b), CCL17 and CCL22. D6 does not 
bind  CCL19  or  CCL20,  which  are  considered  to  be  homeostatic  chemokines 
(Bonecchi et al., 2004). Nibbs et al. also demonstrated enhanced binding of an 
isoform  of  human CCL3,  known  as  CCL3L1,  to  D6.  The  enhanced  binding  was 
found  to  be  due  to  a  proline  residue  at  position  2  (Nibbs  et  al.,  1999). In 
addition, D6 can bind the full length CCL22 but not a truncated form of CCL22 
where  the  first  two  amino  acids  have  been  cleaved  by  an  enzyme,  CD26 
(Bonecchi et al., 2004). CD26 is a serine protease expressed by many cells and is 
selective for substrates with a proline or alanine residues at position 2 of the 
NH2  terminus  (Struyf  et  al.,  2003).  Upon  ligand  binding,  D6  does  not  induce 
calcium  fluxes  or  mediate  chemotaxis,  signs  of  classical  G protein  signalling 
(Nibbs et al., 1997b) and therefore has not been given a CCR name. However, 
ligand  binding  to  D6  results  in  internalisation  and  degradation  of  the  ligand 
leading to the proposal that D6 may act as a ‘scavenging’ or ‘decoy’ receptor for 
inflammatory CC chemokines (Fra et al., 2003). Therefore D6 may be ‘mopping 
up’ CC chemokines regulating the levels available, and limiting the numbers of 
leukocytes within an inflamed area. 
Various properties and mechanisms allow D6 to internalise CC chemokines. In the 
absence of ligand, D6 is phosphorylated and is therefore constantly ‘switched 
on’ and has the ability to internalise (Blackburn et al., 2004). Another feature is 
that only 5% of D6 is present on the cell surface and the rest is within the cell in 
intracellular vesicles (Blackburn et al., 2004). Subsequently, D6 was found to 
move to and from the cell surface in the absence of ligand binding without any 
reduction  in  total  cell  surface  levels  (Weber  et  al.,  2004).  D6  recycling  in 
absence of ligand requires Rab4 and Rab11 (Bonecchi et al., 2008). In addition, 
D6 requires Rab5 and dynamin I to be able to internalise ligand (Weber et al., 
2004) and is dependent on b arrestin (Galliera et al., 2004), all components of 
the  clathrin  coated  endocytosis  pathway.    An  amino  acid  sequence  in  the  C 
terminus of D6 is not homologous to other chemokine receptors and is conserved 
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stability, constitutive phosphorylation and trafficking of D6. The C terminus does 
not  control  internalisation  of  chemokine  but  does  prevent  subsequent 
progressive scavenging of the ligand (McCulloch et al., 2008). Ligand binding to 
D6  has  been  shown  to  increase  D6  scavenging  using  Rab11  and  increases  D6 
expression on the cell membrane (Bonecchi et al., 2008). In addition, LPS can 
downregulate D6 mRNA levels whereas TGF b can upregulate D6 mRNA levels in 
myeloid cells and D6 expression within dendritic cells was GATA 1 dependent 
(McKimmie  et  al.,  2008).  Other  evidence  has  shown  IL 1b  and  TNFa  can 
upregulate D6 mRNA expression in human breast cancer cell lines (Wu et al., 
2008). 
The  role  of  D6  in  vivo  was  examined  using  D6  null  mice  to  investigate  the 
hypothesis  that  D6  may  regulate  the  level  of  inflammatory  chemokines. 
Jamieson et al. used a model of cutaneous inflammation induced by phorbol 12 
myristate  13 acetate  (TPA)  application  to  murine  dorsal  skin  on  three 
consecutive days. It was found that D6 null mice could not clear inflammatory 
CC chemokines as effectively as the wild type mice after 24 hours resulting in 
development  of  a  pathology  similar  to  human  psoriasis.  The  pathology  that 
developed in D6 null mice was characterised by an accumulation of T cells within 
the epidermis, mast cells in the dermis and was dependent on TNFa (Jamieson 
et  al.,  2005).  Another  study  used  a  model  of  skin  inflammation  induced  by 
injection of complete Freund’s adjuvant. In this instance, D6 null mice displayed 
an  increased  inflammatory  response  with  increased  numbers  of  leukocytes, 
angiogenesis and areas of necrosis as well as increased cellularity in lymph nodes 
(Martinez de la Torre et al., 2005). Therefore, these studies suggest that, in 
vivo, D6 plays a role in the resolution of inflammation. 
Further studies have investigated the role of D6 expression in other tissues. D6 
within the placenta plays a role in reducing fetal loss in two separate models 
induced  either  by  systemic  inflammation  or  anti phospholipid  antibodies 
(Martinez  de  la  Torre  et  al.,  2007).  In  a  model  of  allergic  pulmonary 
inflammation, D6 null and wild type mice were sensitised to ovalbumin and then 
exposed to ovalbumin aerosol on a single occasion or consecutively for seven 
days (Whitehead et al., 2007). D6 was shown to scavenge certain chemokines in 
the lung in a concentration dependent way and the lungs of D6 null mice had 
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the increase in leukocyte numbers, the absence of D6 also resulted in reduced 
reactivity of the airway leading to the proposal that inhibition of D6 may help 
allergen induced asthmatic patients (Whitehead et al., 2007).   
D6 has also been shown to play a role in the development of skin tumours. A 
chemically  induced  skin  tumour  model  was  used  in  which  a  cutaneous 
application of 7, 12 dimethylbenz(a)anthracene (DMBA) followed by 12 2 week 
cycles  of  phorbol  12 myristate  13 acetate  (TPA)  was  applied  to  murine  skin. 
Deletion  of  D6  made  an  otherwise  resistant  strain  susceptible  to  tumour 
development,  which  correlated  with  prolonged  skin  inflammation,  including 
infiltration of epidermal T cells and dermal mast cells (Nibbs et al., 2007). In a 
tumour  susceptible  mouse  strain,  deletion  of  D6  resulted  in  enhanced 
susceptibility  to  papilloma  formation  (Nibbs  et al.,  2007).  After  discontinuing 
TPA  use,  which  was  used  as  a  tumour  promoting  agent  to  drive  tumour 
emergence after mutagenesis by DMBA, D6 deficient mice developed enlarged 
papillomas whereas papilloma size in wild type mice did not increase (Nibbs et 
al.,  2007).  In  a  model  of  liver  injury  induced  by  carbon  tetrachloride,  D6 
deficient mice displayed prolonged liver damage with increased levels of CCL2, 
CCL3  and  CCL5  after  48  hours  (Berres  et  al.,  2009).  Additionally,  increased 
numbers of leukocytes, in particular T cells and NK cells was found in the liver of 
D6 deficient mice compared to wild type (Berres et al., 2009). In a model of 
colitis  induced  by  dextran  sodium  sulphate,  D6  deficient  mice  were  less 
susceptible to colitis (Bordon et al., 2009). There was no difference in the level 
of  pro inflammatory  chemokines  released  from  colon  explants  or  leukocytes 
recruited to the colon in D6 deficient mice compared to wild type. However, D6 
deficient mice displayed higher levels of IL 17A and increased numbers of IL 17A 
gd T cells suggesting that D6 plays a role in regulating IL 17A secretion by gd T 
cells  in  the  colon  (Bordon  et  al.,  2009).  Another  study  examining  D6  in 
experimental colitis induced by dextran sodium sulphate found that D6 deficient 
mice  were  more  susceptible  to  colitis  with  higher  levels  of  pro inflammatory 
chemokines  and  increased  leukocyte  infiltration  (Vetrano  et  al.,  2009). 
Additionally,  using  chimeric  mice,  the  ability  of  D6  to  control  intestinal 
inflammation was located to D6 expression in the stromal/lymphatic area, i.e. 
on lymphatic vessels (Vetrano et al., 2009). Also in the same study, D6 deficient 
mice were more susceptible to chronic colitis associated cancer than wild type 
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Other roles for D6 have been suggested. D6 null mice are relatively resistant to 
EAE due to an impaired adaptive immune response (Liu et al., 2006). In addition, 
the role of D6 in the immune response to Mycobacterium tuberculosis has been 
examined and D6 null mice were more susceptible to mortality after infection by 
Mycobacterium tuberculosis (Di Liberto et al., 2008). Mortality was associated 
with increased local and systemic inflammation, increased CC chemokine levels 
as well as infiltration of macrophages and T cells to the lungs. However blocking 
CC  chemokines  in  D6  deficient  mice  resulted  in  prolonged  survival  yet 
uncontrollable growth of Mycobacterium tuberculosis within the lung (Di Liberto 
et al., 2008).  
 
Studies involving D6 in human diseases are emerging. D6 is expressed in atopic 
dermatitis and rheumatoid arthritis synovium as well as kaposi sarcoma, a form 
of malignant vascular tumour (McKimmie et al., 2008, Nibbs et al., 2001). D6 is 
also expressed in human breast cancer cell lines and tissues. Overexpression of 
D6  in  breast  cancer cell  lines  was  found  to  inhibit  proliferation  and  invasion 
ability  of  the  tumour  in  vitro.  D6  protein  expression  in  human  tissues  was 
correlated positively with disease free survival (Wu et al., 2008). One study has 
shown that genetic variation in the D6 receptor correlates with the grade of liver 
inflammation in hepatitis C (Wiederholt et al., 2008). Additionally, patients with 
high levels of liver inflammation expressed lower levels of D6 mRNA (Wiederholt 
et al.,  2008).  To add  to  this, expression  levels  of  D6  mRNA  varied  widely  in 
control human hepatocytes suggesting that variation in D6 levels may be due to 
certain  genotype  variations  in  the  D6  receptor  (Wiederholt  et  al.,  2008). 
Increased  expression  of  D6  has  also  been  found  on  lymphatic  vessels  and 
leukocytes within ulcerative colitis, crohns disease and colon cancer compared 
to normal colon mucosa (Vetrano et al., 2009). 
 
These  studies  show  that  D6  is  a  key  chemokine  receptor  involved  in  the 
regulation of inflammation and the immune response. However, the precise role 
and  mechanisms  of  D6  function  in  inflammation  and  chronic  inflammatory 
diseases are still poorly understood and further work is required to clarify the 
function of D6 in these processes.  
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1.7  Aims 
The overall aim of the work within this thesis was to determine whether the 
manipulation of the expression of the atypical chemokine receptor, D6, has the 
potential to be of future therapeutic value. 
D6 was reported to play an important role in the resolution of the cutaneous 
inflammatory  response  in  mice.  Therefore,  we  hypothesised  that  increased 
expression of D6 would be able to limit inflammation in vivo.  
To test our hypothesis, K14D6 transgenic mice were generated to allow ectopic 
expression of D6 to be targeted to the epidermis. Characterisation of the K14D6 
transgenic  mice  was  required  to  ensure  the  D6  transgene  was  transcribed, 
expressed at the protein level and was functional. To test whether increased 
expression  of  D6  within  K14D6  mice  could  limit  inflammation,  a  well 
characterised model of skin inflammation was used. 
Using a microarray approach, the transcriptional consequences of ligand binding 
to D6 and basal expression of D6 were examined. Primary murine keratinocytes 
from  wild type  and  K14D6  mice  were  isolated,  cultured  and  incubated  with 
either PBS or CCL3. By examining changes in the cellular transcriptome after 
ligand binding to D6, it was hoped that this would give an insight into cellular 
functions mediated by D6. 
The  final  aim  of this  thesis  was  to determine  whether there is  a  correlation 
between D6 expression levels and cutaneous inflammatory diseases, in particular 
psoriasis. This was assessed by analysing D6 expression in peripheral blood and 
skin biopsies collected from psoriatic patients. Other inflammatory diseases such 
as  atopic  dermatitis,  psoriatic  arthritis  and  rheumatoid  arthritis  were  also 
examined for D6 expression.  
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2  Materials and Methods 
2.1 Materials 
2.1.1  Antibodies 
 
 
 
Abcam (Cambridge, UK) 
   
fluorescein isothiocyanate (FITC) 
conjugated mouse anti pan cytokeratin 
BD Pharmingen (Oxford, UK)  FITC conjugated  mouse  IgG1  (isotype 
control) 
 
Allophycocyanin  (APC) conjugated  mouse 
anti human CD3 
 
phycoerythrin (PE) conjugated mouse anti 
human CD14 
 
PE conjugated mouse anti human CD20 
 
Viaprobe 
 
Chemicon (Harrow, UK)  HRP conjugated donkey anti chicken IgY  
 
DAKO UK  (Ely, UK)  Mouse IgG2a  (isotype control) 
 
Mouse IgG1 
 
In house  
 
Mouse anti human D6 
Miltenyi Ltd (Surrey, UK)  APC conjugated mouse anti human CD1c 
 
APC conjugated mouse anti human CD304 
(BDCA) 
 
Sigma (Poole, UK)  FITC conjugated  goat  anti mouse  IgG  (Fc 
specific) F(ab’)2 fragment 
 
Vector Laboratories 
(Peterborough, UK)   
Biotinylated anti mouse IgG 
 Vicky King, 2010      Chapter 2, 95 
2.1.2   Chemicals, reagents and solutions 
Ambion (Warrington, UK)  Nuclease free water 
 
RNase Zap 
 
Biogenesis (Poole, UK) 
 
Normal Human serum 
Bioline (London, UK)  5x DNA Loading Buffer 
 
Hyperladder I 
 
Hyperladder IV 
 
BDH (Letterworth, UK)  DPX mounting solution 
 
Hydrogen Peroxide 30% Solution 
 
Sodium Chloride (NaCl) 
 
Cell Path (Newtown, UK)  Haematoxylin Z 
 
Putts Eosin 
 
Scotts tap water solution 
 
Fisher scientific (Loughborough, UK)  Chloroform 
 
Citric Acid 
 
Diaminoethanetetra acetic acid  
(EDTA) disodium salt  
 
Ethanol 
 
Sodium dodecyl sulfate (SDS) 
Gibco (Invitrogen, Paisley, UK)  Phosphate buffered Saline (PBS) 
Invitrogen (Paisley, UK)  Ethidium Bromide 
 
MES running buffer 
 
Multimark multicolour standard 
 
Nitrocellulose transfer membrane 
 
NuPage 4 12% Bis tris gel 
 
NuPage Transfer Buffer 
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Melford (Ispwich, UK) 
 
Tris Hydrochloric acid (HCl) 
Sigma (Poole, UK)  Ammonium Thiocyanate 
 
Bovine serum albumin (BSA) 
 
Dithiothreitol (DTT) 
 
Fibronectin 
 
Histopaque 1077 
 
Cell lytic M mammalian cell lysis buffer 
 
2 Mercaptoethanol 
 
Phorbol 12 Myristate 13 Acetate 
 
Sample buffer Laemmli 2x concentrate 
 
Tween 20 
 
Surgipath (Peterborough, UK) 
 
Neutral buffered formalin 
Thermo Scientific  
(Loughborough, UK) 
 
Xylene 
 
Vector Laboratories 
(Peterborough, UK)  
 
Normal Horse Serum 
 
 
2.1.3  Chemokines 
Almac sciences (Gladsmuir, UK)  Biotinylated CCL3 
 
CCL2  conjugated to Alexa 647 
 
CCL3 
 
Peprotech (London, UK)  CCL22 
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2.1.4   Enzymes, kits and PCR master mix 
Abgene (Epsom, UK)  Pre aliquoted ReddyMix PCR  
master mix  
Ambion (Warrington, UK) 
 
RNase free DNase kit 
Applied Biosystems (Foster City, CA)  Power SYBR Green PCR master mix 
 
BD Pharmingen (Oxford, UK) 
  
Standard Fix Permabilisation kit 
BIOS Europe Ltd (Skelmersdale, UK)  RAPI DIFF II kit 
 
Invitrogen (Paisley, UK)  Superscript  First  strand  synthesis 
system for RT PCR kit  
Perbio science Ltd (Cramlington, UK)  bicinchoninic acid (BCA) protein assay 
 
Supersignal West Femto  
chemiluminescent substrate 
 
Supersignal West Pico 
chemiluminesent substrate 
Qiagen (Crawley, UK)  QIA quick PCR purification kit 
 
RNase free DNase I 
 
RNeasy mini kit 
 
Sigma (Poole, UK)  Proteinase K 
 
Vector Laboratories  
(Peterborough, UK) 
Avidin/biotin blocking kit 
 
DAB  Substrate  Kit,  3,3’ 
diaminobenzidine 
Standard Vectastain ABC kit 
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2.1.5  Primers 
VH Bio (Gateshead, UK) 
 
Primers 
 
 
PRIMER NAME 
   
SEQUENCES 
 
mD6                                      Forward  
Reverse 
5’ AGCTTTACCTGCTGAACCTGG 3’ 
5’ AAGAAGATCATGGCCAAGAGTG 3’ 
K14mD6 Forward  Forward  
Reverse 
5’ ATGACAAGCTCCAAAGAGATG 3’ 
5’ CTCTTCACTGATCTCCCTCCAC 3’ 
b b b b-Actin  Forward  
Reverse 
5’ TGAACCCTAAGGCCAACCGTG 3’ 
5’ GCTCATAGCTCTTCTCCAGGG 3’ 
CCR1  Forward  
Reverse 
5’ GCGCTCATTTCCCCTACAA 3’ 
5’ CGGCTTTGACCTTCTTCTCA 3’ 
CCR2  Forward  
Reverse 
5’ TGGGACAGAGGAAGTGGTGT 3’ 
5’ TGAGGAGGCAGAAAATAGCAG 3’ 
CCR3  Forward  
Reverse 
5’ GCAGGTGACTGAGGTGATTG 3’ 
5’ CTGTGGAAAAAGAGCCGAAG 3’ 
CCR4  Forward  
Reverse 
5’ CTCGCCTTGTTTCAGTCA 3’ 
5’ GATTTCCTCCACCCAGCA 3’ 
CCR5  Forward  
Reverse 
5’ TTTGTTCCTGCCTTCAGACC 3’ 
5’ TTGGTGCTCTGTTCCTCATCTC 3’ 
Col3a1 outer  Forward  
Reverse 
5’ GGGTATCAAGGGTGAAAGTGG 3’ 
5’ AACTCCAACAATGGCAGCA 3’ 
Lzp-s outer  Forward  
Reverse 
5’ AGACCGAAGCACCGACTATG 3’ 
5’ TCCTGGCTGAAGAACTGACC 3’ 
Ptx3 outer  Forward  
Reverse 
5’ TTGGGTCAAAGCCACAGA 3’ 
5’ AATGAACAATGGGCAACAGAG 3’ 
Laptm5 outer  Forward  
Reverse 
5’ CGCAGCCATAGGAAGTTAGG 3’ 
5’ CGGCGAGACTGTTGGACT 3’ 
CCL6 outer  Forward  
Reverse 
5’ CTTTATCAGCAGGAGGGGAAC 3’ 
5’ CCCAAGAGCCCAGTTTCAG 3’ 
Npm3 outer  Forward  
Reverse 
5’ ACACCCGCTCCTTCACTTT 3’ 
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STEAP4 outer  Forward  
Reverse 
5’ AAAGCAGCACTCGGCATACT 3’ 
5’ AGAAAGCACACCACCACTCC 3’ 
Slc6a14 outer  Forward  
Reverse 
5’ TGGAGGATTTTGCCACTGTT 3’ 
5’ ATGAGCCAAGCCAGAAGAAG 3’ 
Lcn2 outer  Forward  
Reverse 
5’ CCCTGTATGGAAGAACCAAGG 3’ 
5’ AGGTGGATGGGGAGTGCT 3’ 
ApoE outer  Forward  
Reverse 
5’ GTGCTGTTGGTCACATTGCT 3’ 
5’ GCGTATTTGCTGGGTCTGTT 3’ 
Aldh1a7 outer  Forward  
Reverse 
5’ TCAAGCCAGCAGAGCAAAC 3’ 
5’ GGACAGGGACAGCCAAATAG 3’ 
Dkk2 outer  Forward  
Reverse 
5’ TCTTCCAAAGCCAGACTCCA 3’ 
5’ TTCCCTGTTCTTCAGCGTTC 3’ 
Nrk outer  Forward  
Reverse 
5’ CAGATTCAAGTCGTGGAGCA 3’ 
5’ GAACCAACAGCCAGGTCAA 3’ 
Bcat1 outer  Forward  
Reverse 
5’ GGATGCTGGGGTGATTGA 3’ 
5’ TTCTTCCAACTGACTGTGCTG 3’ 
Col3a1 QPCR  Forward  
Reverse 
5’ AGGTTCTCCTGGTGCTGCT 3’ 
5’ TGCCCACTTGTTCCATCTTT 3’ 
Lzp-s QPCR  Forward  
Reverse 
5’ GCCCATTCTGTCTCTTTCTCAC 3’ 
5’ TGTTTTGCCCTGTTTCTGCT 3’ 
Ptx3 QPCR  Forward  
Reverse 
5’ ACGGAGGAGCCCAGTATGTT 3’ 
5’ TCGTCTATTACGCACCGAAGT 3’ 
Laptm5 QPCR  Forward  
Reverse 
5’ GATTGTGGTGCCCGTTTG 3’ 
5’ CTCCGTTTCTATTTCTTTTTCTCCT 3’ 
CCL6 QPCR  Forward  
Reverse 
5’ CCTAAGCACCCTGAAGCAAG 3’ 
5’ GGTCACTGGGGAAGACAGAA 3’ 
Npm3 QPCR  Forward  
Reverse 
5’ CGGACGAGTGTAATGTGGTG 3’ 
5’ CAGGTGGTTGGAGTTGGAAA 3’ 
STEAP4 QPCR  Forward  
Reverse 
5’ GGAGAAAAGCCCCAAATGA 3’ 
5’ ACCCCAAATACCCCCAGA 3’ 
Slc6a14 QPCR  Forward  
Reverse 
5’ TCTTGGGCAGACGAAAACTG 3’ 
5’ GCAGGTGAGATTGCTGGTATTT 3’ 
Lcn2 QPCR  Forward  
Reverse 
5’ CTGAATGGGTGGTGAGTGTG 3’ 
5’ CTTGGTATGGTGGCTGGTG 3’ 
ApoE QPCR  Forward  
Reverse 
5’ GTGGCAAAGCAACCAACC 3’ 
5’ TCCGTCATAGTGTCCTCCATC 3’ Vicky King, 2010      Chapter 2, 100 
Aldh1a7 QPCR  Forward  
Reverse 
5’ CAGATGCCGACTTGGACAG 3’ 
5’ TCCTCAACAAAAAGCCTGGA 3’ 
Dkk2 QPCR  Forward  
Reverse 
5’ TTGGAATGCGGAAGAATGAG 3’ 
5’ GAGGCACATAACGGAAGCAC 3’ 
Nrk QPCR  Forward  
Reverse 
5’ GCGATGAGGAAGAAAGAGGA 3’ 
5’ CACAGCAACCGCAATGTATG 3’ 
Bcat1 QPCR  Forward  
Reverse 
5’ AGGTGTCTGAGGCTGGTTGT 3’ 
5’ CTATGTGCTGGGCTTTGAGG 3’ 
Mouse D6 QPCR  Forward  
Reverse 
5’ TTCTCCCACTGCTGCTTCAC 3’ 
5’ TTCCATCTCAACATCACAGA 3’ 
Mouse GAPDH QPCR  Forward  
Reverse 
5’ CAGCAAGGACACTGAGCAAG 3’ 
5’ TATTATGGGGGTCTGGGATG 3’ 
Human D6 QPCR  Forward  
Reverse 
5’ AGGAAGGATGCAGTGGTGTC 3’ 
5’ CGGAGCAAGACGATGAGAAG 3’ 
Human GAPDH QPCR  Forward  
Reverse 
5’ CAAGGCTGAGAACGGGAAG 3’ 
5’ GGTGGTGACGCCGCCAGT 3’ 
  
2.1.6  Tissue culture media and reagents 
 
 
Gibco (Invitrogen, Paisley, UK)  Dulbecco’s  modified  Eagle’s  Medium 
(DMEM) 
 
Fetal Calf Serum (FCS) 
 
Glutamine 
 
Streptomycin/Penicillin 
 
Trypsin (0.25%) 
 
Cambrex (Walkersville, MD)  Keratinocyte  bullet  kit  (keratinocyte 
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2.2 Methods 
2.2.1   Molecular Biology 
2.2.1.1    Preparation of genomic DNA from tail tips 
Tail tips from weaned mice were digested in screwcap eppendorfs with 100ml 
lysis  buffer  (100mM  TrisHCl,  5mM  EDTA,  0.2%  SDS,  200mM  NaCl)  and  1ml 
(10mg/ml)  proteinase  K  in  a  water  bath  at  55°C  overnight.  The  tubes  were 
heated for 5 minutes in a heating block at 96°C then each sample was diluted 
with  500ml  of  double  distilled  water  (ddH2O).  The  tubes  were  centrifuged  at 
12,000x g and stored at 4°C. For neonates, the tail tips were only incubated for 
6 hours in the water bath and were then processed as described above. 
2.2.1.2   RNA extraction using Trizol 
Trizol  was  used  for  RNA  extraction  from  tissues  following  manufacturer’s 
instructions. Tissues were ‘snap frozen’ with liquid nitrogen and ground with a 
mortar  and  pestle.  For  homogenisation,  1ml  Trizol  was  added  per  50 100mg 
tissue,  thoroughly  mixed  and  left  for  5  minutes  to  dissociate  complexes. 
Chloroform, 0.2ml per ml Trizol, was added and the tubes inverted 15 times 
before  incubation  at  room  temperature  for  2  minutes.  The  tubes  were 
centrifuged  (12,000x  g,  15  minutes,  2 8°C)  and  the  RNA  layer  (colourless 
aqueous layer) was transferred to a fresh RNase free tube. RNA was precipitated 
from the aqueous layer with isopropyl alcohol (0.5ml/1ml trizol) and incubated 
for 10 minutes at room temperature, centrifuged (10 minutes, 12,000 x g) and 
the supernatant carefully removed. The pellet was washed with 75% ethanol, 
centrifuged  (7,500x  g,  5  minutes,  2 8°C),  supernatant  removed  and  the  RNA 
pellet left to dry. The pellet was resuspended in 100ml RNase free water. RNA 
concentration was measured using a spectophotometer. 
RNA was DNase treated, to remove any DNA present, using the RNase free DNase 
kit according to manufacturer’s instructions. 10x DNA buffer (5ml) was added to 
5mg  RNA  sample  along  with  1ml  DNase  and  made  up  to  50ml  with 
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minutes. DNase inactivating reagent (5ml) was added and mixed thoroughly for 
two minutes at room temperature then spun at 12,000x g at 4°C for 2 minutes. 
The DNase free RNA was transferred to a fresh clean tube. However, most of the 
RNA  was  DNase  treated  using  RNeasy  mini  columns  and  on column  DNase 
treatment (see 2.2.1.4).  
2.2.1.3   RNA extraction using RNeasy Mini Kit 
The RNeasy kit technology involves the lysis of tissue or cells by using a buffer 
containing  guanidinium isothiocyanate  (buffer  RLT),  which  will  denature  any 
RNase  enzymes  present,  preventing  RNA  from  being  destroyed.  The  kit  also 
contains silica gel membrane columns, which allow RNA to bind, in ideal binding 
conditions with the use of ethanol, and any contaminants present are removed 
by washing and centrifuging the columns. 
Extraction  of  RNA  from  cells  was  performed  following  manufacturer’s 
instructions. In brief, cells were disrupted with either 350ml or 600ml buffer RLT 
containing 2 mercaptoethanol, depending on the number of cells. This process 
lyses the cells and inactivates any RNases present by denaturing them. The cells 
were then homogenised by passing the lysate through a 20 gauge needle at least 
five  times.  One  volume  of  70%  ethanol  was  added  to  the  lysate,  and  mixed 
thoroughly  before  applying  to  the  RNeasy  spin  column.  The  columns  were 
centrifuged for 15 seconds at 8,000 x g and the flow through discarded. Wash 
buffer, RW1, (350ml) was then applied to the column, centrifuged (15 seconds, 
8,000x g) and the flow through discarded followed by a 15 minute incubation 
with DNase1 at room temperature. The columns were washed with 350ml of wash 
buffer RW1, centrifuged and the flow through was discarded. Buffer RPE (500ml) 
was applied to the column, which was then centrifuged at 8,000x g. A second 
volume of RPE was added, to ensure all contaminants were removed, and the 
column was centrifuged at 8,000x g for 2 minutes. RNA was eluted in RNase free 
water and centrifuged at 8,000x g for 1 minute before the concentration of RNA 
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2.2.1.4   RNA clean up 
This method was applied to RNA extracted from tissues, which was required for 
quantitative PCR (QPCR). The RNA clean up method involved DNase treatment 
using the RNeasy mini kit to remove any contaminating DNA. In brief, no more 
than  100mg  RNA  was  loaded  onto  an  RNeasy  mini  column.  The  sample  was 
adjusted to a volume of 100ml, if required, with RNase free water. Buffer RLT 
(350ml) was added to the RNA sample and mixed thoroughly before addition of 
250ml ethanol and was applied to the RNeasy mini column. From this point on, 
the method followed was the same as in 2.2.1.3 
2.2.1.5   RNA quality test 
Once RNA was isolated from tissues or cells and had been DNase treated, a small 
sample was tested to check the quality of RNA and to ensure no degradation had 
occurred.  RNA  (1 l)  was  mixed  with  3 l  ddH2O  and  1 l  5x  loading  dye  and 
electrophoresed on a 1% agarose gel (see 2.2.1.8) for 20 minutes at 120V and 
visualised  under  a  ultraviolet  (UV)  light  for  the  presence  of  the  28s  and  18s 
ribosomal  bands  of  RNA.  Intact  RNA  displays  2  clear  and  sharp  bands  which 
correspond to the 28s and 18s bands, with the 28s band being twice as intense as 
the 18s band. If no distinct bands but a smear appeared, this indicated that the 
RNA was degraded and was of no use.  
The  quality  of  RNA  can  also  be  checked  when  quantifying  RNA  using  a 
spectophotometer. The absorbance of the RNA is measured at 260 and 280nm 
and the ratio of these readings give an indication of the quality of the RNA and 
whether there are any contaminants such as protein or phenol. A ratio of 1.8 to 
2.1 indicates that the RNA is good quality and has limited contamination.  
2.2.1.6   cDNA synthesis from RNA 
cDNA was transcribed from RNA using Superscript first strand cDNA synthesis kit 
following  manufacturer’s  instructions.  For  each  sample,  a  minus  reverse 
transcriptase (RT) reaction was performed as a control. In brief, 1mg RNA was 
placed in an RNase free tube with 1ml dNTP and 1ml Oligo (dT) and made up to a 
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placed on ice for 1 minute. An RT master mix was made up per reaction to 
contain 2ml 10xRT buffer, 4ml 25mM MgCl2, 2ml 0.1M DTT and 1ml RNase OUT 
recombinase  inhibitor.  Master  mix  (9ml)  was  added  to  each  denatured  RNA 
sample and incubated for 2 minutes at 42°C. Superscript II RT (1ml) or DEPC 
treated  water  (1ml)  was  added  to  the  +RT  and   RT  samples  respectively.  All 
samples  were  incubated  at  42°C  for  50  minutes  followed  by  a  15 minute 
incubation at 70°C to inactivate the reaction and then chilled on ice. RNase H 
(1ml) was added and the samples were incubated for 20 minutes at 37°C. The 
first strand cDNA could then be amplified by polymerase chain reaction (PCR) or 
diluted 1:5 in nuclease free water for quantitative polymerase chain reaction 
(QPCR). 
2.2.1.7   Polymerase chain reaction 
Polymerase chain reaction is a method that amplifies DNA, in which one PCR 
cycle  ideally  doubles  the  amount  of  the  targeted  sequence.  Each  PCR  cycle 
consists  of  three  steps,  a  denaturing  step,  an  annealing  step  and  a  primer 
extension step. The denaturing step is first where the temperature is high to 
separate double stranded DNA into single strands. The annealing step involves a 
decrease in temperature and allows the primers to bind (or anneal) to the target 
DNA template. The temperature is increased in the primer extension step, to an 
optimum temperature that will allow DNA polymerase to bind and elongate the 
primers generating new DNA and the cycle starts again. After 25 to 35 cycles, 
the amplified product can be analysed. 
ReddyMix PCR master mix tubes were used for PCR applications. 1ml (or 0.4ml for 
genotyping)  of  each  of  the  appropriate  forward  and  reverse  primers  at  a 
concentration of 10mM (20mM for murine D6) were normally used.  When the DNA 
template  concentration  was  not  known,  2ml  was  used  unless  it  was  for 
genotyping of primary keratinocytes where 3.75ml was added. The tubes were 
incubated in a PCR thermocycler. Primer sequences used are detailed in section 
2.1.5. 
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The PCR programmes were as follows;  
WT/K14mD6 genotyping: 96°C for 5 minutes, (96°C for 15 seconds, 55°C for 15 
seconds, 68°C for 30 seconds) x 35 cycles, 68°C for 10 minutes, using K14mD6 
primers. 
Primary keratinocyte genotyping: same as WT/ K14mD6 genotyping. 
Detection of murine D6:  94°C for 2 minutes, (92°C for 15 seconds, 55°C for 15 
seconds, 72°C for 30 seconds) x 30 cycles, 68°C for 10 minutes, using 20mM mD6 
primers. 
Detection of CCR1, 3 and 5: 94°C for 10 minutes, (94°C for 15 seconds, 59°C for 
30 seconds, 72°C for 30 seconds) x 35 cycles, 72°C for 10 minutes. 
Detection of CCR2 and 4: 94°C for 10 minutes, (94°C for 15 seconds, 61°C for 30 
seconds, 72°C) x 35 cycles, 72°C for 10 minutes. 
b b b b-Actin: 94°C for 2 minutes, (92°C for 15 seconds, 55°C for 15 seconds, 72°C for 
30 seconds) x 30 cycles, 68°C for 10 minutes. 
2.2.1.8   Agarose gel electrophoresis 
Electrophoresis grade agarose was dissolved in 1x tris acetate EDTA (TAE) buffer 
by  heating.  Ethidium  bromide  was  added  to  the  cooled  gel  to  give  a  final 
concentration of 0.05mg/ml and then the gel was poured to set in a flat cassette 
apparatus  at  room  temperature.  Samples  were  run  alongside  a  DNA  ladder 
marker and, unless otherwise stated, all gels were run at 90V in 1xTAE buffer. 
DNA was visualised under UV light and the gel image captured using an Alpha 
Imager gel documentation system. 
2.2.1.9   Quantitative polymerase chain reaction 
Standard PCR gives an indication of the presence of transcripts however; it is not 
accurate in assessing quantitatively if one sample contains more transcripts than 
another sample. To do this, requires a method known as quantitative PCR or Vicky King, 2010      Chapter 2, 106 
real time  PCR.  This  QPCR  protocol  determined  transcript  number  utilising  a 
methodology  based on a SYBR Green master mix, which contains SYBR Green I 
dye  that  binds  double  stranded  DNA  resulting  in  a  fluorescent  signal  being 
emitted (Morrison et al., 1998). Therefore, as SYBR Green detects new copies of 
double stranded DNA formed during the PCR reaction, the fluorescent intensity 
increases.  This  method  involved  using  a  standard  curve,  which  required  the 
generation  and  isolation  of  standards  for  the  gene  of  interest  as  well  as 
designing and validating primers to use in the QPCR machine.  
Designing primers 
 
Two sets of primers were required for each gene of interest in SYBR Green based 
QPCR. One is a set of ‘inner’ (nested) primers for use in the QPCR machine and 
the second set, ‘outer’ primers were designed to generate PCR products of the 
gene of interest to act as standard templates. Therefore, standard templates are 
generated by PCR using outer primers to amplify a specific part of DNA in which 
the inner primers bind. 
All primers were designed using Primer3 software and the nucleotide sequence 
of the gene of interest. Primer3 software is available at;    
(http://www.broad.mit.edu/cgi bin/primer/primer3_www.cgi/).  Primers  were 
designed with QPCR specification, which are more stringent than required for 
standard PCR primers, such as optimal melting temperature of the primers (Tm), 
maximum  self complementarity  and  maximum  3’  self complementarity.  The 
maximum  self complementarity  determines  the  alignment  and  self 
complementarity of a single primer as well as a maximum alignment score for 
the complementarity between the left and right primers as a pair. Maximum 3’ 
self complementarity is the maximum alignment score allowed when testing a 
single  primer  for  self complementarity  and  for  the  complementarity  between 
the  3’  of the  left and  right  primers.  Maximum  3’  self complementarity  score 
between primers gives an indication of the likelihood of primer dimers occurring 
during PCR. The specifications of the primers were designed to the conditions of; 
·  between 18 and 23 base pair (bp) in length 
 
·  between 40 and 65% GC content,  
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·  melting temperature of the primers should be between 59.5°C and 61.5°C 
with an optimal Tm of 60°C,  
 
·  product size should be between 100 and 180bp,  
 
·  maximum self complementarity : 2  
 
·  maximum 3’ self complementarity: 1  
 
·  avoid stretches of 4 G or C bases in a row. 
  
Primers were designed to bind within the last 1500bp of the 3’ end of the mRNA. 
Using these specifications, primers were usually generated however if no primers 
were suggested by Primer3, some conditions were relaxed until primers were 
suggested.  These  conditions  were  increasing  maximum  self complementarity 
from 2 to 3, decrease the optimal melting temperature of the primers to 59°C or 
examine more of the 5’ sequence on the template until suitable primers are 
found.  One  condition  that  was  not  relaxed  was  the  maximum  3’  self 
complementarity, which remained at 1. These specifications were used to design 
‘inner’ QPCR primers. Once these were designed, outer primers were designed 
to  amplify  the  region  in  which  inner  QPCR  primers  would  bind.  The  ‘outer’ 
primers were designed using the same software and similar parameters however, 
they were allowed to have higher self complementarity and generate a larger 
product size. 
Validation of primers 
 
Both  sets  of  primers  were  tested  for  specificity  by  standard  PCR  using  cDNA 
prepared from RNA isolated from tissue or cells known to express the gene of 
interest. In general, 2ml of cDNA and 1ml of the forward and reverse primer were 
added to Reddy mix tubes. The PCR programme was 95°C for 3 minutes, (95°C 
for 15 seconds, 59°C for 20 seconds, 72°C for 20 seconds) x35 cycles, 72°C for 10 
minutes. PCR products were separated using electrophoresis on an agarose gel
 
(1% for PCR products containing standards and 2% for PCR products generated 
using inner QPCR primers) and visualised using ethidium bromide under a UV 
light. Inner QPCR primers were suitable for QPCR if a single, clear and distinct 
band of the correct size occurred, therefore indicating specificity. However if 
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unsuitable for QPCR. However, if primer dimer or low molecular weight bands 
occurred,  then  altering  PCR  conditions,  such  as  increasing  annealing 
temperature  or  decreasing  primer  concentration  or  both,  could  correct  for 
these.  On  the  other  hand,  if  no  product  was  visible,  then  increasing  primer 
concentration  and/or  decreasing  annealing  temperature  helped  primers  to 
produce a specific product.  
Generating standards for QPCR 
 
To  quantify  the  levels  of  the  gene  of  interest  in  unknown  samples,  the 
generation  of a  standard  curve  was  required.  A  PCR  product  using  the  outer 
primers  generated  a  standard  DNA  template  for  each  gene  of  interest.  The 
product generated was required to be a clear distinct band of the predicted size. 
If  this  was  the  case,  the  PCR  product  was  purified  using  a  PCR  purification 
column following manufacturer’s instructions (Qiagen QIAquick PCR purification 
kit). In brief, 5 volumes of binding buffer PB were added to 1 volume of PCR 
sample and mixed. A yellow coloured sample indicated the pH was less than or 
equal to 7.5, which is optimal for DNA adsorption. The sample was applied to 
the QIAquick column and centrifuged for 30 seconds to allow binding of DNA. 
The flow through was discarded and 0.75ml Buffer PE was added to the column 
and centrifuged for 30 seconds to wash impurities through the column. The flow 
through was discarded and the column was centrifuged for a further 30 seconds 
to remove any ethanol residue then the QIAquick column was placed in a clean 
eppendorf  tube.  Buffer  EB  (50ml)  was  added  to  the  centre  of  the  QIAquick 
membrane  and  the  column  was  centrifuged  for  1  minute  to  elute  DNA.  The 
purified PCR products were diluted in nuclease free water to generate serial 
dilutions,  each  being  10  fold  more  dilute  than  the  previous.  The  range  of 
standards was from 1x10
 4 fold dilution to 1x10
 9 fold dilution
 to generate a good 
standard curve. Each of these standards was used as a template for QPCR using 
the inner QPCR primers for amplification. Using standards where different levels 
of template are present gives an indication of the range and sensitivity of the 
assay. The use of standards allows relative or absolute quantification of unknown 
transcript levels. 
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Calculating transcript numbers 
 
Relative  quantification  was  used  to  determine  relative  differences  of  gene 
transcript levels between samples and was expressed as fold change. For relative 
quantification, arbitrary values were given to the standards. For example, 1x10
 4 
fold dilution was given the arbitrary value of 10,000,000 copies and 1x10
 9 fold 
dilution standard was given the arbitrary value of 100 copies. 
To  quantify  the  absolute  level  of  transcripts,  the  number  of  copies  of  PCR 
products within each standard was determined. To do this, 3ml of each standard 
PCR product, after purification, was mixed with 1ml ddH20 and 1ml 5x loading dye 
and run on a 1% agarose gel alongside 5ml Hyperladder I marker, where the mass 
of each band is known. The intensity of the bands in Hyperladder I and standard 
PCR products were quantified by densitometric analysis using software on the 
Alpha Imager gel documentation system. A standard curve was generated using 
the known mass of the Hyperladder band and the band’s intensity. Therefore 
using the intensity of the standard PCR product, the mass per ml was determined 
using  the  standard  curve.  Transcript  copy  numbers  within  each  standard  was 
calculated using a series of formulae and facts as follows.  
Firstly, the molecular weight of the standard was calculated; 
 
·  Average molecular weight for double stranded nucleotide = 660 Daltons 
 
·  Molecular weight of double stranded DNA = 660 Daltons x bp length 
 
The number of moles/ml was calculated; 
 
·  Moles of standard = (mass/ml)/(molecular weight DNA) 
 
 
Then to convert moles into copy number, the number of molecules per mole is 
6.023x10
23 copies (Avogadro’s constant) 
·  Copies DNA per ml = Avogadro’s Constant x moles 
The known value of copies of DNA per ml was used to calculate the number of 
copies in each of the diluted standards.        
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Setting up SYBR green based QPCR 
 
Before starting, a plan was made of the 96 well QPCR plate, and a master mix 
was made to cover all reactions within the QPCR plate. For each reaction, 7.5ml 
of Power SYBR Green master mix, 0.6ml of primer mix and 5.4ml of nuclease free 
water were mixed together.  
Standard or sample cDNA (4.5ml) was placed in a mixing well, along with 40.5ml 
master mix and was mixed thoroughly and carefully by pipetting up and down 
three times. Of this, 15ml was placed in three of the wells on the QPCR plate 
(each sample was applied in triplicate). A non template control (NTC) was also 
included to determine the level of contamination and the detection limit of the 
assay. The plate was spun for 20 seconds at 400x g before being placed in the 
QPCR machine (Applied Biosystems 7900HT Real time PCR system). In general, 
the QPCR conditions were; 94°C for 10 minutes, (94°C for 3 seconds, 60°C for 30 
seconds) x 40 cycles followed by a dissociation stage. A dissociation stage for 
SYBR  Green  based  QPCR  is  important,  as  a  melt  curve  analysis  can  be 
determined at the end, which allows determination of the specificity of the PCR 
reaction.   
The  software  on  the  QPCR  machine  automatically  works  out  the  level  of 
fluorescence that indicates exponential PCR amplification and the cycle number 
at which each well crosses the threshold. This is known as the Ct value. By using 
arbitrary or absolute copy numbers, the software can then use the Ct value to 
calculate  the  copy  numbers  in  each  sample  taken  from  the  standard  curve. 
However, before using these values, certain analysis of the data is required. The 
standard curve should have a correlation of r
2>0.97 and a slope of approximately 
3.3  (this  means  the  PCR  product  has  amplified  10 fold  every  3.3  cycles  and 
indicates  the  reaction  was  100%  efficient).  The  Ct  value  generated  the  NTC 
sample was noted as this signifies the sensitivity level of the assay. Examination 
of  the  dissociation  curve  should  reveal  one  peak  indicating  the  reaction  was 
specific and no primer dimer occurred. 
Normalising QPCR data  
 
All QPCR data was normalised using a housekeeping gene. To allow comparison 
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samples  was  assessed.  The  housekeeping  gene  used  was  glyceraldehyde 3 
phosphate  dehydrogenase  (GAPDH).  The  GAPDH  gene  codes  for  an  enzyme 
(catalyses the oxidative phosphorylation of glyceraldehyde  3 phosphate to 1, 3 
diphosphoglycerate) involved in cell metabolism. The amount of transcripts of 
the gene of interest is normalised using the housekeeping gene to control for 
varying  amounts  of  cDNA  between  samples  due  to  differential  rates  of  RNA 
degradation,  varying  efficiency  during  the  RNA  extraction  procedure  and  the 
efficiency of the reverse transcription reaction.  
To calculate absolute transcript levels for the gene of interest, the data was 
normalised to GAPDH using the following calculation: 
·  Copy number of gene of interest/ copy number of GAPDH gene x 10
5 
This gives the copy number of the gene of interest per 10,000 copies of GAPDH 
When  calculating  relative  levels  for  the  gene  of  interest,  each  sample  was 
allocated a ratio of its GAPDH content compared to the 75
th percentile of the 
GAPDH levels of all the samples. The levels of the gene of interest were then 
normalised by dividing by the GAPDH ratio. An example is shown below: 
 
Sample 
   Gene of interest 
(copy number) 
GAPDH 
(copy number) 
GAPDH 
ratio 
Corrected level 
of gene of 
interest 
 skin  40  14  0.86  46.4 
 skin + x  40  17  1.04  38.2 
  75
th percentile  16.25     
         
WT keratinocyte  88  36  1.10  39.7 
WT keratinocyte + x  44  22  0.67  32.5 
  75
th percentile  32.5     
   
Table 2-1. Example of normalisation of QPCR data using a housekeeping gene to determine 
levels of ‘gene of interest’. 
In the first example, skin and skin  + x  appear to express  a similar  level of the ‘gene of 
interest’. Once the data has been normalised, skin actually has higher levels of ‘gene of 
interest’  than  skin+x.  This  was  because  the  skin  expressed  a  lower  level  of  GAPDH  (14 
copies) than skin+ x (17 copies). In the second example, initially the level of the’ gene of 
interest’  in  WT  keratinocytes  appears  to  be  2-fold  higher  than  WT  keratinocyte+x.  Once 
normalised, it can be seen that the difference in the levels of the ‘gene of interest’ between 
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2.2.2    In vivo analysis 
2.2.2.1    Maintenance of mice 
Mice were housed within the animal facility at the Central Research Facility at 
Glasgow University. All procedures performed on mice were in accordance with 
United Kingdom Home Office guidelines as well as under appropriate project and 
personal licences. 
2.2.2.2    Genotyping of mice  
A K14D6 mouse colony was maintained by crossing of K14D6 x FVB/N wild type 
mice resulting in littermates being either K14D6 or wild type. Weaned mice and 
neonates were tail tipped and DNA was extracted (see 2.2.1.1). Genotype was 
determined by PCR. DNA (2ml) and 0.4ml of 10mM K14mD6 primers were added to 
pre aliquoted reddy master mix tubes. PCR conditions were 96°C for 5 minutes, 
(96°C for 15 seconds, 55°C for 15 seconds, 68°C for 30 seconds) x 35 cycles and 
68°C for 10 minutes. PCR products were electrophoresed on a 1% agarose gel 
containing  ethidium  bromide.  A  band  of  approximately  400bp  size  indicated 
K14D6 transgenic and no band indicated D6 wild type littermate. 
2.2.2.3   Epidermal sheet preparation 
Two methods were tested to determine the best method to isolate epidermal 
sheets from mouse skin. Subcutaneous fat was removed from dorsal skin and the 
skin  was  cut  into  small  sections.  One  method  involved  incubating  the  skin, 
dermal side down, in 0.5M ammonium thiocyanate in PBS for 10 and 20 minutes 
at 37°C. The second method involved incubating the skin, dermal side down, in 
0.025M EDTA for 2 hours at 37°C. Dermal and epidermal sections were separated 
carefully and were fixed in formalin to be stained with haematoxylin and eosin 
or were ‘snap frozen’ in liquid nitrogen for RNA extraction following the method 
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2.2.2.4    Harvesting of primary keratinocytes      
Neonates (from K14D6 x WT crosses) were sacrificed, placed into 70% ethanol 
and tail tipped for genotyping using K14mD6 primers (see 2.2.1.1 and 2.2.2.2). A 
clean cut of the skin was made from the tail to the head and the body was 
separated from the skin. The skin was placed dermal side down, stretched on 
the tissue culture dish with forceps and left for 20 minutes to dry before the skin 
was placed dermal side down in 0.25% trypsin overnight at 4°C. The epidermis 
was carefully peeled apart from the dermis, placed into 15ml tubes containing 
DMEM/10% FCS, and shaken for 20 minutes. The suspension was filtered through 
a gauze swab, centrifuged (1000x g for 5 minutes) and the supernatant carefully 
discarded (Yao et al., 2006). The pellet was resuspended in 1ml supplemented 
keratinocyte growth media (KGM) per skin containing 0.05mM calcium ready to 
seed and be cultured for five days for either RNA isolation, western blotting or 
flow cytometry. 
2.2.2.5   Staining of primary keratinocytes 
Keratinocytes  were  harvested  and  resuspended  before  seeding  500ml  into 
chambered slides coated with fibronectin. The cells were fed every two days 
with fresh keratinocyte growth media. On day 5, the media was aspirated and 
the slides were allowed to dry before the sides of the chambered slides were 
broken off. Cells were fixed in methanol for 10 minutes and allowed to air dry. 
The cells were incubated in the red stain from the RAPI Diff II kit, which is a 
staining kit similar to giemsa, for 3 minutes and 30 seconds then put into the 
blue stain for 10 seconds and rinsed in ddH2O and allowed to air dry. A coverslip 
was applied, mounted with DPX solution and dried for 24 hours. Pictures were 
taken with Axiovision software and microscope. 
2.2.2.6    Assessment of keratinocyte purity  
Keratinocytes from individual neonates were isolated and cultured for five days 
to  be  assessed  for  purity  by  flow  cytometry.  At  the  stage  of  isolation, 
keratinocytes  were  resuspended  in  1ml  KGM.  200ml  of  keratinocytes  was 
aliquoted into wells in 24 well plate and cultured for five days. Keratinocytes 
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PBS/2mM  EDTA/0.1%  FCS  (PEF)  then  permeabilised  using  a  standard  fix 
permeablisation kit, which permeablises cells. Keratinocytes were labelled for 
10  minutes  at  room  temperature  with  1.5mg/ml  FITC conjugated  mouse  anti 
cytokeratin  (pan)  antibody  or  FITC conjugated  mouse  IgG1  antibody  (isotype 
control). Keratinocytes  were  washed  and analysed  by  flow  cytometry  using a 
FACS  Calibur  machine,  in  which  cytokeratin  expression  was  measured  and 
compared to the isotype control.   
2.2.2.7    Incubation of keratinocytes with biotinylated CCL3 
Keratinocytes  from  individual  neonates  were  isolated  and  cultured  in  6cm 
plates. On day 5, media was aspirated from primary keratinocytes, washed with 
PBS  and  1ml  of  fresh  KGM  containing  1%  BSA  was  added.    To  each  plate  of 
2.5x10
5  cells,  10nM  biotinylated  CCL3  (BioCCL3)  was  added  and  incubated  at 
37°C.  Media  was  sampled  from  the  plates  at  various  timepoints  for  western 
blotting.  To  ensure  the  result  was  D6  specific,  keratinocytes  were  incubated 
with 10nM BioCCL3 and 100nM CCL22. Both are D6 ligands and therefore this is a 
D6 specific competition assay. Media was also sampled at various time points for 
western blotting. 
2.2.2.8    Detection of biotinylated CCL3 by western blotting  
15ml of KGM media sampled from keratinocytes incubated with BioCCL3 were 
mixed with 15ml 2x Laemmli buffer and heated at 90°C for 5 minutes. Samples 
were  added  to  a  well  in  a  4 12%  NuPage  Bis Tris  gel  alongside  a  multimark 
multicolour standard, in the inner chamber of the tank containing MES running 
buffer  with  0.1M  DTT.  The  outer  chamber  of  the  tank  was  filled  with  MES 
running buffer and the gel set to run at 120V for one and a half hours or until the 
bromophenol blue marker was approximately ¾ of the way down the gel. The gel 
was then placed onto a nitrocellulose transfer membrane in a blot module with 
transfer  buffer  and  run  at  150mV  for  approximately  two  hours.  The  transfer 
membrane  was  left  overnight  in  10%  powdered  milk  in  PBS  at  4°C.  The 
membrane was washed several times with PBS/0.1% Tween 20 for approximately 
half an hour. The detection agent, strepavidin labelled horseradish peroxidase 
(HRP) was diluted 1:2000 and incubated with the transfer membrane for 1 hour 
before  thoroughly  washing  with  PBS/0.1%  Tween  20.  The  chemiluminescent Vicky King, 2010      Chapter 2, 115 
substrate for HRP was detected by ‘west femto’ and the membrane was drained, 
exposed to x ray film, which was then placed through a film developer. 
2.2.2.9    Assessment of CCL2 binding by keratinocytes using 
flow cytometry 
Individual keratinocytes were isolated and cultured for five days to be assessed 
in  their  ability  to  bind  CCL2  by  flow  cytometry.  At  the  stage  of  isolation, 
keratinocytes  were  resuspended  in  1ml  KGM.  200ml  of  keratinocytes  were 
aliquoted into wells in 24 well plates and cultured for five days. On day 5, 250ml 
fresh  media  containing  1%  BSA  was  added  to  the  cells.  Keratinocytes  were 
incubated with either PBS, 25nM CCL2 conjugated to Alexa 647 (CCL2 alexa 647) 
or 25nM CCL2 alexa 647 and 250nM CCL3 for 100 minutes at 37°C.  Keratinocytes 
were trypsinised in 1ml 0.25% trypsin for 5 minutes at 37°C and washed twice 
with  PEF  (PBS/2mM  EDTA/0.1%  FCS).  Keratinocytes  were  then  analysed  for 
binding of CCL2 alexa 647 using the FACS Calibur flow cytometry. 
2.2.2.10  Testing an anti-mouse D6 antibody 
A polyclonal antibody raised in chicken against murine D6 became available. It 
was not known whether this antibody would be specific for D6 and therefore the 
antibody was required to be tested and optimised. It was decided to test the 
antibody on cells known to express murine D6 using western blotting. A stable 
transfected cell line (Human Embryonic Kidney cells (HEKs)) expressing murine 
D6 had been made and used within our lab previously known as HEKmD6. HEKs 
and HEKmD6 were cultured in complete DMEM (containing 10% fetal calf serum, 
4mM L glutamine, penicillin and streptomycin). Once the cells were confluent, 
the  cells  were  trypsinised,  centrifuged  for  5  minutes  and  the  cell  pellet 
resuspended  in  5  ml  of  media.  The  cells  were  counted  and  2x10
6  cells  were 
aliquoted and centrifuged again for 5 minutes. The cell pellet was lysed in 500ml 
of cell lytic M mammalian cell lysis buffer and placed on ice for 15 minutes. The 
lysed cells were then centrifuged and the supernatant was carefully taken off. 
Total protein levels within the supernatants were measured using a bicinchoninic 
acid  (BCA)  protein  assay  following  manufacturer’s  instructions.  In  brief,  25ml 
sample  or  standard  was  added  in  duplicate  to  a  96  well  plate  and  200ml  of 
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shaker for 30 seconds and incubated at 37°C for 30 minutes before absorbance 
was  measured  at  562nm  in  a  plate  reader.  For  the  western  blot,  15ml  of 
supernatant  contained  a  total  of  10mg  protein  and  was  mixed  with  15ml  HU 
buffer (8M urea, 5% SDS, 200mM Tris HCl pH8.0, 0.1mM EDTA, 0.5% bromophenol 
blue, 100mM DTT). The gel and transfer membrane were run as described in 
2.2.2.8.  The  primary  antibody,  anti mouse  D6  antibody,  was  diluted  and 
incubated with the transfer membrane for 1 hour at room temperature before 
thoroughly  rinsing  with  PBS/0.1%  Tween  20.  The  secondary  antibody,  donkey 
anti chicken conjugated to HRP, was diluted 1:5000 and added to the membrane 
for  1  hour  before  washing  with  PBS/0.1%  Tween.  The  chemiluminescent 
substrate for HRP was detected by incubation with ‘west pico’ for 5 minutes and 
then  membrane  was  drained,  exposed  to  x ray  film,  which  was  then  placed 
through a film developer. 
2.2.2.11  Cutaneous skin inflammation model 
The dorsal skin of mice was shaved and two days later 150ml of a 50mM solution 
of Phorbol 12 Myristate 13 Acetate, (PMA, also known as TPA) was applied to the 
dorsal skin of each mouse on three consecutive days to induce inflammation. 
2.2.2.12  Haematoxylin staining 
Mouse dorsal skin was placed into 10% neutral buffered formalin and transported 
to the University of Glasgow Veterinary School, where the sections were cut and 
stained with haematoxylin and eosin.  
2.2.2.13  Measuring skin thickness 
Haematoxylin  and  eosin  skin  sections  were  analysed  for  skin  thickness,  in 
particular epidermal and dermal thickness. A specialised eyepiece containing a 
grid was used in the microscope. Thickness was assessed by counting the number 
of  squares  the  skin  filled,  which  was  then  multiplied  by  50  to  convert  the 
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2.2.3  Keratinocyte microarray 
Microarrays allow the analysis of expression of thousands of genes in one assay. 
Microarray  platforms  are  chips  with  a  solid  matrix  consisting  of  fixed  DNA 
sequences (probes) that correspond to specific genes, in a known order. RNA is 
harvested from the cells or tissues of interest and labelled. The labelled targets 
are hybridised to the probes, which then provides a quantitative measure of the 
abundance of RNA sequences within the target population. In this project, an 
oligonucleotide microarray was used (Affymetrix GeneChip). These chips contain 
thousands of oligonucleotides, which are single stranded probes made based on 
sequence  information  in  databases,  on  a  glass  surface.  Target  RNA  is 
biotinylated and added to the GeneChip. A streptavidin phycoerythin conjugate 
recognises  any  hybridised  probes  and  fluorescent  signals  emitted  are  then 
detected.      
2.2.3.1   Keratinocyte incubation and RNA extraction 
Keratinocytes were isolated from 1 neonate skin, pooled into groups of three and 
seeded into T75 flasks and cultured for 5 days. On day 5, media was removed 
and 5ml fresh KGM was added along with PBS or 10nM CCL3 in PBS and incubated 
for 6 hours at 37°C. Media was removed and RNA was extracted from cells using 
RNeasy  mini  kit  (see  2.2.1.3).  Samples  were  transferred  to  the  Sir  Henry 
Wellcome  Functional  Genomics  Facility  (University  of  Glasgow)  where  further 
processing of samples was carried out and the microarray analysis performed. 
RNA  quantity  and  quality  was  assessed  using  a  Nanodrop  1000  and  the 
Bioanalyser 2100 respectively.  Each sample was subject to linear amplification 
before being converted to biotinylated cRNA and applied to Affymetrix GeneChip 
Mouse genome 430 2.0 Array for generation and analysis of data. 
2.2.3.2   Microarray analysis  
The data from the Affymetrix gene chips were analysed using combinations of 
Rank Products (RP) and Iterative Group Analysis (iGA). Rank Products generates 
lists of differentially expressed genes and determines statistical significance to 
each  gene.  Rank  products  are  more  reliable  and  consistent,  when  datasets 
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significance  analysis  of  microarrays  (SAM)  for  differential  gene  expression 
analysis (Jeffrey IB et al. 2006). The lists of genes produced by Rank products 
are processed using Iterative group analysis (iGA), which identifies functional 
changed  groups  of  genes,  assigned  according  to  Gene  Ontology 
(http://www.geneontology.org). Iterative group analysis combines the relative 
position of the genes in RP list and the number of changed genes within the 
group to determine the strength of changes within the group statistically. An 
important  feature  is  that  experimental  replicates  are  not  required  because 
statistical significance can be determined by using group members as internal 
replicates. Terminology used by this software can be found in Appendix One. Full 
microarray data using Rank Products and iGA analysis can be found in Appendix 
Two and Three respectively. Validation of microarray data was performed by 
quantitative PCR. 
2.2.4  Human analysis 
2.2.4.1   Collection of human psoriasis skin biopsies 
Skin  biopsies  were  obtained  from  control,  psoriasis  and  eczema  patients  and 
stored in 10% neutral buffered formalin by a dermatologist, Anne Sergeant, from 
clinics  at  Glasgow  Royal  Infirmary.  Some of  the  samples  were  processed  and 
made into cDNA (see 2.2.1.2 and 2.2.1.6) and analysed for D6 transcripts using 
quantitative  PCR.  Other  skin  biopsies  were  kept  for  embedding  into  paraffin 
blocks to use for immunohistochemistry.   
 Embedding of human tissue 
 
Skin biopsy samples were placed in trays and placed in an embedding machine 
(Thermo) to be embedded in paraffin wax blocks. Samples were placed in 10% 
neutral buffered formalin for 30 minutes, 70% alcohol for 1 hour, 90% alcohol for 
1 hour, 95% alcohol for 1 hour then 5.5 hours in 100% alcohol, 3.5 hours in xylene 
and 9 hours in wax. The samples were placed in a known orientation and allowed 
to set in wax ready for sections to be cut onto poly lysine coated slides. 
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Haematoxylin and eosin staining 
 
Sections were placed in xylene for 3 minutes, 10 dips in 100% alcohol, 10 dips in 
70%  alcohol,  washed  in  running  water  and  placed  in  haematoxylin  Z  for  7 
minutes. The sections were then washed in running water followed by 12 dips in 
1% acid alcohol, rinsed in running water, placed in Scotts tap water solution for 
2  minutes  and  the  sections  were  checked  for  staining  microscopically.  Once 
staining occurred, the sections were washed in running water and then placed in 
Putts eosin (diluted 1:2 with water) before being washed again in running water 
for 2 minutes. The sections were dehydrated in 70% alcohol, two sets of 100% 
alcohol and three sets of xylene for 1 minute each. The sections were mounted 
with coverslips using DPX mounting solution and allowed to air dry. 
 Immunohistochemistry using anti-human D6 antibody 
 
A monoclonal anti human D6 antibody had previously been optimised for use on 
human  placenta.  However,  none  of  this  clone  was  available  and  therefore  a 
different clone of antibody was used and required testing on human placenta 
and optimisation on human skin sections. Once optimised the protocol was as 
follows;  Slides  were  heated  in  an  oven  at  60°C  for  35  minutes,  dewaxed  in 
xylene for 10 minutes before being rehydrated in 100% ethanol (2x 5 minutes), 
95%  ethanol  (2x  5  minutes),  70%  ethanol  (5  minutes),  PBS  (5  minutes). 
Endogenous  peroxidase  activity  was  blocked  by  immersing  slides  in  freshly 
prepared 0.5% hydrogen peroxide in methanol for 30  minutes then the slides 
were washed in PBS twice each for 5 minutes. To retrieve antigens, slides were 
immersed in 1mM citrate buffer (pH 6.0) and boiled in the microwave for 3x 5 
minutes. The slides were left to cool for 20 minutes before being washed in 
double distilled water for 5 minutes and then PBS (2x 5 minutes). Sections were 
blocked with 20% horse/20% human serum in PBS containing diluent of avidin D 
(from  Avidin/Biotin  blocking  kit)  for  30  minutes  at  room  temperature  in  a 
humidified box. Blocking serum was tapped off and sections were incubated, in 
mouse anti human D6 or mouse IgG2a isotype control  (diluted 1:1000 to give 
final concentration 0.1 g/ml) in 2% horse serum with 4 drops/ml of Biotin (from 
Avidin/Biotin blocking kit), overnight at 4°C in a humidified box. Sections were 
washed in PBS (2x 5 minutes) and incubated for 30 minutes in biotinylated anti 
mouse IgG (diluted 1:200) in PBS containing 2% horse serum and 5% human serum 
at room temperature. An avidin biotin enzyme complex (with peroxidase as the Vicky King, 2010      Chapter 2, 120 
enzyme) was made (2 drops of solution A into 5mls PBS mixed followed by 2 
drops solution B, from Standard Vectastain ABC kit) and applied to the sections, 
which were then incubated at room temperature for 30 minutes. The slides were 
washed in PBS (2x 5 minutes). The substrate, DAB 3,3’ diaminobenzidine was 
made following manufacturer’s instructions (5mls distilled water, add 2 drops 
buffer, 4 drops DAB and 2 drops hydrogen peroxide and mix) and incubated on 
sections until appropriate staining was seen under the microscope. Sections were 
washed  in  water  for 5  minutes,  stained in  haematoxylin  for  15  seconds  then 
washed in water. The sections were then dehydrated through the alcohols (70% 
alcohol, 95% alcohol, 100% alcohol) then in xylene and finally mounting sections 
with DPX and allowing to air dry before analysis. Pictures of sections were taken 
using a microscope and Axiovision software.  
2.2.4.2   Collection of peripheral blood samples 
Peripheral  blood  samples  were  collected  from  control,  psoriasis,  psoriatic 
arthritis  and  rheumatoid  arthritis  patients  at  various  clinics.  Axel  Hueber,  a 
rheumatologist at Glasgow Royal Infirmary and Clinical Research Fellow within 
the department, collected samples from psoriatic arthritis patients and controls. 
Hilary  Wilson,  a  consultant  at  Glasgow  Stobhill  Hospital  sent  us  rheumatoid 
arthritis peripheral blood samples from her clinic. Psoriasis blood samples were 
collected  mainly  by  David  Burden,  a  consultant  dermatologist  at  Glasgow 
Western  Infirmary  as  well  as  samples  from  a  clinic  run  by  Susan  Holmes,  a 
consultant  dermatologist  at  Glasgow  Royal  Infirmary.  All  10ml  samples  were 
collected into lithium heparin vacuettes.  
Isolation of peripheral blood mononuclear cells 
 
Blood  samples  were  placed  into  sterile  50ml  centrifuge  tubes  and  an  equal 
volume of PBS added and thoroughly mixed. The blood was slowly applied using 
a sterile pasteur pipette onto 4ml Histopaque 1077 in a 15ml centrifuge tube (2 
for  each  sample).  The  samples  were  spun  at  400x  g  for  20  minutes,  which 
separates the blood samples into different layers. The very bottom layer is red 
blood  cells  then  histopaque,  followed  by  a  white  ring  layer,  which  is  the 
peripheral blood mononuclear cell (PBMC) layer. The PBMC layer was carefully 
taken up into a pasteur pipette and transferred to a new 15ml tube and placed 
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centrifuge  and  spun  at  300x  g  for  5  minutes.  The  supernatant  was  carefully 
taken off, and the pellet was composed of T and B lymphocytes, monocytes and 
dendritic cells. The PBMCs were either counted for cell surface analysis by FACS 
or  RNA  was  extracted  from  them  using  350ml  buffer  RLT  containing  2 
mercaptoethanol. 
 Detection of D6 surface levels on specific PBMCs by flow cytometry. 
 
PBMCs were isolated from peripheral blood and cell numbers counted. No more 
than half a million cells were placed into various tubes to stain specific lineage 
markers  for  monocytes,  T  and  B  lymphocytes  and  myeloid  and  plasmacytoid 
dendritic cells. Anti human D6 antibody or anti human IgG2a (both 1.5mg/ml) 
were  added  to  the  appropriate  tubes  containing  500,000  cells  and  incubated 
with the cells for 10 minutes at room temperature. The cells were washed with 
PEF  (PBS/2mM  EDTA/0.1%  FCS)  and  spun  at  300x  g  for  5  minutes.  The 
supernatant  was  removed  and  the  cell  pellets  dispersed.  The  secondary 
antibody, FITC conjugated goat anti mouse IgG antibody F(ab)2 fragment, was 
added to all tubes, incubated for 10 minutes at 4°C, washed and spun (300x g, 5 
minutes). Unlabelled mouse IgG1 was added to all tubes, to block the remaining 
active sites of the secondary antibody to prevent non specific binding, incubated 
for  10  minutes  at  4°C  and  washed  as  previously  stated.  The  next  step  was 
lineage specific antibodies, where four separate antibody cocktails were made. 
An APC conjugated anti human CD3 antibody was used for T cells, PE conjugated 
anti human CD20 antibody for B cells and for monocytes, a PE conjugated anti 
human CD14 antibody was used. For myeloid and plamacytoid DCs, antibodies 
against markers on monocytes and B cells are required as these cells can also 
contain a myeloid DC marker (CD1c) and plasmacytoid DC marker (CD304) and 
therefore need to be excluded when analysing DC population for D6 staining. 
The lineage specific antibodies were added to the appropriate tubes, incubated 
for 10 minutes at 4°C. The tubes were washed with PEF and centrifuge (300x g, 5 
minutes).  Before  samples  were  run  through  the  FACs  Calibur  machine,  5 l 
viaprobe was added to detect any dead cells present. Vicky King, 2010      Chapter 2, 122 
2.2.5  Statistical Analysis 
All graphs and statistical analysis were performed using Graphpad Prism version 
4.0. Graphs were mean ± standard error mean (SEM). Statistics used in this thesis 
were  unpaired  student’s  t test,  a  Krusal  Wallis  test  with  Dunn’s  multiple 
comparison test (Figure 3 11A), two way ANOVA with Bonferroni post test (Figure 
3 9,  Figure 4 8, Figure 4 9, Figure 4 10, Figure 4 11 and Figure 4 12) and one 
way ANOVA with Bonferroni post test (Figure 5 1A, Figure 5 12 and Figure 5 22). 
A ‘p value’ of less than or equal to 0.05 was determined statistically significant.    
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3  Characterisation of K14D6 mice 
3.1 Introduction  
Inflammation  is  the  host’s  natural  response  to  infection  and  helps  restore 
damaged tissue. The initiation of inflammation, which is well characterised, is 
mediated  by  pro inflammatory  mediators,  such  as  chemokines  and  cytokines, 
involved in controlling the migration and behaviour of leukocytes in tissues. The 
resolution  of  inflammation  occurs  naturally  but  little  is  known  about  the 
mechanisms involved. 
D6 is an atypical chemokine receptor with high affinity for 12 pro inflammatory 
CC  chemokines  (Fra  et  al.,  2003,  Nibbs  et  al.,  1997a).  In  vitro  studies  have 
shown  that  D6  can  reduce  extracellular  CC  chemokines  by  constitutively 
recycling to and from the cell surface (Weber et al., 2004). Surface D6 binds and 
internalises ligand, targeting it for degradation within the cell (Weber et al., 
2004).  In  vivo  studies,  using  a  model  of  skin  inflammation  involving  topical 
applications of TPA, have shown that D6 null mice demonstrate a prolonged and 
exaggerated  cutaneous  inflammatory  response  (Jamieson  et  al.,  2005).  As  a 
consequence,  D6  null  mice  demonstrated  a  psoriasis like  pathology, 
characterised by a large influx of mast cells into the dermis and CD3
+ T cells into 
the  epidermis  (Jamieson  et  al.,  2005).  One  mechanism  proposed  for  the 
exaggerated inflammatory response was that D6 null mice were less effective at 
clearing bioavailable CC chemokines (Jamieson et al., 2005). As a result of the in 
vivo studies, D6 was proposed to play an important role in aiding the resolution 
of the inflammatory response.  
We hypothesised that if the absence of D6 results in exaggerated inflammation, 
then  increased  expression  of  D6  would  suppress  the  inflammatory  response. 
Therefore, the aim was to determine whether increased expression of D6 within 
murine  skin,  using  epidermis specific  D6  transgene,  would  suppress  the 
cutaneous inflammatory response in a skin inflammation model. This study, as a 
result, would give an indication of the therapeutic potential of D6. 
Scientific  advances  in  genetic  engineering have resulted  in the production of 
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animals (transgenic) can now give us a better understanding of the function of 
these  proteins.  Within  this  chapter,  details  of  how  D6  transgenic  mice  were 
generated and the characterisation of these mice will be described. Validation 
of  these  mice  was  performed  to  ensure  that  the  transgene  is  specifically 
transcribed where expected, that the resulting protein is functional and plays 
the biological role hypothesised. 
3.2 Generation of K14D6 transgenic mice 
D6 null mice used in the skin inflammation model were generated on a C57BL/6 
background  (Jamieson  et  al.,  2005).  In  addition,  D6  null  mice had  also  been 
backcrossed on to an FVB/N background, to use for a cancer model within our 
laboratory (Nibbs et al., 2007). As D6 transgenic mice were required for both the 
cancer and skin inflammation models, transgenic mice were generated on an 
FVB/N background.  
To examine the role of  increased D6 expression in the skin, a well characterised 
keratin 14 (K14) promoter (Vassar et al., 1989) was used to drive expression of 
D6 in the basal keratinocyte layer within the skin. Murine D6 was cloned into an 
expression  vector  (pG32.K14  vector,  gift  of  E.Fuchs)  containing  the  human 
keratin  14  promoter,  rabbit  b globin  intron,  the  human  K14  3'  untranslated 
region and poly adenylation signal (K14pA). Figure 3.1 illustrates the construct 
used  to  express  D6  in  K14D6  transgenic  mice  (D.S.Gilchrist  and  S.Forrow 
generated  these  mice).  The  transgene  construct  was  introduced  into  FVB/N 
embryos by pronuclear injection and surviving embryos were then transferred 
into  psuedopregnant  foster  mice.  Two  founders  were  generated,  known  as 
Transgenic  (K14mD6)1  and  Transgenic  (K14mD6)2.  Offspring  carrying  the 
transgene were identified by PCR using tail tip DNA (see 2.2.1.1 and 2.2.1.7). 
Female offspring from the two founders were assessed for susceptibility to skin 
inflammation and papilloma formation. Transgenic offspring from both founders 
were  protected  in  comparision  to  their  wild type  littermates  (Nibbs  et  al., 
2007).  Subsequent  experiments  were  performed  using  female  offspring  from 
Transgenic (K14mD6)1 founder.  
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Figure 3-1. K14D6 transgene construct. 
The K14D6 transgene was constructed by cloning the open reading frame of murine D6 
(mD6) into an expression vector containing the human K14 promoter (K14P), the rabbit B 
globin  intron  (bgint),  (K14pA)  the  human  keratin  14  3’  untranslated  region  and 
polyadenylation signal (Vassar et al., 1989). Transgenic mice were generated on an FVB/N 
background in which murine D6 transgene is expressed by keratin 14 promoter in basal 
keratinocytes within the epidermis. 
 
3.3 The  D6  transgene  is  expressed  in  the  epidermis  in 
K14D6 mice 
To  confirm  that  the  transgene  expression  was  directed  to  the  epidermis,  a 
method of separating the murine epidermis from the dermis was required before 
reverse  transcription  (RT) PCR  on  epidermal  sheets  could  be  performed.  Two 
methods of separating the epidermis were compared.  
Dorsal skin was dissected and subcutaneous fat was removed before cutting the 
skin  into  thin  sections.  Skin  was  placed  dermal  side  down  in  either  0.5M 
ammonium thiocyanate for 10 minutes at 37°C, 0.5M ammonium thiocyanate for 
20 minutes at 37°C or 25mM EDTA for 2 hours at 37°C (Komatsu et al., 1996, 
Ratzinger et al., 2002). After incubation, the epidermis was separated from the 
dermis.  Sections  were  fixed  in  10%  neutral  buffered  formalin  and  sent  to 
Glasgow Veterinary School for sections to be paraffin embedded, cut and stained 
with haematoxylin and eosin (Figure 3 2). 
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The  epidermis  is  only  1 2  cell  layers  thick,  which  consists  mainly  of 
keratinocytes,  whilst  the  dermis  is  thicker  and  contains  both  blood  and 
lymphatic  vessels.  By  incubating  the  skin  in  ammonium  thiocyanate  for  10 
minutes,  staining  showed  that  separation  of  the  skin  layers  was  incomplete 
(Figure  3 2A).  The  epidermal  section  showed  parts  of  the  dermis  were  still 
present  in  epidermal  sections  (Figure  3 2A).  Similarly,  within  the  dermal 
sections,  parts  of  the  epidermis  were  also  still  attached  (Figure  3 2B).  By 
increasing the incubation time of the skin in ammonium thiocyanate, there were 
fewer traces of the dermis in epidermal sections (Figure 3 2C). However, within 
the  dermal  sheet  section,  no epidermis  remained  (Figure  3 2D).  Additionally, 
when  using  ammonium  thiocyanate,  it  was  difficult  to  separate  the  skin 
epidermal and dermal sheets in one piece.  
When the skin was incubated in EDTA for two hours, the epidermis was easier to 
separate from the dermis and came apart in a single piece. Analysis of epidermal 
sections showed the separation looked cleaner with little evidence of the dermis 
being  present  (Figure  3 2E).  In  the  dermis,  there  are  many  nucleated  cells 
present (stained in blue) with no evidence of epidermis present at the surface 
(Figure3 2F).  
It was therefore concluded that separation of skin layers was best achieved by 
incubating sections in 25mM EDTA for 2 hours.  
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Figure 3-2. Optimising a method to separate the epidermis from the dermis. 
Dorsal skin was dissected, subcutaneous fat removed and cut into thin sections. Skin was 
placed  dermal  side  down  in  either  (A&B),  0.5M  ammonium  thiocyanate  at  37° ° ° °C  for  10 
minutes at 37° ° ° °C (C&D), 0.5M ammonium thiocyanate for 20 minutes at 37° ° ° °C or (E&F), 25mM 
EDTA  for  2  hours  at  37° ° ° °C.  Epidermal  sheets  were  separated  from  the  dermis,  fixed  in 
formalin and stained in haematoxylin and eosin. Images of epidermal sections are shown in 
A,  C  and  E  while  dermal  sections  are  shown  in  B,  D  and  F.  HF  indicates  hair  follicle. 
Magnification 100x. 
 
 Vicky King, 2010      Chapter 3, 129 
Having decided on the best method to use, RNA was isolated from the epidermal 
sheets of wild type and K14D6 transgenic mice and converted to cDNA to analyse 
for the expression of D6 transcripts. This was to confirm that within the K14D6 
mice, the D6 transgene was being expressed within the epidermis as anticipated.  
Using  RT PCR,  D6  was  detected in the  epidermis  of  K14D6  mice  whilst  being 
absent  from  wild type  epidermis  (Figure  3 3).  D6  is  known  to  be  expressed 
within the skin, specifically on lymphatic endothelial cells present within the 
dermis  (Nibbs  et  al.,  2001).  Extraction  of  RNA  was  attempted  from  dermal 
sheets, which were separated from the epidermis using 25mM EDTA however, 
obtaining  intact  RNA  proved  extremely  difficult.  One  possible  reason  for  this 
failure may be that as the skin sections were dermal side down in the solutions, 
RNA was degraded during processing.  
 
 
 
Figure 3-3. Transgenic expression of D6 in the epidermis of K14D6 mice.  
RNA  was  extracted  from  the  epidermis  of  dorsal  skin  separated  by  25mM  EDTA  in  PBS 
(37° ° ° °C for 2 hours) from wild-type (WT) and K14D6 mice. RT-PCR was performed (+/- reverse 
transcriptase (RT)) to detect mouse D6 and b b b b-actin. Products were run on a 1% agarose gel 
and visualised by UV light. 
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3.4 The D6 transgene is expressed by K14D6 epidermal 
keratinocytes 
The  next  step  was  to  confirm  that  D6  transgene  expression  was  targeted 
specifically to proliferative epidermal keratinocytes within the K14D6 transgenic 
mice, which in turn would allow the functional ability of the D6 transgene to be 
assessed. 
Primary epidermal keratinocytes were isolated and cultured from the skins of 
12 24hr  old  neonates  (Yao  et  al.,  2006)  and  examined  for  D6  expression. 
Neonates were from K14D6 x FVB/N crosses therefore neonatal tail tips were 
obtained in which DNA was extracted and used for genotyping to determine wild 
type and K14D6 mice within the litter. Skin was taken from neonates and placed 
into individual plates dermal side down in 0.25% trypsin overnight at 4°C. The 
epidermis  was  carefully  separated  from  the  dermis  and  either  placed, 
individually  or  pooled,  in  DMEM  containing  10%  FCS  solution,  shaken  for  20 
minutes,  then  filtered  and  centrifuged.  The  keratinocyte  cell  pellet  was 
resuspended in keratinocyte growth media and cultured for 5 days. With very 
efficient  technique,  one  skin  can  yield  initially  approximately  2.5  million 
keratinocytes with a plating efficiency of 40%. To determine how successful the 
method  was,  the  morphology  and  purity  of  the  keratinocytes  cultures  was 
assessed by RAPI DIFFII staining.  
Prior to staining, keratinocytes from individual neonates were resuspended in 
1ml of keratinocyte growth media and 500 l plated into chambered slides and 
cultured. On day 5, the media was aspirated and the cells were stained using 
RAPI DIFFII.  Staining  of  wild type  and  K14D6  keratinocytes  showed  the 
morphology  of  K14D6  keratinocytes  to  be  phenotypically  similar  to  wild type 
keratinocytes  (Figure  3 4).  Within  both  sets  of  cultured  keratinocytes,  the 
majority of the cells were round and small, features typical of keratinocytes 
(examples  shown  within  red  circle  in  Figure  3 4).  However,  there  were 
occasional  larger  cells  within  both  populations,  which  could  have  been 
fibroblasts (examples shown in black circle in Figure 3 4). 
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Figure 3-4. Morphology of wild-type and K14D6 epidermal keratinocytes. 
WT and K14D6 keratinocytes were harvested and cultured in chamber slides for 5 days, 
before cells were fixed with methanol then stained with RAPI-DIFFII. Magnification is 200x. 
Red circles denote keratinocytes and black circles denote fibroblasts. 
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To  further  assess  the  purity  of  the  keratinocytes  cultures,  flow  cytometric 
analysis  was  performed  on  cells  stained  with  the  keratinocyte specific  anti 
cytokeratin  antibody.  Keratinocytes  were  isolated  from  individual  neonates 
(wild type  and  K14D6),  trypsinised,  washed,  permeabilised  and  stained  with 
either  FITC conjugated  mouse  anti cytokeratin  (pan)  antibody  or  FITC 
conjugated matched isotype antibody and the cell populations analysed by flow 
cytometry.  
Figure  3 5A  shows  the  whole  cell  population  using  forward  and  side  scatter 
detectors indicating size and granularity of the cells respectively. The majority 
of the cells are of the same size, within log 2 and 3, and the majority of the 
cells are of similar granularity, between 200 and 400 on the forward scatter. The 
keratinocyte population was gated, R1 shown in Figure 3 5A and cells within this 
gate were then analysed for antibody staining. Figure 3 5B shows in the left hand 
plot,  the  cell  population  gated  by  R1,  stained  with  FITC conjugated  isotype 
control to detect non specific binding and the baseline was set just to the right 
of  log  1.  The percentage of  R1  gated  cells  stained  with  the  FITC conjugated 
isotype antibody, detected in the lower left quadrant, was 95.65%. The right 
plot in Figure 3 5B shows cells gated through R1 that have stained positively with 
FITC conjugated anti cytokeratin antibody, shown in the lower right quadrant 
indicating  that  the  population  was  96%  pure  epidermal  keratinocytes.  A 
representative overlay plot of a population of wild type and K14D6 keratinocytes 
shows a log shift in positively stained anti cytokeratin cells compared to isotype 
(Figure 3 5C) and therefore shows that the isolation method yields a highly pure 
keratinocyte population for wild type and K14D6 keratinocytes. Anti cytokeratin 
staining  showed  epidermal  keratinocytes  that  were  isolated  to  be  96%  pure 
populations. 
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Figure 3-5. Purity of primary epidermal keratinocytes. 
Keratinocytes from wild-type (WT) and K14D6 mice were isolated, cultured and stained for 
intracellular cytokeratin analysed by flow cytometry. (A) Keratinocyte population was gated 
using  forward  and  side  scatter  (B)  The  left  hand  plot  shows  keratinocytes  stained  with 
isotype antibody whereas the right hand plot shows keratinocytes from the same population 
stained with anti-cytokeratin. The box below shows the number of events and % gated cells 
with positive anti-cytokeratin cells appearing in lower right quadrant of plot. (C) A histogram 
plot of isotype (blue) and anti-cytokeratin (green) positive keratinocytes in WT and K14D6 
population. These are all representative examples and n=3/group. Vicky King, 2010      Chapter 3, 134 
To  confirm  the  D6  transgene  was  targeted  to  proliferative  epidermal 
keratinocytes  within  K14D6  mice,  RNA  was  extracted  from  keratinocytes  and 
assessed for D6 transcripts. For RNA extraction, the epidermis from 3 neonates 
were pooled together after genotype was determined and the cell pellet was 
resuspended in 3ml keratinocyte growth media and cultured for five days in a 
T75 flask.  
Using RT PCR, D6 transcripts were detected in K14D6 epidermal keratinocytes 
but  not  in  wild type  keratinocytes  (Figure  3 6A).  Quantitative  PCR  (QPCR) 
showed D6 transcripts were present at high levels in K14D6 compared to wild 
type epidermal keratinocytes (p<0.001), which had no detectable D6 transcripts 
above  background  levels  (Figure  3 6B).  This  confirms  that  D6  is  ectopically 
expressed in K14D6 epidermal keratinocytes, after explant and culture, at a high 
level. 
 
Figure 3-6. D6 transcripts are detected in K14D6 epidermal keratinocytes at high levels. 
RNA was extracted from epidermal keratinocytes isolated and cultured from wild-type and 
K14D6 mice. (A) RT-PCR was performed (+/- reverse transcriptase (RT)) to detect mouse D6 
and b-actin. Products were run on a 1% agarose gel and visualised using ethidium bromide 
under  a  UV  light.  (B)  RNA  from  epidermal  keratinocytes  from  WT  and  K14D6  mice  was 
converted  to  cDNA  and  diluted  with  nuclease  free  water.  Levels  of  D6  transcripts  in 
epidermal keratinocytes were assessed by quantitative PCR using SYBR green. Levels were 
normalised using a ‘housekeeping’ gene, GAPDH (n=3/group, bars show mean ± SEM). Vicky King, 2010      Chapter 3, 135 
In this study, D6 is under the transcriptional control of the human K14 promoter. 
This promoter is able to drive expression in epithelial cells within the skin as 
well  as  within  the  thymus,  tongue  and  oesophagus  (Wang  et  al.,  1997). 
Expression of D6 in the tongue, thymus and oesophagus is unlikely to contribute 
to skin pathology. However, thymus from K14D6 mice have been analysed by 
Professor  G.  Anderson  and  the  architecture  of  the  thymus  was  considered 
normal. 
3.5 Detection of mouse D6 protein 
The  next  step  was  to  examine  the  presence  of  the  D6  protein  in  K14D6 
transgenic  mice  either  by  immunohistochemistry  or  by  western  blotting. 
However, no antibody to mouse D6 was available. During this project, an anti 
mouse  D6  antibody (raised  in  chicken)  was  made  through collaborations.  The 
antibody was required to be tested and optimised to determine whether it was 
D6 specific.  
The antibody was tested by western blotting using human embryonic kidney cells 
293  (HEK)  that  had  been  stably  transfected  with  murine  D6  (HEKmD6)  and 
untransfected HEK cells as a negative control. The cells were cultured and 2x10
6 
cells were lysed in mammalian cell lysis buffer, centrifuged and the supernatant 
was  retained.  Total  protein  within  the  supernatant  was  analysed  by  a  BCA 
protein assay following manufacturer’s instructions. A total of 10 g protein from 
HEK  and  HEKmD6  was  loaded  into  the  wells  of  a  NuPAGE  4 12%  Bis tris  gel 
alongside  a  multimark  colour  molecular  weight  standard.  The  gel  was 
electrophoresed and transferred to membrane using a semi dry transfer system 
before being incubated in different concentrations of the chicken anti mouse D6 
antibody for 1 hour at room temperature. Primary antibody dilutions tested were 
1:50,  1:250  and  1:1000.  The  secondary  antibody,  donkey  anti chicken  IgY 
conjugated to horseradish peroxidase was used at 1:5000 dilution. Horseradish 
peroxidase was detected by chemiluminescent substrate ‘west pico’(Pierce). 
The concentration of the primary antibody at 1:50 and 1:100 was too high as no 
specific bands could be determined in the blot due to high background staining 
(data  not  shown).  However,  bands  were  easily  detected  using  the  1:1000 
dilution. A band of 52kDa, the approximate molecular weight of D6 was detected Vicky King, 2010      Chapter 3, 136 
in both HEKmD6 and the HEK negative control (Figure 3 7A). Additionally a band 
of approximately 98kDa was also detected in both HEKs and HEKmD6 (Figure 3 
7A). The experiment was repeated three times using fresh cells with the same 
result, indicating non specific binding. To try to eliminate non specific binding, 
the experiment was repeated with the antibodies diluted in 5% milk. A band 
appeared  at  approximately  52kDa  and  98kDa  in  extracts  of  both  HEK  and 
HEKmD6 cells (Figure 3 7B). Therefore, it was concluded that the antibody was 
actually detecting some non specific proteins and was not specific for murine 
D6.  As  a  result,  the  chicken  anti mouse  D6  antibody  could  not  be  used  for 
further studies. 
Since the antibody was not specific, another assay was required to determine 
the  presence  of  the  D6  protein  within  K14D6  keratinocytes.  A  ligand binding 
assay was used to determine D6 receptor expression in K14D6 transgenics.   
 
Figure 3-7. Optimising an anti-mouse D6 antibody 
Protein was extracted from human embryonic kidney (HEK) cells and HEKmD6 (HEK stably 
transfected  with  murine  D6)  and  10µg  total  protein  was  used  in  western  blotting.  The 
primary  antibody,  chicken  anti-mouse  D6  antibody,  was  used  at  1:1000  dilution  and  the 
secondary antibody conjugated to horseradish peroxidase (HRP) was used at 1:5000. HRP 
was detected using West Pico. (A) Antibodies are diluted in PBS/0.1% Tween 20 (PBST) (B) 
Antibodies were diluted in 5% milk in PBST. Images are a representative of three replicate 
experiments. Vicky King, 2010      Chapter 3, 137 
3.6 Characterisation of chemokine receptor transcripts in 
primary keratinocytes 
Although  there  was  no  antibody  against  mouse  D6  available  to  detect  the 
presence  of  the  protein,  D6  transcripts  were  present  in  the  transgenic 
keratinocytes and therefore the functional ability of D6 to bind and internalise a 
D6 specific ligand was assessed (McKimmie et al., 2008, McKimmie and Graham, 
2006).  To  examine  the  functional  ability  of  D6,  fluorescently  labelled 
chemokines or biotinylated chemokines were used. Ligand binding to cells can 
be  detected  by  flow  cytometry  using  fluorescently  labelled  chemokines.  A 
biotinylated  chemokine,  which  could  be  detected  by  western  blotting  using 
streptavidin conjugated to HRP, was used to determine the capability of the D6 
transgene to internalise and degrade chemokines. 
However,  before  going  on  to  examine  the  functional  ability  of  D6,  it  was 
important  to  determine  which  chemokine  receptors  were  present  on  primary 
keratinocytes, as this would help determine the most suitable ligand to use to 
assess D6 function because all D6 ligands bind other chemokine receptors. D6 
can bind many inflammatory CC chemokines, which are also capable of binding 
to  other  chemokine  receptors,  mainly  CCR1,  CCR2,  CCR3,  CCR4  and  CCR5 
(summarised in Table 3 1.) It is of note that murine CCR3 is able to bind CCL3 
whilst human CCR3 is not able to (Menten et al., 2002). Studies have shown that 
CCR1  and  CCR5  are  present  in  a  human  keratinocyte  cell  line  (HaCaT)  and 
primary human keratinocytes express CCR3 (Petering et al., 2001, Szabo et al., 
2001). These studies indicated the possibility of the presence of CCR1, CCR3 and 
CCR5 on murine keratinocytes. 
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Chemokine 
receptor 
 D6 Ligands 
D6  CCL2  CCL3  CCL3L1  CCL4  CCL5  CCL7  CCL8  CCL11  CCL13  CCL14  CCL17  CCL22 
CCR1                         
CCR2                         
CCR3                         
CCR4                         
CCR5                         
 
 
Table 3-1. Summary of D6 ligands, which CCR1, CCR2, CCR3, CCR4 and CCR5 can bind. 
D6  can  bind  12  pro-inflammatory  chemokines  as  listed.  CCR1,  CCR2,  CCR3,  CCR4  and 
CCR5 can bind several D6 ligands (indicated by grey shaded box). Murine CCR3 can bind 
CCL3 whereas human CCR3 does not (indicated by black shaded box). 
 
Wild type and K14D6 keratinocytes were isolated and cultured in T75 flasks for 5 
days  before  RNA  was  extracted  using  the  RNeasy  mini  kit.  To  determine  a 
suitable ligand to use to test D6 function, cDNA was synthesised from 1 g RNA 
and examined for the expression of chemokine receptors CCR1 CCR5 using RT 
PCR.  
Strong  expression  of  CCR1  transcripts  was  seen  in  the  wild type  and  K14D6 
keratinocytes  as  well  as  weak  expression  of  CCR3  and  CCR5  transcripts. 
Conversely,  CCR2  and  CCR4  transcripts  were  absent  from  both wild type  and 
K14D6 keratinocytes (Figure 3 8A). DNA from tail tips of wild type and K14D6 
mice were used as a positive control to ensure that the primers and PCR worked. 
CCR1, CCR3 and CCR5 transcripts were quantified by quantitative PCR. There 
was  no  significant  difference  in  the  transcript  levels  of  CCR1,  CCR3  or  CCR5 
between  wild type  and  K14D6  epidermal  keratinocytes.  This  indicates  that 
ectopic expression of D6 in resting epidermal keratinocytes does not affect the 
transcript levels of CCR1, CCR3 or CCR5 (Figure 3 8B). 
Therefore, to test the ability of transgenically expressed D6 to bind ligands, any 
ligand that binds CCR1, CCR3 and CCR5 were not suitable. The most suitable 
ligands would be chemokines that only bind D6 and CCR2 or CCR4, such as CCL2, 
CCL17 or CCL22.  Vicky King, 2010      Chapter 3, 139 
 
 
Figure  3-8.  Expression  of  chemokine  receptors  CCR1,  CCR3  and  CCR5  on  primary 
epidermal keratinocytes. 
(A) RNA was extracted from WT and K14D6 epidermal keratinocytes and subjected to RT-
PCR (+/- reverse transcriptase (RT)) for chemokine receptors CCR1-5 and b b b b-actin. DNA was 
extracted  from  tail  tips  as  a  positive  control.  Products  were  electrophoresed  on  a  1.5% 
agarose  gel  and  visualised  with  ethidium  bromide  by  UV  light.  (B)  RNA  from  epidermal 
keratinocytes from WT and K14D6 mice were converted to cDNA and diluted with nuclease 
free water.  Levels of CCR1, CCR3 and CCR5 transcripts in epidermal keratinocytes were 
examined by quantitative PCR using SYBR Green. Levels were normalised against a ‘house 
keeping’ gene, GAPDH and represented as fold change in transcript level of CCR1, CCR3 
and  CCR5  in  K14D6  keratinocytes  compared  to  transcript  levels  in  WT  keratinocytes 
respectively (n=3/group, bars are mean ± SEM). Vicky King, 2010      Chapter 3, 140 
3.7 The function of D6 in K14D6 epidermal keratinocytes 
D6 is capable of binding many inflammatory chemokines and has been proposed 
to  function  as  a  scavenging  receptor  (Fra  et  al.,  2003),  internalising  and 
targeting chemokines for degradation (Weber et al., 2004), thereby removing CC 
chemokines  from  its  surroundings.  Therefore,  the  ability  of  D6  in  K14D6 
keratinocytes to function was assessed in two ways. One was to examine the 
ability of D6 in K14D6 keratinocytes to bind a D6 ligand and the second was to 
assess the ability of D6 in K14D6 keratinocytes to remove chemokines from its 
surroundings.  
3.7.1  K14D6 keratinocytes can bind CCL2, a D6 ligand. 
To assess whether D6 from K14D6 keratinocytes was functional, the ability of 
these cells to bind a fluorescent labelled CCL2 (CCL2 Alexa 647) was examined. 
CCL2  is  a  ligand  for  D6  (Nibbs  et  al.,  1997a)  which  can  also  bind  CCR2.  To 
determine whether any binding of CCL2 by keratinocytes was specifically due to 
D6, a competition assay was set up using a 10 fold excess of CCL3, another D6 
ligand (Nibbs et al., 1997a). In this assay, it is only binding of CCL2 by D6 that 
can be outcompeted by CCL3.  
Individual populations of epidermal keratinocytes were isolated from wild type 
and K14D6 mice, resuspended in 1ml of keratinocyte growth media and 200 l 
was seeded in triplicate into 24 well plates and cultured for five days. Fresh 
keratinocyte media was added (250ml) and cells were treated with either PBS, 
25nM fluorescent labelled CCL2, or 25nM fluorescent labelled CCL2 and 250nM 
CCL3,  and  incubated  for  100  minutes  at  37°C.  Keratinocytes  were  washed, 
trypsinised,  resuspended  and  labelled,  CCL2  binding  was  assessed  by  flow 
cytometry. 
Keratinocytes  were  gated  (R1)  using  forward  and  side  scatter  (Figure  3 9A) 
before going on to analyse non specific and specific fluorescent labelled CCL2 
binding. Figure 3 9B shows keratinocytes that have been gated through R1 and 
shows cells treated with PBS (left panel), keratinocytes stained with fluorescent 
labelled CCL2 (middle panel) and keratinocytes stained with fluorescent labelled 
CCL2 in the presence of excess CCL3 (right panel). The top panel in Figure 3 9B Vicky King, 2010      Chapter 3, 141 
illustrates an example of a wild type keratinocyte population and the bottom 
panel shows an example of K14D6 keratinocyte population. Non specific binding 
was determined and set within the lower left quadrant of the plot for wild type 
and  K14D6  keratinocytes.  In  the  presence  of  fluorescently  labelled  CCL2,  a 
number of cells were seen to shift from the lower left quadrant to the lower 
right quadrant in K14D6 keratinocytes but not in the wild type, indicating K14D6 
keratinocytes are positive for CCL2 binding (Figure 3 9B middle panel). In the 
presence of CCL2 and excess CCL3, wild type keratinocytes remained within the 
lower left quadrant whereas K14D6 keratinocytes shifted from the lower right 
quadrant to the lower left quadrant (Figure 3 9B right panel). This data indicates 
that CCL2 binding in K14D6 keratinocytes was outcompeted by CCL3. Figure 3 9C 
shows an overlay plot of K14D6 keratinocytes treated with PBS, fluorescently 
labelled CCL2 and labelled CCL2 in the presence of excess CCL3 (blue, pink and 
green respectively). Figure 3 9C illustrates that K14D6 keratinocytes can bind 
the fluorescently labelled CCL2, shown by a shift in the green line compared to 
the  control  (blue  line),  yet  in  the  presence  of  excess  CCL3  this  binding  is 
inhibited, illustrated by the pink line being similar to control (blue). The data 
were quantified using the mean percentage of keratinocytes that were positively 
labelled for CCL2 under the different conditions using the percentage of cells 
gated by R1 present in the lower right quadrant. In the wild type population, the 
percentage of keratinocytes positively labelled with CCL2 was found to be lower 
than 1% and there was no significant difference between wild type keratinocytes 
treated  with  PBS,  fluorescent labelled  CCL2  or  fluorescent labelled  CCL2  and 
excess CCL3 (Figure 3 9D). Whereas in the K14D6 population, the percentage of 
cells  positive  for  fluorescent labelled  CCL2  in  the  PBS  treated  group  was 
significantly  increased  to  approximately  45%  in  keratinocytes  treated  with 
fluorescently  labelled  CCL2  (p<0.001).  In  the  presence  of  excess  CCL3,  the 
percentage of K14D6 keratinocytes labelled with CCL2 was significantly reduced 
from 45% to 2% (p< 0.001; shown in Figure 3 9D).  
In summary, binding of CCL2 occurred in K14D6 keratinocytes but not in wild 
type keratinocytes, indicating that CCL2 binding by K14D6 keratinocytes was due 
to D6. These data further confirmed the absence of CCR2 on primary epidermal 
keratinocytes. Vicky King, 2010      Chapter 3, 142 
 
 
Figure 3-9. K14D6 keratinocytes are able to bind CCL2 in a D6 dependent manner 
Keratinocytes were cultured from individual WT and K14D6 mice in 250µl KGM with 1% BSA 
and incubated with (i) PBS (ii) 25nM CCL2-alexa 647 or (iii) 25nM CCL2-alexa 647 with 250nM 
CCL3 for 100 minutes at 37° ° ° °C. Keratinocytes were trypsinised and resuspended in PBS/2mM 
EDTA/0.1%FCS and samples analysed by FACS. (A) Representative plots of WT and K14D6 
keratinocytes  stained  with  CCL2-alexa  647  under  the  different  conditions.  (B)  A 
representative histogram plot of K14D6 keratinocytes showing uptake of CCL2 in untreated 
cells (blue), cells treated with CCL2 (green) and cells treated with CCL3 and CCL2 (pink). (C) 
The mean % of WT and K14D6 keratinocytes labelled with CCL2-Alexa 647; n=3/group and 
columns are mean ± SEM. 
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3.7.2  K14D6 keratinocytes can remove extracellular CCL3 from 
the media. 
D6 in K14D6 keratinocytes was able to bind CCL2 and therefore the next step 
was to determine whether D6 from the transgene was able to internalise and 
degrade ligands. D6 activity in K14D6 keratinocytes was assessed by its ability to 
deplete  extracellular  biotinylated  CCL3,  a  D6  ligand.  Keratinocytes  were 
individually  isolated  and  seeded  into  6ml  plates  with  5ml  of  keratinocytes 
growth media. After five days, the number of keratinocytes within the plates 
was 2.5x10
5 cells. Wild type and K14D6 keratinocytes were treated with 10nM 
biotinylated CCL3 and samples of supernatant were taken at various timepoints 
over 24 hours. Any remaining biotinylated CCL3 in the media was detected using 
streptavidin labelled with HRP on a western blot (McCulloch et al., 2008).  
Wild type keratinocytes did not deplete biotinylated CCL3 from the surrounding 
media as there was no decrease in the amount of biotinylated CCL3 detected at 
0 hours from 2, 4, 6, 8, 12 and 24 hours whereas by 4 hours in the presence of 
K14D6 keratinocytes, less biotinylated CCL3 was detected than was present at 
0hrs (Figure 3 10A). By 12 hours, the levels of biotinylated CCL3 in the media in 
the  presence  of  K14D6  keratinocytes  was  markedly  less  and  very  little 
biotinylated  CCL3  remained  after  24  hours  (Figure  3 10A).  Therefore,  K14D6 
keratinocytes  were  able  to  remove  extracellular  CCL3  from  the  media 
progressively whereas wild type keratinocytes did not.  
To  ensure  that  the  progressive  removal  of  CCL3  was  D6  dependent in  K14D6 
keratinocytes,  a  competition  assay  was  set  up,  with  10nM  biotinylated  CCL3 
added  along  with  a  10 fold  molar  excess  of  CCL22,  a  high  affinity  D6  ligand 
(Bonecchi et al., 2004). An excess of CCL22 should bind all D6 receptors and 
prevent binding of biotinylated CCL3 to D6. As a result, excess CCL22 prevented 
depletion  of  biotinylated  CCL3  by  K14D6  keratinocytes  as  the  levels  of 
biotinylated CCL3 remained the same at 0, 2, 4, 6, 8, 12 and 24 hours, indicating 
that depletion of biotinylated CCL3 is D6 dependent (Figure 3 10B). Therefore, 
D6 in K14D6 keratinocytes is functional. 
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Figure  3-10.  Transgenic  expression  of  D6  in  epidermal  keratinocytes  is  able  to  degrade 
extracellular biotinylated CCL3. 
Keratinocytes  from  neonatal  wild-type  (WT)  or  K14D6  mice  were  cultured  in  1ml 
keratinocyte growth media containing (A) 10nM biotinylated CCL3 (BioCCL3) or (B) 10nM 
BioCCL3  in  competition  with  100nM  CCL22.  The  remaining  BioCCL3  was  detected  by 
western  blotting  using  streptavidin  conjugated  to  HRP  at  the  timepoints  indicated.  Data 
shown is representative of three experiments. 
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3.8 Transgenic  expression  of  D6  dampens  cutaneous 
inflammation. 
To assess the ability of the K14D6 transgene to dampen down inflammation in 
vivo,  a  well characterised  cutaneous  inflammation  model  was  used  involving 
application  of  12 O tetradecanoyl phorbol 13 acetate,  also  known  as  TPA 
(Stanley et al., 1991) to the skin of FVB/N wild type and K14D6 transgenic mice. 
In this model, the lower dorsal skin of the mice was shaved two days before 
starting the TPA application. TPA was applied to the dorsal skin of the mice once 
on three consecutive days. TPA is a tumour promoter, which activates protein 
kinase C and application of the chemical on three consecutive days results in 
acute inflammation, which eventually resolves (Jamieson et al., 2005).  
This model was used previously with D6 null mice, on a C57BL/6 background, in 
which  these  mice  demonstrated  a  prolonged  and  exaggerated  inflammatory 
response (Jamieson et al., 2005). These studies showed that in comparison to 
wild type  mice,  D6  null  mice  were  unable  to  clear  CCL5  and  CCL3,  both  D6 
ligands, from the site of skin inflammation 24 hours after TPA application. These 
data suggested that D6 was involved in regulating chemokine levels at sites of 
inflammation by playing a role in chemokine removal. Histological analysis of the 
skin  after  TPA  induced  inflammation  revealed  D6  null  mice  demonstrated 
increased  skin  thickening,  hyperkeratosis,  epidermal  hyperplasia,  increased 
angiogenesis  and  increased  infiltration  of  inflammatory  cells,  in  particular 
epidermal  T  cells  and  dermal  mast  cells  (Jamieson  et  al.,  2005).  The 
exaggerated  inflammatory  response  was  shown  to  be  TNF dependent,  and 
histological changes within D6 null mice skin showed similar characteristics to 
those found in human psoriasis. Therefore, since absence of D6 resulted in an 
exaggerated cutaneous inflammatory response, we examined whether increased 
expression  of  D6  within  the  epidermis  would  suppress  the  inflammatory 
response. 
Four days after the final application of TPA, mice were sacrificed and the dorsal 
skin was harvested, fixed in 10% neutral buffered formalin for haematoxylin and 
eosin staining as well as for CD3 staining and astra blue staining to identify T 
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by counting the number of squares the skin filled within the grid in the eyepiece 
in which twenty random points per skin section were counted.  
There was no significant difference in skin thickness between untreated D6 null 
mice,  wild type  and  K14D6  mice  (Figure  3 11A).  Four  days  after  the  final 
application  of  TPA,  D6  null  mice  demonstrated  a  significant  increase  in  skin 
thickness compared to resting skin thickness (p<0.001; Figure 3 11A). Wild type 
mice also demonstrated a significant increase in skin thickness after four days 
compared  to  resting  skin  thickness  (p<0.001;  Figure  3 11A).  However,  K14D6 
mice showed no significant difference in skin thickness four days after the final 
application of TPA compared to resting skin thickness (Figure 3 11A). This data 
illustrated that D6 null mice on a different background also demonstrated an 
exaggerated inflammatory response within the skin to TPA. Four days after the 
final application of TPA, K14D6 mice contained fewer T cells in the epidermis in 
comparison  to  wild type  mice  (p<0.001;  Figure  3 11B).  K14D6  mice  also 
demonstrated a significant reduction in the number of mast cells present within 
the skin in comparison to wild type mice (p<0.001; Figure 3 11C). 
These  data  confirm  D6  null  mice  demonstrate  an  exaggerated  inflammatory 
response to TPA in comparison to wild type mice and indicate that K14D6 mice 
can suppress in vivo inflammation due to the increased expression of D6. 
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Figure  3-11.  Transgenic  expression  of  D6  in  murine  epidermis  limits  cutaneous 
inflammation. 
(A) D6 null mice (KO), Wild-type (WT) and K14D6 mice (n=5/group) received an application of 
TPA on the dorsal skin on three consecutive days. Four days later, the skin was harvested. 
Dorsal skin from untreated mice (n=5/group) was harvested immediately. Skin sections were 
scored for epidermal thickness. (B) Skin sections from WT and K14D6 mice four days after 
the final application of TPA were  stained with an anti-mouse CD3 antibody to identify T 
cells. The number of T cells within the epidermis was counted using 20 random points per 
skin section. (C) Mast cells were stained with astra blue in WT and K14D6 skin and the 
number of mast cells were counted in 20 random fields per section. 
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3.9  Summary of Chapter 3 
D6 was proposed to play a role within the resolution phase of inflammation and 
the  main  aim  of  this  chapter  was  to  test  the  hypothesis  that  increased 
expression  of  D6  would  suppress  inflammation.  To  test  this  hypothesis, 
transgenic  mice  were  generated  where  D6  expression  would  be  increased 
ectopically.  Since  the  biological  role  of  D6  was  hypothesised  using  a  skin 
inflammation model, it was decided to transgenically express D6 within the skin 
so  that  the  skin  inflammation  model  could  be  used  to  test  the  hypothesis. 
Therefore, K14D6 mice were generated so that increased expression of D6 would 
be  targeted  to  the  epidermal  layer  of  murine  skin  under  the  control  of  the 
human K14 promoter. Therefore, the work in this chapter was to characterise 
and validate the K14D6 transgenic mice. 
In  summary,  K14D6  mice  express  D6  transcripts  within  the  epidermis,  more 
specifically within epidermal keratinocytes after explant and culture, and such 
transcripts  are  absent  from  wild type  mice.  Ectopic  expression  of  D6  within 
K14D6 keratinocytes does not change the morphology in comparison to wild type 
keratinocytes. CCR1, CCR3 and CCR5 transcripts are present in primary murine 
keratinocytes  and  ectopic  expression  of  D6  in  K14D6  keratinocytes  does  not 
affect CCR1, CCR3 or CCR5 transcript levels. K14D6 keratinocytes are able to 
bind CCL2, a D6 specific ligand, whereas wild type keratinocytes are not able to. 
K14D6  keratinocytes  are  able  to  progressively  deplete  extracellular  CCL3 
whereas wild type keratinocytes do not and therefore the K14D6 transgene is 
functional. In terms of skin inflammation, K14D6 mice were able to suppress 
inflammation in response to a topical application of a skin irritant whereas D6 
null and wild type could not. Therefore, D6 can suppress skin inflammation and 
has the potential to be of therapeutic use.  
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4  Characterisation of the transcriptional 
consequences of D6 ligand binding 
4.1  Introduction 
Many members of the chemokine receptor family signal through the activation of 
G proteins as they belong to the family of G protein coupled receptors (Murphy 
et al., 2000). Conversely, there are four chemokine receptors, DARC, D6, CCX 
CKR and CXCR7, which are unconventional because there does not seem to be 
any signalling activity after high affinity ligand binding (Graham, 2009). In vitro 
studies have examined ligand dependent functional responses, such as calcium 
fluxes  and  chemotaxis,  for  both  human  and  murine  D6  and  have  shown  that 
ligand binding to D6 does not trigger these responses (Fra et al., 2003, Nibbs et 
al.,  1997a).  However,  the  possibility  that  D6  may  signal  via  a  different 
mechanism  other  than  G protein  coupling  has  not  been  investigated.  Human 
lymphatic endothelial cells are known to express D6 by immunohistochemistry 
(Nibbs et al., 2001, Vetrano et al., 2009). However, D6 was not expressed on 
isolated  human  lymphatic  endothelial  cells  indicating  that  D6  had  been 
transcriptionally silenced (Amatschek et al., 2007). Within our laboratory, we 
had D6 transgenic mice (K14D6), where ectopic expression of D6 was targeted to 
epidermal keratinocytes. In the previous chapter, a method of isolating primary 
keratinocytes was utilised to characterise the level of D6 transcripts and the 
functional activity of D6 in wild type and K14D6 mice. D6 transcripts were only 
expressed and functional in K14D6 epidermal keratinocytes (see Chapter 3). As a 
result, epidermal keratinocytes from K14D6 mice are a primary cell type that 
can be isolated and cultured whilst still expressing D6. Therefore, the aim of this 
work  was,  using  a  microarray  approach,  to  determine  any  transcriptional 
consequences  of  ligand  binding  to  D6.  By  assessing  the  transcriptional 
consequences, this would give an indication into cell functions mediated through 
D6 in vivo. 
The  work  described  in  this  chapter  exploits  microarray  technology  to 
characterise the changes to the cellular transcriptome after ligand binding to D6 
using  primary  keratinocytes  isolated  from  wild type  and  K14D6  mice.  It  was 
hoped  that  the  microarray  analysis  would  yield  information  on  altered  gene Vicky King, 2010      Chapter 4, 151 
expression after ligand binding to D6. A second aspect was to determine if there 
were  any  transcriptional  consequences  induced  by  basal  D6  expression, 
independent of ligand, within K14D6 keratinocytes. 
4.2 Experimental details 
Primary keratinocytes were isolated from neonatal mice and after genotyping; 
keratinocytes were pooled from three mice of the same genotype and cultured 
for 5 days in a T75 flask. On day 5, wild type and K14D6 keratinocytes were 
incubated  with  10nM  CCL3,  a  high  affinity  D6  ligand,  or  PBS  for  6  hours  at 
37°C. Keratinocytes  were  incubated  for  6  hours  since  transcriptional  changes 
through ligand binding to chemokine receptors can occur between 2 and 8 hours 
(Valerio et al., 2004). RNA was isolated from primary keratinocytes, transcribed 
into biotinylated cRNA and applied to an Affymetrix Mouse genome 430 2.0 Array 
Gene  Chip  (http://www.affymetrix.com/).  The  data  generated  was  analysed 
using rank products (Breitling et al., 2004b) and iterative group analysis (iGA) 
methods  (Breitling  et  al.,  2004a).  The  experimental  design  is  summarised  in 
Figure 4 1. 
 
 
Figure 4-1. Summary of experimental design to characterise transcriptional consequences 
of D6 ligand binding. 
Primary wild-type (WT) and K14D6 keratinocytes were isolated and cultured from neonatal 
mice. Keratinocytes were incubated with PBS or 10nM CCL3 for 6hrs. RNA was isolated 
from  primary  keratinocytes  and  prepared  for  application  to  an  Affymetrix  gene  chip  to 
measure changes in gene transcription.  Vicky King, 2010      Chapter 4, 152 
4.3 Generation  and  validation  of  RNA  for  microarray 
application 
RNA was extracted from the samples and subsequently processed by staff at the 
Sir Henry Wellcome Functional Genomics Facility at the University of Glasgow 
(http://www.gla.ac.uk/faculties/fbls/functionalgenomicsfacility/)  where  the 
microarray  analyses  were  performed.  The  RNA  samples  were  assessed  for 
quantity, using a Nanodrop ND 1000, in which 1ml of each sample was analysed 
(Table 4 1). The quality of RNA was assessed using an Agilent 2100 Bioanalyser. 
Each experimental condition was repeated in triplicate for statistical analysis.  
The concentration of the samples varied from 38.1ng/ml to 1742.4ng/ml (Table 
4 1). One sample, wild type control 2, was below the recommended level of 2µg 
total RNA required for the microarray (Table 4 1). Therefore all samples prior to 
being transcribed into biotinylated cRNA underwent linear amplification (Phillips 
and  Eberwine,  1996).  If  only  one  sample  underwent  linear  amplification  this 
would skew the data, therefore all the samples were amplified to give a fair 
comparison. The cRNA was then applied to Affymetrix GeneChip Mouse genome 
430 2.0 Array for generation and analysis of data. 
 
 
 
 
 
 
 
 
 
Table 4-1. Concentration and total yield of RNA extracted from keratinocytes analysed by a 
Nanodrop ND-1000. 
Primary keratinocytes were isolated and cultured for 5 days before addition of PBS or 10nM 
CCL3  for  6  hours  at  37° ° ° °C.  RNA  was  isolated  and  1µl  of  each  sample  was  analysed  for 
quantity using a Nanodrop ND-1000 by staff at the Functional Genomics Facility. n=3/group 
and each sample consisted of keratinocytes from 3 neonatal mice. 
Sample  Concentration  
of RNA (ng/m m m ml) 
Total yield 
RNA (m m m mg) 
WT control 1  1742.4  52.3 
WT control 2      38.1    1.1 
WT control 3    269.9    8.1 
WT + CCL3 1  1566.5  47.0 
WT + CCL3 2    402.5  12.1 
WT + CCL3 3    421.7  12.7 
K14D6 control 1  1020.8  30.6 
K14D6 control 2    304.9    9.1 
K14D6 control 3    482.1          14.5 
K14D6 + CCL3 1     857.9  25.7 
K14D6 + CCL3 2    717.8  21.5 
K14D6 + CCL3 3    799.7  24.0 Vicky King, 2010      Chapter 4, 153 
4.4 Analysis of microarray Data 
The  analysis  of  the  microarray  was  carried  out  in  the  Sir  Henry  Wellcome 
Functional Genomics Facility, where the data were generated and automatically 
analysed by FunAlyse, in house microarray data analysis software. This software 
generates a directory for each project and data is normalised using the robust 
multichip average (RMA) method (Irizarry et al., 2003). The software performs 
two different sets of analysis producing two reports. These are known as the 
rank product (RP) report (Breitling et al., 2004b) and the iterative group analysis 
report (Breitling et al., 2004a). The iGA report is generated using the list of 
genes produced by the rank product analysis and identifies functional changed 
groups of genes. Terminology used by this software can be found in Appendix 
One. All data generated by the microarray can be found in Appendices Two and 
Three. The comparisons made were: 
1) WT control (baseline) versus K14D6 control 
 
2) WT control (baseline) versus WT + CCL3 
 
3) K14D6 control (baseline) versus K14D6 + CCL3 
 
4) WT + CCL3 (baseline) versus K14D6 + CCL3 
 
 
4.4.1  Rank product differential expression analysis reports 
The rank products analysis report lists genes sorted according to a measure of 
differential  expression  calculated  using  the  rank  product  method.  The  rank 
products method is a non parametric statistical test where the RP score is a 
measure of differential expression based on ranks of fold changes (Breitling et 
al., 2004b). It is a biologically motivated test based on the idea that a gene is 
highly up or downregulated in one experiment but if the same gene is at the top 
of a list in a replicate experiment then it is likely that this gene is actually 
changed. Therefore rank product values are calculated using the position of the 
gene (the most strongly upregulated or downregulated gene is assigned a value 
of 1) in each of the replicate experiments sorted by increasing or decreasing fold 
change. The smaller the RP score is, the higher the likelihood the gene is up or 
downregulated. The FunAlyse software cuts the list of differentially expressed 
genes  at  a  level  of  50%  false  discovery  rate  (FDR),  which  is  the  expected Vicky King, 2010      Chapter 4, 154 
percentage of false positives, or the software lists the top 100 genes according 
to their rank product score, regardless of their FDR, depending on the list that is 
longer.  The  full  rank  product  differential  expression  analysis  reports  can  be 
found in Appendix Two. 
4.4.1.1   WT keratinocytes versus K14D6 keratinocytes 
To  investigate  basal  differences  in  transcription  upon  D6  expression,  a 
comparison  between  resting  K14D6  keratinocytes  and  wild type  keratinocytes 
was made. 
i)  Potential upregulated genes 
The software generated a list of the top 100 genes according to rank product 
score (The full list can be found in Appendix Two) however, only six genes were 
potentially upregulated with less than 50% false discovery rate (Table 4 2).  
Out of the six genes, only 2, chemokine binding protein 2 (Ccbp2, which is also 
known as D6) and dickkopf homolog 2 (Dkk2), changed more than 2 fold, which 
was  identified  as  an  arbitrary  cut  off  (Table  4 2).  Of  the  six  potentially 
upregulated genes, the rank product (RP) score varied from 1.00, which was the 
highest ranked gene (Ccbp2) to an RP score of 470.76 for the lowest ranked gene 
with  an  FDR  of  less  than  50%,  which  was  tissue  factor  pathway  inhibitor  2 
(Tfpi2). The fold change (FC), varied from 49.59 to 1.48 (Ccbp2 and branched 
chain aminotransferase 1 (Bcat1) respectively) within the top six genes shown to 
be expressed at higher levels in resting K14D6 keratinocytes by the microarray 
(Table 4 2). One gene, Ccbp2, within this comparison was found to have an RP 
score of 1.00, which is the smallest RP value that can be achieved and was found 
to  be  expressed  at  higher  levels  (49.59  fold  change),  in  K14D6  keratinocytes 
compared to wild type keratinocytes and also had a 0% false discovery rate.  
This data indicates that the gene, Ccbp2, is potentially upregulated by 49.52 
fold in K14D6 keratinocytes compared to wild type keratinocytes. In chapter 3, 
the  levels  of  D6  transcripts  were  shown  to  be  significantly  higher  in  K14D6 
keratinocytes compared to WT keratinocytes (see Figure 3 6). Therefore, these 
data confirm that the K14D6 transgene is expressed within K14D6 keratinocytes. Vicky King, 2010      Chapter 4, 155 
 
Table 4-2. The top 6 genes listed by RP score as potentially upregulated genes in K14D6 
keratinocytes compared to wild-type keratinocytes. 
Potentially upregulated genes were listed in order of rank product score (RP score) with 
details of % false discovery rate (FDR) and fold change (FC).  
 
ii)  Potential downregulated genes 
A  list  of  100  potentially  downregulated  genes  was  generated  by  the  analysis 
software according to RP scores in the comparison between K14D6 keratinocytes 
and wild type keratinocytes; however only 81 of these genes had an FDR of less 
than 50% (Full list can be found in Appendix Two). Of the 81 genes, the RP score 
varied from 80.91 to 1158.63 with fold change varying between  2.92 and  1.02 
(Appendix Two). The top 25 potentially downregulated genes listed in the RP 
report are summarised in Table 4 3.   
Of the top 25 genes listed, only 24 genes were potentially downregulated as P 
lysozyme structural (Lzp s) appeared twice in the RP report (Table 4 3). Of the 
24 genes, only 4 changed more than 2 fold and these were within the top 5 
ranked genes shown in Table 4 3. Lzp s had the lowest RP score of 80.91, an FDR 
of 0% and a fold change of  2.92. Additionally, Lzp s was third in the list with an 
RP score of 119.46, an FDR of 1.67 and a fold change of  2.73. Cathepsin S (Ctss) 
was second in the list with an RP score of 99.49 and changed by  2.81 fold. The 
other two genes found to be potentially downregulated more than 2 fold were C 
type lectin domain family member n (Clec4n) and lysosomal associated protein 
transmembrane 5 (Laptm5) which were placed 4
th and 5
th in the RP report with 
5.75% and 8.20% FDR respectively. This data indicates that ectopic expression of 
D6 may have a negative impact on the transcription of Lzp s, Ctss, Clec4n and 
Laptm5. 
RP score  FDR (%)  FC  Gene Symbol  Gene Title 
1.00  0.00    49.59  Ccbp2  Chemokine binding protein 2 
206.84  15.50  2.66  Dkk2  Dickkopf homolog 2 (Xenopus laevis) 
348.58  43.33  1.81  Nrk  Nik related kinase 
359.51  34.50  1.48  Bcat1  Branched chain aminotransferase 1, 
cytosolic 
389.02  32.50  1.56  Stc2  Stannocalcin 2 
470.76  47.67  1.62  Tfpi2  Tissue factor pathway inhibitor 2 Vicky King, 2010      Chapter 4, 156 
 
Table  4-3.  Twenty-five  top  genes  potentially  downregulated  in  K14D6  keratinocytes 
compared to wild-type keratinocytes. 
Genes  were  listed  in  order  of  rank  product  score  (RP  score)  with  details  of  %  false 
discovery rate (FDR) and fold change (FC). 
 
 
 
 
 
 
 
 
 
 
 
RP score  FDR (%)  FC  Gene Symbol  Gene Title 
80.91  0.00      -2.92  Lzp-s  P lysozyme structural 
99.49  0.50  -2.81  Ctss  Cathepsin S 
119.46  1.67  -2.73  Lzp-s  P lysozyme structural 
204.14  5.75  -2.04  Clec4n  C-type lectin domain family, member n 
241.21  8.20  -2.02  Laptm5  Lysosomal associated protein 
transmembrane 5 
288.72  11.17  -1.84  Clec4d  C-type lectin domain family 4, member d 
314.02  13.14  -1.94  1110014K05Rik  RIKEN cDNA 1110014K05 gene 
349.82  16.00  -1.84  Fcgr3  Fc receptor, IgG, low affinity III 
391.54  19.33  -1.96  A030004J04Rik  RIKEN cDNA A030004J04 gene 
395.41  17.70  -1.88  Lyzs  Lysozyme 
395.62  16.09  -1.74  Ms4a11  Membrane-spanning 4-domains, 
subfamily A, member 11  
412.07  17.00  -1.79  Apoe  Apolipoprotein E 
436.82  18.77  -1.76  Jarid1d  Jumonji, AT rich interactive domain 1D 
(Rbp2 like) 
458.61  20.36  -1.75  Sepp1  Selenoprotein P, plasma, 1 
463.19  19.87  -1.87  2310002A05Rik  RIKEN cDNA 2310002A05 gene 
464.93  19.06  -1.73  Gp49a /// Lilrb4  Glycoprotein 49A /// leukocyte 
immunoglobulin-like receptor, subfamily 
B, member 4 
529.00  26.29      -1.75  Sprrl5  Small proline rich-like 5 
530.23  24.89  -1.86  Lce5a  Late cornified envelope 5A 
533.51  23.89  -1.78  Sprrl7  Small proline rich-like 7 
577.80  28.95  -1.73  1110055J05Rik  RIKEN cDNA 1110055J05 gene 
601.17  30.43  -1.73  1110001M24Rik  RIKEN cDNA 1110001M24 gene 
626.85  32.00  -1.60  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked 
639.19  32.13  -1.32  Cxcl4  Chemokine (C-X-C motif) ligand 4 
646.43 
 
31.58  -1.56  Rbm5  RNA binding motif protein 5 
648.49  30.68  -1.72  Sprrl2  Small proline rich-like 2 Vicky King, 2010      Chapter 4, 157 
4.4.1.2   WT keratinocytes versus WT keratinocytes + CCL3 
Wild type keratinocytes at rest and after ligand binding were compared to assess 
the  basic  differences  in  transcripts  induced  after  ligand  binding  through 
chemokine receptors CCR1, CCR3 and CCR5. 
i)  Potential upregulated genes 
The microarray showed higher levels of 217 genes, with an FDR of less than 50%, 
in  wild type  keratinocytes  incubated  with  CCL3  compared  to  control  WT 
keratinocytes. The RP score varied from 145.79 to 1681.26 and the FC ranged 
from 3.72 to 1.3 (The full list can be found in Appendix Two). Of the 217 genes 
potentially upregulated using the rank product score, 71 genes demonstrated a 
2 fold change with 9 of these changing more than 3 fold (Appendix Two). Table 
4 4 lists the top 25 genes found to be potentially upregulated by CCL3 in wild 
type keratinocytes using the rank product method.  
The  first  five  genes  listed  as  potentially  upregulated  by  RP  score  were 
membrane spanning 4 domain subfamily A member 7 (Ms4a7), chemokine (C X C 
motif)  ligand  4  (CXCL4)  also  known  as  platelet  derived  factor  4,  pleckstrin 
(Plek),  procollagen  type  III  alpha  1  (Col3a1)  and  dickkopf  homolog  2  (Dkk2). 
Ms4a7 had an RP score of 145.79, a 14% FDR and a fold change of 2.46 whereas 
CXCL4 had an RP score of 171.94, a FDR of 9.5% and fold change of 2.10. Plek 
was ranked third in the list with an RP score of 189.97, an FDR of 8.33% and was 
expressed at higher levels by 2.61 fold. The fourth ranked gene was Col3a1 with 
an RP score of 224.73, a FDR of 10.25% and a fold change of 3.72 whereas the 
fifth ranked gene with an RP score of 228.64, an 8.2% FDR and changed by more 
than 3 fold was Dkk2.   
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Table  4-4.  The  first  25  genes  listed  as  potentially  upregulated  by  CCL3  in  wild-type 
keratinocytes. 
Genes  were  listed  in  order  of  rank  product  score  (RP  score)  with  details  of  %  false 
discovery rate (FDR) and fold change (FC).  
 
 
 
 
 
 
 
 
 
 
 
RP score  FDR (%)  FC  Gene Symbol  Gene Title 
145.79  14.00  2.46  Ms4a7  Membrane-spanning 4-domains, 
subfamily A, member 7 
171.94   9.50  2.10  Cxcl4  Chemokine (C-X-C motif) ligand 4 
189.97   8.33  2.61  Plek  Pleckstrin 
224.73       10.25        3.72  Col3a1  Procollagen, type III, alpha 1 
228.64   8.20  3.50  Dkk2  Dickkopf homolog 2 (Xenopus laevis) 
236.57   7.00  3.11  Tfpi2  Tissue factor pathway inhibitor 2 
287.28    9.86  3.29  Lum  Lumican 
288.57    8.75  2.86  Thbs2    Thrombospondin 2 
288.84    7.78  2.48  B130021B11Rik  RIKEN cDNA B130021B11 gene 
269.29    7.20  2.71  Mmp2  Matrix metallopeptidase 2 
303.38    7.55  3.20  Pdgfrb  Platelet  derived  growth  factor  receptor, 
beta polypeptide 
314.50    7.50  3.25  Col6a1  Procollagen, type VI, alpha 1 
319.04    7.15  2.86  Crabp1  Cellular retinoic acid binding protein 1 
322.66    7.00  2.96  Col6a2  Procollagen, type VI, alpha 2 
329.93    7.00  2.13  C1qa  Complement  component  1,  q 
subcomponent, alpha polypeptide 
335.60    6.88  2.65  Mmp2  Matrix metallopeptidase 2 
339.17    6.71  2.78  Il1rl1  Interleukin 1 receptor-like 1 
373.12    8.39  2.55  Dpep1  Dipeptidase 1 (renal) 
394.70    9.68  2.21  Col11a1  Procollagen, type XI, alpha 1 
397.90    9.35  2.16  Ms4a6d  Membrane-spanning  4-domains, 
subfamily A, member 6D 
415.35    9.67  1.88  Laptm5  Lysosomal-associated protein 
transmembrane 5 
417.60    9.32  2.82  Postn  Periostin, osteoblast specific factor 
421.55    9.22  2.10  Nr2f1  Nuclear  receptor  subfamily  2,  group  F, 
member 1 
437.53  10.04  2.56  Cdh11  Cadherin 11 
439.43    9.72  1.97  F13a1  Coagulation factor XIII, A1 subunit Vicky King, 2010      Chapter 4, 159 
ii)  Potential downregulated genes 
Addition  of  CCL3  to  wild type  keratinocytes  resulted  in  the  potential 
downregulation of 13 genes with an FDR of less than 50%, as summarised in Table 
4 5. The RP score varied from 228.87 to 574.12 and the FC,  4.27 to  1.47, for 
the highest ranked gene and 15
th ranked gene respectively (one gene, Ddx3y, 
appeared in the list three times). Of the 13 listed genes, one gene was expressed 
more than 4 fold lower, which was DEAD box polypeptide (Ddx3y). Eukaryotic 
translation initiation factor 2 (Eif2s3y) was potentially downregulated more than 
3 fold. Genes potentially downregulated more than 2 fold were jumonji (Jarid1d) 
and Ddxy3 (Table 4 5). All three of these genes are linked to the Y chromosome 
(Isensee  and  Ruiz  Noppinger,  2007).  One  explanation  could  be  that  the 
population  of  keratinocytes  treated  with  CCL3  were  isolated,  coincidentally, 
from  more  females  than  males  in  comparison  to  the  keratinocyte  population 
used as resting wild type keratinocytes. 
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Table 4-5. Top 15 genes potentially downregulated gene by CCL3 in wild-type keratinocytes. 
Genes  were  listed  in  order  of  rank  product  score  (RP  score)  with  details  of  %  false 
discovery rate (FDR) and fold change (FC). 
 
 
 
 
 
 
 
 
 
 
 
 
RP score  FDR (%)  FC  Gene Symbol  Gene Title 
228.87  45.00     -4.27  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y linked 
263.41  32.50  -1.59  1110014K05Rik  RIKEN cDNA 1110014K05 gene 
265.52  22.00  -1.79  Hrnr  Hornerin 
302.93  23.50  -2.63  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y linked 
319.33  21.20  -3.57  Eif2s3y  Eukaryotic translation initiation factor 2, 
subunit 3, structural gene Y-linked 
332.57  19.83  -1.63  Sprrl5  Small proline rich-like 5 
387.48  28.00  -1.55  Lce5a  Late cornified envelope 5A 
415.16  30.12  -1.58  Rptn  Repetin 
443.01  32.11  -2.14  Jarid1d  Jumonji, AT rich interactive domain 1D 
(Rbp2 like) 
453.86  30.90  -1.49  Sprrl7  Small proline rich-like 7 
494.01  36.36  -1.51  ---  --- 
506.99  35.75  -1.84  Uty /// LOC546404 
/// LOC546411 
Ubiquitously transcribed 
tetratricopeptide repeat gene, Y 
chromosome /// similar to male-specific 
histocompatibility antigen H-YDb /// 
similar to male-specific 
histocompatibility antigen H-YDb 
508.76  33.62  -1.53  LOC433621  /// 
LOC545581 
Similar to Acidic ribosomal 
phosphoprotein P0 /// similar to Acidic 
ribosomal phosphoprotein P0 
544.39  36.79  -1.98  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y linked 
574.12  38.80  -1.47  1110001M24Rik  RIKEN cDNA 1110001M24 gene Vicky King, 2010      Chapter 4, 161 
4.4.1.3   K14D6 keratinocytes versus K14D6 + CCL3 
To assess the transcriptional consequences of ligand binding to D6, a comparison 
between  resting  K14D6  keratinocytes  and  K14D6  keratinocytes  after  ligand 
binding was made. 
i)  Potential upregulated genes 
The  microarray  showed  higher  levels  of  171  genes  in  K14D6  keratinocytes 
incubated with CCL3 compared to K14D6 keratinocytes at rest (see full list in 
Appendix Two). The RP score of the 171 genes varied from 97.20 to 1538.85 and 
the FC ranged from 3.31 to 1.24. Out of 171 genes, 11 genes were potentially 
differentially expressed more than 2 fold and all were within the first top 25 
genes  summarised  in  Table  4 6.  It  is  of  note  that  Table  4 6  lists  the  top  25 
potentially upregulated genes as listed in the RP report; however only 24 genes 
are potentially upregulated as Lzp s appears twice.  
One gene potentially differentially expressed by more than 3 fold was aldehyde 
dehydrogenase family 1 (Aldh1a7), which was also the first gene on the rank 
product list with an RP score of 97.20 and a 3% false discovery rate (Table 4 6). 
P lysozyme structural (Lzp s) was ranked 2
nd and 4
th in the RP report with RP 
scores of 106.48 and 132.50 respectively, both times with an FDR of 1.5% and a 
fold change of 2.47 and 2.33 respectively. Cathepsin S (Ctss) was listed 3
rd with 
an  RP  score  of  110.66,  an  FDR  of  1.33%  and  was  changed  by  2.33  fold. 
Nucleoplasmin 3 (Npm3) was listed 5
th with an RP score of 147.22, an FDR of 
1.4% and was potentially upregulated by 2.11 fold.  Selenoprotein P plasma 1 
(Sepp1)  was  listed  6
th  with  an  RP  score  of  162.85  and  was  potentially 
differentially  expressed  by  2.31  fold,  followed  by  pentraxin  related  gene  3 
(Ptx3) with an RP score of 199.63, potentially upregulated by 2.18 fold and an 
FDR of 2.71%. Aldehyde dehydrogenase family 1 subfamily A1 (Aldh1a1) had an 
RP  score  of  210.40  and  changed  by  2.31  fold  whereas  lysosomal–associated 
protein transmembrane 5 (Laptm5) and Fc receptor IgG low affinity III (Fcrg3) 
had  an  RP  score  of  234.4  and  242.06  respectively  (listed  9
th  and  10
th)  and 
changed by 1.89 and 1.97 fold respectively.  
Within the top 25 genes listed, seven genes expressed at higher levels by CCL3 in 
K14D6 keratinocytes were found to be expressed at lower levels in resting K14D6 Vicky King, 2010      Chapter 4, 162 
keratinocytes  compared  to  wild type  keratinocytes  (Table  4 6  and  4 3 
respectively). These genes were Lzp s, Ctss, Laptm5, Fcgr3, Lysozyme (Lyzs), 
apolipoprotein E (Apoe) and Sepp1. This suggests that in absence of ligand, basal 
D6 may have a negative impact on the transcription of these genes but CCL3 
binding may be able to induce transcription of these genes.  
  
Table 4-6. Top 25 genes potentially upregulated by CCL3 in K14D6 keratinocytes.  
Genes  were  listed  in  order  of  rank  product  score  (RP  score)  with  details  of  %  false 
discovery rate (FDR) and fold change (FC). 
 
 
  
 
RP score  FDR (%)  FC  Gene Symbol  Gene Title 
97.20  3.00  3.31  Aldh1a7  Aldehyde dehydrogenase family1, 
subfamily A7 
106.48  1.50  2.47  Lzp-s  P lysozyme structural 
110.66  1.33  2.33  Ctss  Cathepsin S 
132.50  1.50  2.33  Lzp-s  P lysozyme structural  
147.22  1.40  2.11  Npm3  Nucleoplasmin 3 
162.85  1.50  2.31  Sepp1  Selenoprotein P, plasma, 1 
199.63  2.71  2.18  Ptx3  Pentraxin related gene 
210.40  2.75  2.31  Aldh1a1  Aldehyde dehydrogenase family 1, 
subfamily A1 
234.40  3.67  1.89  Laptm5  Lysosomal- associated protein 
transmembrane 5 
242.06  3.90  1.97  Fcrg3  Fc receptor, IgG, low affinity III 
254.35  4.27  2.18  Col3a1  Procollagen, type III, alpha 1 
279.37  5.17  2.22  Steap4  STEAP family member 4 
296.41  6.38  1.61  Slc6a14  Solute carrier family 6 (neurotransmitter 
transporter), member 14 
302.93  6.14  2.05  2610001E17Rik  RIKEN cDNA 2610001E17 gene 
305.98  5.87  1.79  Lcn2  Lipocalin 2 
313.90  5.94  1.92  Apoe  Apolipoprotein E 
373.00  9.29  1.82  Ccl9  Chemokine (C-C motif) ligand 9 
398.97  11.22  1.98  Gpm6b  Glycoprotein m6b 
423.63  12.68  2.11  Gtl2 /// Lphn1  GTL2, imprinted maternally expressed 
untranslated mRNA /// latrophilin 1 
427.48  12.40  1.68  Sprr2f  Small proline-rich protein 2F  
430.38  12.24  1.86  Ccl6  Chemokine (C-C motif) ligand 6 
435.11  12.23  1.60  2310003F16Rik  RIKEN cDNA 2310003F16 gene 
446.67  12.52  1.92  Gp49a /// Lilrb4  Glycoprotein 49 A /// leukocyte 
immunoglobulin-like receptor, subfamily 
B, member 4 
463.36  13.08  1.86  Col1a1  Procollagen, type I, alpha 1 
464.59  12.56  1.85  Lyzs  Lysozyme Vicky King, 2010      Chapter 4, 163 
Genes potentially upregulated by CCL3 in both WT and K14D6 keratinocytes 
The microarray showed that CCL3 binding to K14D6 keratinocytes resulted in the  
potential upregulation  of 171 genes with an FDR of less than 50%, however CCL3 
ligand binding in wild type keratinocytes resulted in the potential upregulation 
of 217 genes (Full results in Appendix Two). Eighty seven genes expressed at 
higher  levels  in  K14D6  keratinocytes  as  a  result  of  ligand  binding  were  also 
expressed  at  higher  levels  in  wild type  keratinocytes  after  ligand  binding, 
accounting for 99 of the 217 genes listed within the wild type + CCL3 RP report 
(some genes were listed twice).  
Comparing the first 25 ranked genes potentially upregulated by CCL3 in the wild 
type and K14D6 keratinocytes (Table 4 4 and Table 4 6 respectively), only two 
genes appear in the top 25 of both lists. The two genes are Laptm5, which is 
listed  9
th  in  K14D6  keratinocytes  (Table  4 6)  and  is  listed  21
st  in  wild type 
keratinocytes  (Table  4 4).  The  second  gene  is  procollagen  type  III  (Col3a1), 
found to be potentially differentially expressed by CCL3 binding in both K14D6 
and wild type keratinocytes, was listed 11
th and 4
th respectively (Table 4 6 and 
Table 4 4). Other genes were potentially upregulated after CCL3 binding in both 
K14D6 keratinocytes and wild type keratinocytes (although these genes are not 
shown in Table 4 4 but are listed in Appendix Two). These genes were, Aldh1a7, 
Lzp s, Ctss, Sepp1, Ptx3, Aldh1a1, Fcgr3, Col3a1, Riken cDNA 2610001E17 gene, 
ApoE,  CCL9,  Gtl2,  CCL6,  glycoprotein  49a  (Gp49a),  Col1a1  and  Lyzs.  Genes 
potentially upregulated in both wild type and K14D6 keratinocytes after ligand 
binding suggest that these may be transcriptional consequences induced through 
ligand binding to CCR1, CCR3 or CCR5. 
Genes  found  only  to  be  potentially  upregulated  in  K14D6  keratinocytes  were 
Npm3, STEAP4, solute carrier family 6 member 14 (Slc6a14), lipocalin 2 (Lcn2), 
glycoprotein m6b (Gpm6b), small proline rich protein 2F (Sprr2f) and Riken cDNA 
2310003F16 gene (Table 4 6). This suggests the possibility that these genes are 
affected by CCL3 binding to D6.  Genes found only to potentially upregulated, 
within  the  first  25  listed  in  Table  4 4,  in  wild type  keratinocytes  after  CCL3 
binding  were  Dkk2,  Tfpi2,  Riken  cDNA  B130021B11  gene,  complement 
component 1 q subcomponent (C1qa), nuclear receptor subfamily 2 (Nr2f1) and 
coagulation factor XIII (F13a1). These genes were not expressed at higher levels Vicky King, 2010      Chapter 4, 164 
after CCL3 binding in K14D6 keratinocytes. This suggests the possibility that the 
presence of D6 on K14D6 keratinocytes may limit the induction of Dkk2, Tfpi2, 
RIKEN cDNA B130021B11 gene, C1qa, Nr2f1 and F13a1. 
ii)  Potential downregulated genes 
The microarray showed lower levels of only four genes, with an FDR of less than 
50%,  in  the  comparison  between  resting  K14D6  keratinocytes  and  K14D6 
keratinocytes  after  addition  of  CCL3  (Table  4 7).  The  RP  score  varied  from 
123.91 to 369.64 for these four genes and the FC varied from  1.85 to  1.44 
(Table  4 7).  Two  genes  were  not  given  a  gene  symbol  or  title  but  the  rank 
product  report  has  hyperlinks  for  each  differentially  expressed  gene  to  a 
database, the Stanford Online Universal Resource for Clones and Ests (SOURCE). 
Using  this  hyperlink,  these  genes  were  identified  as  adapter  related  protein 
complex 2 beta 1 subunit (Ap2b1) and cannabinoid receptor 1 (Cbp1). The first 
gene,  Ap2b1,  had  an  RP  score  of  123.91,  a  2%  false  discovery  rate  and  was 
potentially  downregulated  by  1.85  fold.  The  second  gene  expressed  at  lower 
levels was sulfatase 1 with an RP score of 254.52, changed by 1.62 fold with an 
FDR of 29%. The third gene was uroplakin 1B with an RP score of 294.66, an FDR 
of 26.67% and was potentially downregulated by 1.6 fold. The fourth gene listed 
was cannabinoid receptor 1 with an RP score of 369.64 and a false discovery rate 
of 34%.  
 
 Table 4-7. Top 4 genes listed as potentially downregulated after CCL3 treatment in K14D6 
keratinocytes. 
Genes  were  listed  in  order  of  rank  product  score  (RP  score)  with  details  of  %  false 
discovery rate (FDR) and fold change (FC).   
 
RP score  FDR (%)  FC  Gene Symbol  Gene Title 
123.91  2.00     -1.85  Ap2b1  Adapter related protein complex 2 beta 1 
subunit 
264.52  29.00  -1.62  Sulf1  Sulfatase 1 
294.66  26.67  -1.60  Upk1b  Uroplakin 1B 
369.64  34.00  -1.44  Cbp1  Cannabinoid receptor 1 Vicky King, 2010      Chapter 4, 165 
Genes potentially downregulated by CCL3 binding in both WT and K14D6 
keratinocytes 
CCL3  ligand  binding  in  wild type  keratinocytes  resulted  in  the  potential 
downregulation  of  13  genes  (Table  4 5)  whereas  CCL3  treatment  on  K14D6 
keratinocytes resulted the potential downregulation of 4 genes (Table 4 7). All 
the genes expressed at lower levels in wild type keratinocytes by CCL3 were 
different  from  the  genes  expressed  at  lower  levels  by  CCL3  in  K14D6 
keratinocytes. This suggests that CCL3 binding may have a negative impact on 
the  gene  transcripts  via  different  mechanisms  in  wild type  and  K14D6 
keratinocytes. 
4.4.1.4     WT + CCL3 versus K14D6 + CCL3 
This comparison would give an understanding of the genes that are potentially 
up  or downregulated after CCL3 binding in K14D6 keratinocytes compared to 
wild type keratinocytes.  
i)  Potential upregulated genes 
Seven genes, with less than 50% FDR, were expressed at higher levels after CCL3 
treatment in K14D6 keratinocytes compared to wild type keratinocytes (Table 4 
8). The RP score varied from 1.28 to 423.42 with fold change of between 35.02 
and 1.52. Of the seven genes, 3 genes were potentially differentially expressed 
more than 2 fold. The gene with the smallest RP score of 1.28 was Ccbp2 (D6). 
This gene was potentially upregulated by 35 fold in K14D6 keratinocytes after 
incubation with CCL3 compared to wild type keratinocytes incubated with CCL3. 
Of the seven genes potentially upregulated, three were Y linked meaning these 
are genes encoded within the Y chromosome. The genes were Ddx3y, which was 
ranked  2
nd  and  4
th,  Eif2s3y  and  Uty  (Table  4 8).  As  these  are  Y linked  genes 
(Isensee  and  Ruiz  Noppinger,  2007),  this  data  suggests  that  the  keratinocyte 
population used within the K14D6 + CCL3 group were isolated from more male 
neonates than the wild type + CCL3 group.  
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Table  4-8.  Genes  listed  as  potentially  upregulated  after  CCL3  treatment  in  K14D6 
keratinocytes compared to wild-type keratinocytes after CCL3 treatment. 
Genes  were  listed  in  order  of  rank  product  score  (RP  score)  with  details  of  %  false 
discovery rate (FDR) and fold change (FC).  
 
 
Genes potentially upregulated due to ectopic expression of D6 
Ccbp2 was potentially upregulated, with an RP score of 1.28, in the wild type + 
CCL3 versus K14D6 + CCL3 comparison (Table 4 8). However, Ccbp2 was also 
potentially upregulated and ranked 1
st with an RP score of 1.00 in the WT versus 
K14D6 keratinocytes comparison (Table 4 2). Therefore, these data confirm that 
there are higher levels of D6 within K14D6 keratinocytes confirming that the D6 
transgene is expressed within K14D6 keratinocytes.  
It was noted that three Y linked genes, Ddx3y, Eif2s3y and Uty, were potentially 
upregulated in K14D6 keratinocytes after ligand binding in comparison to wild 
type keratinocytes after CCL3 binding (Table 4 8). Ddx3y and Eif2s3y were also 
potentially  downregulated  in  wild type  keratinocytes  after  CCL3  binding 
compared  to  wild type  keratinocytes  at  rest  (Table  4 5).  This  comparison 
supports evidence that the keratinocyte population used in the wild type + CCL3 
samples were derived from more female neonates than males. 
 
 
RP score  FDR (%)  FC  Gene Symbol  Gene Title 
1.28  0.00     35.02  Ccbp2  Chemokine binding protein 2 
90.60  12.00  3.97  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked 
186.44  9.00  3.73  Eif2s3y  Eukaryotic translation initiation factor 2, 
subunit 3, structural gene Y-linked 
280.18  21.25  2.31  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box  
polypeptide 3, Y-linked 
335.66  27.20  1.55  Slc6a14  Solute carrier family 6(neurotransmitter 
transporter), member 14 
396.73  33.67  1.58  Uty /// LOC546404 
/// LOC546411 
Ubiquitously transcribed 
tetratricopeptide repeat gene, Y 
chromosome /// similar to male-specific 
histocompatibility antigen H-YDb /// 
similar to male-specific 
histocompatibility antigen H-YDb 
407.62  31.86  1.92  Jarid1d  Jumonji, AT rich interactive domain 1D 
(Rbp2 like) 
423.42  32.00  1.52  Slc7a3  Solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 3 Vicky King, 2010      Chapter 4, 167 
ii)  Potential downregulated genes 
Twenty  three  genes,  with  less  than  50%  FDR,  were  found  to  be  potentially 
downregulated with an RP score range of 145.03 to 754.73 and fold change of 
2.12 to  1.39 (Table 4 9 lists top 25 ranked genes as Lzp s and Clec4n appear 
twice).  Four  genes  were  found  to  change  more  than  2 fold,  which  were 
lysosomal associated protein transmembrane 5 (Laptm5), P lysosome structural 
(Lzp s),  C type  lectin  domain  family  4  member  d  (Clec4d)  and  C type  lectin 
family 4 member n (Clec4n), in which three of these were listed within the top 
four in terms of RP score (Table 4 9). 
 
Table 4-9. Top 25 ranked genes potentially downregulated in K14D6 keratinocytes treated 
with CCL3 in comparison to WT keratinocytes treated with CCL3. 
Genes  were  listed  in  order  of  rank  product  score  (RP  score)  with  details  of  %  false 
discovery rate (FDR) and fold change (FC).  
 
 
RP score  FDR (%)  FC  Gene Symbol  Gene Title 
145.03  10.00      -2.01  Laptm5  Lysosomal-associated protein 
transmembrane 5 
154.19  5.50  -1.96  Lzp-s  P lysozyme structural 
163.17  3.67  -2.04  Lzp-s  P lysozyme structural 
186.83  4.50  -2.12  Clec4d  C-type lectin domain family 4, member d 
204.23  4.60  -1.93  Ctss  Cathepsin S 
236.28  6.33  -1.96  Plek  Pleckstrin 
377.58  22.14  -1.93  Ms4a7  Membrane-spanning 4-domains, 
subfamily A, member 7 
378.78  19.62  -1.69  Cxcl4  Chemokine (C-X-C motif) ligand 4 
381.87  17.89  -1.70  Tfpi2  Tissue factor pathway inhibitor 2 
407.64  20.70  -1.82  F13a1  Coagulation factor XIII, A1 subunit 
418.00  20.82  -1.74  Ms4a11  Membrane-spanning 4-domains, 
subfamily A, member 11 
418.30  19.08  -1.77  Mrc1  Mannose receptor, C type 1 
421.12  17.92  -1.73  Ccl6  Chemokine (C-C motif) ligand 6 
421.60  16.86  -1.56  B130021B11Rik  RIKEN cDNA B130021B11 gene 
427.86  16.67  -2.06  Clec4n  C-type lectin domain family 4, member n 
462.57  19.31  -1.86  Fcgr2b  Fc receptor, IgG, low affinity IIb 
502.33  23.24      -1.83  Ms4a6d  Membrane-spanning 4-domains, 
subfamily A, member 6D 
562.57  31.33  -1.66  Lyzs  Lysozyme 
565.86  30.11  -1.82  C1qa  Complement component 1, q 
subcomponent, alpha polypeptide 
572.64  29.65  -1.78  Clec4n  C-type lectin domain family 4, member n 
640.21  37.48  -1.75  Spp1  Secreted phosphoprotein 1 
646.39  36.95  -1.39  Dcn  Decorin 
694.46  43.87  -1.75  C3ar1  Complement component 3a receptor 1 
698.40  42.71  -1.63  Cck  Cholecystokinin 
730.34  46.00  -1.64  Fcgr3  Fc receptor, IgG, low affinity III Vicky King, 2010      Chapter 4, 168 
Genes potentially downregulated due to ectopic expression of D6 
 
Twelve of the potentially downregulated genes, summarised in Table 4 9, were 
also potentially downregulated in resting K14D6 keratinocytes in comparison to 
resting wild type keratinocytes. Nine of the 12 genes are within the top 25 genes 
of both tables (Table 4 9 and 4 3 respectively). These were Laptm5, Lzp s (listed 
twice), Clec4d, Ctss, CXCL4, Ms4a11, Lyzs, Clec4n and Fcgr3. The other three 
genes were mannose receptor c type 1 (Mrc1), CCL6 and Fc receptor IgG low 
affinity IIb (Fcgr2b), listed as potentially downregulated after ligand binding in 
K14D6 keratinocytes compared to wild type (Table 4 9). Mrc1, CCL6 and Fcgr2b 
are ranked 66
th, 64
th and 44
th respectively in the potentially downregulated gene 
comparison  between  resting  K14D6  and  wild type  keratinocytes  (Full  list  in 
Appendix Two). This would suggest that ectopic expression of D6 might affect 
the levels of these genes at rest. To determine a possible explanation as to why 
these genes were potentially downregulated with resting levels of D6, it was 
discovered that four of the genes, Ctss, Lyzs, Lzp s and Laptm5 were associated 
with  the  lysosome.  Ctss,  Lzp s  and  Lyz  are  all  lysosomal  proteins  whereas 
Laptm5 is a transmembrane spanning protein present in the lysosome (Adra et 
al., 1996). However, only Lzp s and Lyz were genes encoded within the same 
chromosome. This ruled out the possibility that basal D6 in absence of ligand was 
affecting the transcription of genes encoded within the same chromosome.  
However,  some  of  these  genes,  Laptm5,  Lzp s,  Ctss,  CCL6  and  Fcgr3  were 
potentially  upregulated  by  CCL3  in  K14D6  keratinocytes  (Table  4 6).  This 
suggests  CCL3  binding  in  K14D6  keratinocytes  may  be  able  to  induce  these 
genes. However, it was noted that the potential downregulation of Laptm5, Lzp 
s, Ctss, CCL6 and Fcgr3 in K14D6 keratinocytes after ligand binding compared to 
wild type  might  be  due  to  lower  levels  of  gene  expression  in  resting  K14D6 
keratinocytes. 
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4.4.1.5     Summary  of  rank  product  differential  analysis 
reports 
From the list of potentially differentially expressed genes using the rank product 
method,  the  conditions  under  which  the  largest  number  of  genes  were 
potentially differentially expressed and with a false discovery rate of less than 
50%  was  after  keratinocytes  were  incubated  with  CCL3.  Two  hundred  and 
seventeen  genes  were  potentially  upregulated  in  wild type  keratinocytes  and 
171  genes  were  potentially  upregulated  in  K14D6  keratinocytes.  The  largest 
number of genes potentially downregulated was in K14D6 keratinocytes at rest 
compared  to  wild type  keratinocytes  at  rest,  with  81  genes  potentially 
differentially expressed.  
One gene in this analysis stood out from the rest and this was Ccbp2 (D6) with an 
RP  score  of  1.  Ccbp2  was  listed  in  two  rank  product  differential  expression 
analysis  reports  with  the  two  smallest  rank  product  score  values  in  the  full 
microarray analysis, along with the highest fold change and 0% false discovery 
rate (summarised in Table 4 10). These data confirm there is upregulation of D6 
with a 49.59 fold change in resting K14D6 keratinocytes compared to the wild 
type. D6 was also expressed at higher levels, with a 35.02 fold change, in K14D6 
keratinocytes compared to wild type keratinocytes after ligand binding, however 
CCL3  does  not  affect  the  levels  of  D6,  as  the  gene  was  not  found  to  be 
differentially expressed in comparison to K14D6 keratinocytes not treated with 
CCL3. 
 
 
 
Table 4-10. Expression of D6 in rank product differential expression analysis reports. 
D6 (Ccbp2) was potentially upregulated in K14D6 keratinocytes at rest compared to wild-
type  (WT)  control  keratinocytes  and  in  K14D6  keratinocytes  after  incubation  with  CCL3 
compared to wild-type keratinocytes after CCL3 incubation. RP score is rank product score, 
FDR is the false discovery rate and FC is the fold change in the gene. 
 
 
Comparison  Gene  RP score  FDR (%)  FC 
WT control v K14D6 control  Ccbp2  1.00  0.00  49.59 
 WT + CCL3 v K14D6 +CCL3  Ccbp2  1.28  0.00  35.02 Vicky King, 2010      Chapter 4, 170 
Transcriptional changes due to ectopic expression of D6 
The microarray showed that only six genes were expressed at higher levels in 
K14D6  keratinocytes  in  comparison  to  wild type  keratinocytes.  These  were 
Ccbp2 (D6), Dkk2, Nrk, Bcat1, Stc2 and Tfpi2 (Table 4 2). Ccbp2 was the only 
gene with an RP score of 1 and confirmed that there is increased expression of 
D6 within K14D6 keratinocytes. 
Eighty one genes were potentially downregulated, with an FDR of less than 50%, 
in  untreated  K14D6  keratinocytes  compared  to  wild type  keratinocytes 
suggesting  transcriptional  changes  may  have  occurred  through  D6  in  a  ligand 
independent  manner.  Within  this  group,  the  1
st  ranked  gene  potentially 
differentially  expressed  was  Lzp s,  which  had  the  third  smallest  RP  score  of 
80.91 in the microarray (after D6 with an RP score of 1 and 1.28).  
Effect of CCL3 binding on keratinocytes 
The largest number of genes potentially upregulated was after ligand binding 
with CCL3 in keratinocytes. CCL3 binding in wild type keratinocytes resulted in 
217  potentially  differentially  expressed  genes  whereas  181  genes  were 
potentially differentially expressed in K14D6 keratinocytes.  
When comparing both RP differential expression reports, 87 genes potentially 
upregulated  in  K14D6  keratinocytes  by  CCL3  binding  were  also  potentially 
upregulated in wild type keratinocytes after CCL3 binding. Two genes, Lzp s and 
Col3a1, were listed within the top twenty five genes expressed at higher levels 
by CCL3 binding in both wild type and K14D6 keratinocytes. Genes potentially 
upregulated in both wild type and K14D6 keratinocytes suggests that these genes 
may be induced through CCL3 binding to common receptors, such as CCR1, CCR3 
and CCR5, shown to be present on wild type and K14D6 keratinocytes previously 
within Chapter 3.  
The microarray showed lower levels of 13 genes in wild type keratinocytes and 
lower levels of 4 genes in K14D6 keratinocytes after CCL3 binding. None of the 
genes potentially downregulated in wild type and K14D6 keratinocytes were the 
same. Many of the genes potentially downregulated in wild type keratinocytes 
after  CCL3  binding  were  Y linked  genes  and  may  have  been  due  to  the Vicky King, 2010      Chapter 4, 171 
keratinocyte  populations  used  being  isolated  from  more  female  neonates 
coincidently than the keratinocyte population used as resting wild type. 
Differential expression of genes after CCL3 binding between WT and K14D6 
keratinocytes 
Differences in gene expression after ligand binding between wild type and K14D6 
keratinocytes were analysed in the WT + CCL3 v K14D6 + CCL3 rank product 
report. Differential gene expression would give an indication into the effect the 
presence of D6 in K14D6 keratinocytes has on the cell transcriptome after CCL3 
binding. Only seven genes were potentially upregulated in K14D6 keratinocytes 
compared to the wild type. One gene potentially upregulated was Ccbp2 (D6) as 
discussed  above  and  summarised  in  Table  4 10.  Three  of  the  seven  genes 
potentially  upregulated  within  K14D6  keratinocytes  were  Y linked  genes.  One 
possibility may be that the keratinocytes used for the WT + CCL3 population 
were isolated from fewer males than the K14D6 + CCL3 population. This also 
correlates with Y linked genes being potentially downregulated in WT v WT + 
CCL3 comparison. The other two genes potentially differentially expressed were 
both solute carrier family genes, Slc6a14 and Slc7a3. These two genes were not 
potentially differentially upregulated in K14D6 keratinocytes at rest compared to 
wild type and therefore the potential upregulation could not be explained by an 
initial higher level of gene expression in resting K14D6 keratinocytes.  
Twelve genes were potentially downregulated at rest and after ligand binding in 
K14D6 keratinocytes compared to wild type keratinocytes (Table 4 3 and Table 
4 9 respectively). Nine out of the twelve genes were listed within the top 25 
genes  in  both  comparisons.  These  genes  were  Laptm5,  Lzp s,  Clec4d,  Ctss, 
CXCL4,  Ms4a11,  Clec4n,  Lyzs  and  Fcgr3.  The  nine  genes  listed  were  also 
potentially upregulated by CCL3 in K14D6 keratinocytes. This suggests that the 
differential  expression  of these  genes  after  ligand  binding  between  wild type 
and K14D6 keratinocytes is due to K14D6 keratinocytes having a lower expression 
of these genes at rest than wild type keratinocytes.  
Eleven  genes  potentially  downregulated  after  ligand  binding  in  K14D6 
keratinocytes  compared  to  wild type  were  not  potentially  downregulated  in 
resting  K14D6  keratinocytes.  These  were  Plek,  Ms4a7,  Tfpi2,  Fl3a1, 
B130021B11Rik, Ms4a6d, C1qa, Spp1, decorin (Dcn), C3ar1 and cholecystokinin Vicky King, 2010      Chapter 4, 172 
(Cck). This result indicates that the difference was potentially due to ectopic 
expression of D6 affecting the transcriptional consequence of CCL3 by inhibiting 
gene expression.  
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4.4.2  Iterative group analysis 
The  lists  of  genes  produced  by  rank  products  are  further  processed  using 
iterative  group  analysis  (iGA),  which  identifies  functional  changed  groups  of 
genes,  where  each  gene  is  assigned  to  a  functional  class  according  to  Gene 
Ontology (http://www.geneontology.org). Iterative group analysis combines the 
relative position of the genes in the RP list and the number of changed genes 
within the group to statistically determine the strength of changes within the 
group. This analysis was performed using various steps, firstly sorting the genes 
according to a differential expression method, in this case by RP score, either by 
increasing or decreasing order. The second step was to count the members of 
each  functional  class  of  interest  and  then  for  each  functional  class  member 
determine the probability of change (p value) for the gene member to be in that 
position by chance (Breitling et al., 2004a). The p value for each member was 
plotted against the position of each class member within a functional group. The 
position with the smallest p value was assigned as the ‘cut off’ point for each 
functional  group.  Therefore,  all  gene  members  above  this  position  were 
determined as potentially differentially expressed and the smallest p value was 
assigned  the  p  value  changed  for  the  group.  This  was  performed  for  all  the 
functional  gene  classes,  which  were  then  sorted  according  to  their  p value 
changed.  The  threshold  of  the  p  value  changed  was  1.2x10
 4  and  therefore 
classes  with  the  smallest  P  value  changed  (below  1.2x10 
 4)  were  the  most 
significantly changed. An advantage of iGA analysis is that it does not require all 
members of the group change. Another important feature is that experimental 
replicates are not required because statistical significance can be determined by 
using group members as internal replicates. Full details of four iGA reports can 
be found in Appendix Three. 
 To identify functional changed groups of genes, four comparisons were made: 
1) WT control (baseline) Versus K14D6 control 
 
2) WT control (baseline) Versus WT + CCL3 
 
3) K14D6 control (baseline) Versus K14D6 + CCL3 
 
4) WT + CCL3 (baseline) Versus K14D6 + CCL3 
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4.4.2.1     WT control v K14D6 control keratinocytes 
i)  Potential upregulated functional genes classes 
Ectopically  expressing  D6  within  keratinocytes  resulted  in  9  classes  of  genes, 
which  involved  18  distinct  gene  members,  being  potentially  upregulated  in 
K14D6 keratinocytes compared to wild type keratinocytes at rest (Table 4 11). 
Four of these groups included genes associated with cell structure, which were 
collagen, extracellular matrix structural constituent conferring tensile strength, 
collagen triple helix repeat and extracellular matrix structural constituent. All of 
these  groups  involved  the  procollagen  family  of  genes,  which  are  also  all 
involved in the phosphate transport group listed. Other functional gene classes 
potentially  differentially  expressed  were  transmembrane  receptor  protein 
tyrosine  kinase  signalling  pathway,  cadherin  cytoplasmic  region,  intracellular 
calcium activated chloride channel activity and prostaglandin biosynthesis. 
 
Table 4-11. Potential upregulated functional gene classes in K14D6 keratinocytes compared 
to wild-type keratinocytes 
 
 
 
 
WT control V K14D6 control  Group members  Changed 
members 
P-value 
Changed 
5581- collagen  34  5  1.9e-07 
7169- transmembrane receptor protein tyrosine 
kinase signalling pathway 
76  6  4.3e-06 
30020- extracellular matrix structural constituent 
conferring tensile strength 
29  4  4.5e-06 
IPR008160- Collagen triple helix  65  5  5.1e-06 
IPR000233- Cadherin cytoplasmic region  12  3  7.8e-06 
6817- phosphate transport  84  5  1.8e-05 
1516- prostaglandin synthesis  9  2  2.9e-05 
5201- extracellular matrix structural constituent  47  4  3.2e-05 
5229- intracellular calcium activated chloride 
channel activity 
3  3  1.0e-04 Vicky King, 2010      Chapter 4, 175 
Comparison with WT control V K14D6 control RP report 
Only  six genes with an FDR of less than 50%  were potentially upregulated in 
resting K14D6 keratinocytes in comparison to wild type, using RP score (Table 4 
2). None of the genes were listed as changed members within the top changed 
groups in the iGA analysis report.  However, genes ranked 9
th and 15
th in the RP 
report,  prostaglandin  I2  synthase  and  prostaglandin endoperoxidase  synthase, 
were the two changed members within the prostaglandin synthesis group, which 
was statistically determined as potentially upregulated. Five procollagen genes 
are members within 5 of the top 9 changed groups in the iGA report. All 5 genes 
were ranked between 32 and 62 in the RP report and all had a false discovery of 
more than 50%.  
ii)  Potential downregulated functional gene classes 
Gene  classes  found  to  be  potentially  downregulated  in  K14D6  keratinocytes 
compared to wild type keratinocytes at rest included 11 groups of genes classes 
involving 21 distinct genes (Table 4 12).  
The  top  changed  group  involved  the  functional  class  of  cornified  envelope, 
followed by keratinisation. Other groups such as glycoside hydrolase, lysozyme 
activity,  cell  wall  catabolism  and  cytolysis  involved  the  same  two  members 
changing, which were P lysozyme structural (Lzp s) and lysozyme (Lyzs). Three 
groups  involving  chemokines  were  potentially  downregulated,  in  which  four 
chemokines  were  consistently  changed  across  all  three  groups;  these  were 
CXCL4, CCL9, CCL6 and CXCL2. The fifth changed member within the chemotaxis 
group was complement component 3a receptor 1 (C3ar1). The other top changed 
groups  were  involved  in  IgG  binding  and  tyrosinase.  This  suggests  that  the 
possibility that the presence of D6 within K14D6 keratinocytes may inhibit the 
expression levels of genes within these functional gene classes. 
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Table  4-12.  Potential  downregulated  functional  gene  classes  in  K14D6  keratinocytes 
compared to wild-type keratinocytes. 
 
 
Comparison with the RP report 
P lysozyme  structural  and  lysozyme  were  two  members  that  changed 
consistently  across  4  top  changed  groups  in  the  iGA  analysis  and  these  were 
genes that were also potentially differentially expressed within the top twenty 
five genes listed in the RP report (Table 4 3). Three of the top changed groups 
contained  four  chemokines  that  changed  consistently  in  the  iGA  analysis  and 
three  of  these  chemokines  (CXCL4,  CCL9  and  CCL6)  were  potentially 
differentially expressed in the rank product report. Changed members within the 
cornified envelope and keratinisation group were listed within the rank product 
report. Fcgr3 was a changed member within the IgG binding group, which was 
potentially differentially expressed in the RP report. Tyrosinase was the 11
th top 
changed  group  in  the  iGA  analysis  report  yet  none  of  the  three  changed 
members, dopachrome tautomerase, tyrosinase related protein 1 and tyrosinase, 
were listed as potentially differentially expressed within the 100 genes listed in 
the RP report. 
 
 
 
 
WT control V K14D6 control 
 
Group 
members 
Changed 
members 
P-value 
Changed 
1533- cornified envelope  14  7  9.3e-13 
31424 – keratinisation  23  4  4.1e-06 
IPR001916- Glycoside hydrolase, family 22  8  2  4.6e-06 
3796- lysozyme activity  10  2  7.4e-06 
16998- cell wall catabolism  16  2  2.0e-05 
IPR001811- Small chemokine, interleukin-8 like  31  4  2.2e-05 
19835- cytolysis  20  2  3.1e-05 
19864 – IgG binding   5  2  4.1e-05 
8009- chemokine activity  38  4  5.0e-05 
6935- chemotaxis  87  5  1.1e-04 
IPR002227- Tyrosinase  3  3  1.2e-04 Vicky King, 2010      Chapter 4, 177 
4.4.2.2    WT control v WT control + CCL3 
i)  Potential upregulated functional gene classes 
CCL3  ligand  binding  to  wild type  keratinocytes  resulted  in  the  potential 
upregulation  of  22  functional  gene  classes  in  comparison  to  wild type 
keratinocytes at rest. These 22 groups consisted of 42 distinct genes (Table 4 
13).  
The  top  three  groups  had  the  highest  numbers  of  changed  members.  The  8 
changed members within the top changed group of collagen triple helix repeat 
were also seven of the members that change within the second listed changed 
gene  group  involved  in  phosphate  transport.  The  third  top  changed  group 
involved  in  extracellular  matrix  structural  constituent  contains  five  changed 
members that were also classified within the collagen triple helix repeat class of 
genes. Eight of the top 23 changed groups are all involved in structural support 
involving collagen and the extracellular matrix. Three groups identified involved 
chemokines,  with  the  changed  members  identified  as  CXCL2,  CXCL4,  CXCL5, 
CCL2, CCL6 and CCL9. Of note, CXCL2, CXCL4, CCL6 and CCL9 were members of 
functional  groups  that  were  potentially  downregulated  in  resting  K14D6 
keratinocytes  compared  to  wild type  keratinocytes  (Table  4 12).  Other  gene 
class  groups  potentially  differentially  expressed  in  wild type  keratinocytes  by 
CCL3 were phosphate transport, transmembrane receptor protein tyrosine kinase 
pathway,  CD20/IgE  Fc  receptor  beta  subunit,  cysteine rich  flanking  region, 
heparin  binding,  inflammatory  response  pathway,  eicosanoid  synthesis,  von 
willebrand factor, lysl oxidase, intracellular calcium activated chloride channel 
activity and positive regulation of phagocytosis. (Table 4 13). 
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WT control V  WT + CCL3  Group members  Changed 
members 
P-value 
changed 
IPR008160- Collagen triple helix repeat  71  8  7.6e-11 
6817- phosphate transport  84  7  1.3e-10 
5201- extracelular matrix structural constituent  48  8  4.3e-10 
30020- extracellular matrix structural constituent 
conferring tensile strength 
29  5  1.1e-09 
5581- collagen  35  5  2.9e-09 
IPR000885- Fibrillar collagen, C-terminal  11  5  3.2e-09 
IPR-001811- small chemokine, interleukin-8 like  31  6  1.8e-08 
8009- chemokine activity  38  6  6.4e-08 
7169- transmembrane receptor protein tyrosine 
kinase signalling pathway 
76  6  4.7e-07 
IPR007237- CD20/Ig E Fc receptor beta subunit  15  4  5.5e-07 
IPR000372- Cysteine-rich flanking region, N-
terminal 
39  5  2.2e-06 
1527-microfibril  6  3  3.8e-06 
30023- extracellular matrix constituent conferring 
elasticity 
2  2  4.9e-06 
6935- chemotaxis  87  6  9.4e-06 
8201- heparin binding  57  5  2.3e-05 
Inflammatory_Response_Pathway-GenMAPP  40  3  4.1e-05 
Eicosanoid_Synthesis- GenMAPP  21  3  4.6e-05 
IPR001007- von Willebrand factor, type C  22  2  5.0e-05 
IPR001695- Lysyl oxidase  4  2  7.2e-05 
5229- intracellular calcium activated chloride 
channel activity  
3  3  9.8e-05 
50766- positive regulation of phagocytosis  21  3  1.1e-04 
5588- collagen type V  3  3  1.2e-04 
    
Table 4-13. Potential downregulated functional gene classes in Wild-type (WT) keratinocytes 
after CCL3 treatment compared to wild-type keratinocytes at rest. 
 
Comparison with the RP report 
Seven  of  the  top  changed  functional  groups  induced  by  CCL3  in  wild type 
keratinocytes, reported in the iGA report, consisted of the same changed gene 
members  (Full  list  in  Appendix  Three).  These  were  Col3a1,  Col6a1,  Col6a2, 
C1qa, Col11a1, Col1a2 and Emilin 1. Five of these, Col3a1, Col6a1, Col6a2, C1qa 
and Col11a1, were listed within the top 25 genes in the RP report (Table 4 4). 
The other two were ranked 29
th and 36
th in the RP report (Full list in Appendix 
Two). Three of the top changed groups involved chemokines and these were all 
present in the RP report, CXCL4 was listed 2
nd, CXCL5 was listed 39
th, CCL2 was 
listed 50
th, CCL6 was listed 79
th, CCL9 was listed 109
th and CXCL2 was 112
th, all 
had an FDR of less than 50% (Full report in Appendix Two). 
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ii)  Potential downregulated functional gene classes 
 
After  CCL3  binding  to  wild type  keratinocytes,  14  functional  genes  classes 
involving 22 distinct genes,  were  potentially downregulated in comparison to 
wild type  keratinocytes  at  rest  (Table  4 14).  The  top  changed  group  is  the 
cornified envelope and has four changed members (The full iGA analysis report is 
in Appendix Three). Members within this group are also found to be changed 
within the functional gene classes of calcium binding protein, keratinisation and 
one gene is found to be changed within the functional gene class of structural 
constituent of cytoskeleton. Four genes were found to be changed within the 
melanosome class and these genes were also classified as changed within the 
melanin  biosynthesis  from  tyrosine  and tyrosinase  group.  Members  within  the 
intermediate  filament  group  are  also  the  same  members  that  have  changed 
within  intermediate  filament  protein  group,  sarcolemma  and  structural 
constituent  of  cytoskeleton  group.  Another  three  groups  potentially 
differentially  expressed  with  the  same  changed  members  are  calcium 
independent  cell cell  adhesion  group,  identical  protein  binding  and  the  PMP 
22/EMP20  and  claudin  family.  Another  functional  group  potentially 
downregulated was transcription factor jumonji (Takeuchi et al., 2006), which 
involved gene members that are encoded within the Y chromosome. 
 
WT control V WT + CCL3 
 
Group members  Changed 
members 
P-value 
Changed 
1533- cornified envelope  14  4  8.0e-11 
42470- melanosome  7  4  4.6e-08 
IPR003347- Transcription factor jumonji, jmjC  18  3  6.7e-08 
5882- intermediate filament  93  8  9.3e-08 
IPR001664 – Intermediate filament protein  57  6  4.5e-07 
6583- melanin biosynthesis from tyrosine  6  3  4.4e-06 
IPR001751- Calcium binding protein, S-100/ IcaBP 
type 
14  2  7.1e-06 
IPR002227- Tyrosinase  2  2  2.5e-05 
16338- calcium-independent cell-cell adhesion  22  3  2.5e-05 
42383- sarcolemma  14  3  4.6e-05 
42802- identical protein binding  81  4  6.0e-05 
IPR004031-  PMP-22/EMP/MP20  and  claudin 
family 
30  3  6.5e-05 
31424 – keratinisation  23  2  8.9e-05 
5200- structural constituent of cytoskeleton  91  5  1.0e-04 
Table 4-14. Potential downregulated functional gene classes in Wild-type (WT) keratinocytes 
after CCL3 treatment compared to wild-type keratinocytes at rest. 
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Comparison with the RP report 
In the RP report, 13 genes were potentially downregulated with an FDR of less 
than 50% in wild type keratinocytes after CCL3 binding compared to resting wild 
type keratinocytes (Table 4 5). Seven genes potentially differentially expressed 
in the RP report were also listed as changed gene members in the iGA analysis 
report.  The  seven  genes  were  LOC433621,  hornerin  (Hrnr),  repetin  (Rptn), 
DEAD3y,  Jarid1a,  Uty  and  Lce5a.  LOC433621,  Hrnr  and  Rptn  were  the  three 
changed members within the cornified envelope group. Of these three, Hrnr and 
Rptn were also changed members within the calcium binding and keratinisation 
group.  DEAD3y,  Jarid1a  and  Uty  are  all  gene  members  within  transcription 
factor,  jumonji  (Takeuchi  et  al.,  2006).  Other  groups  in  Table  4 14,  such  as 
calcium independent cell cell adhesion, all contain changed gene members that 
were listed in the RP report but with an FDR of more than 50%. 
4.4.2.3    K14D6 control v K14D6 + CCL3 
i)  Potential upregulated functional gene classes 
Twenty two  functional  gene  classes  were  potentially  upregulated  after  CCL3 
ligation in K14D6 keratinocytes compared to K14D6 keratinocytes at rest. These 
22 groups consisted of 39 distinct genes (Table 4 15). The top changed group was 
extracellular matrix structural constituent conferring tensile strength, in which 
seven members within this group changed. These were also the seven members 
that changed within the second top changed group of collagen and the fourth to 
seventh  top  changed  groups  which  were  extracellular  matrix  structural 
constituent,  fibrillar collagen, collagen triple  helix  repeat  and the phosphate 
transport group (Full list is in Appendix Three). Within this comparison, 7 genes 
involved  in  chemotaxis  were  found  to  be  potentially  upregulated  after  CCL3 
binding. Five of the members were also found to be changed within the gene 
class  of  small  chemokine  interleukin 8  like  and  chemokine  activity,  which 
involved CCL9, CCL6, CXCL4, CXCL2 and CCL7. CCL9, CCL6, CXCL2 and CXCL4 
were  also  potentially  upregulated  gene  members  within  top  changed  groups 
after  ligand  binding  in  wild type  keratinocytes  (Table  4 13).  CCL3  binding  to 
K14D6  keratinocytes  resulted  potential  upregulation  of  genes  involved  in  the 
positive regulation of phagocytosis, IgG binding and mast cell activation. Other Vicky King, 2010      Chapter 4, 181 
groups  differentially  expressed  were  glycosidase  hydrolase  family  22  and 
lysozyme activity involving the same two changed members and some members 
within  the  intracellular  activated  chloride  channel  activity  group  were  also 
involved in the functional gene class of Von Willebrand factor. Other potentially 
differentially expressed gene classes were heparin binding, myelin proteolipid 
protein  PLP,  CD20/IgE  Fc  receptor  subunit,  aldehyde  dehydrogenase,  calcium 
binding protein and tyrosinase.  
Thirteen  functional  gene  classes  were  expressed  at  higher  levels  after  CCL3 
binding in both wild type and K14D6 keratinocytes (Table 4 13 and Table 4 15 
respectively). These were three functional groups involving collagen (collagen, 
fibrillar collagen, collagen triple helix repeat) and two involved the extracellular 
matrix  (extracellular  matrix  structural  constituent  conferring  tensile  strength 
and  extracellular  matrix  structural  constituent).  The  other  functional  groups 
were  heparin  binding,  CD20/IgE  Fc  receptor  subunit,  intracellular  calcium 
activated  chloride  channel  activity,  phosphate  transport  and  three  involved 
chemokines  (chemotaxis,  small  chemokine  interleukin 8  like  and  chemokine 
activity). Von willebrand factor was potentially upregulated  in both, although in 
wild type this was type C whilst in K14D6 keratinocytes this was type A. 
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K14D6 control V K14D6 + CCL3 
 
Group members  Changed 
members 
P-value 
changed 
30020- extracellular matrix structural constituent 
conferring tensile strength 
29  7  1.9e-10 
55871- collagen  35  7  6.9e-10 
82017- heparin binding  57  8  1.7e-09 
5201- extracellular matrix structural constituent  48  7  6.8e-09 
IPR000885- Fibrillar collagen, C-terminal  10  4  2.4e-08 
IPR008160- Collagen triple helix repeat  72  6  1.5e-07 
6871- phosphate transport  85  7  3.9e-07 
6935- chemotaxis  87  7  3.9e-07 
IPR001811- Small chemokine, interleukin-8 like  31  5  5.7e-07 
8009- chemokine activity  38  5  1.6e-06 
50766-positive regulation of phagocytosis  21  3  3.9e-06 
19864 – IgG binding  5  2  2.2e-05 
IPR-001614 –Myelin proteolipid protein PLP  3  2  3.1e-05 
IPR007237- CD20/IgE Fc receptor beta subunit  14  3  3.8e-05 
IPR001916- Glycoside hydrolase, family 22  8  2  5.0e-05 
IPR002086- Aldehyde dehydrogenase  26  2  5.3e-05 
45576- mast cell activation  9  2  7.7e-05 
3796- lysozyme activity  10  2  8.1e-05 
IPR001571- Calcium binding protein, S-100/ICaBP 
type 
15  3  9.3e-05 
5229- intracellular calcium activated chloride 
channel activity 
3  3  9.4e-05 
IPR002227- Tyrosinase  3  3  9.8e-05 
IPR002035- von Willebrand factor, type A  44  4  1.1e-04 
    
Table  4-15.  List  of  potential  upregulated  functional  gene  classes  in  K14D6  keratinocytes 
after CCL3 treatment compared to K14D6 keratinocytes at rest. 
 
Comparison to RP report 
In the RP report, 171 genes were potentially upregulated in K14D6 keratinocytes 
after ligand binding (For full list see Appendix Two). Thirty six genes listed as 
potentially differentially expressed within the RP report were members within 
the top changed groups (Table 4 15). Of the top 25 genes listed within the RP 
report (see Table 4 6), 12 genes were found to be changed members within the 
top changed groups in Table 4 15. Genes potentially upregulated were Aldh1a7 
and Aldh1a1, both changed members within the aldehyde dehydrogenase group. 
Col3a1 and col1a1, listed as 11
th and 24
th in Table 4 6, are changed members 
within six functional gene groups. CCL9 and CCL6 were potentially upregulated 
in Table 4 6 and were changed members within the chemotaxis group. Ptx3 and 
Fcgr3 are changed members within the functional group positive regulation of 
phagocytosis, which were also listed in the top 25 genes in the RP report (Table 
4 6). Lzp s and Lyzs were listed 2
nd and 25
th in the RP report (Table 4 6) in which 
both were changed members within the glycoside hydrolase group. 
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ii)  Potential downregulated functional gene classes 
CCL3  binding  in  K14D6  keratinocytes  resulted  in  7  potentially  downregulated 
functional gene classes (Table 4 16). The top changed group was plectin repeat 
with a p value change of 3.8x10
 08 in which 4 members of the group changed. 
The  second  top  changed  group  with  a  p value  changed  of    6.1x10
 07  was 
sarcolemma,  in  which  3  members  changed  and  are  also  the  3  members  that 
changed  within  the  changed  groups  of  Z  disc,  response  to  pest  pathogen  or 
parasite and the intermediate filament protein group with p value changed of 
4.8x10
 06,  7.4x10
 06  and  3.7x10
 05  respectively.  Other  changed  groups  were 
muscle  maintenance  and  spectrin  repeat  with  2  and  3  members  changed 
respectively. 
CCL3 binding resulted in potential downregulation of 14 functional gene classes 
in  wild type  keratinocytes  whereas  in  K14D6  keratinocytes,  only  7  functional 
groups were potentially downregulated (Table 4 14 and 4 16 respectively). Only 
two functional gene classes were expressed at lower levels after ligand binding 
in  both  wild type  keratinocytes  and  K14D6  keratinocytes,  which  were 
sarcolemma  and  intermediate  filament  protein  (Table  4 14  and  Table  4 16 
respectively). 
K14D6 control V K14D6 + CCL3  Group members  Changed 
members 
P-value 
changed 
IPR001101- Plectin repeat  8  4  3.8e-08 
42383- sarcolemma  14  3  6.1e-07 
30018- Z disc  27  3  4.8e-06 
9613- response to pest, pathogen or parasite  31  3  7.4e-06 
IPR001664 – Intermediate filament protein  59  4  3.7e-05 
46716-muscle maintenance  4  2  5.7e-05 
IPR002017- Spectrin repeat  19  3  1.1e-04 
 
 
Table 4-16. Potential downregulated functional gene classes in K14D6 keratinocytes after 
CCL3 treatment compared to K14D6 keratinocytes at rest. 
 
Comparison to the RP report 
In the RP report, only four genes were potentially downregulated with an FDR of 
less than 50% after CCL3 binding in K14D6 keratinocytes (Table 4 7). None of the 
four genes listed were the changed members in any of the 7 top changed groups 
in the respective iGA analysis report. Vicky King, 2010      Chapter 4, 184 
4.4.2.4     WT + CCL3 v K14D6 + CCL3 
To  determine  the  transcriptional  consequences  of  D6  in  K14D6  keratinocytes 
after  ligand  binding,  functional  gene  classes  were  analysed  for  differential 
expression  in  a  positive  or  negative  direction  in  comparison  to  wild type 
keratinocytes after CCL3 ligand binding.  
i)  Potential upregulated functional gene classes  
Seven  gene  classes,  which  consisted  of  14  distinct  genes,  were  expressed  at 
higher  levels  in  K14D6  keratinocytes  after  ligand  binding  (Table  4 17).  Four 
members changed within the top changed group of melanin biosynthesis. Within 
this group, 3 of the members were also changed members in the functional class 
involved  in  melanosome  and  2  were  changed  members  within  the  tyrosinase 
group.  The  second  functional  gene  class  group  was  involved  in  the  cornified 
envelope, involving 5 changed members. Of these, three were members that 
changed within the keratinisation functional gene class. The third top changed 
group  was  transcription  factor  jumonji  in  which  3  members  changed  and  2 
members changed within the amino acid transporter activity group.  
None  of  the  top  changed  groups  in  K14D6  keratinocytes  after  ligand  binding 
(Table 4 17) were the same as the top changed groups potentially upregulated in 
resting K14D6 keratinocytes compared to wild type keratinocytes (Table 4 11). It 
was noted that 6 of the 7 top changed groups in Table 4 17 were expressed at 
lower levels in wild type keratinocytes after ligand binding compared to resting 
wild type keratinocytes (Table 4 14). Therefore, CCL3 potentially induced the 
downregulation  of  these  groups  in  wild type  keratinocytes  but  not  in  K14D6 
keratinocytes, this could explain why these groups are the top groups potentially 
upregulated in K14D6 keratinocytes compared to wild type keratinocytes after 
ligand binding. Vicky King, 2010      Chapter 4, 185 
WT + CCL3 v K14D6 + CCL3  Group members  Changed 
members 
P-value 
changed 
6583- melanin biosynthesis from tyrosine  6  4  3.4e-11 
1533- cornified envelope  14  5  1.2e-08 
IPR003347- Transcription factor jumonji, jmjC  21  3  3.9e-08 
42470- melanosome  7  3  6.8e-08 
IPR002227- Tyrosinase  2  2  1.6e-06 
15171- amino acid transporter activity  18  2  2.5e-05 
31424 – keratinisation  23  3  4.3e-05 
 
 
Table 4-17. Potential upregulated functional gene classes in K14D6 keratinocytes after CCL3 
treatment compared to Wild-type keratinocytes after CCL3 treatment. 
 
Comparison to the RP report 
Only eight genes were potentially upregulated in K14D6 keratinocytes compared 
to  wild type  keratinocytes  after  ligand  binding  in  the  RP  report  (Table  4 8). 
Three genes expressed at higher levels in the RP report, Ddx3y, Uty and Jarid1d, 
are  the  three  gene  members  that  changed  within  the  transcription  factor 
jumonji functional gene class (Table 4 17). Slc6a14 and Slc7a3 were two genes 
listed in the RP report, which were the two changed gene members within the 
amino acid transporter activity group. Genes involved in melanin biosynthesis, 
cornified envelope, melanosome group, tyrosinase and keratinisation were not 
potentially upregulated, with an FDR of less than 50%, in the RP report. 
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ii)  Potential downregulated functional gene classes 
Twelve  functional  gene  classes  were  potentially  downregulated  involving  21 
distinct genes in K14D6 keratinocytes compared to wild type keratinocytes after 
ligand binding by CCL3 (Table 4 18). The top changed group was CD20/IgE Fc 
receptor beta subunit in which 4 members out of 15 changed. The next three 
changed groups all involved chemokines. The second changed group was small 
chemokine  interleukin 8  like  with  four  changed  members,  which  were  also 
within  the  chemotaxis  group  and  the  chemokine  activity  group,  all  involving 
CXCL4,  CCL6,  CXCL5  and  CCL9.    Chemokines  were  also  potentially 
downregulated  in  K14D6  at  rest  compared  to  wild type  keratinocytes,  which 
were CCL9, CCL6, CXCL4, and CXCL2 (Table 4 12). Another group that changed 
was immune cell chemotaxis, involving CXCL4 and CCR1 as two of the changed 
group members. IgG binding and mast cell activation are two other top changed 
groups with p value changed of 1.8x10
 05 and 6.5x10
 05, with only two changed 
members which are the same, Fc receptor IgG low affinity IIb and Fc receptor 
IgG low affinity III. Two changed members occurred in the glycosidase hydrolase 
family 22 group and were also the two changed members within the cell wall 
catabolism  group  and  lysozyme  activity.  Other  functional  gene  classes 
potentially differentially expressed were sarcolemma and C type lectin.  
Several functional gene classes potentially downregulated after ligand binding in 
K14D6 compared to wild type keratinocytes were also expressed at lower levels 
in  resting  K14D6  keratinocytes  compared  to  resting  wild type  keratinocytes 
(Table  4 18  and  4 12  respectively).  These  were  three  groups  involving 
chemokines,  which  were  small  chemokine  interleukin 8  like,  chemotaxis  and 
chemokine activity. The other three groups potentially downregulated in both 
comparisons  were  glycosidase  hydrolase,  lysozyme  activity  and  cell  wall 
catabolism.  This  suggests  that  D6  may  have  a  negative  impact  on  genes 
associated with these functional groups. 
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WT + CCL3 V K14D6 + CCL3  Group members  Changed 
members 
P-value 
changed 
IPR007237 – CD20/IgE Fc receptor beta subunit   15  4  8.0e-08 
IPR001811- Small chemokine, interleukin-8 like   31  4  1.4e-07 
6935- chemotaxis   87  5  2.1e-07 
8009- chemokine activity  38  4  3.3e-07 
30595- immune cell chemotaxis  5  3  3.4e-07 
19864 – IgG binding  5  2  1.8e-05 
IPR001916- Glycoside hydrolase, family 22  8  2  2.6e-05 
3796- lysozyme activity  10  2  4.2e-05 
42383- sarcolemma  14  3  5.4e-05 
IPR001304- C-type lectin  99  3  6.3e-05 
45576- mast cell activation  9  2  6.5e-05 
16988- cell wall catabolism  16  2  1.1e-04 
    
Table 4-18. Potential downregulated functional gene classes in K14D6 keratinocytes after 
CCL3 treatment compared to Wild-type keratinocytes after CCL3 treatment. 
 
 
Comparison with RP report 
Twenty seven genes were expressed at lower levels in K14D6 keratinocytes after 
ligand binding in comparison to wild type keratinocytes after ligand binding in 
the  RP  report  (Table  4 9).  Three  of  the  changed  members  within  the  top 
changed CD20/IgE Fc receptor subunit group were potentially downregulated in 
the  RP  report.  CXCL4  and  CCL6  were  chemokines  potentially  differentially 
expressed in the RP report and were found to be potentially downregulated in 
the iGA analysis as they are members within the small chemokine, chemotaxis 
and  chemokine  activity  group.  Fcg2rb  and  Fcgr3  are  two  genes  potentially 
downregulated  in  the  RP  report  (Table  4 9)  that  are  also  listed  as  changed 
members  within  the  IgG  binding  and  mast  cell  activation  groups.  P  lysozyme 
structural (Lzp s) and lysozyme are genes potentially downregulated in the RP 
report,  which  were  changed  members  of  the  glycoside  hydrolase,  lysozyme 
activity and cell wall catabolism group in Table 4 18. Clec4d, Mrc1 and Clec4n 
are  genes  potentially  downregulated  in  the  RP  report  and  are  the  changed 
members within the C type lectin group.  
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4.4.2.5    Summary of iGA analysis 
To gain a better understanding of the data generated using the iGA analysis, the 
functional  gene  classes  potentially  differentially  expressed  between  all 
comparisons  were  summarised  in  a  Venn  diagram  for  potential  up   and 
downregulated changes (Figure 4 2 and Figure 4 3 respectively).  
Ectopically  expressing  D6  within  keratinocytes  resulted  in  9  potentially 
upregulated functional gene classes, in which two classes were unique to this 
comparison; these were cadherin cytoplasmic region and prostaglandin synthesis 
(Figure 4 2). Genes involved in transmembrane receptor protein tyrosine kinase 
signalling  and  extracellular  matrix  structural  constituent  conferring  tensile 
strength were also potentially upregulated by CCL3 in wild type keratinocytes 
whereas another five functional gene classes were potentially upregulated by 
CCL3  in  both  K14D6  keratinocytes  and  wild type  keratinocytes.  This  suggests 
that basal D6 expression, independent of ligand within K14D6 keratinocytes may 
affect gene transcription. 
The Venn diagram illustrates that several classes of genes are induced by CCL3 in 
both  wild type  and  K14D6  keratinocytes  demonstrating  the  effect  of  CCL3 
through receptors present on both wild type and K14D6 keratinocytes such as 
CCR1, CCR3 and CCR5. These include 3 functional classes of genes involved in 
cell  movement,  CD20/IgE  Fc  receptor  beta  subunit,  positive  regulation  of 
phagocytosis, heparin binding and fibrillar collagen group (Figure 4 2). 
Eight  functional  gene  classes  were  expressed  at  higher  levels  only  in  K14D6 
keratinocytes after CCL3 binding in comparison to control K14D6 thus illustrating 
that genes were potentially differentially expressed because of CCL3 binding to 
D6. These were the functional gene classes of IgG binding, myelin proteolipid 
protein  PLP,  glycoside  hydrolase  family  22,  aldehydrogenase,  mast  cell 
activation, lysozyme activity, calcium binding protein and Von Willebrand factor 
type A (Figure 4 2).   
Ectopically  expressing  D6  within  keratinocytes  resulted  in  the  potential 
downregulation of  11  functional  genes  classes  (Figure  4 3).  Only  one  class  of 
genes  to  do  with  cytolysis  was  specifically  found  in  the  comparison  between 
wild type and K14D6 keratinocytes at rest. Three groups found to be potentially Vicky King, 2010      Chapter 4, 189 
downregulated  due  to  the  presence  of  non ligated  D6  were also  found  to  be 
potentially downregulated in the wild type keratinocytes incubated with CCL3. 
Seven functional gene classes were potentially downregulated in the presence of 
non ligated  D6  as  well  as  being  potentially  downregulated  in  K14D6 
keratinocytes after CCL3 treatment in comparison to wild type. Three of these 
groups  involved  chemokines  and  the  other  four  functional  groups  were  IgG 
binding,  glycoside  hydrolase  family  22,  lysozyme  activity  and  cell  wall 
catabolism.  
Using the Venn diagram, 15 functional classes of genes were shown to be present 
in both the positive and negative differential expression analysis, illustrated in 
blue in Figure 4 2 and Figure 4 3 respectively. Three of these groups involving 
chemokines were found to be expressed at higher levels by CCL3 in both wild 
type and K14D6 keratinocytes indicating that CCL3 is able to induce changes in 
the gene transcripts of chemokines in both wild type and K14D6 keratinocytes. 
However,  at  rest,  the  chemokine  groups  were  potentially  downregulated  in 
K14D6 keratinocytes compared to wild type indicating that the presence of D6 
may affect the transcription of chemokines. In addition, after ligand binding, the 
chemokine  groups  were  potentially  downregulated  in  K14D6  keratinocytes 
compared to wild type. This indicates the possibility that CCL3 may be able to 
induce the transcription of genes through chemokine receptors CCR1, CCR3 and 
CCR5.  However,  the  presence  of  ectopically  expressed  D6  within  K14D6 
keratinocytes may be able to limit the transcription levels of these genes. 
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Figure  4-2.  Venn  diagram 
summarising  potential 
upregulated  functional 
gene  classes  using  iGA 
analysis  of  four  different 
group comparisons. 
Potential upregulated gene 
classes  in  each  of  the 
comparisons  are 
represented  in  a 
corresponding  circle. 
Functional  gene  classes 
found  in  overlapping 
regions show gene classes 
potentially  upregulated  in 
the  other  groups.  Gene 
classes highlighted in blue 
are  groups  that  are  also 
found  to  e  potentially 
downregulated. 
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Figure  4-3.  Venn  diagram 
summarising  the  potential 
downregulated  functional 
gene  classes  using  iGA 
analysis results of 4 different 
group comparisions. 
Potential downregulated gene 
classes  in  each  of  the 
comparisons  are  represented 
in  a  corresponding  circle. 
Potential  functional  gene 
classes  found  in  overlapping 
regions  show  gene  classes 
potentially  downregulated  in 
the  other  groups.  Functional 
gene  classes  shown  in  blue 
are  groups  which  are  also 
found  to  be  potentially 
upregulated. Vicky King, 2010      Chapter 4, 192 
4.5 Validation of microarray data by QPCR 
Validation  of  the  microarray  was  required  to  determine  if  the  potentially 
differentially  expressed  genes  reported  in  the  rank  product  reports  were 
reproducibly  differentially  expressed.  This  was  performed  using  QPCR  to 
measure changes in gene transcript levels. The main objective was to determine 
whether  any  transcriptional  changes  reported  in  the  microarray  could  be 
revalidated. Therefore, genes were identified from the microarray data to be 
validated, primers were designed and validated to generate standards for each 
gene and for use in QPCR using the SYBR green based method (Morrison et al., 
1998). Fresh sets of wild type and K14D6 primary keratinocytes were isolated 
(n=3/group in which 3 neonates were pooled to generate 1 sample), cultured 
and treated with either PBS or CCL3 as previously described for the microarray. 
RNA was extracted, quantified, converted to cDNA for QPCR. 
4.5.1  Identifying  potentially  upregulated  genes  to  validate  by 
QPCR 
The  main  objective  of  the  microarray  was  to  determine  whether  there  were 
transcriptional  consequences  of  ligand  binding  through  D6.  To  obtain  an 
overview  of  the  data  obtained  from  the  microarray,  genes  potentially 
upregulated by CCL3 in wild type and K14D6 keratinocytes with less than 25% 
FDR in the rank product report were summarised in a Venn diagram (Figure 4 4). 
The left hand circle shows genes that were potentially upregulated by CCL3 in 
wild type keratinocytes and the right circle lists genes potentially upregulated 
by  CCL3  in  K14D6  keratinocytes.  Genes  listed  in  the  overlapping  region 
illustrates genes that were found to be potentially upregulated in both wild type 
and K14D6 keratinocytes and suggests that these genes may be induced through 
CCL3 binding to receptors common to both wild type and K14D6 keratinocytes, 
such as CCR1, CCR3 and CCR5. Genes not found in the overlapping region are 
genes  that  were  found  to  be  specifically  potentially  upregulated  after  CCL3 
binding in either wild type or K14D6 keratinocytes.  
 
 Vicky King, 2010      Chapter 4, 193 
 
 
 
Figure 4-4. Venn diagram of genes potentially upregulated  after CCL3 treatment in wild-type 
and K14D6 keratinocytes. 
The genes indicated in bold are genes identified for validation by QPCR. 
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i)  Genes identified only in K14D6 keratinocytes after CCL3 binding 
Using the Venn diagram (Figure 4 4) and by identifying genes listed at a high 
ranking in the RP report (Table 4 6), six genes potentially upregulated only in 
K14D6 keratinocytes after CCL3 treatment were identified for validation. Genes 
found only  to  be  potentially  upregulated  in  K14D6  after  CCL3  treatment  and 
therefore potentially D6 mediated, were identified as:  
Nucleoplasmin 3 (Npm3) 
STEAP family member 4 (Steap4) 
Solute carrier family 6 member 14 (Slc6a14) 
Lipocalin 2 (Lcn2) 
Apolipoprotein E (ApoE) 
 
Nucleoplasmin  3  was  the  highest  ranked  gene,  which  was  only  potentially 
upregulated in K14D6 keratinocytes after CCL3 treatment with an RP score of 
147.22,  fold  change  of  2.11  and  a  false  discovery  rate  of  1.4%  (Table  4 19). 
STEAP4 was the 11
th gene listed on the RP report, with an RP score of 279.37, 
fold change of 2.22 and a false discovery rate of 5.17% (Table 4 19). Slc6a14 has 
an RP score of 296.41, a false discovery rate of 6.38% and a fold change of 1.61 
(Table 4 19). Lipocalin 2 has an RP score of 305.98, a 5.87% FDR and a 1.79 fold 
change (Table 4 19). The last gene identified for validation was apolipoprotein 
E, with an RP score of 313.19, 5.94% FDR and changed by a fold of 1.92 (Table 4 
19).   
 
 
 
 
Table 4-19. Genes potentially upregulated only in K14D6 keratinocytes after CCL3 treatment 
identified for validation. 
Genes  were  listed  in  order  of  Rank  Product  score  (RP  score)  with  details  of  %  false 
discovery rate (FDR) and fold change (FC). Data obtained from the RP report as summarised 
in Table 4-6.   
 
 
Gene  RP score  FDR (%)  FC 
Npm3  147.22  1.40  2.11 
STEAP4  279.37  5.17  2.22 
Slc6a14  296.41  6.38  1.61 
Lcn2  305.98  5.87  1.79 
ApoE  313.90  5.94  1.92 Vicky King, 2010      Chapter 4, 195 
ii)  Genes identified in WT and K14D6 keratinocytes after CCL3 binding 
Genes identified for validation that were potentially upregulated  in both WT 
and K14D6 keratinocytes after CCL3 ligand binding are summarised within the 
overlapping circles in the Venn diagram (Figure 4 4). Using the list of genes from 
the Venn diagram, genes were identified for validation using the highest ranked 
genes in the K14D6 + CCL3 rank product report and were identified as: 
Aldehyde dehydrogenase family 1, subfamily A7 (Aldh1a7) 
P lysozyme structural (Lzp s) 
Pentraxin related gene (Ptx3) 
Lysosomal associated protein transmembrane 5 (Laptm5) 
Procollagen, type III, alpha 1 (Col3a1) 
Chemokine (C C motif) ligand 6 (CCL6) 
 
Aldehyde dehydrogenase was the first gene listed in the RP report as potentially 
differentially expressed in the comparison between K14D6 keratinocytes at rest 
and after CCL3 treatment. The RP score of Aldh1a7 was 97.2, with a fold change 
of  3.31  and  a  3%  false  discovery  rate  (Table  4 20).  The  same  gene  was  also 
potentially upregulated in wild type keratinocytes after CCL3 treatment, with an 
RP score of 711.64, a 3.17 fold change and 15.65% false discovery rate (Table 4 
20). Lzp s was potentially differentially expressed in K14D6 keratinocytes by a 
fold change of 2.7, an FDR of 1.5% and an RP score of 106.48 whereas in the 
wild type, Lzp s had an RP score of 740.13, an FDR of 17.28% and an FC of 1.74 
(Table 4 20). Pentraxin related gene was potentially differentially expressed by 
2.18  fold  in  K14D6  keratinocytes  after  incubation  with  CCL3,  an  RP  score  of 
199.63 and an FDR of 2.71%, whereas Ptx3 was potentially upregulated by 1.75 
fold  in  wild type  keratinocytes  after  CCL3  stimulation,  with  an  RP  score  of 
506.88 and a 10.20% false discovery rate (Table 4 20). The fifth gene identified 
was Col3a1, which in K14D6 keratinocytes had an RP score of 254.35, a 4.27% 
FDR and increased by 2.18 fold whereas within wild type keratinocytes, CCL3 
binding resulted in Col3a1 being potentially differentially expressed by 3.72 fold, 
with a 10.25% false discovery rate and an RP score of 224.73 (Table 4 20). The 
last gene picked for validation was CCL6. CCL6 had an RP score of 430.38, a 
12.24% FDR and changed by 1.86 fold in K14D6 keratinocytes after CCL3. CCL6 Vicky King, 2010      Chapter 4, 196 
was also potentially upregulated by CCL3 in wild type keratinocytes by 1.87 fold, 
an RP score of 868.30 and an FDR of 22.85% (Table 4 20). 
  WT  K14D6 
Gene  RP score  FDR (%)  FC  RP score  FDR (%)  FC 
Aldh1a7  711.64  15.65  3.17  97.2  3.00  3.31 
Lzp-s  740.13  17.28  1.74  106.48  1.50  2.47 
Ptx3  506.88  10.20  1.75  199.63  2.71  2.18 
Laptm5  415.35   9.67  1.88  234.40  3.67  1.89 
Col3a1  224.73  10.25  3.72  254.35  4.27  2.18 
CCl6  868.30  22.85  1.87  430.38      12.24  1.86 
Table 4-20. Comparison of data from the rank product reports on six genes identified as 
potentially  differentially  expressed  in  both  Wild-type  and  K14D6  keratinocytes  after 
incubation with CCL3. 
 
iii) Genes identified in resting K14D6 keratinocytes 
 
It was also decided to validate three genes that were potentially upregulated in 
resting K14D6 keratinocytes compared to resting wild type keratinocytes. In the 
RP analysis, only 6 genes were potentially upregulated in K14D6 keratinocytes 
compared to wild type keratinocytes (Table 4 2).  
CCbp2  (D6)  had  a  rank  product  score  of  1,  the  smallest  value  that  can  be 
achieved  using  the  rank  product  method,  which  indicates  that  the  gene  is 
significantly  differentially  expressed.  Ccbp2  was  chosen  not  to  be  validated 
because the microarray data confirmed that the D6 transgene was present in 
K14D6 keratinocytes at higher levels than wild type confirming PCR and QPCR 
data in chapter 3. Therefore, it was decided to validate three of the genes listed 
after D6 in the RP report. These were dickkopf homolog 2 (Dkk2), nik related 
kinase (Nrk) and branched chain aminotransferase 1 (Bcat1; Table 4 21). The RP 
scores  for  these  genes  are  much  larger  than  one,  being  206.84,  348.58  and 
359.51 for Dkk2, Nrk and Bcat1 respectively, suggesting these genes may not be 
significantly differentially expressed. 
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Gene  RP score  FDR %  FC 
Ccbp2      1.00    0.00        49.59 
Dkk2  206.84  15.50  2.66 
Nrk  348.58  43.33  1.81 
Bcat1  359.51  34.50  1.48 
 
Table  4-21.  Genes  identified  for  validation  that  were  potentially  upregulated  in  K14D6 
keratinocytes in comparison to wild-type keratinocytes at rest. 
 
4.5.2  Identifying potentially downregulated genes to validate 
Overall, in the RP report, the number of genes potentially downregulated was 
far less than the number of genes potentially upregulated. None of the potential 
downregulated genes stood out with their RP score and therefore no potential 
downregulated  genes  were  identified  specifically  for  validation.  However, 
several genes identified for validation, as potential upregulated genes induced 
by CCL3, were also present as potentially downregulated genes, for example, 
Laptm5 and Lzp s. These two genes were potentially downregulated in two RP 
reports,  one  was  resting  K14D6  keratinocytes  compared to  wild type  and  the 
second  was  K14D6  keratinocytes  compared  to  wild type  after  CCL3  binding 
(Table 4 3 and 4 9 respectively). In addition, CCL6 was a gene identified for 
validation  as  being  potentially  upregulated  in  both  wild type  and  K14D6 
keratinocytes after CCL3 binding, but was potentially downregulated in K14D6 
keratinocytes compared to wild type keratinocytes after ligand binding (Table 4 
9).  Another  gene  identified  for  validation  was  ApoE,  which  was  potentially 
upregulated  in  K14D6  keratinocytes  after  ligand  binding  but  was  potentially 
downregulated  in  resting  K14D6  keratinocytes  compared  to  wild type 
keratinocytes  (Table  4 3).  As  a  result,  these  genes  could  be  analysed  for 
potential up  or downregulation of transcripts between the different groups at 
the same time. 
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4.5.3  Design and validation of primers 
Primers were designed according to the specifications described previously in 
Chapter Two for use in QPCR. Transcript levels were quantified using a standard 
DNA  template  alongside  samples  of  interest.  Each  specific  standard  DNA 
template  was  generated  using  standard  PCR  with  ‘outer’  primers  that 
incorporated  the  region  amplified  by  the  ‘nested’  primers,  as  illustrated  in 
Figure 4 5. The number of transcript copies in each standard DNA template was 
calculated (See 2.2.1.9 for details) and used to determine the absolute number 
of copies of transcript in each sample of interest. 
 
 
 
Figure 4-5. A diagram illustrating the use of different primer sets for QPCR.  
(A) ‘Outer’ primers (arrows) were designed to generate a PCR product of the gene of interest 
for use in QPCR as standard DNA template. (B) The standard DNA template generated using 
the ‘outer’ primers would encode the region that would be amplified by the ‘nested’ primers 
(arrows) in QPCR. 
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4.5.4  Validation of outer primers 
The  ‘outer’  primers  were  designed  and  used  to  generate  a  standard  DNA 
template for each gene of interest by PCR. The ‘outer’ primers were optimised 
to produce a clear PCR product of the expected size as shown in Figure 4 6. Most 
‘outer’ primers generated a clear band using an annealing temperature of 60°C 
except for Lzp s primers, which were required to have an annealing temperature 
of 61°C. The intensity of the bands varied, with Aldh1a7 being the most intense 
band under ultraviolet light (Figure 4 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. Specificity of ‘outer’ primers to generate standards for use in QPCR. 
PCR products were amplified from mixed WT and K14D6 keratinocytes cDNA using ‘outer’ 
primers and visualised under UV light on a 1% agarose gel. The single bands indicate the 
specificity  of  the  primers  and  the  specific  product  sizes  expected  are  listed  above.  The 
products  were  used  as  reference  standards  in  QPCR.  Lane  1,  Hyperladder  IV;  lane  2, 
Col3a1;  lane  3,  Lzp-s;  lane  4,  Ptx3;  lane  5,  Laptm5;  lane  6,  ccl6;  lane  7,  Npm3;  lane  8, 
STEAP4; lane 9, slc6a14; lane 10, Lcn2; lane 11, Apoe; lane 12, Aldh1a7; lane 13, Dkk2; lane 
14, Nrk; lane 15, Bcat1; lane 16, Hyperladder 1.  
Lane  Gene  Expected product 
Size (bp) 
2  Col3a1  700 
3  Lzp-s  520 
4  Ptx3  903 
5  Laptm5  867 
6  CCl6  612 
7  Npm3  491 
8  STEAP4  630 
9  Slc6a14  413 
10  Lcn2  307 
11  ApoE  765 
12  Aldh1a7  813 
13  Dkk2  487 
14  Nrk  359 
15  Bcat1  458 Vicky King, 2010      Chapter 4, 200 
4.5.4.1    Calculation  of  gene  transcripts  numbers  within 
standards 
The  bands  within  the  DNA  ladder  were  of  a  known  mass  (supplied  by  the 
manufacturer Bioline). Therefore, the intensity of the bands under UV light were 
measured using densiometric analysis. A standard curve was generated using the 
known mass of the Hyperladder band and the bands intensity. The intensity of 
each standard DNA template was measured and the mass of the DNA template 
for each gene was calculated, using the formula generated from the standard 
curve. The calculated mass for the standard DNA template was then used to 
calculate the absolute copy numbers of transcripts within the template (Table 4 
22), using a series of equations (see 2.2.1.9 for details). Using the known value 
of copy numbers of transcript in each standard, the number of copies in each of 
the diluted standards was calculated.   
 
 
Gene  Mass of Product 
(ng/m m m ml) 
Calculated Copies 
of product/m m m ml 
Col3a1    9.84  12,831,597,359 
Lzp-s    3.54    6,212,534,965 
Ptx3  13.38  13,485,841,751 
Laptm5  10.49  10,946,698,822 
Ccl6  14.64  21,770,598,138 
Npm3  26.96  49,996,512,991 
STEAP4  23.23  33,605,964,406 
Slc6a14  30.39  66,951,683,909 
Lcn2  27.70  82,339,897,345 
Apoe  13.38  15,865,696,177 
Aldh1a7  40.92  45,909,407,730 
Dkk2    7.73  14,485,032,045 
Nrk    5.32  13,523,406,770 
Bcat1    4.22     8,408,449,120 
 
Table 4-22. Calculation of the number of transcripts within each standard for each gene of 
interest. 
For each standard, the mass was calculated using the formula from the standard curve. 
Using  a  series  of  equations,  the  number  of  gene  transcripts  within  each  standard  was 
calculated from the mass.  
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4.5.5  Optimisation of ‘nested’ primers 
The ‘nested’ primers designed for use in QPCR were tested using keratinocyte 
cDNA  (mixed  WT  and  K14D6)  to  ensure  they  generated  the  correct  size  of 
product and were specific. All the ‘nested’ primers were specific and generated 
PCR products of the expected size (Figure 4 7). All QPCR assays involved SYBR 
green and a dissociation melting curve analysis was used to ensure there was no 
primer dimer formation during the reaction.  
 
 
 
 
 
Lane  Gene  Expected product 
Size (bp) 
2  Col3a1  114 
3  Lzp-s               104 
4  Ptx3  117 
5  Laptm5  160 
6  CCl6  102 
7  Npm3  132 
8  Steap4  103 
9  Slc6a14  117 
10  Lcn2  133 
11  ApoE  153 
12  Aldh1a7  100 
13  Dkk2  115 
14  Nrk  108 
15  Bcat1  127 
 
Figure 4-7. Nested primers used in QPCR were specific.  
PCR products were generated by amplifying mixed Wt and K14D6 keratinocyte cDNA. The 
products were electrophoresed on a 2% agarose gel and visualised under a UV light. Lane 1, 
Hyperladder IV; lane 2, Col3a1; lane 3, Lzp-s; lane 4, Ptx3; lane 5, Laptm5; lane 6, ccl6; lane 
7, Npm3; lane 8, STEAP4; lane 9, slc6a14; lane 10, Lcn2; lane 11, Apoe; lane 12, Aldh1a7; 
lane 13, Dkk2; lane 14, Nrk; lane 15, Bcat1. A single band demonstrates the specificity of 
each primer pair. The PCR product sizes expected are summarised in the table.  
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4.5.6   QPCR results 
4.5.6.1    Validation  of  genes  potentially  induced  by  CCL3  in 
both wild-type and K14D6 transgenic keratinocytes. 
Six genes, Aldh1a7, Col3a1, Laptm5, Lzp s, Ptx3 and CCL6 were identified for 
validation  as  being  potentially  upregulated  in  both  wild type  and  K14D6 
keratinocytes  after  CCL3  treatment,  suggesting  that  CCL3  may  be  regulating 
gene transcript levels through other chemokine receptors, such as CCR1.  
CCL3 treatment had no effect on the transcript levels of Col3a1 within wild type 
or K14D6 keratinocytes (Figure 4 8A; Two way ANOVA, WT v WT+CCL3 p>0.05, 
K14D6 v K14D6+CCL3 p>0.05). CCL3 had no significant effect on Lzp s transcripts 
in wild type keratinocytes or K14D6 keratinocytes (Figure 4 8B; Two way ANOVA, 
WT v WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 p>0.05). In wild type keratinocytes, 
CCL3 did not induce any significant changes in the transcript levels of Ptx3 and 
CCL3 had no effect on the transcript levels of Ptx3 within K14D6 keratinocytes 
(Figure  4 8C;  Two way  ANOVA,  WT  v  WT+CCL3  p>0.05,  K14D6  v  K14D6+CCL3 
p>0.05). CCL3 had no significant effect on the transcript levels of Laptm5 within 
wild type  keratinocytes  or  within  K14D6  keratinocytes  (Figure  4 8D;  Two way 
ANOVA,  WT  v  WT+CCL3  p>0.05,  K14D6  v  K14D6+CCL3  p>0.05).  CCL3  had  no 
significant effect on CCL6 transcript levels in wild type or K14D6 keratinocytes 
(Figure  4 8E;  Two way  ANOVA,  WT  v  WT+CCL3  p>0.05,  K14D6  v  K14D6+CCL3 
p>0.05). CCL3 had no effect on the transcript levels of Aldh1a7 in either wild 
type  or  K14D6  keratinocytes  (Figure  4 8F;  Two way  ANOVA,  WT  v  WT+CCL3 
p>0.05, K14D6 v K14D6+CCL3 p>0.05). In the microarray, Laptm5 was listed as 
potentially  downregulated  in  resting  K14D6  keratinocytes  compared  to  WT 
keratinocytes and was identified as a gene to validate by QPCR. However, there 
was  no  significant  difference  in  Laptm5  transcript  levels  in  resting  K14D6 
keratinocytes  compared  to  control  WT  keratinocytes  (Figure  4 8D,  unpaired 
students t test, p=0.1459). 
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Figure 4-8. Validation of gene transcripts potentially upregulated after CCL3 treatment in 
both wild-type and K14D6 keratinocytes.   
Six genes that were found to be potentially upregulated after CCL3 treatment in both wild-
type  (WT)  and  K14D6  keratinocytes  were  identified  for  validation  by  QPCR.  The  copy 
numbers of each gene is normalised to 1x10
5 copies of GAPDH. (A) Col3a1, (B) Lzp-s, (C) 
Ptx3, (D) Laptm5, (E) CCL6 and (F) Aldh1a7. White column is control keratinocytes; Black 
column is keratinocytes treated with 10nM CCL3 for 6hrs at 37° C. Each column is mean ± 
SEM, n=3/group. 
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Although  the  data  was  not  significant,  the  CCL6  and  Laptm5  QPCR  were 
repeated with more samples by including RNA from two sets of keratinocytes 
used in the microarray. The assay was also repeated on fresh sets (n=3/group 
with 3 neonates pooled per sample) of keratinocytes using 30nM concentration of 
CCL3 instead of 10nM. 
By including keratinocyte samples that were involved in the microarray, sample 
size  was  increased  from  three  to  five  and  the  QPCR  was  repeated.  In  the 
increased sample group, CCL3 had no significant effect on CCL6 transcript levels 
in both wild type and K14D6 keratinocytes (Figure 4 9A; Two way ANOVA, WT v 
WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 p>0.05). Increasing the concentration of 
CCL3  to  30nM  also  had  no  effect  on  CCL6  transcripts  within  wild type 
keratinocytes  or  K14D6  keratinocytes  (Figure  4 9B;  Two way  ANOVA,  WT  v 
WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 p>0.05). These data suggest that CCL3 
binding did not have an impact on CCL6 transcript levels in wild type or K14D6 
keratinocytes. 
 
 
 
 
 
 
 
 
Figure 4-9. Repeated QPCR for validation of CCL6 
Wild-type  (WT)  and  K14D6  keratinocytes  were  treated  with  either  PBS  (white)  or  CCL3 
(black) for 6hrs at 37° C. QPCR measuring absolute c opy numbers was performed. The copy 
numbers of each gene is normalised to 1x10
5 copies of GAPDH. (A) 10nM CCL3 was used, 
n=5/group (B) The concentration of CCL3 was increased to 30nM n=3/group. Each column is 
mean ± SEM.  
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Transcript  levels  of  Laptm5  were  re examined  with  increased  sample  size  by 
including  samples  used  within  the  microarray.  CCL3  did  not  induce  any 
transcriptional  changes  in  Laptm5  in  wild type  keratinocytes  or  K14D6 
keratinocytes (Figure 4 10A; Two way ANOVA, WT v WT+CCL3 p>0.05, K14D6 v 
K14D6+CCL3  p>0.05).  Additionally,  there  was  no  significant  difference  in  the 
transcript levels of Laptm5 in resting K14D6 keratinocytes compared to wild type 
(Figure 4 10A; unpaired student’s t test, p=0.22). Increasing the concentration 
of CCL3 to 30nM did not have any significant effect on Laptm5 transcripts within 
WT  or  K14D6  keratinocytes  (Figure  4 10B,  Two way  ANOVA  WT  v  WT+CCL3 
p>0.05,  K14D6  v  K14D6+CCL3  p>0.05).  There  was no difference  in  transcripts 
levels  of  Laptm5  in  resting  wild type  or  K14D6  keratinocytes  (Figure  4 10B; 
unpaired students t test, p=0.41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10. Repeated QPCR for validation of Laptm5 
Wild-type  (WT)  and  K14D6  keratinocytes  were  treated  with  either  PBS  (white)  or  CCL3 
(black) for 6hrs at 37° C. QPCR measuring absolute c opy numbers was performed. The copy 
numbers of each gene is normalised to 1x10
5 copies of GAPDH. (A) 10nM CCL3 was used, 
n=5/group. (B) The concentration of CCL3 was increased to 30nM, n=3/group. Each column 
is mean ± SEM. 
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At rest, there was no significant difference in the transcript levels of Col3a1, 
Lzp s, Ptx3, Laptm5, CCL6 or Aldh1a7 transcript levels between wild type and 
K14D6 keratinocytes (Figure 4 8A, B, C, D, E and F respectively; students t test, 
all  p>0.05),  illustrating  that  ectopic  expression  of  D6  did  not  affect  the 
expression levels of these genes.  
4.5.6.2    Validation of genes potentially induced by CCL3 only 
in K14D6 keratinocytes 
Potential upregulation of gene transcript levels through D6 was investigated by 
identifying five genes from the microarray that were potentially upregulated in 
only  K14D6  keratinocytes  after  CCL3  treatment.  These  genes  were  Npm3, 
STEAP4, slc6a14, Lcn2 and ApoE. CCL3 treatment caused no significant effect on 
the  transcript  levels  of  Npm3,  STEAP4,  Lcn2,  Apoe  or  Slc6a14  in  K14D6 
keratinocytes  or  wild type  keratinocytes  (Figure  4 11A,  B,  C,  D  and  E 
respectively;  Two way  ANOVA,  WT  v  WT+CCL3  p>0.05,  K14D6  v  K14D6+CCL3 
p>0.05 for all genes). Additionally, there were also no significant differences in 
the transcript levels of Npm3, STEAP4, Slc6a14, Lcn2 or ApoE between wild type 
and K14D6 keratinocytes at rest (Figure 4 11, student’s t test, p>0.05). These 
QPCR data would suggest that CCL3 binding to D6 in K14D6 keratinocytes does 
not have an impact on the transcription of these genes. 
 
 
 
 
 
 
 
 
 Vicky King, 2010      Chapter 4, 207 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11. Validation of gene transcripts identified as potentially upregulated after CCL3 
treatment in K14D6 keratinocytes but not wild-type (WT) keratinocytes.   
Five genes that were found to be potentially upregulated after CCL3 treatment in K14D6 
keratinocytes only were identified for validation. QPCR measuring absolute copy numbers 
was performed. The copy numbers of each gene is normalised to 1x10
5 copies of GAPDH. 
(A)  Npm3,  (B)  Steap4,  (C)  slc6a14,  (D)  Lcn2,  (E)  Apoe.  White  column  is  control 
keratinocytes; Black column is keratinocytes treated with 10nM CCL3 for 6hrs at 37° C. Each 
column is mean of three samples ± SEM, n=3/group. 
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4.5.6.3  Validation  of  genes  potentially  upregulated  between 
wild-type and K14D6 keratinocytes at rest 
To  determine  whether  transgenic  overexpression  of  D6  had  any  effect  on 
keratinocytes  at  rest,  the  transcript  levels  of  the  top  three  genes  after  D6 
reported in the microarray were validated. Out of the three genes identified for 
validation, Dkk2 had a fold change above 2, however the RP score varied from 
206.84 to 359.51 with FDR between 15.5 and 43.3% (Table 4 2). The QPCR data 
showed there was no significant difference in the transcript levels of Dkk2 in 
K14D6 keratinocytes compared to  wild type keratinocytes at rest (Figure 4 12A, 
student’s  t test,  p=0.122).  There  was  a  non significant  difference  in  the 
transcript levels of Bcat1 between wild type and K14D6 keratinocytes at rest 
(Figure 4 12B, student’s t test, p=0.119). The transcript levels of Nrk were not 
significantly  different  in  K14D6  keratinocytes  compared  to  wild type 
keratinocytes (Figure 4 12C; student’s t test, p=0.159). Additionally, treatment 
of  wild type  and  K14D6  keratinocytes  with  CCL3  had  no  effect  on  the 
transcriptional  levels  of  Dkk2,  Nrk  and  Bcat1  in  comparison  to  the  control 
keratinocytes (Figure 4 12; Two way ANOVA, WT v WT+CCL3 p>0.05, K14D6 v 
K14D6+CCL3 p>0.05). These QPCR data would suggest that transgenic expression 
in absence of ligand had no impact on the level of transcription of Dkk2, Nrk and 
Bcat1. 
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Figure  4-12.  Validation  of  the  transcript  levels  of  three  genes  potentially  upregulated 
between wild-type (WT) and K14D6 keratinocytes. 
Three genes potentially upregulated in K14D6 keratinocytes compared to wild-type in the 
microarray  data  were  validated  by  QPCR.  Copy  numbers  of  each  gene  is  normalised  to 
1x10
5 copies of GAPDH, a housekeeping gene. (A) DKK2 (B), Nrk (C) Bcat1. White columns 
are control keratinocytes. Black columns are keratinocytes treated with 10nM CCL3 for 6 hrs 
at 37° C. Each column is mean ± SEM, n=3/group. 
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4.5.7  Summary of quantitative PCR results 
Various  genes  were  identified  from  the  microarray  using  the  rank  products 
method  to  validate  by  QPCR.  Six  genes  were  identified  that  were  listed  as 
potentially upregulated in both wild type and K14D6 keratinocytes after ligand 
binding. However, by QPCR, none of the genes identified showed any significant 
changes in gene expression due to CCL3 ligand binding (Figure 4 8). By QPCR, 
CCL3 did not significantly upregulate any of the genes identified for validation 
that  were  identified  as  potentially  upregulated  only  in  K14D6  after  ligand 
binding  in  the  microarray  (Figure  4 11).  Resting  K14D6  keratinocytes  did  not 
show any significant upregulation of Dkk2, Nrk or Bcat transcript levels, which 
were three genes identified for validation from the RP report (Figure 4 12). In 
the  microarray,  Laptm5  was  potentially  downregulated  in  resting  K14D6 
keratinocytes  compared  to  wild type  keratinocytes.  However,  there  was  no 
difference in Laptm5 transcript levels between WT and K14D6 keratinocytes by 
QPCR (Figure 4 10). 
No significant differences were found in any of the individual genes validated by 
QPCR and this correlates with the microarray results. One of the methods for the 
analysis of microarray data was rank products, in which the smaller the RP value 
the more likely the gene is up  or downregulated (Breitling et al., 2004b). Many 
of  the  genes  identified  for  validation  had  high  RP  scores,  for  example,  the 
smallest RP score (excluding D6) was 97.2 and increased to 868, which suggests 
the likelihood that these genes were not actually differentially expressed in the 
microarray. 
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4.6 Discussion of Chapter 4 
To date, in vitro studies have determined that D6 does not seem to signal by 
analysing functional responses after ligand binding using cell lines (Nibbs RJ et 
al., 1997; Fra AM et al., 2003). In this study, we have taken the approach one 
step  further  in  that we  are using  primary  cells,  which contain  high  levels  of 
ectopically expressed D6. These cells are keratinocytes from wild type or K14D6 
transgenic mice. By analysing the transcriptional consequences of ligand binding 
in  wild type  and  K14D6  keratinocytes,  it  was  hoped  that  this  would  give  an 
insight into any altered gene expression after ligand binding to D6. In addition, 
information would also be gained on the transcriptional consequences induced 
through D6 in a ligand independent manner by comparing the cell transcriptome 
in resting wild type and K14D6 keratinocytes. 
Examination  of  the  transcriptional  data  generated  using  the  rank  product 
differential  analysis  method  revealed  that  the  largest  number  of  genes 
potentially upregulated was after ligand binding in both wild type and K14D6 
keratinocytes.  Conversely,  the  largest  number  of  genes  potentially 
downregulated  occurred  in  resting  K14D6  keratinocytes.  Of  note,  the  most 
strongly  differentially  expressed  gene  in  the  microarray  was  D6  in  K14D6 
keratinocytes compared to wild type. These data confirm that D6 is expressed 
from the transgene driven by the keratin 14 promoter in K14D6 keratinocytes. 
Within the RP report, many Y linked genes were listed when a certain population 
of keratinocytes was used (WT+CCL3). This result added an extra complication to 
the analysis of the microarray data and therefore an improvement to the design 
of the experiment would be to ensure that the keratinocytes populations used 
were all isolated from the same ratio of male to female neonates. 
Analysis of the transcriptional data generated using the iGA analysis provided a 
number of insights into the functional differences induced by non ligated D6 and 
ligand  binding  through  D6.  CCL3  binding  in  both  wild type  and  K14D6 
keratinocytes  resulted  in  the  potential  upregulation  of  genes  encoding 
chemokines,  genes involved in CD20/IgE Fc receptor subunit, positive regulation 
of  phagocytosis  and  intracellular  calcium  activated  chloride  channel  activity. 
This  suggests  the  possibility  that  CCL3  exerts  these  effects  through  common 
receptors on both wild type and K14D6 keratinocytes.  Vicky King, 2010      Chapter 4, 212 
It was noted that in wild type keratinocytes, other genes potentially upregulated 
by  CCL3  were  genes  involved  in  transmembrane  receptor  protein  kinase 
signalling pathway, genes involved in the inflammatory response pathway and 
eicosanoid synthesis pathways. This suggests the possibility that CCL3 in wild 
type  keratinocytes  activated  chemokine  receptors  capable  of  signalling  and 
induced genes involved in inflammation. Since these groups were not potentially 
upregulated in K14D6 keratinocytes, this suggests that ectopic expression of D6 
has prevented these genes from being activated. One mechanism may be that D6 
removed CCL3 from its surroundings and targeted it for degradation. In turn, this 
may prevent the ligand binding to chemokine receptors, which would activate 
the  genes  involved  in  the  inflammatory  response.  In  addition  to  this,  genes 
involved in chemokines and CD20/IgE Fc receptor subunit was in fact found to be 
potentially  downregulated  in  K14D6  keratinocytes  compared  to  wild type 
keratinocytes after ligand binding suggesting that ectopic expression of D6 may 
be able to limit transcriptional consequences of CCL3 binding. 
Analysis of the transcriptional consequences of non ligated D6 revealed potential 
upregulation of genes involved with transmembrane receptor protein tyrosine 
kinase  receptor  pathway,  as  well  as  phosphate  transport  and  intracellular 
calcium  activated  chloride  channel  activity.  Interestingly,  non ligated  D6  in 
K14D6 keratinocytes resulted in the potential downregulation of functional genes 
classes involving chemokines. 
Although  this  microarray  has  given  an  insight  and  indication  of  the 
transcriptional consequences of D6 after ligand binding, it has to be kept in mind 
that  D6  is  ectopically  expressed  within  these  keratinocytes.  Therefore,  these 
results may be specific to this cell type and whether the same transcriptional 
consequences occur in a cell that naturally expresses D6 remains to be seen. 
Another point is that only one ligand was used within this study and does not 
take into account that in vivo many different chemokines are within the local 
proximity  of  D6  that  may  affect  the  transcriptional  consequences  of  ligand 
binding.  However,  this  study  is  one  step  forward  in  analysing  the  functional 
response of D6 in vitro. Vicky King, 2010      Chapter 4, 213 
4.7 Conclusion of Chapter 4 
In summary, the main aim of the work within this chapter was to characterise 
the  transcriptional  consequences  of  ligand  binding  through  D6  in  ectopically 
expressed primary keratinocytes. A second aim was to determine if there was 
any  transcriptional  consequence  of  ectopic  expression  of  D6  within  K14D6 
keratinocytes. The microarray results suggested that CCL3 induced the largest 
transcriptional  changes  in  both  wild type  and  K14D6  keratinocytes  mediated 
through common chemokine receptors such as CCR1. However, at the individual 
gene expression level, one conclusion was D6 is expressed at higher levels in 
K14D6 keratinocytes compared to wild type keratinocytes. As a whole, there did 
not seem to be any significant transcriptional consequences of ligand binding 
through D6 at the individual gene level, however by analysing functional gene 
classes, data suggests the possibility that non ligated D6 and ligated D6 is able to 
downregulate the gene expression level of chemokines. Therefore, these data 
suggests  that  D6  within  keratinocytes  does  not  seem  to  affect  the  cellular 
transcriptome as there was no significant upregulation of gene transcripts after 
ligand binding yet D6 may play a role in limiting the expression levels of genes. 
In the presence of ligand, D6 may reduce these levels by removal of the ligand 
leaving less ligand available to bind to other chemokine receptors.  
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5  D6 in human psoriasis 
5.1 Introduction 
Psoriasis  is  a  common  inflammatory  relapsing  skin  disease,  which  varies  in 
location and severity (Naldi and Gambini, 2007). Clinical symptoms of psoriasis 
appear  as  lesions  on  the  skin,  which  in  the  most  common  form  of  psoriasis, 
generally  appear  as  red  plaques.  Pathological  and  histological  changes  occur 
within psoriatic lesions and these make up the hallmark features of the disease. 
Psoriasis has characteristic features that consist of epidermal thickening caused 
by  the  increased  proliferation  of  keratinocytes,  hyperkeratosis,  epidermal 
hyperplasia, angiogenesis and an influx of leukocytes (Murphy et al., 2007). In 
addition,  patients  with  psoriasis  can  also  develop  inflammatory  joint  disease 
(arthritis),  known  as  psoriatic  arthritis  (Kleinert  et  al.,  2007).  Although  the 
trigger  of  psoriasis  is  unknown, the  key mediators  currently  thought  to drive 
psoriasis are T cells (Austin et al., 1999) in particular Th1 and Th17 cells (Lowes 
et  al.,  2008),  cytokines  such  as  TNFa,  IFNg,  IL 23  (Chan  et  al.,  2006)  and 
keratinocytes (Zenz et al., 2005).  
Pathology  similar  to  human  psoriasis  was  demonstrated  in  mice  lacking  the 
atypical  chemokine  receptor,  D6  (Jamieson  et  al.,  2005).  In  the  study,  by 
Jamieson  et  al.,  D6  null  mice  demonstrated  an  exaggerated  inflammatory 
response within the skin in response to a chemical irritant, TPA, although skin 
inflammation in D6 null mice did eventually resolve. Histological analysis of skin 
from D6 null mice revealed several characteristics similar to human psoriasis, 
such as hyperkeratosis, epidermal hyperproliferation and increased angiogenesis 
(Jamieson et al., 2005). The pathology displayed in D6 null mice was dependent 
on  TNF  (Jamieson  et  al.,  2005)  as  well  as  IL 15  and  IL 17  (personal 
communication  Professor  G.J.Graham),  which  are  all  hallmarks  of  human 
psoriasis.  Thus,  D6  null  mice  displayed  psoriasis like  pathology  suggesting 
possible  involvement  of  D6 dysfunction,  as  a  contributing  factor  in  the 
pathogenesis of the disease. 
The aim of the work in this chapter was to determine whether there was any 
correlation between D6 expression levels and cutaneous disease development. 
D6  expression  levels  were  examined  in  human  skin  biopsies  from  control Vicky King, 2010      Chapter 5, 216 
subjects,  atopic  dermatitis  patients  and  patients  with  psoriasis.  In  psoriasis 
patients, skin biopsies from psoriatic lesions and uninvolved skin from the same 
patient were also examined. Samples were taken from atopic dermatitis patients 
because atopic dermatitis is another chronic inflammatory disease of the skin. 
Diagnosis of atopic dermatitis is based on presentation of skin lesions that are 
dry (eczema), very itchy (puritus) and chronic lesions display lichenification of 
the skin (Beltrani, 1999). Atopic dermatitis is thought to be induced by the skin 
in  individuals  who  are  hypersensitive  to  allergens,  resulting  in  increased  Th2 
type cytokines, increased serum IgE levels and eosinophilia (Leung, 1995).  
Specifically, the levels of D6 transcripts were examined by quantitative PCR. The 
presence and location of D6 within the human skin biopsies was examined by 
immunohistochemistry using an antibody available for human D6 (Nibbs et al., 
2001). The main aim of this work was to gain further understanding of the role 
for D6 in the pathogenesis of human cutaneous inflammatory disorders. 
5.2 Collection of human skin samples 
To examine the association of D6 with human psoriasis, patient samples were 
required. Skin samples were taken from volunteers at a Dermatology clinic in 
Glasgow Royal Infirmary. Skin biopsies were taken from various parts of the body 
from psoriatic, atopic dermatitis patients and controls. Control samples were 
obtained  from  various  types  of  patients,  such  as  patients  having  a  naevus 
removed,  patients  with  atypical  fibroxanthoma  or  patients  with  basal  cell 
carcinoma.  These  skin  samples  are  considered  normal  by  dermatologists. 
Psoriasis patients had a skin biopsy taken from the centre of a psoriatic lesion 
and a biopsy taken from uninvolved skin (non lesional) from the same part of the 
body. Skin samples were either ‘snap frozen’ and RNA was extracted from the 
biopsies for quantitative PCR or samples were placed in 10% neutral buffered 
formalin and embedded in paraffin wax blocks for immunohistochemistry. 
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5.3 D6 transcripts in human skin 
RNA was extracted from human skin biopsies using Trizol and was DNase treated, 
(see 2.2.1.2 and 2.2.1.4). RNA was obtained from 9 control samples, 9 atopic 
dermatitis  samples,  10  uninvolved  psoriatic  samples  and  13  lesional  psoriatic 
samples. RNA was transcribed into cDNA (by a dermatologist, Anne Sergeant) and 
used for QPCR. Using QPCR, human skin samples were examined for D6 transcript 
levels  to  determine  any  correlation  between  presence  of  disease  and  D6 
expression.  
There  was  no  significant  difference  in  D6  transcripts  levels  between  atopic 
dermatitis samples and control samples or between psoriatic lesions and control. 
However, D6 transcript levels in uninvolved skin from psoriatic patients were 
significantly  higher  than  control,  atopic  dermatitis  and  psoriatic  lesional  skin 
(Figure  5.1A).  Uninvolved  skin  from  psoriasis  patients  contained  an  8 fold 
increase in D6 transcript levels in comparison to control skin (Figure 5 1A). D6 
transcript  levels  were  also  8 fold  higher  in  uninvolved  skin  from  psoriasis 
patients  compared  to  lesional  skin  of  psoriasis  patients  (Figure  5 1A).  In 
individual psoriasis patients (where matching samples were obtained), 9 out of 
the  10  patients  had  higher  D6  levels  in  uninvolved  skin  than  within  psoriatic 
lesions  (Figure  5 1B).  Conversely,  one  patient  (patient  25)  had  higher  D6 
transcript levels in psoriatic lesions than in uninvolved skin, illustrated by the 
red dotted box in Figure 5 1B. In addition, patient 29 only had slightly higher 
levels of D6 transcripts within non lesional skin compared to lesional skin (Figure 
5.1B). These results indicate a consistent pattern of expression within psoriasis 
patients suggesting that D6 is abnormally expressed within uninvolved skin (non 
lesional) of psoriasis patients. 
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Figure 5-1. D6 transcript levels in human skin. 
Levels of D6 transcripts were examined in human skin biopsies from control individuals, 
atopic dermatitis patients and psoriasis patients (lesions and uninvolved skin). (A) Levels of 
D6  transcripts  are  normalised  to  GAPDH,  a  housekeeping  gene,  and  expressed  as  fold 
change in D6 transcripts compared to control samples. Control n=9, psoriasis non-lesional 
n=10, psoriatic lesional n=13 and atopic dermatitis n=9, columns show mean ± SEM. (B) The 
individual transcript levels of D6 in non-lesional skin and lesion of each patient. Transcript 
levels  were  normalised  to  GAPDH  and  expressed  as  fold  change  normalised  to  control 
samples with a fold change of 1 (shown by black dotted line). Blue column is psoriatic non-
lesional and green column is psoriatic lesional skin. 
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5.4 D6 protein in human skin 
Within our laboratory, monoclonal antibodies to human D6 had been generated 
(Nibbs et al., 2001). In brief, human D6 was transfected into a murine cell line 
(L1.2) and used to immunise C57BL/6 mice. Spleen cells from the immunised 
mice  were  fused  with  myeloma  SP2/0  cells  to  generate  hybridomas. 
Supernatants  from  the  hybridomas  were  screened  and  several  clones  that 
specifically  stained  for  D6  were  further  subcloned,  expanded  and  the 
supernatant collected.  
As anti human D6 antibodies were available for use, human skin biopsies were 
obtained to stain for the presence of D6 in control human skin and psoriatic skin 
(within  lesions  and  uninvolved  skin).  Staining  for  D6,  using 
immunohistochemistry would allow us to determine the location of D6 within the 
skin. Human placental samples were used as a positive control as D6 is highly 
expressed within human placenta, specifically on syncytiotrophoblasts (Martinez 
de la Torre et al., 2007). Previous studies using one of the monoclonal antibodies 
generated  revealed  the  presence  of  D6  on  lymphatic  endothelial  cells  by 
immunohistochemistry  (Nibbs  et  al.,  2001).  This  study  used  a  new  clone  of 
antibody and as a result required optimisation for use in immunohistochemistry. 
Human skin biopsy samples were obtained from patients and collected into 10% 
neutral buffered formalin. Samples were processed, embedded in paraffin wax 
blocks and cut into 4 micron sections to stain either with haematoxylin and eosin 
or with the anti human D6 antibody. In sections stained with the anti human D6 
antibody (or isotype control), a biotinylated secondary antibody was used. Bound 
antibodies were detected using the avidin biotin  horseradish peroxidase method 
(Vector  Laboratories)  and  DAB  substrate,  which  results  in  brown  staining. 
Sections of placenta were used to test the clone of anti human D6 antibody, 
initially following the previously optimised protocol.  
Firstly,  placental  sections  were  cut  and  then  to  enable  identification  of 
placental structure, sections were stained with haematoxylin and eosin.  Figure 
5 2 illustrates aspects of the placental structure, which consists of chorionic villi 
surrounded by maternal blood in the intervillous space. The villus area consists 
mainly of connective tissue and contains umbilical blood vessels linked to the Vicky King, 2010      Chapter 5, 220 
fetus. The outer lining of the villus is lined with syncytiotrophoblasts, which are 
the interface between the mother and the fetus.   
To  test  the  clone  of  antibody,  placental  sections  were  stained  with  high 
concentrations of the primary antibody using dilutions of 1:10 and 1:50 (stock 
concentration was 100 g/ml). No brown staining was seen anywhere within the 
placental sections using 1:10 or 1:50 dilutions of either IgG2a antibody or anti 
human  D6  antibody  (Figure  5 3).  This  suggested  that  the  conditions  used  for 
staining the placental sections were not optimal. 
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Figure 5-2. Haematoxylin and eosin staining in human placenta 
Placental  sections  were  processed  and  sections  cut  for  staining  with  haematoxylin  and 
eosin to identify placental features, such as chorionic villus, intervillous space (IVS) and 
syncytiotrophoblasts (ST) lining the villi. Magnification is 100x.  
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Figure 5-3. Optimisation of D6 antibody on placental sections. 
Placental sections were stained with either anti-human D6 antibody (4a5) or Isotype IgG2a 
using either 1:50 or 1:10 dilutions. Magnification is 100x. 
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There  are  many  factors,  which  can  contribute  to  staining  not  occurring  in 
immunohistochemistry, and it was decided to try a different antigen retrieval 
step. In the next set of staining, the antigen retrieval step was changed from 
EDTA pH 8 to 1mM citrate buffer pH 6. As a result, brown staining was present in 
the placental section stained with the anti human D6 antibody (Figure 5 4). This 
was  evident  in  the  connective  tissue  within  the  villus  as  well  as  the 
syncytiotrophoblast  layer  (Figure  5 4).  However,  placenta  stained  with  the 
isotype  IgG2a  antibody,  as  a  negative  control,  also  displayed  brown  staining 
within  the  villi  as  well  as  within  syncytiotrophoblasts,  indicating  high  non 
specific staining (Figure 5 4).  
To  reduce  background  staining,  the  primary  antibody  concentration  was 
reduced. Using a 1:50 dilution of the anti human D6 antibody, brown staining 
was present in the connective tissue of the villus as well as in the outer layer of 
the villus (Figure 5 5). However, within the negative control section using an 
isotype antibody, the connective tissue of the villi and the syncytiotrophoblast 
layer  also  stained  brown,  illustrating  high  non specific  binding  had  occurred 
(Figure 5 5). As a result, a 1:250 dilution of primary antibody was tested and 
resulted  in  strong  specific  D6  staining  within  syncytiotrophoblast  cells  in  the 
placenta, as the isotype stained section contained no brown staining within the 
syncytiotrophoblast layer (Figure 5 5). Since the syncytiotrophoblast layer was 
only brown in sections stained with the anti human D6 antibody and was not 
seen using the isotype control, this suggested that the anti human D6 antibody 
(4a5 clone) was working and was specific for D6. This staining confirmed that D6 
is expressed on syncytiotrophoblasts within the placenta.  
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Figure 5-4. Change of antigen retrieval method. 
Placental sections were stained with either anti-human D6 antibody (4a5) or Isotype IgG2a 
using 1:10 dilutions. IVS; intervillous space, ST; syncytiotrophoblasts, Magnification 100x. 
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Figure 5-5. Different concentrations of primary antibody on placental sections. 
Sections were stained with either 1:50 or 1:250 dilution of isotype IgG2a or anti-human D6 
antibody.  IVS; intervillous space, ST; syncytiotrophoblasts. Magnification x100. 
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Since  the  anti human  D6  antibody  was  shown  to  be  specific  for  D6  in  the 
placenta, it was decided to stain human skin sections and use placental sections 
as  a  positive  control.  First,  skin  sections  were  cut  then  stained  with 
haematoxylin and eosin to ensure the skin biopsy was embedded in the correct 
orientation.  The  structure  and  features  within  a  control  skin  sample  are 
illustrated in Figure 5 6. Features illustrated within this sample are the multi 
layered epidermis including the outermost layer, known as the stratum corneum. 
Below  the  epidermis  is  the  dermis,  in  which  blood  vessels,  hair  follicles  and 
sebaceous glands can be identified (Figure 5 6).  
It was decided to test the anti human D6 antibody on skin sections using a 1:250 
dilution. This concentration of antibody resulted in brown staining within the 
epidermis as well as within the connective tissue in the dermis (Figure 5 7). The 
isotype control stained skin section did not display any brown staining, which 
would  suggest  that  the  brown  staining  seen  in  the  anti human  D6  antibody 
stained section is due to primary antibody binding (anti human D6 antibody). 
However, in the D6 stained section, brown staining covered the whole tissue and 
as a result indicated that the staining was non specific (Figure 5 7).  
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Figure 5-6. Structure and features of human skin 
A  skin  biopsy  was  taken  from  a  control  patient,  processed  and  sections  were  cut  and 
stained  with  haematoxylin  and  eosin.  Annotations  illustrate  epidermal  and  dermal 
compartments of skin as well as stratum corneum (SC), blood vessels (BV), hair follicles 
(HF) and sebaceous glands (SG). Magnification 100x. 
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Figure 5-7. D6 staining in skin section 
Control  skin  sections  were  stained  with  either  isotype  IgG2a  or  anti-human  D6  antibody 
(1:250 dilution).Magnification 100x. 
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To  optimise  the  anti human  D6  antibody  for  staining  in  human  skin  sections, 
decreasing concentrations of anti human D6 antibody were tested using 1:300, 
1:400 and 1:500 dilutions (Figure 5 8; 1:400 dilution not shown). Using 1:300 
dilution  of  antibody,  D6  was  specifically  expressed  on  syncytiotrophoblasts 
within placental sections as no brown staining appeared on syncytiotrophoblasts 
with the negative control, which was stained with isotype IgG2a antibody (Figure 
5 8A). On the other hand, in the skin sections, brown staining was present in the 
epidermis  and  in  hair  follicles  with  no  brown  staining  appearing  in  dermal 
connective tissues (Figure 5 8A). As no brown staining appeared in the negative 
control skin section, this suggested that the anti human D6 antibody was working 
but possibly not specific to D6 and potentially cross reacting to other proteins, 
for example in hair follicles. (Figure 5 8A). The 1:500 dilution of antibody also 
resulted in similar staining to the 1:300 dilution where brown staining occurring 
in the epidermis as well as hair follicles and no brown staining occurred in the 
negative control (Figure 5 8B). In addition, it was noted that in both 1:300 and 
1:500 stained skin sections, the dermal connective tissue did not stain brown in 
comparison  to  the  staining  seen  previously  with  a  1:250  dilution  of  antibody 
(Figure 5 7). This suggested that by increasing the dilution of the antibody, non 
specific binding had been reduced slightly.  
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Figure  5-8.  Different  concentrations  of  primary  antibody  on  human  placenta  and  skin 
sections.  
Placental and skin sections were stained with either isotype IgG2a antibody or anti-human 
D6 antibody. (A) Antibodies were used at 1:300 dilution (B) Antibodies were used at 1:500 
dilution. HF indicates hair follicles. Magnification 50x. 
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To  determine  optimal  conditions  for  D6  staining  within  skin  sections  and  to 
reduce non specific binding within the tissue, further dilutions, 1:750 and 1:1000 
were  tested.  In  the  1:750  dilution,  D6  was  seen  to  be  expressed  within  the 
placenta indicated by brown staining using the anti human D6 antibody (Figure 
5 9A). Within the skin, brown staining was present within the epidermis (Figure 
5 9A)  however,  it  was  noted  that  this  was  less  intense  than  when  the  1:500 
dilution  was  used  (Figure  5 8).  This  indicated  that  non specific  staining  was 
reduced by using a lower concentration of anti human D6 antibody. In the 1:1000 
antibody dilution, brown staining still occurred in the epidermis and surrounding 
hair follicles in skin sections stained with the anti human D6 antibody although 
no brown staining was seen in the negative control (Figure 5 9B). However, it 
was noted that several cells within the skin were stained brown and others did 
not (within black circle in Figure 5 9B). On closer examination, it was noted that 
there  was  non specific  staining in the  epidermal tissue (indicated  by  the  red 
arrow in Figure 5 10) yet not all the cells within the epidermis were stained 
brown (example within black circle in Figure 5 10). Within the dermis, there was 
a mixture of cells that had stained brown (examples in red circle in Figure 5 10), 
which  could  possibly  be  leukocytes  and  others  cells  did  not.  These  data 
indicated that the D6 antibody may be specific for D6 expressing cells but there 
was still some staining within the epidermis, which was likely to be non specific, 
and indicates cross reactivity with other proteins within the epidermis.  
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Figure 5-9. Optimisation of primary antibody on human placenta and human skin sections 
using 1:750 and 1:1000 dilutions. 
Human placenta and skin sections were stained with either isotype IgG2a or anti-human D6 
antibody  (A)  Sections  were  stained  with  primary  antibody  at  1:750  dilution  (B)  Primary 
antibody was used at 1:1000 dilution. Black circle contains some cells, which have stained 
brown which indicates that these cells express D6. Magnification 100x. 
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Figure 5-10. D6 staining within human skin 
Human  skin  section  was  stained  with  anti-human  D6  antibody  (1:1000  dilution)  and 
examined  for  positive  brown  staining.  BV  indicates  a  blood  vessel.  Red  arrow  denotes 
background  staining  in  the  epidermis.  Red  circles  illustrate  positive  brown  stained  cells 
indicating D6 protein expression. Black circle highlights that some cells in the epidermis did 
not stain brown (negative for D6).  Magnification x200. 
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In  order  to  reduce  non specific  staining  within  the  epidermis,  sections  were 
tested with the extra steps of blocking endogenous biotin as well as reducing the 
time the tissues were incubated in DAB. There was less epidermal staining in 
both sets of skin sections, indicating that non specific staining was reduced by 
the amount of time DAB was incubated with the samples and not by the use of 
avidin biotin  block  in  this  case  (Figure  5 11).  Once  again,  there  are  positive 
stained cells within the epidermis and the dermis (Figure 5 11B).However, with 
non specific staining still present in the epidermis, there is the possibility that 
positive brown stained cells are not D6 expressing cells and the antibody is cross 
reactive with proteins on these cells. If these cells are positive for D6, they 
could be leukocytes as D6 has been reported to be expressed on B cells and 
dendritic  cells  as  well  as  within  atopic  dermatitis  (McKimmie  et  al.,  2008, 
McKimmie and Graham, 2006). Further staining would be required to confirm the 
cell types. As for cells positively stained within the epidermis, this would suggest 
that  D6,  or  the  antibody  is  cross reacting  with  proteins,  expressed  on 
keratinocytes,  melanocytes  and  merkel  cells  or  possibly  by  resident  immune 
cells within the skin. Blood vessels did not stain positively for D6 and it was 
noted that using his clone of anti human D6 antibody, positive brown staining 
was not seen on lymphatic vessels within control skin. With non specific staining 
occurring  in  the  skin,  this  clone  of  antibody  may  not  be  optimal  for 
immunohistochemistry on skin.  
Whilst  trying  to  optimise  the  anti human  D6  antibody,  the  next  step  was  to 
obtain, embed and cut psoriasis skin biopsies ready for immunohistochemistry 
staining. There were only five psoriasis patient samples available (lesional and 
non lesional)  however;  several  attempts  to  cut  sections  were  unsuccessful. 
While trying to cut sections, the skin would ribbon, tear or the section would 
split down the middle, therefore not giving good sections to stain. To try to 
improve this, a new blade was used, embedded sections were left on ice longer 
but  sections  were  still  difficult  to  cut.  Another  possibility  could  be  that  the 
sections  were  not  in  the  exact  correct  orientation  during  the  embedding 
procedure.   
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Figure 5-11. Comparison using avidin/biotin block during D6 staining on human skin. 
Skin  sections  were  stained  using  1:1000  dilution  of  anti-human  D6  antibody.  (A)  Skin 
stained section without or without the use of avidin/biotin block. Magnification 200x (B) Skin 
sections with/without avidin biotin block, showing brown staining on some cells within the 
tissue. Same pictures as in (A) but magnification is 400x. 
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5.5 D6 transcripts in peripheral blood 
As described in section 5.3, D6 transcripts were elevated in psoriatic uninvolved 
skin  compared  to  control  skin.  Therefore,  it  was  decided  to  examine  D6 
transcript levels within the peripheral blood of psoriasis patients to determine if 
PBMCs had enhanced D6 expression compared to healthy controls. These cells 
may contribute to the enhanced expression of D6 within psoriatic uninvolved skin 
due  to  increased  leukocyte  infiltration.  It  was  also  decided  to  extend  the 
analysis  of  D6  transcripts  within  peripheral  blood  to  other  inflammatory 
diseases, such as psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Psoriatic 
arthritis is a chronic inflammatory disease that involves joint inflammation as 
well  as  the  presence  of  psoriasis.  Over  time,  cartilage  within  the  joints  is 
reduced and erosion of the bone occurs resulting in joint deformities leading to a 
reduced function and quality of life (Gladman et al., 2005). Rheumatoid arthritis 
is  also  chronic  inflammatory  disease  that  leads  to  swelling  and  destruction 
within the joints. The lining of the synovium becomes inflamed and hyperplastic 
due to infiltration of inflammatory cells (Sweeney and Firestein, 2004). Joint 
destruction occurs through cartilage damage and bone erosion leading to severe 
disability (Goldring, 2003). PsA and RA can be distinguished from each other by 
the psoriatic component and by the joints that are affected.  
A small sample of peripheral blood was collected from control (n=12), psoriatic 
(n=12), psoriatic arthritis (n=15) and RA patients (n=15). Cells from peripheral 
blood were isolated and RNA was extracted from total PBMCs, which includes 
monocytes, T cells, B cells, myeloid dendritic cells and plasmacytoid dendritic 
cells,  and  analysed  for  D6  transcripts  by  QPCR.  In  the  PBMCs  from  psoriasis 
patients, D6 transcripts were increased 2.3 fold compared to control PBMCs but 
the change was not significant (Figure 5 12). There was no significant difference 
in D6 transcripts in PBMCs within PsA patients compared to controls. However, 
there  was  a  significant  2 fold  decrease  found  in  PBMCs  from  RA  patients  in 
comparison to controls (Figure 5 12). There was large variation in D6 transcripts 
within psoriasis patients and it is not known whether this variation correlates 
with disease severity at the time (Figure 5 12). In PsA patients, there are two 
distinct  populations  and  it  may  be  possible  that  these  correlate  with  the 
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Figure 5-12. Levels of D6 transcripts in peripheral blood from human inflammatory diseases. 
RNA was extracted from peripheral blood cells of control, psoriatic, psoriatic arthritis (PsA) 
or  rheumatoid  arthritis  (RA)  patients  and  examined  for  D6  transcripts.  Levels  were 
normalised using GAPDH as a housekeeping gene. D6 transcripts levels are expressed as 
fold  change  in  comparison  to  controls.  Control  n=12,  psoriasis  n=12,  psoriatic  arthritis 
(PsA) n=15 and rheumatoid arthritis (RA) n=15. 
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5.6 D6 surface expression on peripheral blood cells 
D6 transcript levels were found to be lower in peripheral blood of RA patients 
than in healthy controls. As a result, it was decided to examine PBMCs in more 
detail to determine which cell types were responsible for lower D6 expression in 
RA patients. 
PBMCs were extracted from control or RA patient blood and examined for D6 
expression  on  the  cell  surface  by  flow  cytometry  using  an  anti human  D6 
antibody  (McKimmie  et  al.,  2008).  To  identify  cell  types,  antibodies  against 
lineage specific markers were used. CD3 was used to identify T cells, CD20 was 
used to identify B cells and monocytes were identified by CD14. Myeloid DCs 
were  identified  by  CD1c  expression  and  plasmacytoid  DCs  were  identified  by 
CD304 (BDCA4) expression. 
PBMCs were profiled using forward and side scatter and the main population of 
cells were gated as show in Figure 5 13.  
 
 
Figure 5-13. Profile of peripheral blood mononuclear cells from a healthy control patient. 
Peripheral blood mononuclear cells were profiled by flow cytometry using forward and side 
scatter. The main population of cells were gated for further analysis. 
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Control PBMCs were stained with viaprobe to detect and exclude dead cells. Live 
cells do not stain positive for viaprobe. Live T lymphocytes were gated (R2) by 
selecting cells which were negative for viaprobe and stained positive for CD3 
using an anti human CD3 antibody, as shown in Figure 5 14A. The plots shown in 
Figure 5 14 are from one representative sample. A profile of CD3 positive T cells 
stained with isotype antibody or anti human D6 antibody is shown in Figure 5 
14B. T cells stained with isotype antibody had a mean fluorescent intensity (MFI) 
of  1.79  whereas  D6  expressing  CD3  positive  cells  had  an  MFI  of  3.36.  The 
corresponding histogram plot shows that T cells from a control patient weakly 
express  D6  on  their  surface  (Figure  5 14B).  Live  B  cells  were  gated  on  CD20 
positive cells (R2; Figure 5 14C) and were then analysed using either isotype 
antibody staining or anti human D6 antibody. Isotype stained B cells had an MFI 
of  1.74  whereas  B  cells  express  different  levels  of  surface  D6  (fluorescent 
intensity spread is 3 3865) with an MFI of 49.76 (Figure 5 14D). Control B cells 
express  surface  D6  at  various  levels  with  some  B  cells  expressing  D6  at  high 
levels.  
Monocytes from controls were gated (R2) using an anti human CD14 antibody 
(Figure  5 15A).  Cells  positively  expressing  CD14  were  gated  and  analysed  for 
expression  of  D6  (Figure  5 15A).  In  a  representative  sample,  isotype  stained 
monocytes had an MFI of 5.09 whereas D6 positive cells had an MFI of 53.83 
(Figure 5 15B). It can be concluded that monocytes express surface D6 (Figure 5 
11B).  
 
 
 
 
 
 
 Vicky King, 2010      Chapter 5, 240 
 
 
Figure 5-14. Analysis of D6 expression on control human T and B cells. 
(A)  Live  positive  CD3  T  cells  were  gated  using  R2.  (B)  T  cells  gated  through  R2  were 
analysed using isotype or anti-human D6 antibody. A representative histogram showing T 
cells intensity for isotype (purple) and D6 (green). (C) Live B cells were gated using an anti-
human CD20 antibody. (D) A representative plot of cells positive for CD20 and stained with 
either isotype control or anti-human D6 antibody. A representative overlay is shown plotting 
B cell fluorescent intensity for isotype (purple) and D6 (green). 
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Figure 5-15. Analysis of D6 expression on control monocytes. 
(A) Monocytes were gated using an anti-human CD14 antibody (R2) (B) Cells were gated 
through R2 and analysed for isotype and D6 expression. A representative histogram shows 
fluorescent intensity for isotype (purple) and D6 (green) positive monocytes. 
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There  are  two  subtypes  of  dendritic  cells  in  human  PBMCs,  myeloid  and 
plasmacytoid dendritic cells, which are characterised by distinct lineage markers 
(Shortman and Liu, 2002). For mDCs, an antibody against CD1c was used and for 
pDCs, an antibody against CD304 (BDCA 4) was used. However, monocytes and B 
cells can also express these surface molecules and therefore identification of 
monocytes  and  B  cells  was  required  in  order  to  exclude  them  from  further 
analysis of dendritic cells. Cells were stained with a cocktail of antibodies in 
order to identify dendritic cells. Cells negative for CD14 and CD20 were gated 
through R2, therefore excluding monocytes and B cells respectively (Figure 5 
16A). Cells gated in R2, which were positive for CD1c, were classed as mDCs (R3; 
Figure  5 16B).  In  a  representative  sample,  mDCs,  which  stained  positive  for 
isotype control had an MFI of 3.32 whereas D6 positive cells gave an MFI of 44.21 
(Figure 5 16B). Myeloid DCs express a range of D6 on their surface with some 
expressing very little D6 and some with high expression of D6, the fluorescent 
intensity  ranged  from  3  to  5474  (Figure  5 16B).  Plasmacytoid  DCs  were  also 
gated through R2, to exclude monocytes and B cells. Positively stained BDCA 4 
(CD304)  cells  indicated  that  these  cells  were  pDCs  and  were  gated  (R3)  for 
further analysis (Figure 5 16C). Plasmacytoid DCs, in a representative sample, 
express very high levels of D6 (MFI is between 5 and 2916 with a mean of 268.3) 
as shown in Figure 5 16D. Vicky King, 2010      Chapter 5, 243 
 
 
 
 
Figure 5-16. Analysis of D6 expression on control myeloid and plasmacytoid dendritic cells. 
(A) Live cells were gated (R2) to exclude monocytes and B cells using anti-human CD14 and 
anti-human CD20 antibody and positive CD1c cells were gated (R3) as myeloid DCs. (B) 
Cells were gated through R3 and analysed for isotype and D6 expression. A representative 
histogram  plot  shows  fluorescent  intensity  for  isotype  stained  mDCs  (purple)  and  D6 
positive mDCs (green). (C) Live pDCs were gated to exclude monocytes and B cells (R2) and 
were gated using an anti-human BDCA-4 antibody (R3). (D) Representative plots of cells 
positive  for  CD20  and  stained  with  either  isotype  control  or  anti-human  D6  antibody.  A 
representative histogram plot shows fluorescent intensity for isotype stained pDCs (purple) 
and D6 positive pDCs (green). 
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Peripheral blood was taken from RA patients and PBMCs were isolated. PBMCs 
were stained with antibodies specific for lineage markers to identify monocytes, 
T  and  B  lymphocytes,  myeloid  and  plasmacytoid  dendritic  cells  as  well  as 
staining for surface D6 expression. PBMCs from RA patients were all gated using 
the  same  antibodies  and  parameters  as  the  control  peripheral  mononuclear 
cells. A profile of PBMCs from one RA patient is shown in Figure 5 17, which is 
similar to control PBMCs although the profile will vary slightly from patient to 
patient.  
 
 
 
 
Figure 5-17. Cell profile of peripheral blood mononuclear cells from a rheumatoid arthritis 
patient using flow cytometry. 
Peripheral blood mononuclear cells were profiled by flow cytometry using forward and side 
scatter. The main population of cells were gated for further analysis. 
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Live T cells were identified using the anti human CD3 antibody and were gated 
as shown in Figure 5 18A.  T cells from one RA patient expressed low levels of 
D6, as the MFI was 3.65 and only shifted to 7.32 for D6 positive T cells (Figure 5 
18B). B cells were gated using CD20 and an MFI of 3.52 was obtained with cells 
stained with isotype antibody whereas cells stained with anti human D6 antibody 
resulted in an MFI of 190.16 with a spread of 12 to 1322. High levels of D6 was 
expressed on B cells from RA patients shown by a 2 log fold shift in the MFI of D6 
positive cells compared to isotype stained cells (Figure 5 18D). 
Monocytes  from  RA  patient  peripheral  blood  were  gated  using an anti human 
CD14  antibody  (Figure  5 19A).  In  a  representative  sample,  isotype  stained 
monocytes had an MFI of 8.55 and moved to 100.67 on D6 stained monocytes. 
The corresponding histogram shows that monocytes expressing D6 resulted in a 
log  fold  shift  of  the  MFI  compared  to  the  isotype  control.  Therefore,  D6  is 
expressed on monocytes within the peripheral blood of RA patients (Figure 5 
19B).  
Live  mDCs  from  a  RA  patient  were  gated  (Figure  5 20A)  and  isotype  stained 
mDCs had an MFI of 5.22 whereas mDCs positively bound to D6 antibody yielded 
an MFI of 44.56 with a spread of 53 1241, resulting in a log fold shift (Figure 5 
20B). Although there were low numbers of mDCs, they express moderate levels 
of D6. Low numbers of pDCs were also seen yet pDCs express a broad and high 
range of D6 expression levels. In a representative sample, the MFI was 4.09 for 
isotype stained pDCs and positively D6 stained pDCs varied from 5 4598 with a 
mean of 359.34 resulting in a 2 log fold shift compared to the isotype control 
(Figure 5 20D). 
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Figure 5-18.  Analysis of D6 expression on T and B cells from a RA patient. 
(A) Positive CD3 cells were gated and selected as T cells. (B) Cells were gated through R2 
and  analysed  for  isotype  or  D6  expression.  A  representative  histogram  plotting  T  cells 
intensity  for  isotype  (purple)  and  D6  (green).  (D)  Live  B  cells  were  gated  using  an  anti-
human CD20 antibody. (E) Representative plots of cells positive for CD20 and stained with 
either  isotype  control  or  anti-human  D6  antibody  with  a  histogram  plot  showing  T  cell 
intensity for isotype (purple) and D6 (green). Vicky King, 2010      Chapter 5, 247 
 
 
Figure 5-19. Analysis of D6 expression on monocytes from a RA patient. 
Cells were gated through R1 and live cells were detected using viaprobe. (A) Monocytes 
were  selected  using  an  anti-human  CD14  antibody  and  gated  (R2)  (B)  Cells  were  gated 
through R2 and analysed for isotype control or D6 expression. A representative histogram 
shows fluorescent intensity for isotype (purple) and D6 (green) positive monocytes. 
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Figure 5-20. Analysis of D6 expression on myeloid and plasmacytoid dendritic cells from a 
RA patient. 
Cells were gated through R1 and live cells were detected using viaprobe. (A) Live cells were 
gated using R2 to exclude monocytes and B cells and positive CD1c cells were gated and 
selected as myeloid DCs (R3). (B) Cells were gated through R3 and analysed for isotype and 
D6 expression. A representative overlay plotting fluorescent intensity for isotype positive 
(purple)  and  D6  positive  (green)  monocytes.  (C)  Live  pDCs  were  gated  to  exclude 
monocytes and B cells (R2) and was gated using an anti-human BDCA-4 antibody (R3). (D) 
A  representative  overlay  plot  of  cells  positive  for  CD20  and  stained  with  either  isotype 
control or anti-human D6 antibody. 
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To compare D6 expression levels between healthy samples and RA patients, the 
corrected  mean  fluorescent  intensity  was  calculated,  by  subtracting  the  MFI 
from the isotype control from MFI of D6, for each cell type. Overall, in control 
peripheral blood, pDCs and B cells expressed the highest levels of D6 on their 
surface, followed by mDCs and monocytes whereas T cells expressed very weak 
levels of D6 (Figure 5 21). This trend in levels of expression was similar to D6 
expression  found on leukocytes (McKimmie et al., 2008, McKimmie and Graham, 
2006). In peripheral blood from RA patients, the trend of D6 expression on the 
same cell types was similar, in that B cells and pDCs expressed highest levels of 
surface D6 followed by mDCs and monocytes then T cells (Figure 5 21). However, 
D6 expression on B cells and mDCs was found to be significantly higher in RA 
patients than in healthy control patients (Figure 5 21). In addition, D6 expression 
was increased on T cells, monocytes and pDCs from RA patients compared to 
healthy control but were not significant (Figure 5 21). As a result, these data 
contradicted the D6 transcript levels data obtained earlier (Figure 5 12), where 
in  peripheral  blood,  D6  transcript  levels  were  lower  in  RA  patients  than  in 
healthy controls. 
 
Figure 5-21. Analysis of D6 expression on peripheral blood cells in control and RA patients. 
Peripheral blood cells were isolated from control (white) and RA patients (black) stained for 
specific  lineage  markers  to  identify  T  cells,  B  cells,  monocytes,  myeloid  DCs  and 
plasmacytoid DCs. D6 surface expression on these cells was detected by an anti-human D6 
antibody and expression levels are represented as mean fluorescent intensity (MFI). Control 
n=6, RA n=9, column is mean ± SEM. Vicky King, 2010      Chapter 5, 250 
Due to the apparent contradiction in these data, it was decided to reanalyse the 
QPCR data to try to find a possible explanation. Upon doing so, it was seen that 
the housekeeping gene, GAPDH, was significantly higher in peripheral blood of 
RA patients compared to healthy controls (Figure 5 22). Housekeeping genes are 
used  to  normalise  sample  cDNA  levels  to  allow  comparison  of  gene  levels 
between samples. Having significantly higher levels of housekeeping gene within 
a sample group would skew the data because this would result in the transcript 
levels of D6 in the RA samples to be calculated lower than they actually are. 
This suggests that GAPDH is not the most suitable housekeeping gene to use in 
order to normalise the data, as an ideal housekeeping gene should be expressed 
at a constant level between control and test sample. There is evidence that 
GAPDH transcript levels can vary in nucleated blood cells between individuals 
(Bustin et al., 1999) as well as in whole blood from healthy and in pulmonary 
tuberculosis samples (Dheda et al., 2004). To correct for this, it would be more 
suitable to use a housekeeping gene that does not significantly change between 
peripheral blood of RA patients and control samples. 
 
 
Figure  5-22  Copy  numbers  of  GAPDH  in  control,  psoriatic  arthritis  (PsA),  rheumatoid 
arthritis (RA) and psoriasis patients. 
RNA was extracted from peripheral blood cells converted to cDNA and diluted with nuclease 
free  water.  Levels  of  GAPDH  transcripts  were  assessed  by  QPCR  using  SYBR  Green. 
Control n=12, Psoriatic arthritis n=15, RA n=15 and psoriasis n=12. Columns are mean ± 
SEM, 
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5.7 Summary of Chapter 5 
In a cutaneous model of inflammation, absence of D6 results an exaggerated 
inflammatory  response  resulting  in  pathology  similar  to  human  psoriasis 
(Jamieson et al., 2005). This led to the hypothesis that D6 dysfunction may play 
a role in the pathogenesis of human psoriasis. To examine this possibility, the 
aim of the work within this chapter was to examine the expression of D6 within 
human psoriasis and other inflammatory diseases. 
Analysis of skin biopsies from psoriatic (uninvolved and lesional samples) as well 
as control and atopic dermatitis samples revealed that D6 transcript expression 
was increased in psoriatic uninvolved skin. This suggests that D6 is dysfunctional 
within psoriatic patients in that D6 expression may be upregulated in uninvolved 
skin to limit skin inflammation. Anti human D6 antibody was tested for use with 
psoriatic  skin  however  obtaining  good  skin  sections  from  these  biopsies  was 
difficult and results suggest that the antibody may not be ideal to use on skin by 
immunohistochemistry.  Examination  of  D6  transcripts  within  peripheral  blood 
revealed  a  non significant  2.3  fold  increase  in  D6  transcripts  within  psoriatic 
blood, no change in psoriatic arthritis blood and a 2 fold decrease in RA blood 
compared  to  control.  However,  it  was  discovered  that  GAPDH  may  not  be  a 
suitable housekeeping gene for peripheral blood from RA patients and that the 
2 fold decrease in transcript levels was a false result. This was confirmed by the 
analysis of D6 expression on isolated cells from RA blood indicating that in fact B 
cells and mDCs expressed significantly higher levels of surface D6 in comparison 
to healthy control.  
To  conclude,  the  work  within  this  chapter  suggests  that  more  studies  are 
required to determine the correlation between D6 and inflammatory diseases 
especially  regarding  the  mechanisms  underlying  the  dysregulation  of  D6  in 
uninvolved skin of psoriasis patients.  
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6  General Discussion 
Inflammation is the body’s response to internal or external insults such as tissue 
injury  or  infection  (Medzhitov,  2008).  Chemokines  are  key  players  in  the 
inflammatory  process  by  controlling  the  migration  of  leukocytes  into  tissues 
(Charo and Ransohoff, 2006). In particular, pro inflammatory CC chemokines are 
involved,  which  signal  through  chemokine  receptors  present  on  various 
leukocytes (Murphy et al., 2000). A controlled inflammatory response results in 
the tissue returning to its normal physiological state and is beneficial to the 
body (Serhan et al., 2007). When inflammation becomes dysregulated, this can 
be detrimental as demonstrated by chronic inflammatory diseases. Although the 
initiation and maintenance of inflammatory processes is well understood, the 
mechanisms  responsible  for  the  resolution  of  inflammation  are  only  just 
beginning to emerge.  
D6 is an atypical chemokine receptor, which has the ability to bind inflammatory 
CC chemokines (Graham, 2009). D6 does not seem to signal (Graham, 2009) but 
studies suggest that D6 sequesters CC chemokines by constitutively moving to 
and from the cell surface in a ligand independent manner (Weber et al., 2004). 
Evidence has shown that D6 is a key mediator in the resolution of inflammation. 
D6  null  mice  display  enhanced  skin  inflammation  in  response  to  TPA  and 
complete Freund’s adjuvant  (Martinez de la Torre et al., 2005, Jamieson et al., 
2005).  Additionally,  D6  null  mice  are  susceptible  to  inflammation  dependent 
tumour development (Nibbs et al., 2007). During skin inflammation, D6 has been 
shown  to  be  involved  in  the  clearance  of  CC  chemokines  at  the  site  of 
inflammation  (Jamieson  et  al.,  2005).  D6  null  mice  displayed  enhanced 
recruitment of leukocytes to the lung after allergen exposure (Whitehead et al., 
2007) and infection with  Mycobacterium tuberculosis leads to enhanced local 
and  systemic  inflammation  with  increased  CC  chemokines  and  leukocyte 
infiltration (Di Liberto et al., 2008). In inflammation induced miscarriage models 
using LPS or anti phospholipid antibodies, enhanced susceptibility to miscarriage 
occurs  in  D6  null  mice  and  is  associated  with  enhanced  chemokines  and 
leukocyte infiltration in the placenta (Martinez de la Torre et al., 2007). D6 has 
been implicated in the development of experimental colitis and is thought to 
regulate the production of IL 17A by gd T cells in the later stages of the disease 
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Evidence indicated that D6 was involved in controlling cutaneous inflammation 
therefore, we hypothesised that increased expression of D6, using a transgenic 
approach, should be able to suppress cutaneous inflammation in vivo. To test 
this,  transgenic  mice  were  generated,  in  which  the  expression  of  D6  was 
targeted  to  epidermal  keratinocytes.  Validation  studies  confirmed  ectopic 
expression of D6 in the epidermis and in keratinocytes from K14D6 mice, whilst 
D6 transcripts were absent from wild type epidermis. In addition, D6 expressed 
from the transgene in K14D6 keratinocytes was functional, as demonstrated by 
the  ability  of  K14D6  keratinocytes  to  bind  CCL2  and  progressively  remove 
extracellular CCL3, both D6 ligands, in a D6 dependent manner. It is of note that 
only  45%  of  K14D6  keratinocytes  were  able  to  bind  CCL2.  These  primary 
keratinocytes  were  isolated  and  cultured  in  keratinocytes  growth  media 
containing low concentrations of calcium and no fetal calf serum. As a result, 
culture of these keratinocytes should generate a homogenous population, which 
would proliferate but not differentiate due to the low concentration of calcium 
(Hennings et al., 1980). An explanation as to why only 45% keratinocytes were 
able  to  bind  CCL2  is  that  the  majority  of  D6  expression  is  inside  the  cell 
(Blackburn et al., 2004) and keratinocytes expressing low levels of surface D6 
were not identified i.e. these cells were not able to bind high levels of CCL2. 
Retrospectively,  it  may  have  been  of  interest  to  confirm  that  D6  positive 
keratinocytes were keratin 14 expressing cells. 
Having characterised the K14D6 transgenic mice, we examined whether ectopic 
expression of D6 within the skin was able to dampen down inflammation. We 
used  a  well characterised  model  of  skin  inflammation  previously  used  by 
colleagues, which involved application of TPA to murine dorsal skin once a day 
for three consecutive days (Jamieson et al., 2005). Work presented here shows 
that  D6  null  mice  demonstrated  an  exaggerated  cutaneous  inflammatory 
response and wild type mice had increased skin thickness four days after the last 
application  of  TPA  compared  to  resting  thickness.  This  was  consistent  with 
previous findings in a different strain of mice (Jamieson et al., 2005). K14D6 
mice displayed  no  significant  difference  in  skin  thickness  four  days  after  the 
final  application  of  TPA  compared  to  resting  skin  thickness.  In  addition,  the 
numbers of mast cells and epidermal T cells were reduced in inflamed K14D6 
skin  compared  to  inflamed  wild type  skin.  Within  the  skin,  D6  is  involved  in 
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most  likely  explanation  is  that  by  increasing  D6  levels  in  K14D6  mice,  lower 
levels of CC chemokines were present than in wild type skin. As a result, this 
directly affected the recruitment of mast cells and T cells into the skin and 
subsequent inflammation. 
In the epidermis, keratinocytes and Langerhans cells are rich sources of various 
chemokines,  which  can  drain  into  the  dermis.  Following  TPA  stimulation, 
keratinocytes  produce  CCL3  and  CCL5  (personal  communication,  Prof. 
G.Graham). Murine mast cells express CCR1, CCR2, CCR3 and CCR5 (Ma et al., 
2002, Oliveira and Lukacs, 2001), which are all capable of supporting migration 
towards ligands which also bind to D6. Human mast cells also express a range of 
chemokine receptors. One of these is CCR3 (de Paulis et al., 2001) which is able 
to support migration towards CCL11 and CCL5 in the  skin (Romagnani et al., 
1999), both of which are D6 ligands. Activated T cells express various chemokine 
receptors  (Bonecchi  et  al.,  1998)  including  CCR4,  which  is  implicated  in  the 
homing of T cells into inflamed skin (Reiss et al., 2001). In addition, activated T 
cells  recruited  into  the  skin  during  inflammation  may  release  CXCL12  which 
influences the migration of mast cells (Brill et al., 2004), through the presence 
of CXCR4 on mast cells (Oliveira and Lukacs, 2001). Therefore, it is feasible that 
a reduction in mast cells and T cells recruited into the skin was due to a lower 
abundance of CC chemokines. 
D6 may not just have an impact on the level of chemokines but also indirectly 
affect nearby leukocytes. In turn, this may affect the function and recruitment 
of  leukocytes  into  the  skin.  Degranulation  of  mast  cells  can  be  mediated  by 
chemokines,  such  as  CCL3  binding  to  CCR1  (Miyazaki  et  al.,  2005).  One 
possibility is that D6 may affect degranulation of mast cells by scavenging CCL3 
resulting  in  a  reduction  of  the  levels  of  histamine  secreted  from  mast  cells. 
Histamine mediates vasodilatation and is required for leukocyte infiltration into 
tissues.  
The  ability  of  K14D6  mice  to  dampen  down  cutaneous  inflammation  suggests 
that  D6  has  the  potential  to  be  therapeutic.  By  generating  K14D6  transgenic 
mice, we have used a prophylactic approach. Therefore, the therapeutic ability 
of D6 remains to be examined. To assess this, one approach would be to induce 
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rescue the phenotype of the D6 null mice, i.e. dampen down the exaggerated 
skin  inflammation.  This  could  be  tested  using  a  ‘gene  gun’,  also  known  as 
particle mediated gene delivery (Yang et al., 2001). This method involves gold 
particles coated with plasmid DNA and directly delivered at high speed into the 
target tissue. In D6 null mice, skin inflammation would be initiated using the TPA 
induced inflammation model and then D6 would be expressed in the skin of the 
D6 null mice using the gene gun. The type of promoter used within the plasmid 
would determine the location of transgene expression. For example, using a CMV 
promoter, genes are expressed in the epidermis and dermis of the skin whereas 
when using a K14 promoter, genes are only expressed in the epidermis (Lin et 
al., 2001a). The gene gun technology has been used to deliver cytokines in vivo 
(Sun et al., 1995) and studies using IL 23 and IL 18 cDNA delivered by the gene 
gun  have  been  shown  to  have  anti tumour  effects  in  the  skin  (Wang  et  al., 
2004b). 
If  D6  was  indeed  therapeutic,  it  may  be  useful  in  a  variety  of  inflammatory 
diseases. In particular, pathologies involving CC chemokines could be targeted 
with  D6.  These  include  psoriasis,  atopic  dermatitis,  rheumatoid  arthritis, 
asthma, inflammatory bowel disease (as reviewed by D'Ambrosio et al., 2003). 
CC  chemokines  have  also  been  implicated  in  atherosclerosis  (Sheikine  and 
Hansson, 2004) and transplantation (Colvin and Thomson, 2002) 
In order to use D6 as a therapeutic agent against these diseases, development of 
additional methods to deliver D6 would be required. This could involve the use 
of viral delivery systems. Viral vectors are modified where their own viral genes 
are replaced with a gene of choice. The most common types of viruses used as 
vectors  for  gene  therapy  are  retroviruses,  adenoviruses  and  adeno associated 
viruses, all with different properties and length of time in which the transgene is 
expressed. There is evidence that CC chemokines can be targeted using viral 
based gene therapy in a murine model of atherosclerosis. A chemokine binding 
protein derived from Vaccinia virus can block chemokine activity (Alcami et al., 
1998) and gene therapy using an adenoviral mediated delivery system blocked 
CC chemokines (Bursill et al., 2006), inhibited recruitment of macrophages and 
reduced  atherosclerotic  plaque  formation  in  vivo  (Bursill  et  al.,  2004).  As 
adenoviral  gene  therapy  results  in  short term  transgene  expression,  the  viral 
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demonstrating that long term inhibition of CC chemokines resulted in reduction 
of  atherosclerotic  plaques  (Bursill  et  al.,  2009).  Alternative  methods  of  gene 
delivery,  which  are  non viral,  have  also  been  developed.  Non viral  methods 
include  the  use  of  naked  plasmid  DNA  and  synthetic  vectors  (Li  and  Huang, 
2000). So far, although these non viral methods are thought to be safer, the 
transfection efficiency of non viral therapy is lower than viral delivery methods. 
Another approach altogether would be to use peptides, based on a short linear 
sequence  from  D6.  Peptides  have  been  derived  based  on  the  sequences  of 
chemokine receptors. One example is  the synthesis of a peptide using a short N 
terminal fragment of CCR5 sequence (Chain et al., 2008). The peptide was used 
to  generate  antibodies  which  would  be  specific  for  CCR5  to  reduce  HIV 
infectivity (Chain et al., 2008). CCR3 is another receptor where peptides were 
synthesised based on the N terminus of the receptor to characterise the binding 
properties between CCR3 and CCL11 (Ye et al., 2000). The development of the 
best delivery method for D6 may depend on the type of disease, where D6 is to 
be targeted and whether expression of the transgene is only required for short 
term or longer. 
In vitro studies suggest that D6 does not seem to have the ability to signal (Fra 
et al., 2003) however, D6 may signal via other mechanisms that do not elicit a 
calcium  flux  response.  We  have  begun  to  examine  this  by  isolating  murine 
keratinocytes that express D6 ectopically at high levels and to determine the 
transcriptional  consequences  of  ligand  binding  using  microarray  technology. 
Keratinocytes are capable of producing chemokines such as CCL5 and CCL2 upon 
stimulation with IFN g or TNF a (Li et al., 1996), which contribute to recruiting 
leukocytes into the skin during inflammation. Therefore, D6 may have had an 
impact on cellular transcription within these cells or scavenged the chemokines 
produced from it. 
By analysing individual differential gene expression using rank products (Breitling 
et al., 2004b), one conclusion can be made from our microarray experiment. D6 
was expressed at higher levels in K14D6 keratinocytes compared to wild type. 
This was an expected result. By analysing groups of functional gene classes, our 
results from the microarray suggests that non ligated D6 may have an impact on 
the transcription of some genes, in particular, chemokines. Although we do not 
provide firm evidence of this, it would be intriguing to examine whether D6’s Vicky King, 2010      Chapter 6, 258 
 
ability to reduce the levels of CC chemokines, also regulates the transcription of 
these  genes.  It  is  of  note  that  as  a  functional  gene  class,  chemokines  were 
downregulated  in  keratinocytes  in  the  presence  of  non ligated  D6  (using  iGA 
analysis) particularly CXCL4, CCL6 and CCL9. CXCL4 is involved in the migration 
of T lymphocytes mediated by CXCR3B, a splice variant of CXCR3 (Lasagni et al., 
2003, Mueller et al., 2008). CCL6 and CCL9 are chemokines which to date have 
only been found in rodents, both which are able to bind to CCR1 (Lean et al., 
2002, Ma et al., 2004). It is interesting to note that CCL6 and CCL9 both contain 
an extended N terminal domain. Whilst there are no direct human homologues 
of CCL6 and CCL9, two chemokines CCL15 and CCL23 also contain extended N 
termini and have only been found in humans (Berger et al., 1993, Youn et al., 
1998). Studies have shown that all four can be truncated by proteases at their N 
termini,  which increases  their  signalling  and  chemotaxis  ability  through CCR1 
(Berahovich et al., 2005). In addition, N terminal truncated CCL15 and CCL23 
are detected at high levels in synovial fluid from rheumatoid arthritis patients 
(Berahovich  et  al.,  2005).  One  possibility  may  be  that  D6  inhibits  the 
transcription of these genes, although the mechanisms are unclear, to prevent 
their release and limit the levels of potential potent chemoattractants during 
the inflammatory response. It may be that D6 it is unable to scavenge these 
chemokines once they are cleaved by proteases during inflammation. Evidence 
has shown that D6 is not able to scavenge a truncated form of CCL22 (Bonecchi 
et al., 2004) although it is of note that neither human nor murine D6 has been 
shown  to  bind  CCL6,  CCL9,  CCL15  or  CCL23.  However,  by  inhibiting  the 
transcription of genes for CCL6, CCL9 and CXCL4, D6 may indirectly affect the 
recruitment of cells into the tissue.  
Other studies have examined the downstream consequences induced by CCL5 in 
human monocytes (Locati et al., 2002). CCL5 induced the upregulation of genes 
but  did  not  suppress  the  transcription  of  any  genes.  CCL5  induced  gene 
expression of several chemokines including CCL2, CCL3, CCL4 and CXCL8 as well 
as CCR1 and induced expression of molecules involved in matrix degradation, 
potentially amplifying leukocyte recruitment (Locati et al., 2002). Additionally, 
gene transcripts induced by CCL5 binding to CCR5 in human neuronal cells has 
also been examined. Upregulated genes induced by CCL5 included those involved 
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genes  (Valerio  et  al.,  2004).  Therefore,  depending  on  the  cell  type  and  the 
environment, chemokines can induce different transcriptional responses.  
The  microarray  data  generated  in  this  study  used  primary  cells  that  did  not 
normally express D6. Human lymphatic endothelial cells express D6 (Nibbs et al., 
2001,  Vetrano  et  al.,  2009)  however  D6  expression  is  lost  when  lymphatic 
endothelial cells have been cultured (Amatschek et al., 2007). It would be more 
suitable to use primary cells that express D6.  In keeping with this consideration, 
leukocytes  and  murine  B  cells  derived  from  the  spleen  have  been  found  to 
express D6 (McKimmie et al., 2008) and in a separate study, expression of D6 on 
splenic B cells was located in marginal zone B cells (Kin et al., 2008). Although 
what role D6 has on B cells remains to be determined. 
Studies performed in our lab illustrated that D6 was important in regulating the 
resolution  of  inflammation  (Jamieson  et  al.,  2005).  Jamieson  et  al., 
demonstrated that D6 null mice had enhanced levels of CC chemokines within 
the skin, which resulted in a psoriasis like pathology. We decided to determine 
whether there was any association between D6 levels and human psoriasis. We 
obtained skin biopsies from control, psoriatic and atopic dermatitis patients. In 
some psoriatic patients, we obtained lesional and uninvolved skin from the same 
patient.  Within  this  study,  examination  of  D6  transcript  levels  revealed  that 
there was no significant difference in D6 transcripts between atopic dermatitis, 
lesional psoriatic skin and control skin. Interestingly, D6 expression in psoriatic 
uninvolved  skin  was  8 fold  higher  than  control  and  psoriatic  lesional  skin. 
Analysis of individual psoriatic patients, where we had matching uninvolved and 
lesional skin, revealed that 9 out of the 10 patients had increased expression of 
D6 mRNA in their uninvolved skin compared to their lesional skin. These data 
suggest that D6 expression is dysregulated in psoriatic uninvolved skin. These 
data were obtained from matched samples in psoriatic patients and therefore 
are  internally  controlled,  further  strengthening  the  evidence  of  the 
dysregulation of D6 expression in psoriatic uninvolved skin. 
This led us to hypothesise that D6 is upregulated in uninvolved skin of psoriatic 
patients in order to suppress ongoing inflammation in the area. Gene expression 
profiles have revealed that there are differences between psoriatic lesional and 
uninvolved  skin  as  well  as  psoriatic  uninvolved  and  healthy  skin  (Itoh  et  al., Vicky King, 2010      Chapter 6, 260 
 
2005, Zhou et al., 2003). Differences have also been shown in cytokines levels 
such as TNF a and IL 1b (Uyemura et al., 1993) and expression levels of CXCL8 
and CCL5 higher in uninvolved skin than normal skin have been shown as well as 
increased mRNA expression of IL 17 and IFN g (Lowes et al., 2008). In addition, 
psoriatic lesional skin has increased transcript levels of IL 17A, IL 17F, IL 22 and 
IL 26, all Th17 derived cytokines, compared to normal skin (Wilson et al., 2007). 
Keratinocyte  treatment  with  IL 22  and  IL 17  resulted  in  upregulation  of 
antimicrobial  peptides  such  as  b defensins  (Liang  et  al.,  2006)  suggesting  a 
protective role for these cytokines in the skin. Indeed psoriatic lesions contain 
higher levels of antimicrobial peptides than normal skin (Harder and Schroder, 
2005). However, in addition to anti microbial properties, b defensins can also 
bind CCR6 (Yang et al., 1999) and attract CCR6
+ T cells, such as Th17 cells into 
the  skin.  Additionally,  Th17  cytokines  can  also  stimulate  CCL20  from 
keratinocytes  (Harper  et  al.,  2009)  which  can  also  bind  CCR6,  in  turn  this 
recruits more CCR6+ Th17 cells into the skin and contributes to skin pathology. 
Subcutaneous injection of IL 23, a cytokine which enhances the proliferation of 
Th17  cells  (Aggarwal  et  al.,  2003),  induced  a  psoriasis like  pathology  in  vivo 
(Chan et al., 2006) and IL 22 is a downstream mediator in this process (Zheng et 
al., 2007). IL 15 secretion can induce IL 17 (McInnes and Gracie, 2004) and has 
been  implicated  in  psoriasis.  Indeed,  the  use  of  anti IL 15  antibodies  in  vivo 
resulted in resolution of psoriatic lesions (Villadsen et al., 2003). It is of note 
that the pathology displayed in D6 null mice after induction of inflammation by a 
chemical stimulant was dependent on IL 15 and IL 17 (personal communication 
Prof. G. Graham) therefore further confirming its similarity to human psoriasis. 
The  presence  of  inflammatory  cytokines  and  chemokines  present  within  the 
uninvolved skin of psoriatic patients suggests the presence of ongoing low level 
inflammation. As a result, D6 may be enhanced in uninvolved psoriatic skin to 
prevent  a  psoriatic  lesion  occurring.  This  then  raises  the  question  of  how 
psoriatic lesions occur in these individuals, i.e. if D6 prevents psoriatic lesions in 
some areas, why does D6 not work in all areas. One possibility is that there is 
low level ongoing inflammation in the psoriatic skin and lesions form when a 
reduction in the expression level of D6 occurs. D6 can be dynamically regulated, 
McKimmie  et  al.,  have  shown  that  LPS  can  downregulate  D6  expression 
(McKimmie et al., 2008). Others have also shown that inflammatory mediators 
can upregulate D6 in a breast cancer cell line (Wu et al., 2008). This suggests 
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result in the downregulation of D6 levels and, in turn, a psoriatic lesion may 
erupt. A recent study revealed that D6 regulates the levels of IL 17 production 
by gd T cells in the later stages of colitis (Bordon et al., 2009) therefore it may 
be possible that the lack of D6 in the skin may lead to the dysregulation of the 
IL 17 levels in the skin and contribute to the pathology of psoriasis. 
Having examined the mRNA expression of D6 within psoriatic skin, we went on to 
examine  the  expression  of  the  D6  protein  within  the  skin.  Previous  studies 
revealed D6 protein to be expressed on lymphatic endothelial cells within the 
skin  (Nibbs  et al.,  2001)  and others  have shown  D6  expression on  leukocytes 
within atopic dermatitis skin (McKimmie et al., 2008). In this study, the clone of 
antibody  used  is  an  alternative  clone  to  that  used  previously  to  reveal  D6 
staining on lymphatic endothelial cells (Nibbs et al., 2001). The clone used in 
this study has been validated using HEK293 cells stably transfected with human 
D6  and  detected  by  western  blotting  and  flow  cytometry  (McCulloch  et  al., 
2008). For use in immunohistochemistry, anti human D6 staining was optimised 
using  placental  sections  as  a  positive  control  and  on  control  skin  sections. 
Staining  of  control  skin  sections  revealed  positive  D6  staining  on  leukocytes 
however,  lymphatic  endothelial  vessels  did  not  stain  positive  for  D6.  An 
explanation for this may be the use of different clones of antibody. One clone of 
antibody was specific for D6 expressed on lymphatic endothelial cells (Nibbs et 
al., 2001) whilst the other seems to be specific for D6 on leukocytes (McKimmie 
et  al.,  2008).  This  suggests  that  the  different  clones  of  the  anti human  D6 
antibodies have slightly altered specificities and bind different D6 epitopes on 
lymphatic endothelial cells and leukocytes. Different epitopes of D6 may occur 
because the N terminus of D6 is glycosylated and also contains tyrosine residues 
which are sulphated (Blackburn et al., 2004). Therefore, the antibody used in 
this study may be specific for one epitope revealed on leukocytes for which the 
other antibody has lower affinity. Different antibody specificities using different 
clones  of  antibodies  have  also  been  demonstrated  for  another  atypical 
chemokine  receptor,  DARC  (Chaudhuri  et  al.,  1997,  Nielsen  et  al.,  1997).  It 
would  be  interesting  to  determine  the  location  and  number  of  leukocytes 
expressing D6 in psoriatic skin, including uninvolved and lesional skin biopsies, 
compared to control skin. To determine the specific leukocyte subset expressing 
D6,  sections  could  be  co stained  using  antibodies  specific  for  each  subset  of 
leukocytes.  This  would  identify  the  leukocytes  involved  in  the  enhanced  D6 Vicky King, 2010      Chapter 6, 262 
 
expression in uninvolved psoriatic skin. The level of D6 protein expression by 
individual subsets of leukocytes could be determined by flow cytometry. 
With enhanced D6 expression in uninvolved skin of psoriatic patients compared 
to controls, we decided to examine peripheral blood to determine if enhanced 
expression within the skin was a general phenomenon or only located within the 
skin in psoriatic patients. We also extended the study into other inflammatory 
diseases such as PsA and RA and examined D6 expression within these diseases. 
Peripheral blood mononuclear cells (PBMCs) from psoriasis patients displayed a 
non significant  2.3 fold  increase  in  D6  mRNA  expression  over  normal  PBMCs 
whereas PsA PBMCs showed no significant change in mRNA expression and RA 
PBMCs showed a significant 2 fold decrease. However, GAPDH levels in PBMCs 
from  RA  patients  were  increased  compared  to  control  peripheral  blood 
mononuclear cells. Retrospectively, the housekeeping gene, GAPDH was not a 
suitable choice for a housekeeping gene for RA patients. In addition, there is 
evidence that GAPDH varies in nucleated blood cells between individuals (Bustin 
et al., 1999) and in peripheral blood cells from tuberculosis patients (Dheda et 
al.,  2004).  Subsequently,  since  completion  of  this  work,  a  colleague  has 
continued  the  research  into  psoriasis.  The  QPCR  of  peripheral  blood  from 
psoriasis  patients  has  been  repeated  using  TATA  binding  protein  as  the 
housekeeping  gene  and  with  increased  sample  size.  In  doing  so,  PBMCs  from 
psoriatic patients displayed a 10 fold increase in D6 mRNA expression compared 
to  controls,  which  correlates  with  the  enhanced  D6  expression  observed  in 
psoriatic  uninvolved  skin.  Further  work  is  required  to  determine  whether 
enhanced expression of D6 in psoriatic peripheral blood is restricted to a distinct 
subset of leukocytes. 
As mentioned above, before we had determined the problematic issue regarding 
GAPDH  in  this  context,  we  had  observed  a  2 fold  decrease  in  D6  transcripts 
within  peripheral  blood  of  RA  patients.  We  resolved  to  examine  surface  D6 
expression on specific leukocytes within peripheral blood to determine which 
cell types were expressing D6. Examination of D6 expression on specific subsets 
of leukocytes by flow cytometry revealed that expression of D6 was highest on B 
cells and dendritic cells. The trends in D6 expression on leukocyte subsets within 
control  peripheral  blood  correlated  with  previous  findings  (McKimmie  et  al., 
2008).  Surface  expression  of  D6  on  B  cells  and  mDCs  from  RA  patients  was Vicky King, 2010      Chapter 6, 263 
 
significantly increased on these cells compared to control B cells and mDCs. This 
data  contradicted  the  QPCR  data,  which  suggested  that  D6  transcripts  in 
peripheral blood of RA patients were 2 fold lower than control peripheral blood. 
Retrospectively, it may have been useful to examine D6 transcript expression in 
each of the subpopulations of leukocytes from the same samples in which D6 
protein expression was analysed.  
All  leukocytes  analysed  by  flow  cytometry  revealed  that  D6  expression  was 
increased  on  all  cells  in  RA  peripheral  blood  but  this  was  only  significantly 
different in B cells and mDCs compared to control. One reason for this enhanced 
D6  expression  may  be  that  RA  can  be  considered  a  systemic  inflammatory 
disease (with increased inflammatory mediators in the blood). Many chemokines 
and their receptors  are  implicated  in  the pathology  of  RA  (Szekanecz et al., 
2003). Within the blood, there are increased levels of inflammatory mediators 
and chemokines.  Increased levels of CCR1 and CCR5  on RA peripheral blood 
monocytes and increased levels of CCL5 and CCL15 have also been reported in 
rheumatoid arthritis peripheral blood compared to controls (Haringman et al., 
2006). An inflammatory environment surrounds PBMCs and it is possible that D6 
is upregulated in the peripheral blood of RA patients to try to counteract the 
systemic inflammation. It would be interesting to correlate the expression of D6 
on leukocytes from RA patients with the circulating levels of chemokines within 
their  blood.  This  could  be  analysed  by  collecting  peripheral  blood  from  RA 
patients and using half to isolate PBMCs to examine surface D6 expression by 
flow cytometry and from the other half, plasma would be extracted to examine 
the  levels  of  multiple  chemokine  at  the  same  time.  The  chemokines  and 
cytokines  would  be  analysed  using  Luminex  technology.  In  addition,  as 
mentioned, a significant increase in D6 protein expression was observed in B 
cells  and  mDCs  in  RA  patients  compared  to  controls.  Both  these  cells  are 
involved  in  the  adaptive  response  and  play  a  role  in  antigen  presentation. 
Therefore, D6 may be involved in the adaptive immune response. A recent study 
has revealed D6 expression on leukocytes within human rheumatoid synovium 
suggesting  that  D6  is  involved  in  the  pathogenesis  of  rheumatoid  arthritis 
(McKimmie et al., 2008). The exact role of D6 in human or murine models of 
arthritis has not yet been determined. Vicky King, 2010      Chapter 6, 264 
 
Inflammation is an important mechanism within the body. However, there are 
many  diseases  driven  by  chronic  inflammation,  which  are  detrimental  to  our 
body.  The  work  presented  here  shows  that  increased  expression  of  D6  can 
suppress cutaneous inflammation in vivo; therefore, D6 has the potential to be 
of therapeutic value. Our microarray studies have indicated that non ligated D6 
may have a negative impact on the transcription of certain genes. Further work 
using a primary cell that naturally expresses D6 is required to determine the 
transcriptional  response  of  cells  to  D6  after  ligand  binding.  Additionally,  this 
study shows evidence to suggest that D6 is dysregulated in inflammatory diseases 
suggesting D6 is involved in the pathogenesis of these inflammatory diseases. 
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Appendix One  
Terminology used on the web pages automatically generated by FunAlyse, 
microarray data analysis software 
http://www.gla.ac.uk/functionalgenomics/rp/termin.html 
 
Experiment report 
  
Software 
This refers to software that actually runs the whole analysis automatically. In 
particular it:  
·  ·         Generates a directory structure for a project and its experiments  
·  ·         Manages the security of the project 
·  ·         Performs RMA low-level analysis  
·  ·         Performs RP identification of differentially expressed genes for a 
number of between-group comparisons  
·  ·         Functionally annotates the list of RP-identified top genes  
·  ·         Performs iGA to find differentially expressed functional classes of 
genes (written by Rainer Breitling).  
·  ·         Presents the RP and iGA results in form of web pages and/or 
downloadable tab-delimited text files suitable for reading in Excel. 
The software has been written and implemented by Pawel Herzyk in the Autumn 
2003 – Spring 2004. 
 
Project  
Project refers to data that belongs to a particular researcher or a group of 
researchers. Each PI (principal investigator) can only have one project that can be 
divided into many experiments. Each project has associated:  
·  ·         Name - this is usually constructed from the PI's name e.g. john_dav 
would be a name of a project owned by John Davis.  
·  ·         Class - this could be Microarray or Proteomics  
·  ·         Type - e.g. Affymetrix or Spotted depending on the type of 
microarrays used  
  
Experiment  
Each project can be divided into experiments. Each experiment contains data from 
a number of replicated (or not) samples corresponding to different conditions. 
 
Array  
This refers to an identifiable type of array e.g. U133 is the Affymetrix human array 
HG-U133. 
 
Chip  318 
 
Some Affymetrix arrays may consist of several subarrays. E.g. HG-U133 array is in 
fact represented by two arrays HG-U133A and HG-U133B. In this case we say that 
the array has two chips A and B. If the array has only one chip it is denoted as N 
(for none). 
 
 
 
Normalisation  
This really is a shorthand for low-level analysis. In case of Affymetrix data this 
consists of  
·  ·         Background correction  
·  ·         Multichip normalisation on the probe level  
·  ·         Summary of the log-normalised probe level data into a probe-set level 
data  
By default we use Robust Multichip Average (RMA) method implemented in 
module Affy in the Bioconductor microarray analysis software. 
 
Differential Expression  
A method of identification of differentially expressed genes between two groups of 
replicated samples. We use the RankProducts method(RP) developed in University 
of Glasgow. 
 
Differentially expressed gene classes  
A method for identification of functional gene classes that are differentially 
expressed in a given comparison. We use the Iterative Group Analysis method 
developed in the University of Glasgow.  
 
Baseline  
For every comparison between two groups of replicated samples we select one of 
the groups as a reference (baseline). This is usually done upon suggestion from a 
researcher who owns the data.  
 
Treatment  
This refers to the group of replicated samples that has not been selected as baseline. 
The software analyses the expression of a treatment group with respect to the 
baseline. 
 
Direction  
This refers to the direction of the differential expression of the treatment with 
respect to the baseline:  
·  ·         Positive - means a list of genes with significantly higher expression in 
the treatment group than in the baseline group  
·  ·         Negative - means a list of genes with significantly lower expression in 
the treatment group than in the baseline group  
RPhtml  
Results of RP in html format 
 
RPtext  
Results of RP in tab-delimited text format 
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iGAcla 
Results of iGA in Classic mode (html format). Look at paragraph Mode in section 
iGA report for more explanations. 
 
iGArep 
Results of iGA in Representative mode (html format). Look at paragraph Mode in 
section iGA report for more explanations. 
RP report 
Comparison  
This refers to a comparison between two groups of replicated samples. E.g.: 
Samples: A,B,C vs Samples: D,E,F means that samples A,B,C 
correspond to the treatment group and D,E,F correspond to the baseline group. 
 
Probe-set ID  
The Affymetrix probe-set identificator 
 
RPscore  
This is a measure of differential expression calculated by the RP method. For every 
gene this is calculated as a geometric mean of fold-change ranks over the number 
of all possible between-chip comparisons contributing to a given between-group 
comparison. 
 
FDR  
This is a conservative estimate of False Discovery Rate. If you cut the differentially 
expressed gene-list at the particular position associated with a particular FDR then 
it shows the expected percentage of false positives. 
 
FCrma  
Before FunAlyse version 1.4.1 this is a mean fold-change over all possible 
between-chip comparisons contributing to a given between-group comparison.  
From FunAlyse version 1.4.1 onwards this is calculated as an antilog of a mean 
log-fold-change over all possible between-chip comparisons contributing to a given 
between-group comparison.  
In both cases if you have two groups of three Affymetrix chips the FCrma is 
calculated over all nine comparisons.  
 
FCnom  
It has been demonstrated in the experiment where selected genes were spiked-in at 
known concentrations on the HG-U95A chip that the fold-changes calculated after 
RMA low-level analysis are significantly lower than the nominal fold-changes 
calculated from the spiked-in gene concentrations. The relation between these two 
fold-changes was calculated by a fitting procedure:  
log2(rma FC) = 0.61 x log2(nominal FC)  
Consequently, the FCnom corresponds to the mean nominal fold-change obtained 
from the rma fold-changes using the above equation over all possible between-chip 
comparisons contributing to a given between-group comparison. Please, treat it 
with caution as it is not known how universal the above equation is. Consult Figure 
6 in the original paper Cope et al. 2003 (PubMed abstract).  
 
Gene annotation database  320 
 
This is a database that contains functional annotation of your genes. Every gene in 
the reported list of differentially expressed genes has a hyperlink to it. Currently, 
we use the following databases:  
·  ·         Human, Mouse and Rat - SOURCE database  
·  ·         Arabidopsis - MIPS and TAIR databases  
·  ·         Drosophila - FlyBase  
·  ·         Yeast - SGD database  
  
 
Gene symbol  
Common gene symbol used by biologists. 
 
Gene ID  
Publicly used gene identificator. 
 
Title  
Short functional annotation of a gene. This is very brief, you shouldn't rely on it too 
much. 
iGA report 
Mode  
The iGA module in the FunAlyse software can work in two modes: Classic - all 
probe-sets on the chip are taking part in the iGA calculations. Representative - 
only one probe-set per gene is selected. This is to remove a bias towards a 
particular groups in case more then one probe-set represent a gene contributing to 
this group. A probe set producing the best RPscore in a given comparison 
(calculated seperately for positive and negative expression) is selected as a 
representative for that gene. The non-redundant set of genes is defined differently 
for different organisms. For Human, Mouse and Rat they are defined using Unigene 
IDs, for Arabidopsis and Yeast they are defined on the base of gene IDs whilst for 
Drosophila it is based on gene symbols. 
 
Number of probe-sets on the chip  
A number of Affymetrix probe-sets on a given chip. In the Classic mode some 
probe-sets may refer to the same gene. 
 
Number of annotated probe-sets  
A number of probe-sets on a given chip that have functional annotation in the 
current Affymetrix annotation file that has been used for functional group 
construction. 
 
Number of groups  
A total number of functionally annotated gene-groups. They are pre-constructed 
independently of the microarray experiment. Usually we use GeneOntology (GO) 
annotations present in the Affymetrix annotation file but you may advise us to use 
other annotation sources. 
 
Number of singletons  
A number of functionally annotated gene-groups that contain a single gene. These 
are not particularly useful for iGA. 
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Significance threshold  
A threshold for P-value changed. P-values lower than the threshold are considered 
statistically significant. (see also P-value changed) 
 
File Name  
A name of the input file that contains full list of genes sorted by RankProducts 
score RPscore that is our measure of gene differential expression.  
Annotations  
This is a name of the Affymetrix functional annotation file used for the functional 
group construction. 
 
Top changed groups  
A list of significantly differentially expressed gene-groups. 
 
Group Members  
Number of probe-sets that belong to a particular group. 
 
Changed Members  
Number of group members that have actually contributed to achieving a given P-
value changed for this group. 
 
P-value changed  
This tells you what is a probability of a random event that 'that many' of changed 
members out of 'that many' group members has been found 'that high' on the RP 
list of 'that many' sorted genes. This is calculated from the hyper-geometric 
distribution. Consult Figure 1 in the original paper 
 
P-value  
Going down from the top of the RP list, for every encountered subset of a particular 
gene group we calculate the p-value that tells you how probable a random event is 
that such subset was found 'that high' on the RP list. This is calculated from the 
hyper-geometric distribution. In this context P-value changed is a smallest p-value 
over all the above subsets. Consult Figure 1 in the original paper 
 
Percent changed  
This is simply changed members over group members times 100. 
Rank  
This is rank of a particular gene in the list of differentially expressed genes. This 
list was created from the RP list by exclusion of genes that are not assigned to the 
functional gene-groups. 
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Appendix Two 
The Rank Product (RP) differential expression analysis report 
 
 
 
General Information 
Experiment   VK1mouse4302 
Normalisation   rma across replicates 
Chip   one chip only 
Comparison   Treatment samples: K14D6 Control vs Baseline samples: WT Control 
RP comparison   not paired 
Direction   Positive 
 
0  Probe-set ID  RPscore  FDR  FC_rma FC_nom "SOURCE" "EntrezGene"  Gene Symbol  Title 
1  1422111_at  1.00  0.00  49.59  603.20  BE631540  59289  Ccbp2  chemokine binding 
protein 2 
2  1420512_at  206.84  15.50  2.66  4.96  NM_020265  56811  Dkk2  dickkopf homolog 2 
(Xenopus laevis) 
3  1450079_at  348.58  43.33  1.81  2.65  AK012873  27206  Nrk  Nik related kinase 
4  1450871_a_at  359.51  34.50  1.48  1.90  X17502  12035  Bcat1 
branched chain 
aminotransferase 1, 
cytosolic 
5  1449484_at  389.02  32.20  1.56  2.08  AF031035  20856  Stc2  stanniocalcin 2 
6  1418547_at  470.76  47.67  1.62  2.21  NM_009364  21789  Tfpi2  tissue factor pathway 
inhibitor 2 
7  1437935_at  507.32  NA  1.57  2.09  BB821151  75033  4930486G11Rik  RIKEN cDNA 
4930486G11 gene 
8  1420991_at  511.93  NA  1.55  2.05  AK009959  107765  Ankrd1 
ankyrin repeat 
domain 1 (cardiac 
muscle) 
9  1448816_at  529.66  NA  1.75  2.51  NM_008968  19223  Ptgis 
prostaglandin I2 
(prostacyclin) 
synthase 
10  1421038_a_at  531.04  NA  1.12  1.20  NM_008433  16534  Kcnn4 
potassium 
intermediate/small 
conductance calcium-
activated channel, 
subfamily N, member 
4 
11  1416405_at  607.93  NA  1.71  2.41  BC019502  12111  Bgn  biglycan 
12  1448323_a_at  643.49  NA  1.71  2.40  BC019502  12111  Bgn  biglycan 
13  1416200_at  667.15  NA  1.65  2.27  NM_133775  77125  9230117N10Rik  RIKEN cDNA 
9230117N10 gene 
14  1423607_at  680.73  NA  1.94  2.96  AK014312  17022  Lum  lumican 
15  1427262_at  691.34  NA  1.87  2.78  L04961  213742  Xist  inactive X specific 
transcripts 
16  1418815_at  723.08  NA  1.43  1.79  BC022107  12558  Cdh2  cadherin 2 
17  1454672_at  798.97  NA  1.87  2.78  BE952212  ---  ---  --- 
18  1436448_a_at  821.49  NA  1.60  2.15  AA833146  19224  Ptgs1 
prostaglandin-
endoperoxide 
synthase 1 
19  1455626_at  829.09  NA  1.07  1.12  AA987181  15405  Hoxa9  homeo box A9 
20  1451016_at  832.05  NA  1.38  1.69  BB540964  15983  Ifrd2  interferon-related 323 
 
developmental 
regulator 2 
21  1416778_at  841.85  NA  1.68  2.34  BE197945  20324  Sdpr  serum deprivation 
response 
22  1434278_at  855.72  NA  1.34  1.62  BG976607  17772  Mtm1  X-linked myotubular 
myopathy gene 1 
23  1424186_at  887.84  NA  1.44  1.82  BG074158  67896  2610001E17Rik  RIKEN cDNA 
2610001E17 gene 
24  1439774_at  913.38  NA  1.62  2.20  BB051738  18933  Prrx1  paired related 
homeobox 1 
25  1415834_at  946.19  NA  1.24  1.42  NM_026268  67603  Dusp6  dual specificity 
phosphatase 6 
26  1416072_at  956.02  NA  1.45  1.85  NM_133654  12490  Cd34  CD34 antigen 
27  1425458_a_at  966.35  NA  1.37  1.67  AF022072  14783  Grb10  growth factor receptor 
bound protein 10 
28  1436319_at  980.06  NA  1.31  1.55  BB751459  240725  Sulf1  sulfatase 1 
29  1434877_at  984.15  NA  1.53  2.01  AI152800  18164  Nptx1  neuronal pentraxin 1 
30  1453252_at  994.13  NA  1.34  1.61  AK010138  71916  Dus4l 
dihydrouridine 
synthase 4-like (S. 
cerevisiae) 
31  1428960_at  1004.42  NA  1.35  1.63  AK017056  71233  4933434I06Rik  RIKEN cDNA 
4933434I06 gene 
32  1436936_s_at  1014.15  NA  1.74  2.49  BG806300  213742  Xist  inactive X specific 
transcripts 
33  1425415_a_at  1016.60  NA  1.36  1.65  U75214  20510  Slc1a1 
solute carrier family 1 
(neuronal/epithelial 
high affinity glutamate 
transporter, system 
Xag), member 1 
34  1427610_at  1020.80  NA  1.39  1.72  BC026631  109620  Dsp  desmoplakin 
35  1449519_at  1023.57  NA  1.36  1.65  NM_007836  13197  Gadd45a 
growth arrest and 
DNA-damage-
inducible 45 alpha 
36  1415998_at  1035.12  NA  1.38  1.69  NM_011694  22333  Vdac1  voltage-dependent 
anion channel 1 
37  1437889_x_at  1046.43  NA  1.57  2.09  AI931862  12111  Bgn  biglycan 
38  1427263_at  1065.74  NA  1.35  1.63  L04961  213742  Xist  inactive X specific 
transcripts 
39  1428944_at  1089.81  NA  1.42  1.78  BB417360  231380  5730469D23Rik  RIKEN cDNA 
5730469D23 gene 
40  1448590_at  1187.50  NA  1.63  2.24  NM_009933  12833  Col6a1  procollagen, type VI, 
alpha 1 
41  1436698_x_at  1189.66  NA  1.26  1.47  AV167328  407831  BC054438  cDNA sequence 
BC054438 
42  1423606_at  1208.13  NA  1.57  2.09  BI110565  50706  Postn  periostin, osteoblast 
specific factor 
43  1438989_s_at  1236.84  NA  1.31  1.56  BB386167  320860  B130021B11Rik  RIKEN cDNA 
B130021B11 gene 
44  1455121_at  1248.43  NA  1.30  1.54  BB553784  212391  A630025C20Rik  RIKEN cDNA 
A630025C20 gene 
45  1454904_at  1261.59  NA  1.29  1.52  BG976607  17772  Mtm1  X-linked myotubular 
myopathy gene 1 
46  1421917_at  1262.81  NA  1.47  1.88  AW537708  18595  Pdgfra 
platelet derived 
growth factor 
receptor, alpha 
polypeptide 
47  1423271_at  1266.24  NA  1.31  1.57  AV239646  14619  Gjb2 
gap junction 
membrane channel 
protein beta 2 
48  1423110_at  1271.66  NA  1.67  2.32  BF227507  ---  ---  --- 
49  1450196_s_at  1289.33  NA  1.31  1.56  NM_030678  14936 14937  Gys1 /// Gys3 
glycogen synthase 1, 
muscle /// glycogen 
synthase 3, brain 
50  1431295_a_at  1318.68  NA  1.31  1.56  AK016910  71116  Stx18  syntaxin 18 
51  1416121_at  1323.10  NA  1.72  2.43  M65143  16948  Lox  lysyl oxidase 
52  1450757_at  1324.74  NA  1.38  1.69  NM_009866  12552  Cdh11  cadherin 11 
53  1444368_at  1328.00  NA  1.30  1.54  BE956442  110834  Chrna3  Cholinergic receptor, 324 
 
nicotinic, alpha 
polypeptide 3 
(Chrna3), mRNA 
54  1420992_at  1331.31  NA  1.45  1.85  AK009959  107765  Ankrd1 
ankyrin repeat 
domain 1 (cardiac 
muscle) 
55  1450857_a_at  1334.16  NA  1.81  2.64  BF227507  12843  Col1a2  procollagen, type I, 
alpha 2 
56  1452445_at  1339.62  NA  1.33  1.60  BC026874  338365  Slc41a2  solute carrier family 
41, member 2 
57  1453783_at  1344.55  NA  1.32  1.59  BE864772  70733  6330411E07Rik  RIKEN cDNA 
6330411E07 gene 
58  1449735_at  1372.35  NA  1.31  1.56  BG074689  ---  ---  --- 
59  1418601_at  1383.54  NA  0.96  0.94  NM_011921  26358  Aldh1a7 
aldehyde 
dehydrogenase 
family 1, subfamily A7 
60  1415802_at  1390.45  NA  1.29  1.51  NM_009196  20501  Slc16a1 
solute carrier family 
16 (monocarboxylic 
acid transporters), 
member 1 
61  1442845_at  1412.33  NA  1.27  1.48  AV320517  320395  C130075A20Rik  RIKEN cDNA 
C130075A20 gene 
62  1435945_a_at  1437.93  NA  0.95  0.92  BG865910  16534  Kcnn4 
potassium 
intermediate/small 
conductance calcium-
activated channel, 
subfamily N, member 
4 
63  1418736_at  1456.53  NA  1.32  1.58  BC003835  26879  B3galt3 
UDP-Gal:betaGlcNAc 
beta 1,3-
galactosyltransferase, 
polypeptide 3 
64  1454174_a_at  1465.43  NA  1.29  1.51  AK021190  77644  C330007P06Rik  RIKEN cDNA 
C330007P06 gene 
65  1456292_a_at  1479.27  NA  1.43  1.79  AV147875  22352  Vim  vimentin 
66  1421817_at  1481.12  NA  1.20  1.35  AK019177  14782  Gsr  glutathione reductase 
1 
67  1422995_at  1485.51  NA  1.29  1.52  NM_138313  171543  Bmf  Bcl2 modifying factor 
68  1419404_s_at  1487.00  NA  1.27  1.49  NM_009173  20437 20438  Siah1a /// 
Siah1b 
seven in absentia 1A 
/// seven in absentia 
1B 
69  1435831_at  1515.03  NA  1.09  1.15  BB427704  22268  Upk1b  uroplakin 1B 
70  1449475_at  1541.88  NA  1.31  1.55  NM_138652  192113  Atp12a 
ATPase, H+/K+ 
transporting, 
nongastric, alpha 
polypeptide 
71  1428796_at  1554.27  NA  1.29  1.53  AK017436  74503  5530401J07Rik  RIKEN cDNA 
5530401J07 gene 
72  1425092_at  1559.88  NA  1.16  1.28  AF183946  320873  Cdh10  cadherin 10 
73  1452250_a_at  1581.58  NA  1.38  1.69  BI455189  12834  Col6a2  procollagen, type VI, 
alpha 2 
74  1423744_x_at  1589.37  NA  1.31  1.56  BC006682  26905  Eif2s3x 
eukaryotic translation 
initiation factor 2, 
subunit 3, structural 
gene X-linked 
75  1449244_at  1621.01  NA  1.35  1.63  BC022107  12558  Cdh2  cadherin 2 
76  1418157_at  1625.70  NA  1.32  1.58  NM_010151  13865  Nr2f1 
nuclear receptor 
subfamily 2, group F, 
member 1 
77  1430676_at  1636.38  NA  1.30  1.54  AK019854  12823  Col19a1  procollagen, type 
XIX, alpha 1 
78  1450315_at  1638.11  NA  1.28  1.49  NM_030736  81011  V1rd14  vomeronasal 1 
receptor, D14 
79  1451090_a_at  1643.54  NA  1.30  1.53  BC006682  26905  Eif2s3x 
eukaryotic translation 
initiation factor 2, 
subunit 3, structural 
gene X-linked 
80  1437672_at  1643.85  NA  1.27  1.48  AV286336  16369  Irs3  insulin receptor 
substrate 3 325 
 
81  1418926_at  1648.07  NA  1.36  1.66  NM_011546  21417  Zfhx1a  zinc finger homeobox 
1a 
82  1427883_a_at  1666.33  NA  1.28  1.50  AW550625  12825  Col3a1  procollagen, type III, 
alpha 1 
83  1440910_at  1680.56  NA  1.35  1.64  AW495307  Mm.381907  ---  CDNA clone 
IMAGE:5252333 
84  1450004_at  1685.90  NA  1.08  1.14  NM_021367  53603  Tslp  thymic stromal 
lymphopoietin 
85  1426255_at  1696.96  NA  1.29  1.52  M20480  18039  Nefl  neurofilament, light 
polypeptide 
86  1446584_at  1706.52  NA  1.29  1.52  BB485470  76299  Txndc4 
Thioredoxin domain 
containing 4 
(endoplasmic 
reticulum) (Txndc4), 
mRNA 
87  1422567_at  1709.08  NA  1.29  1.51  NM_022018  63913  Niban  niban protein 
88  1459085_at  1711.18  NA  1.27  1.49  BG066528  52305  D1Ertd259e 
DNA segment, Chr 1, 
ERATO Doi 259, 
expressed 
89  1420650_at  1717.02  NA  1.27  1.48  NM_007496  11906  Atbf1  AT motif binding 
factor 1 
90  1430342_at  1717.63  NA  1.28  1.51  BF011273  67589  4930518J20Rik  RIKEN cDNA 
4930518J20 gene 
91  1433491_at  1728.77  NA  1.27  1.49  BE951907  13822  Epb4.1l2  erythrocyte protein 
band 4.1-like 2 
92  1437219_at  1729.38  NA  1.33  1.59  AW553541  16001  Igf1r 
Insulin-like growth 
factor I receptor 
(Igf1r), mRNA 
93  1416473_a_at  1735.26  NA  1.32  1.58  NM_020043  56741  Nope  neighbor of Punc E11 
94  1449351_s_at  1736.95  NA  1.18  1.31  NM_019971  54635  Pdgfc 
platelet-derived 
growth factor, C 
polypeptide 
95  1450078_at  1760.15  NA  1.32  1.57  AK012873  27206  Nrk  Nik related kinase 
96  1460039_at  1760.67  NA  1.30  1.53  BB035924  243653  Clec1a  C-type lectin domain 
family 1, member a 
97  1437556_at  1761.93  NA  1.32  1.58  BF147593  80892  Zfhx4  zinc finger 
homeodomain 4 
98  1458640_at  1768.52  NA  1.29  1.51  BB284122  Mm.37652  --- 
6 days neonate skin 
cDNA, RIKEN full-
length enriched 
library, 
clone:A030007I19 
product:hypothetical 
protein, full insert 
sequence 
99  1438148_at  1774.82  NA  1.10  1.17  BB829808  330122  Gm1960  gene model 1960, 
(NCBI) 
100  1451332_at  1786.80  NA  1.22  1.39  BC021376  225207  Zfp521  zinc finger protein 
521 
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The Rank Product (RP) differential expression analysis report 
 
 
General Information 
Experiment   VK1mouse4302 
Normalisation   rma across replicates 
Chip   one chip only 
Comparison   Treatment samples: WT + CCL3 vs Baseline samples: WT Control 
RP comparison   not paired 
Direction   Positive   
 
0  Probe-set ID  RPscore  FDR  FC_r
ma 
FC_no
m  "SOURCE"  "EntrezGe
ne"  Gene Symbol  Title 
1  1424754_at  145.79  14.00  2.46  4.38  BC024402  109225  Ms4a7 
membrane-spanning 
4-domains, subfamily 
A, member 7 
2  1448995_at  171.94  9.50  2.10  3.39  NM_019932  56744  Cxcl4  chemokine (C-X-C 
motif) ligand 4 
3  1448748_at  189.97  8.33  2.61  4.83  AF181829  56193  Plek  pleckstrin 
4  1427883_a_at  224.73  10.25  3.72  8.61  AW550625  12825  Col3a1  procollagen, type III, 
alpha 1 
5  1420512_at  228.64  8.20  3.50  7.79  NM_020265  56811  Dkk2  dickkopf homolog 2 
(Xenopus laevis) 
6  1418547_at  236.57  7.00  3.11  6.44  NM_009364  21789  Tfpi2  tissue factor pathway 
inhibitor 2 
7  1423607_at  287.28  9.86  3.29  7.06  AK014312  17022  Lum  lumican 
8  1450663_at  288.57  8.75  2.86  5.61  NM_011581  21826  Thbs2  thrombospondin 2 
9  1438989_s_at  288.84  7.78  2.48  4.42  BB386167  320860  B130021B11Ri
k 
RIKEN cDNA 
B130021B11 gene 
10  1416136_at  296.29  7.20  2.71  5.12  NM_008610  17390  Mmp2  matrix 
metallopeptidase 2 
11  1436970_a_at  303.38  7.55  3.20  6.74  AA499047  18596  Pdgfrb 
platelet derived 
growth factor 
receptor, beta 
polypeptide 
12  1448590_at  314.50  7.50  3.25  6.91  NM_009933  12833  Col6a1  procollagen, type VI, 
alpha 1 
13  1448326_a_at  319.04  7.15  2.86  5.59  NM_013496  12903  Crabp1  cellular retinoic acid 
binding protein I 
14  1452250_a_at  322.66  7.00  2.96  5.92  BI455189  12834  Col6a2  procollagen, type VI, 
alpha 2 
15  1417381_at  329.93  7.00  2.13  3.47  NM_007572  12259  C1qa 
complement 
component 1, q 
subcomponent, alpha 
polypeptide 
16  1439364_a_at  335.60  6.88  2.65  4.95  BF147716  17390  Mmp2  matrix 
metallopeptidase 2 
17  1422317_a_at  339.17  6.71  2.78  5.34  NM_010743  17082  Il1rl1  interleukin 1 receptor-
like 1 
18  1435943_at  373.12  8.39  2.55  4.63  AI647687  13479  Dpep1  dipeptidase 1 (renal) 327 
 
19  1449154_at  394.70  9.68  2.21  3.68  NM_007729  12814  Col11a1  procollagen, type XI, 
alpha 1 
20  1419598_at  397.90  9.35  2.16  3.53  NM_026835  68774  Ms4a6d 
membrane-spanning 
4-domains, subfamily 
A, member 6D 
21  1436905_x_at  415.35  9.67  1.88  2.82  BB218107  16792  Laptm5 
lysosomal-associated 
protein 
transmembrane 5 
22  1423606_at  417.60  9.32  2.82  5.47  BI110565  50706  Postn  periostin, osteoblast 
specific factor 
23  1418157_at  421.55  9.22  2.10  3.38  NM_010151  13865  Nr2f1 
nuclear receptor 
subfamily 2, group F, 
member 1 
24  1450757_at  437.53  10.04  2.56  4.67  NM_009866  12552  Cdh11  cadherin 11 
25  1448929_at  439.43  9.72  1.97  3.03  NM_028784  74145  F13a1  coagulation factor 
XIII, A1 subunit 
26  1419100_at  455.66  10.42  2.15  3.51  NM_009252  20716  Serpina3n 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 3N 
27  1416414_at  461.95  10.37  1.85  2.75  NM_133918  100952  Emilin1  elastin microfibril 
interfacer 1 
28  1449368_at  469.99  10.50  2.97  5.97  NM_007833  13179  Dcn  decorin 
29  1450857_a_at  470.68  10.17  3.18  6.68  BF227507  12843  Col1a2  procollagen, type I, 
alpha 2 
30  1416121_at  472.91  9.97  3.12  6.45  M65143  16948  Lox  lysyl oxidase 
31  1438672_at  475.20  9.87  1.96  3.02  BI134721  170736  Parvb  Parvin, beta (Parvb), 
mRNA 
32  1421425_a_at  476.88  9.62  1.80  2.61  NM_030598  53901  Dscr1l1 
Down syndrome 
critical region gene 1-
like 1 
33  1435477_s_at  482.60  9.64  2.03  3.19  BM224327  14130  Fcgr2b  Fc receptor, IgG, low 
affinity IIb 
34  1416405_at  489.25  9.65  2.93  5.82  BC019502  12111  Bgn  biglycan 
35  1418666_at  506.88  10.20  1.75  2.50  NM_008987  19288  Ptx3  pentraxin related 
gene 
36  1423110_at  506.90  9.92  2.96  5.91  BF227507  ---  ---  --- 
37  1424186_at  539.75  11.89  2.80  5.40  BG074158  67896  2610001E17Rik  RIKEN cDNA 
2610001E17 gene 
38  1437558_at  540.30  11.61  1.85  2.74  BM119919  320860  B130021B11Ri
k 
RIKEN cDNA 
B130021B11 gene 
39  1419728_at  546.18  11.62  1.93  2.95  NM_009141  20311  Cxcl5  chemokine (C-X-C 
motif) ligand 5 
40  1418454_at  549.59  11.47  2.01  3.15  NM_015776  50530  Mfap5  microfibrillar 
associated protein 5 
41  1448323_a_at  549.62  11.22  2.98  5.99  BC019502  12111  Bgn  biglycan 
42  1420498_a_at  552.08  11.05  2.16  3.53  NM_023118  13132  Dab2  disabled homolog 2 
(Drosophila) 
43  1419473_a_at  566.01  11.88  1.99  3.10  NM_031161  12424  Cck  cholecystokinin 
44  1423537_at  566.36  11.61  2.13  3.45  BB622036  14432  Gap43  growth associated 
protein 43 
45  1421917_at  569.08  11.51  2.40  4.22  AW537708  18595  Pdgfra 
platelet derived 
growth factor 
receptor, alpha 
polypeptide 
46  1436698_x_at  575.44  11.67  1.92  2.91  AV167328  407831  BC054438  cDNA sequence 
BC054438 
47  1416200_at  582.79  11.77  1.90  2.87  NM_133775  77125  9230117N10Rik  RIKEN cDNA 
9230117N10 gene 
48  1452905_at  585.62  11.65  2.60  4.79  AV015833  17263 
330814  Gtl2 /// Lphn1 
GTL2, imprinted 
maternally expressed 
untranslated mRNA /// 
latrophilin 1 
49  1419248_at  591.51  11.67  2.01  3.13  AF215668  19735  Rgs2  regulator of G-protein 
signaling 2 
50  1420380_at  628.06  13.48  2.33  3.99  AF065933  20296  Ccl2  chemokine (C-C 
motif) ligand 2 
51  1437889_x_at  657.21  15.35  2.68  5.04  AI931862  12111  Bgn  biglycan 328 
 
52  1422571_at  657.44  15.06  2.69  5.06  NM_011581  21826  Thbs2  thrombospondin 2 
53  1420804_s_at  659.19  14.89  1.80  2.63  NM_010819  17474  Clec4d  C-type lectin domain 
family 4, member d 
54  1416221_at  661.34  14.85  2.60  4.80  BI452727  14314  Fstl1  follistatin-like 1 
55  1448228_at  661.58  14.60  2.53  4.58  M65143  16948  Lox  lysyl oxidase 
56  1448816_at  664.14  14.50  2.23  3.73  NM_008968  19223  Ptgis 
prostaglandin I2 
(prostacyclin) 
synthase 
57  1426947_x_at  667.96  14.46  2.20  3.65  BI455189  12834  Col6a2  procollagen, type VI, 
alpha 2 
58  1450430_at  672.42  14.72  1.74  2.47  NM_008625  17533  Mrc1  mannose receptor, C 
type 1 
59  1452141_a_at  680.30  14.97  1.95  3.00  BC001991  20363  Sepp1  selenoprotein P, 
plasma, 1 
60  1418599_at  682.21  14.87  1.77  2.55  NM_007729  12814  Col11a1  procollagen, type XI, 
alpha 1 
61  1448162_at  694.27  15.39  1.91  2.90  BB250384  22329  Vcam1  vascular cell adhesion 
molecule 1 
62  1448925_at  701.70  15.76  2.09  3.36  NM_007855  13345  Twist2  twist homolog 2 
(Drosophila) 
63  1437165_a_at  704.76  15.70  2.35  4.05  BB250811  18542  Pcolce 
procollagen C-
endopeptidase 
enhancer protein 
64  1436448_a_at  706.91  15.59  2.24  3.77  AA833146  19224  Ptgs1 
prostaglandin-
endoperoxide 
synthase 1 
65  1418601_at  711.64  15.65  3.17  6.64  NM_011921  26358  Aldh1a7 
aldehyde 
dehydrogenase family 
1, subfamily A7 
66  1451978_at  721.02  16.06  2.24  3.75  AF357006  16949  Loxl1  lysyl oxidase-like 1 
67  1439426_x_at  740.13  17.28  1.74  2.48  AV058500  17110  Lzp-s  P lysozyme structural 
68  1447862_x_at  752.36  17.85  2.00  3.13  BB233297  21826  Thbs2  thrombospondin 2 
69  1438405_at  763.85  18.36  2.41  4.22  BB791906  14178  Fgf7  fibroblast growth 
factor 7 
70  1415983_at  766.61  18.29  1.57  2.10  NM_008879  18826  Lcp1  lymphocyte cytosolic 
protein 1 
71  1450652_at  770.50  18.41  2.28  3.87  NM_007802  13038  Ctsk  cathepsin K 
72  1436996_x_at  783.94  19.10  1.66  2.29  AV066625  17110  Lzp-s  P lysozyme structural 
73  1450641_at  805.95  20.26  2.13  3.45  M24849  22352  Vim  vimentin 
74  1425575_at  811.40  20.24  1.76  2.54  M68513  13837  Epha3  Eph receptor A3 
75  1425528_at  821.92  20.69  2.20  3.63  L06502  18933  Prrx1  paired related 
homeobox 1 
76  1418990_at  822.12  20.43  1.76  2.52  NM_025658  66607  Ms4a4d 
membrane-spanning 
4-domains, subfamily 
A, member 4D 
77  1456292_a_at  853.38  22.35  2.11  3.39  AV147875  22352  Vim  vimentin 
78  1449254_at  853.87  22.12  2.22  3.70  NM_009263  20750  Spp1  secreted 
phosphoprotein 1 
79  1417266_at  868.30  22.85  1.87  2.80  BC002073  20305  Ccl6  chemokine (C-C 
motif) ligand 6 
80  1418736_at  870.45  22.73  1.70  2.39  BC003835  26879  B3galt3 
UDP-Gal:betaGlcNAc 
beta 1,3-
galactosyltransferase, 
polypeptide 3 
81  1425145_at  871.16  22.47  2.23  3.73  D13695  17082  Il1rl1  interleukin 1 receptor-
like 1 
82  1425810_a_at  875.10  22.50  1.60  2.16  BF124540  13007  Csrp1  cysteine and glycine-
rich protein 1 
83  1448259_at  885.57  22.84  2.41  4.24  BI452727  14314  Fstl1  follistatin-like 1 
84  1418945_at  889.73  22.88  1.95  2.99  NM_010809  17392  Mmp3  matrix 
metallopeptidase 3 
85  1460227_at  894.34  22.94  1.95  2.98  BC008107  21857  Timp1  tissue inhibitor of 
metalloproteinase 1 
86  1448591_at  897.68  22.99  1.61  2.17  NM_021281  13040  Ctss  cathepsin S 
87  1418815_at  900.46  22.91  1.68  2.35  BC022107  12558  Cdh2  cadherin 2 
88  1440397_at  908.51  23.31  1.74  2.47  BB464523  ---  ---  --- 329 
 
89  1448620_at  920.24  23.66  1.76  2.53  NM_010188  14131  Fcgr3  Fc receptor, IgG, low 
affinity III 
90  1449244_at  933.40  24.27  1.73  2.46  BC022107  12558  Cdh2  cadherin 2 
91  1419599_s_at  937.95  24.34  1.58  2.12  NM_026835  64382  Ms4a11 
membrane-spanning 
4-domains, subfamily 
A, member 11 
92  1439774_at  941.15  24.33  2.29  3.89  BB051738  18933  Prrx1  paired related 
homeobox 1 
93  1460419_a_at  942.93  24.22  1.66  2.29  X59274  18751  Prkcb1  protein kinase C, beta 
1 
94  1427086_at  954.53  24.83  1.83  2.68  BM570006  ---  ---  --- 
95  1416168_at  964.23  25.19  1.97  3.04  NM_011340  20317  Serpinf1 
serine (or cysteine) 
peptidase inhibitor, 
clade F, member 1 
96  1418492_at  967.73  25.18  2.19  3.62  NM_011825  23893  Grem2 
gremlin 2 homolog, 
cysteine knot 
superfamily (Xenopus 
laevis) 
97  1451867_x_at  982.96  26.14  2.00  3.13  AF177664  11856  Arhgap6  Rho GTPase 
activating protein 6 
98  1427262_at  984.23  25.98  1.94  2.95  L04961  213742  Xist  inactive X specific 
transcripts 
99  1448293_at  985.81  25.81  1.88  2.83  BB125261  13591  Ebf1  early B-cell factor 1 
100  1447830_s_at  990.58  25.97  1.82  2.67  BB034265  19735  Rgs2  regulator of G-protein 
signaling 2 
101  1417936_at  995.22  26.11  1.58  2.12  AF128196  20308  Ccl9  chemokine (C-C 
motif) ligand 9 
102  1418511_at  1004.36  26.59  1.76  2.52  NM_019759  56429  Dpt  Dermatopontin 
103  1434423_at  1014.89  27.27  1.70  2.38  BB138485  ---  ---  --- 
104  1423311_s_at  1023.04  27.63  1.44  1.82  BQ177165  21983  Tpbg  trophoblast 
glycoprotein 
105  1449408_at  1026.36  27.55  1.52  1.99  NM_023844  67374  Jam2  junction adhesion 
molecule 2 
106  1438009_at  1038.87  28.45  1.42  1.79  W91024  319171  Hist1h2ao  histone 1, H2ao 
107  1423477_at  1039.21  28.21  1.69  2.37  BB361162  22771  Zic1  zinc finger protein of 
the cerebellum 1 
108  1437673_at  1039.26  27.95  1.60  2.15  AV164956  Mm.25771
4  ---  Transcribed locus 
109  1460208_at  1043.57  28.02  2.12  3.42  NM_007993  14118  Fbn1  fibrillin 1 
110  1452296_at  1044.06  27.82  2.10  3.37  BM570006  20564  Slit3  slit homolog 3 
(Drosophila) 
111  1429022_at  1044.37  27.57  1.82  2.67  AK013587  11517  Adcyap1r1 
adenylate cyclase 
activating polypeptide 
1 receptor 1 
112  1449984_at  1047.97  27.60  1.53  2.00  NM_009140  20310  Cxcl2  chemokine (C-X-C 
motif) ligand 2 
113  1426640_s_at  1050.29  27.55  1.91  2.90  BB354684  217410  Trib2  tribbles homolog 2 
(Drosophila) 
114  1438118_x_at  1057.27  27.73  1.95  2.99  AV147875  22352  Vim  Vimentin 
115  1426236_a_at  1071.93  28.56  1.67  2.32  AI391218  14645  Glul 
glutamate-ammonia 
ligase (glutamine 
synthetase) 
116  1440910_at  1084.85  29.08  1.65  2.27  AW495307  Mm.38190
7  ---  CDNA clone 
IMAGE:5252333 
117  1454830_at  1091.86  29.35  1.47  1.88  AV010392  14119  Fbn2  fibrillin 2 
118  1423326_at  1092.49  29.13  1.97  3.03  BI151440  12495  Entpd1 
ectonucleoside 
triphosphate 
diphosphohydrolase 1 
119  1451332_at  1097.99  29.24  1.78  2.57  BC021376  225207  Zfp521  zinc finger protein 521 
120  1416740_at  1100.12  29.12  2.04  3.22  AW744319  12831  Col5a1  procollagen, type V, 
alpha 1 
121  1425357_a_at  1102.12  29.03  1.70  2.39  BC015293  23892  Grem1  gremlin 1 
122  1437726_x_at  1102.12  28.80  1.57  2.10  BB111335  12260  C1qb 
complement 
component 1, q 
subcomponent, beta 
polypeptide 
123  1424542_at  1102.94  28.61  1.78  2.58  D00208  20198  S100a4  S100 calcium binding 330 
 
protein A4 
124  1448942_at  1113.88  29.19  1.89  2.85  NM_025331  66066  Gng11 
guanine nucleotide 
binding protein (G 
protein), gamma 11 
125  1420992_at  1116.76  29.22  1.82  2.67  AK009959  107765  Ankrd1 
ankyrin repeat 
domain 1 (cardiac 
muscle) 
126  1455494_at  1131.87  29.91  2.15  3.50  BI794771  12842  Col1a1  procollagen, type I, 
alpha 1 
127  1419693_at  1144.97  30.70  1.89  2.83  NM_130449  140792  Colec12  collectin sub-family 
member 12 
128  1457042_at  1147.07  30.63  1.73  2.45  BB328287  58871  AI256396  EST AI256396 
129  1448606_at  1150.23  30.65  1.72  2.43  U70622  14745  Edg2 
endothelial 
differentiation, 
lysophosphatidic acid 
G-protein-coupled 
receptor, 2 
130  1423271_at  1150.59  30.44  1.65  2.28  AV239646  14619  Gjb2 
gap junction 
membrane channel 
protein beta 2 
131  1418892_at  1162.74  30.97  2.02  3.17  AF309564  80837  Rhoj  ras homolog gene 
family, member J 
132  1455426_at  1172.64  31.50  1.97  3.04  AV226618  13837  Epha3  Eph receptor A3 
133  1439380_x_at  1173.55  31.34  2.02  3.18  BB093563  17263  Gtl2 
GTL2, imprinted 
maternally expressed 
untranslated mRNA 
134  1429273_at  1174.13  31.18  1.87  2.80  AK014221  73230  Bmper  BMP-binding 
endothelial regulator 
135  1448919_at  1178.48  31.22  1.85  2.74  NM_025422  66205  Cd302  CD302 antigen 
136  1437360_at  1179.09  31.04  1.74  2.48  BB053591  279653  Pcdh19  protocadherin 19 
137  1448201_at  1180.52  30.89  1.55  2.06  NM_009144  20319  Sfrp2 
secreted frizzled-
related sequence 
protein 2 
138  1416778_at  1182.06  30.72  1.84  2.72  BE197945  20324  Sdpr  serum deprivation 
response 
139  1435459_at  1185.11  30.68  1.87  2.79  BM936480  55990  Fmo2  flavin containing 
monooxygenase 2 
140  1436791_at  1186.03  30.51  1.64  2.25  BB067079  22418  Wnt5a 
wingless-related 
MMTV integration site 
5A 
141  1425951_a_at  1188.07  30.39  1.81  2.65  AF240358  56620  Clec4n  C-type lectin domain 
family 4, member n 
142  1427919_at  1188.31  30.20  1.67  2.32  BC028307  68792  Srpx2 
sushi-repeat-
containing protein, X-
linked 2 
143  1442257_at  1192.88  30.28  1.56  2.08  BI134319  Mm.20430
6  --- 
12 days embryo 
female mullerian duct 
includes surrounding 
region cDNA, RIKEN 
full-length enriched 
library, 
clone:6820438B06 
product:unclassifiable
, full insert sequence 
144  1420991_at  1194.70  30.18  1.44  1.81  AK009959  107765  Ankrd1 
ankyrin repeat 
domain 1 (cardiac 
muscle) 
145  1420394_s_at  1197.25  30.08  1.75  2.50  U05264  14727 
14728  Gp49a /// Lilrb4 
glycoprotein 49 A /// 
leukocyte 
immunoglobulin-like 
receptor, subfamily B, 
member 4 
146  1456046_at  1198.63  30.01  1.62  2.20  AV319144  17064  C1qr1 
complement 
component 1, q 
subcomponent, 
receptor 1 
147  1452183_a_at  1204.70  30.21  1.75  2.50  Y13832  17263  Gtl2 
GTL2, imprinted 
maternally expressed 
untranslated mRNA 
148  1456014_s_at  1209.43  30.34  1.65  2.26  BB113173  108101  BC032204  cDNA sequence 331 
 
BC032204 
149  1452445_at  1213.81  30.38  1.76  2.53  BC026874  338365  Slc41a2  solute carrier family 
41, member 2 
150  1422124_a_at  1214.38  30.20  1.50  1.94  NM_011210  19264  Ptprc 
protein tyrosine 
phosphatase, 
receptor type, C 
151  1455688_at  1226.72  30.73  2.17  3.55  BB795075  98434  LOC98434  hypothetical 
LOC98434 
152  1450241_a_at  1231.15  30.84  1.78  2.56  NM_010161  14017  Evi2a  ecotropic viral 
integration site 2a 
153  1421045_at  1241.21  31.37  1.88  2.82  BB528408  17534  Mrc2  mannose receptor, C 
type 2 
154  1439327_at  1246.77  31.51  1.68  2.34  BB197647  320924  Ccbe1 
collagen and calcium 
binding EGF domains 
1 
155  1416072_at  1256.35  31.96  2.02  3.16  NM_133654  12490  Cd34  CD34 antigen 
156  1452366_at  1258.53  31.87  1.56  2.07  AV371987  234356  4732435N03Rik  RIKEN cDNA 
4732435N03 gene 
157  1449473_s_at  1259.58  31.71  1.60  2.17  NM_011611  21939  Cd40  CD40 antigen 
158  1424131_at  1267.67  32.21  1.70  2.40  AF064749  12835  Col6a3  procollagen, type VI, 
alpha 3 
159  1423547_at  1267.81  32.02  1.63  2.23  AW208566  17105  Lyzs  Lysozyme 
160  1434877_at  1268.95  31.91  2.11  3.40  AI152800  18164  Nptx1  neuronal pentraxin 1 
161  1416468_at  1276.93  32.25  1.89  2.85  NM_013467  11668  Aldh1a1 
aldehyde 
dehydrogenase family 
1, subfamily A1 
162  1439181_at  1277.63  32.12  1.46  1.86  AV020760  210104  BC043301  cDNA sequence 
BC043301 
163  1428432_at  1283.31  32.37  1.55  2.06  BB813478  71918  2310047A01Rik  RIKEN cDNA 
2310047A01 gene 
164  1433695_at  1284.05  32.23  1.62  2.21  BQ174762  380686  1500041B16Rik  RIKEN cDNA 
1500041B16 gene 
165  1437056_x_at  1287.99  32.23  1.51  1.97  BB558800  78892  Crispld2 
cysteine-rich 
secretory protein 
LCCL domain 
containing 2 
166  1436936_s_at  1289.80  32.15  1.75  2.49  BG806300  213742  Xist  inactive X specific 
transcripts 
167  1450826_a_at  1292.53  32.15  1.81  2.64  NM_011315  20210  Saa3  serum amyloid A 3 
168  1448194_a_at  1307.72  32.86  1.40  1.75  NM_023123  14955  H19  H19 fetal liver mRNA 
169  1437385_at  1309.05  32.76  1.85  2.74  AV264768  320924  Ccbe1 
collagen and calcium 
binding EGF domains 
1 
170  1450684_at  1318.88  33.22  1.70  2.38  NM_007960  14009  Etv1  ets variant gene 1 
171  1424382_at  1321.77  33.29  1.88  2.82  BC025602  52377  Rcn3 
reticulocalbin 3, EF-
hand calcium binding 
domain 
172  1451161_a_at  1330.77  33.72  1.42  1.78  U66888  13733  Emr1 
EGF-like module 
containing, mucin-
like, hormone 
receptor-like 
sequence 1 
173  1434298_at  1331.24  33.55  1.59  2.14  BQ174116  24136  Zfhx1b  zinc finger homeobox 
1b 
174  1419442_at  1335.10  33.75  1.50  1.95  BC005429  17181  Matn2  matrilin 2 
175  1452339_at  1343.82  34.11  1.52  1.98  AL359935  108153  Adamts7 
a disintegrin-like and 
metallopeptidase 
(reprolysin type) with 
thrombospondin type 
1 motif, 7 
176  1448433_a_at  1347.37  34.24  1.75  2.50  NM_008788  18542  Pcolce 
procollagen C-
endopeptidase 
enhancer protein 
177  1420772_a_at  1362.23  35.11  1.40  1.74  NM_010286  14605  Tsc22d3  TSC22 domain family 
3 
178  1456475_s_at  1367.93  35.22  1.58  2.13  BB216074  19088  Prkar2b 
protein kinase, cAMP 
dependent regulatory, 
type II beta 332 
 
179  1417649_at  1371.14  35.28  1.87  2.79  NM_009876  12577  Cdkn1c 
cyclin-dependent 
kinase inhibitor 1C 
(P57) 
180  1428642_at  1376.30  35.43  1.57  2.09  AK018094  76157  Slc35d3  solute carrier family 
35, member D3 
181  1437903_at  1380.77  35.54  1.50  1.94  BB820958  16948  Lox  lysyl oxidase 
182  1423327_at  1392.35  36.16  1.67  2.33  AK005645  68172  4930517K11Rik  RIKEN cDNA 
4930517K11 gene 
183  1449314_at  1406.49  36.84  1.71  2.41  NM_011766  22762  Zfpm2  zinc finger protein, 
multitype 2 
184  1420249_s_at  1412.65  37.03  1.68  2.34  AV084904  20305  Ccl6  chemokine (C-C 
motif) ligand 6 
185  1436659_at  1419.14  37.39  1.90  2.86  BB757120  13175  Dcamkl1 
Double cortin and 
calcium/calmodulin-
dependent protein 
kinase-like 1, mRNA 
(cDNA clone 
IMAGE:5006471) 
186  1427076_at  1420.25  37.26  1.65  2.27  L20315  17476  Mpeg1  macrophage 
expressed gene 1 
187  1427300_at  1421.31  37.15  1.81  2.65  D49658  16875  Lhx8  LIM homeobox 
protein 8 
188  1451289_at  1426.94  37.30  1.87  2.78  AW105916  13175  Dcamkl1 
double cortin and 
calcium/calmodulin-
dependent protein 
kinase-like 1 
189  1420688_a_at  1428.63  37.24  1.52  1.98  NM_011360  20392  Sgce  sarcoglycan, epsilon 
190  1460292_a_at  1437.47  37.61  1.42  1.78  NM_053123  93761  Smarca1 
SWI/SNF related, 
matrix associated, 
actin dependent 
regulator of 
chromatin, subfamily 
a, member 1 
191  1452382_at  1439.22  37.55  1.83  2.68  BB542096  ---  ---  --- 
192  1450079_at  1442.66  37.59  1.73  2.45  AK012873  27206  Nrk  Nik related kinase 
193  1457753_at  1461.09  38.58  1.54  2.03  BI655907  279572  Tlr13  toll-like receptor 13 
194  1421228_at  1472.68  39.19  1.67  2.33  AF128193  20306  Ccl7  chemokine (C-C 
motif) ligand 7 
195  1424659_at  1507.79  41.70  1.77  2.56  BG963150  20563  Slit2  slit homolog 2 
(Drosophila) 
196  1433885_at  1507.90  41.49  1.72  2.44  BM240173  544963  Iqgap2 
IQ motif containing 
GTPase activating 
protein 2 
197  1417148_at  1546.39  44.16  1.51  1.96  NM_008809  18596  Pdgfrb 
platelet derived 
growth factor 
receptor, beta 
polypeptide 
198  1450852_s_at  1563.76  45.34  1.76  2.54  BQ173958  14062  F2r  coagulation factor II 
(thrombin) receptor 
199  1451016_at  1573.54  45.88  1.31  1.55  BB540964  15983  Ifrd2 
interferon-related 
developmental 
regulator 2 
200  1438530_at  1577.96  45.97  1.46  1.86  BB756069  21788  Tfpi  tissue factor pathway 
inhibitor 
201  1450004_at  1598.64  47.40  1.21  1.36  NM_021367  53603  Tslp  thymic stromal 
lymphopoietin 
202  1416805_at  1599.80  47.27  1.52  1.98  NM_133187  68659  1110032E23Rik  RIKEN cDNA 
1110032E23 gene 
203  1434325_x_at  1606.07  47.50  1.58  2.11  BB274009  19085  Prkar1b 
protein kinase, cAMP 
dependent regulatory, 
type I beta 
204  1422748_at  1619.25  48.26  1.74  2.48  NM_015753  24136  Zfhx1b  zinc finger homeobox 
1b 
205  1440969_at  1622.67  48.29  1.32  1.58  BE944957  407797  BC030308  cDNA sequence 
BC030308 
206  1442082_at  1635.09  48.95  1.55  2.05  BB333624  12267  C3ar1 
complement 
component 3a 
receptor 1 333 
 
207  1424086_at  1638.55  48.96  1.52  1.99  BC025514  102644  D9Ucla1 
DNA segment, Chr 9, 
University of 
California at Los 
Angeles 1 
208  1431079_at  1641.74  48.98  1.59  2.13  BF148029  69183  C1qtnf2 
C1q and tumor 
necrosis factor related 
protein 2 
209  1432466_a_at  1647.20  49.19  1.48  1.89  AK019319  11816  Apoe  apolipoprotein E 
210  1455393_at  1651.60  49.27  1.49  1.92  BB009037  ---  ---  --- 
211  1427263_at  1653.60  49.18  1.39  1.73  L04961  213742  Xist  inactive X specific 
transcripts 
212  1429514_at  1654.13  49.00  1.56  2.08  AW111876  67916  Ppap2b  phosphatidic acid 
phosphatase type 2B 
213  1443673_x_at  1659.77  49.19  1.30  1.54  BB710847  ---  ---  --- 
214  1432517_a_at  1664.55  49.35  1.41  1.76  AK006371  18113  Nnmt  nicotinamide N-
methyltransferase 
215  1456389_at  1669.64  49.54  1.47  1.88  BB244754  24136  Zfhx1b  zinc finger homeobox 
1b 
216  1418826_at  1678.82  49.93  1.60  2.15  NM_027209  69774  Ms4a6b 
membrane-spanning 
4-domains, subfamily 
A, member 6B 
217  1446085_at  1681.26  49.93  1.35  1.63  BB022048  216233  Socs2 
Suppressor of 
cytokine signaling 2 
(Socs2), mRNA 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
General Information 
Experiment   VK1mouse4302 
Normalisation   rma across replicates 
Chip   one chip only 
Comparison   Treatment samples: K14D6 + CCL3 vs Baseline samples: TG Control 
RP comparison  not paired 
Direction   Positive   
 
 
0  Probe-set ID  RPscore  FDR  FC_rma FC_nom "SOURCE" "EntrezGene"  Gene Symbol  Title 
1  1418601_at  97.20  3.00  3.31  7.11  NM_011921  26358  Aldh1a7 
aldehyde 
dehydrogenase 
family 1, 
subfamily A7 
2  1436996_x_at  106.48  1.50  2.47  4.41  AV066625  17110  Lzp-s  P lysozyme 
structural 
3  1448591_at  110.66  1.33  2.33  4.01  NM_021281  13040  Ctss  cathepsin S 
4  1439426_x_at  132.50  1.50  2.33  4.01  AV058500  17110  Lzp-s  P lysozyme 
structural 
5  1423522_at  147.22  1.40  2.11  3.39  BB811478  18150  Npm3  nucleoplasmin 3 
6  1452141_a_at  162.85  1.50  2.31  3.96  BC001991  20363  Sepp1  selenoprotein P, 
plasma, 1 
7  1418666_at  199.63  2.71  2.18  3.58  NM_008987  19288  Ptx3  pentraxin related 
gene 
8  1416468_at  210.40  2.75  2.31  3.94  NM_013467  11668  Aldh1a1 
aldehyde 
dehydrogenase 
family 1, 
subfamily A1 
9  1436905_x_at  234.40  3.67  1.89  2.85  BB218107  16792  Laptm5 
lysosomal-
associated protein 
transmembrane 5 
10  1448620_at  242.06  3.90  1.97  3.04  NM_010188  14131  Fcgr3  Fc receptor, IgG, 
low affinity III 
11  1427883_a_at  254.35  4.27  2.18  3.59  AW550625  12825  Col3a1  procollagen, type 
III, alpha 1 
12  1460197_a_at  279.37  5.17  2.22  3.71  NM_054098  117167  Steap4  STEAP family 
member 4 
13  1420504_at  296.41  6.38  1.61  2.18  AF320226  56774  Slc6a14 
solute carrier 
family 6 
(neurotransmitter 
transporter), 
member 14 
14  1424186_at  302.93  6.14  2.05  3.26  BG074158  67896  2610001E17Rik  RIKEN cDNA 
2610001E17 gene 
15  1427747_a_at  305.98  5.87  1.79  2.61  X14607  16819  Lcn2  lipocalin 2 
16  1432466_a_at  313.90  5.94  1.92  2.92  AK019319  11816  Apoe  apolipoprotein E 
17  1417936_at  373.00  9.29  1.82  2.66  AF128196  20308  Ccl9  chemokine (C-C 
motif) ligand 9 
18  1423091_a_at  398.97  11.22  1.98  3.05  AK016567  14758  Gpm6b  glycoprotein m6b 
19  1452905_at  423.63  12.68  2.11  3.40  AV015833  17263 
330814  Gtl2 /// Lphn1 
GTL2, imprinted 
maternally 
expressed 
untranslated 335 
 
mRNA /// 
latrophilin 1 
20  1449833_at  427.48  12.40  1.68  2.34  NM_011472  20760  Sprr2f  small proline-rich 
protein 2F 
21  1417266_at  430.38  12.24  1.86  2.77  BC002073  20305  Ccl6  chemokine (C-C 
motif) ligand 6 
22  1425087_at  435.11  12.23  1.60  2.16  BC021588  67693  2310003F16Rik  RIKEN cDNA 
2310003F16 gene 
23  1420394_s_at  446.67  12.52  1.92  2.90  U05264  14727 14728  Gp49a /// Lilrb4 
glycoprotein 49 A 
/// leukocyte 
immunoglobulin-
like receptor, 
subfamily B, 
member 4 
24  1455494_at  463.36  13.08  1.86  2.77  BI794771  12842  Col1a1  procollagen, type 
I, alpha 1 
25  1423547_at  464.59  12.56  1.85  2.73  AW208566  17105  Lyzs  lysozyme 
26  1452250_a_at  482.72  13.31  1.90  2.85  BI455189  12834  Col6a2  procollagen, type 
VI, alpha 2 
27  1435477_s_at  496.59  13.89  1.72  2.43  BM224327  14130  Fcgr2b  Fc receptor, IgG, 
low affinity IIb 
28  1419100_at  508.00  14.46  1.85  2.75  NM_009252  20716  Serpina3n 
serine (or 
cysteine) 
peptidase 
inhibitor, clade A, 
member 3N 
29  1422939_at  508.61  13.97  1.53  2.01  NM_009126  383548  Serpinb3b 
serine (or 
cysteine) 
peptidase 
inhibitor, clade B 
(ovalbumin), 
member 3B 
30  1448590_at  512.09  13.70  1.85  2.74  NM_009933  12833  Col6a1  procollagen, type 
VI, alpha 1 
31  1420503_at  535.10  14.87  1.49  1.92  AF320226  56774  Slc6a14 
solute carrier 
family 6 
(neurotransmitter 
transporter), 
member 14 
32  1435459_at  539.54  14.88  1.85  2.74  BM936480  55990  Fmo2  flavin containing 
monooxygenase 2 
33  1422940_x_at  583.05  18.36  1.53  2.01  NM_009126  383548  Serpinb3b 
serine (or 
cysteine) 
peptidase 
inhibitor, clade B 
(ovalbumin), 
member 3B 
34  1423271_at  591.98  18.88  1.45  1.83  AV239646  14619  Gjb2 
gap junction 
membrane 
channel protein 
beta 2 
35  1433530_at  613.80  20.00  1.51  1.96  BI694945  70164  2210411K19Rik  RIKEN cDNA 
2210411K19 gene 
36  1423537_at  615.70  19.67  1.87  2.79  BB622036  14432  Gap43  growth associated 
protein 43 
37  1448326_a_at  627.16  20.08  1.75  2.51  NM_013496  12903  Crabp1 
cellular retinoic 
acid binding 
protein I 
38  1424754_at  644.48  21.11  1.55  2.05  BC024402  109225  Ms4a7 
membrane-
spanning 4-
domains, 
subfamily A, 
member 7 
39  1448259_at  653.72  21.44  1.76  2.52  BI452727  14314  Fstl1  follistatin-like 1 
40  1424843_a_at  663.67  21.62  1.48  1.89  BC004622  14455  Gas5  growth arrest 
specific 5 
41  1438405_at  665.38  21.44  1.86  2.77  BB791906  14178  Fgf7  fibroblast growth 
factor 7 
42  1449154_at  671.67  21.45  1.86  2.78  NM_007729  12814  Col11a1  procollagen, type 
XI, alpha 1 
43  1436970_a_at  682.68  21.84  1.73  2.45  AA499047  18596  Pdgfrb  platelet derived 336 
 
growth factor 
receptor, beta 
polypeptide 
44  1418599_at  696.26  22.52  1.81  2.65  NM_007729  12814  Col11a1  procollagen, type 
XI, alpha 1 
45  1420804_s_at  720.74  24.69  1.57  2.09  NM_010819  17474  Clec4d 
C-type lectin 
domain family 4, 
member d 
46  1448756_at  729.95  25.20  1.40  1.74  NM_009114  20202  S100a9 
S100 calcium 
binding protein A9 
(calgranulin B) 
47  1448748_at  730.24  24.68  1.55  2.05  AF181829  56193  Plek  pleckstrin 
48  1417785_at  734.92  24.60  1.58  2.12  NM_134102  85031  Pla1a  phospholipase A1 
member A 
49  1416221_at  735.00  24.12  1.74  2.48  BI452727  14314  Fstl1  follistatin-like 1 
50  1452296_at  738.70  24.00  1.72  2.43  BM570006  20564  Slit3  slit homolog 3 
(Drosophila) 
51  1448475_at  739.77  23.61  1.64  2.25  NM_133859  99543  Olfml3  olfactomedin-like 
3 
52  1424265_at  742.77  23.38  1.51  1.97  BC022734  74091  Npl 
N-
acetylneuraminate 
pyruvate lyase 
53  1426947_x_at  743.55  22.98  1.75  2.51  BI455189  12834  Col6a2  procollagen, type 
VI, alpha 2 
54  1440739_at  753.02  23.33  1.63  2.24  AW228853  22341  Vegfc 
vascular 
endothelial growth 
factor C 
55  1423110_at  757.87  23.31  1.76  2.53  BF227507  ---  ---  --- 
56  1418892_at  764.07  23.25  1.72  2.44  AF309564  80837  Rhoj  ras homolog gene 
family, member J 
57  1448228_at  776.52  23.63  1.86  2.77  M65143  16948  Lox  lysyl oxidase 
58  1419627_s_at  777.85  23.34  1.67  2.31  NM_020001  56620  Clec4n 
C-type lectin 
domain family 4, 
member n 
59  1419394_s_at  794.29  24.37  1.42  1.77  NM_013650  20201  S100a8 
S100 calcium 
binding protein A8 
(calgranulin A) 
60  1435943_at  807.08  25.17  1.89  2.84  AI647687  13479  Dpep1  dipeptidase 1 
(renal) 
61  1448995_at  827.30  26.46  1.65  2.28  NM_019932  56744  Cxcl4  chemokine (C-X-
C motif) ligand 4 
62  1451718_at  827.63  26.06  1.45  1.84  BB768495  18823  Plp1  proteolipid protein 
(myelin) 1 
63  1423259_at  834.40  26.32  1.56  2.07  BB121406  15904  Id4  inhibitor of DNA 
binding 4 
64  1450857_a_at  834.80  25.92  1.71  2.41  BF227507  12843  Col1a2  procollagen, type 
I, alpha 2 
65  1417649_at  835.68  25.65  1.86  2.76  NM_009876  12577  Cdkn1c 
cyclin-dependent 
kinase inhibitor 
1C (P57) 
66  1449984_at  838.10  25.42  1.56  2.06  NM_009140  20310  Cxcl2  chemokine (C-X-
C motif) ligand 2 
67  1448293_at  858.04  26.76  1.58  2.12  BB125261  13591  Ebf1  early B-cell factor 
1 
68  1424382_at  861.21  26.69  1.67  2.31  BC025602  52377  Rcn3 
reticulocalbin 3, 
EF-hand calcium 
binding domain 
69  1457040_at  863.35  26.49  1.47  1.88  BE947711  246316  Lgi2 
leucine-rich 
repeat LGI family, 
member 2 
70  1419599_s_at  866.01  26.29  1.58  2.12  NM_026835  64382  Ms4a11 
membrane-
spanning 4-
domains, 
subfamily A, 
member 11 
71  1416121_at  870.48  26.28  1.71  2.42  M65143  16948  Lox  lysyl oxidase 
72  1443790_x_at  902.84  28.36  1.37  1.68  AV208084  78108  4930414L22Rik  RIKEN cDNA 
4930414L22 gene 337 
 
73  1448194_a_at  909.59  28.47  1.50  1.94  NM_023123  14955  H19  H19 fetal liver 
mRNA 
74  1429273_at  914.94  28.57  1.70  2.39  AK014221  73230  Bmper 
BMP-binding 
endothelial 
regulator 
75  1419417_at  915.86  28.24  1.59  2.14  NM_009506  22341  Vegfc 
vascular 
endothelial growth 
factor C 
76  1437517_x_at  918.09  27.99  1.37  1.68  BB699605  20248  Serpinb3a 
serine (or 
cysteine) 
peptidase 
inhibitor, clade B 
(ovalbumin), 
member 3A 
77  1449368_at  922.52  27.90  1.67  2.32  NM_007833  13179  Dcn  decorin 
78  1450757_at  925.19  27.76  1.56  2.07  NM_009866  12552  Cdh11  cadherin 11 
79  1439380_x_at  928.28  27.68  1.75  2.51  BB093563  17263  Gtl2 
GTL2, imprinted 
maternally 
expressed 
untranslated 
mRNA 
80  1457642_at  932.93  27.65  1.38  1.70  BB255999  70622  5730507N06Rik 
RIKEN cDNA 
5730507N06 
gene 
81  1420867_at  945.78  28.28  1.37  1.67  BB609648  56334  Tmed2 
transmembrane 
emp24 domain 
trafficking protein 
2 
82  1437165_a_at  956.17  28.85  1.62  2.20  BB250811  18542  Pcolce 
procollagen C-
endopeptidase 
enhancer protein 
83  1460250_at  971.86  30.01  1.57  2.10  BC021458  66042  Sostdc1  sclerostin domain 
containing 1 
84  1448397_at  974.60  29.90  1.28  1.50  BC016507  14623  Gjb6 
gap junction 
membrane 
channel protein 
beta 6 
85  1420249_s_at  977.46  29.84  1.51  1.97  AV084904  20305  Ccl6  chemokine (C-C 
motif) ligand 6 
86  1419463_at  978.22  29.53  1.55  2.04  AF108501  80797  Clca2 
chloride channel 
calcium activated 
2 
87  1430655_at  988.47  29.91  1.47  1.88  BE685884  70800  4631405K08Rik  RIKEN cDNA 
4631405K08 gene 
88  1450652_at  993.62  30.05  1.63  2.24  NM_007802  13038  Ctsk  cathepsin K 
89  1419483_at  1011.87  31.35  1.38  1.70  NM_009779  12267  C3ar1 
complement 
component 3a 
receptor 1 
90  1448323_a_at  1017.20  31.40  1.52  1.99  BC019502  12111  Bgn  biglycan 
91  1443897_at  1022.26  31.38  1.44  1.82  BB200603  13198  Ddit3 
DNA-damage 
inducible 
transcript 3 
92  1432517_a_at  1022.64  31.12  1.51  1.97  AK006371  18113  Nnmt  nicotinamide N-
methyltransferase 
93  1438069_a_at  1027.87  31.16  1.38  1.70  BE446879  83486  Rbm5  RNA binding motif 
protein 5 
94  1419598_at  1033.12  31.26  1.54  2.03  NM_026835  68774  Ms4a6d 
membrane-
spanning 4-
domains, 
subfamily A, 
member 6D 
95  1427086_at  1033.55  30.94  1.58  2.12  BM570006  ---  ---  --- 
96  1438403_s_at  1033.62  30.63  1.41  1.75  BF537798  80291  BC003324 
CDNA sequence 
BC003324, 
mRNA (cDNA 
clone MGC:7036 
IMAGE:3156139) 
97  1450826_a_at  1039.65  30.82  1.61  2.18  NM_011315  20210  Saa3  serum amyloid A 
3 
98  1424903_at  1043.42  30.77  1.58  2.12  AF127244  20592  Jarid1d  jumonji, AT rich 338 
 
interactive domain 
1D (Rbp2 like) 
99  1423606_at  1051.64  31.16  1.71  2.42  BI110565  50706  Postn 
periostin, 
osteoblast specific 
factor 
100  1420499_at  1055.47  31.16  1.43  1.79  NM_008102  14528  Gch1  GTP 
cyclohydrolase 1 
101  1439766_x_at  1058.94  31.08  1.52  1.99  BB089170  22341  Vegfc 
vascular 
endothelial growth 
factor C 
102  1433695_at  1062.92  31.13  1.51  1.97  BQ174762  380686  1500041B16Rik  RIKEN cDNA 
1500041B16 gene 
103  1420676_at  1070.91  31.50  1.38  1.71  NM_025984  67127  Sprrl3  small proline rich-
like 3 
104  1455607_at  1087.25  32.29  1.55  2.05  BG072958  72780  Rspo3 
R-spondin 3 
homolog 
(Xenopus laevis) 
105  1429297_at  1090.31  32.27  1.41  1.75  AK009018  71869  Serpinb12 
serine (or 
cysteine) 
peptidase 
inhibitor, clade B 
(ovalbumin), 
member 12 
106  1421228_at  1129.88  35.33  1.69  2.37  AF128193  20306  Ccl7  chemokine (C-C 
motif) ligand 7 
107  1416779_at  1130.25  35.03  1.46  1.86  BE197945  20324  Sdpr  serum deprivation 
response 
108  1435934_at  1144.23  35.91  1.43  1.80  AI643884  70316  Ndufab1 
NADH 
dehydrogenase 
(ubiquinone) 1, 
alpha/beta 
subcomplex, 1 
109  1434479_at  1161.59  37.06  1.49  1.93  AV246911  12831  Col5a1 
Procollagen, type 
V, alpha 1 
(Col5a1), mRNA 
110  1416077_at  1162.52  36.79  1.54  2.03  NM_009627  11535  Adm  adrenomedullin 
111  1422963_at  1167.55  36.90  1.31  1.56  NM_011475  20763  Sprr2i  small proline-rich 
protein 2I 
112  1425357_a_at  1176.66  37.24  1.52  1.99  BC015293  23892  Grem1  gremlin 1 
113  1460259_s_at  1182.29  37.41  1.52  1.99  AF108501  12722 80797  Clca1 /// Clca2 
chloride channel 
calcium activated 
1 /// chloride 
channel calcium 
activated 2 
114  1435639_at  1183.14  37.14  1.43  1.80  BF580962  70045  2610528A11Rik  RIKEN cDNA 
2610528A11 gene 
115  1451939_a_at  1186.41  37.15  1.35  1.64  AB028050  51795  Srpx  sushi-repeat-
containing protein 
116  1436055_at  1204.38  38.34  1.52  1.99  AI506528  74488  Lrrc15  leucine rich repeat 
containing 15 
117  1421492_at  1208.73  38.34  1.36  1.66  NM_019455  54486  Ptgds2 
prostaglandin D2 
synthase 2, 
hematopoietic 
118  1448303_at  1210.06  38.14  1.41  1.76  NM_053110  93695  Gpnmb 
glycoprotein 
(transmembrane) 
nmb 
119  1422571_at  1215.82  38.34  1.69  2.35  NM_011581  21826  Thbs2  thrombospondin 2 
120  1424542_at  1217.79  38.22  1.40  1.75  D00208  20198  S100a4  S100 calcium 
binding protein A4 
121  1452138_a_at  1219.78  38.05  1.38  1.69  BB497528  70008  Ace2 
angiotensin I 
converting 
enzyme (peptidyl-
dipeptidase A) 2 
122  1450618_a_at  1228.45  38.52  1.34  1.61  NM_011468  20755  Sprr2a  small proline-rich 
protein 2A 
123  1416136_at  1242.21  39.27  1.71  2.41  NM_008610  17390  Mmp2 
matrix 
metallopeptidase 
2 
124  1417256_at  1246.90  39.42  1.22  1.39  NM_008607  17386  Mmp13  matrix 
metallopeptidase 339 
 
13 
125  1417852_x_at  1252.74  39.53  1.40  1.74  AF047838  12722  Clca1 
chloride channel 
calcium activated 
1 
126  1419665_a_at  1253.73  39.26  1.38  1.69  NM_019738  56312  Nupr1  nuclear protein 1 
127  1435343_at  1255.50  39.16  1.53  2.00  BF715043  210293  Dock10  dedicator of 
cytokinesis 10 
128  1448061_at  1264.04  39.57  1.48  1.91  AA183642  ---  ---  --- 
129  1416405_at  1265.70  39.38  1.45  1.85  BC019502  12111  Bgn  biglycan 
130  1418492_at  1266.15  39.11  1.52  1.99  NM_011825  23893  Grem2 
gremlin 2 
homolog, cysteine 
knot superfamily 
(Xenopus laevis) 
131  1448925_at  1268.43  38.96  1.54  2.02  NM_007855  13345  Twist2  twist homolog 2 
(Drosophila) 
132  1449314_at  1270.69  38.87  1.46  1.86  NM_011766  22762  Zfpm2  zinc finger protein, 
multitype 2 
133  1443768_at  1273.77  38.83  1.41  1.75  BG101505  11848  Rhoa 
Ras homolog 
gene family, 
member A 
(Rhoa), mRNA 
134  1417494_a_at  1273.90  38.54  1.55  2.06  BB332449  12870  Cp  ceruloplasmin 
135  1456379_x_at  1274.42  38.31  1.34  1.61  BB038556  227325  Dner 
delta/notch-like 
EGF-related 
receptor 
136  1420380_at  1282.63  38.65  1.67  2.32  AF065933  20296  Ccl2  chemokine (C-C 
motif) ligand 2 
137  1417210_at  1294.04  39.26  1.55  2.05  NM_012011  26908  Eif2s3y 
eukaryotic 
translation 
initiation factor 2, 
subunit 3, 
structural gene Y-
linked 
138  1450430_at  1297.13  39.17  1.47  1.89  NM_008625  17533  Mrc1  mannose 
receptor, C type 1 
139  1422837_at  1299.90  39.14  1.24  1.43  NM_022886  64929  Scel  sciellin 
140  1419247_at  1311.81  39.72  1.45  1.84  AF215668  19735  Rgs2  regulator of G-
protein signaling 2 
141  1416740_at  1314.96  39.72  1.47  1.88  AW744319  12831  Col5a1  procollagen, type 
V, alpha 1 
142  1422317_a_at  1327.48  40.41  1.74  2.48  NM_010743  17082  Il1rl1  interleukin 1 
receptor-like 1 
143  1426302_at  1327.77  40.16  1.33  1.59  BC021368  214523  Tmprss4  transmembrane 
protease, serine 4 
144  1417009_at  1334.11  40.38  1.48  1.90  NM_023143  50909  C1r 
complement 
component 1, r 
subcomponent 
145  1455426_at  1342.39  40.70  1.51  1.96  AV226618  13837  Epha3  Eph receptor A3 
146  1423634_at  1354.58  41.49  1.28  1.50  AI506986  57911  Gsdm1  gasdermin 1 
147  1444176_at  1375.02  42.96  1.32  1.58  AV204216  242341  Atp6v0d2 
ATPase, H+ 
transporting, V0 
subunit D, isoform 
2 
148  1420498_a_at  1377.68  42.91  1.53  2.00  NM_023118  13132  Dab2  disabled homolog 
2 (Drosophila) 
149  1421194_at  1383.73  43.09  1.42  1.78  NM_010576  16401  Itga4  integrin alpha 4 
150  1455431_at  1391.19  43.42  1.35  1.63  AV371434  20537  Slc5a1 
solute carrier 
family 5 
(sodium/glucose 
cotransporter), 
member 1 
151  1434195_at  1405.67  44.29  1.45  1.83  BB042892  244954  Prss35  protease, serine, 
35 
152  1428642_at  1410.00  44.40  1.41  1.75  AK018094  76157  Slc35d3 
solute carrier 
family 35, 
member D3 
153  1416072_at  1415.04  44.40  1.46  1.85  NM_133654  12490  Cd34  CD34 antigen 
154  1450783_at  1415.15  44.11  1.30  1.54  NM_008331  15957  Ifit1  interferon-induced 340 
 
protein with 
tetratricopeptide 
repeats 1 
155  1455930_at  1424.05  44.67  1.30  1.54  BI651113  ---  ---  --- 
156  1455899_x_at  1427.58  44.75  1.31  1.56  BB241535  12702  Socs3 
suppressor of 
cytokine signaling 
3 
157  1436530_at  1429.16  44.57  1.44  1.83  AA666504  Mm.24097  --- 
CDNA clone 
MGC:107680 
IMAGE:6766535 
158  1421045_at  1443.93  45.50  1.48  1.91  BB528408  17534  Mrc2  mannose 
receptor, C type 2 
159  1439364_a_at  1450.22  45.77  1.62  2.20  BF147716  17390  Mmp2 
matrix 
metallopeptidase 
2 
160  1449254_at  1464.84  46.70  1.36  1.66  NM_009263  20750  Spp1  secreted 
phosphoprotein 1 
161  1437658_a_at  1475.87  47.36  1.33  1.60  AW552536  83673  Rnu22  RNA, U22 small 
nucleolar 
162  1418266_at  1478.82  47.39  1.26  1.45  NM_009659  11686  Alox12b 
arachidonate 12-
lipoxygenase, 
12R type 
163  1444061_at  1482.07  47.46  1.29  1.51  BB150166  109314  A030004J04Rik  RIKEN cDNA 
A030004J04 gene 
164  1417516_at  1492.32  48.02  1.31  1.56  NM_007837  13198  Ddit3 
DNA-damage 
inducible 
transcript 3 
165  1455573_at  1494.80  47.92  1.34  1.62  BE197934  16664  Krt1-14  keratin complex 1, 
acidic, gene 14 
166  1448162_at  1495.67  47.71  1.46  1.86  BB250384  22329  Vcam1 
vascular cell 
adhesion 
molecule 1 
167  1416593_at  1501.01  47.82  1.40  1.74  AF276917  93692  Glrx1  glutaredoxin 1 
(thioltransferase) 
168  1454830_at  1502.75  47.65  1.41  1.76  AV010392  14119  Fbn2  fibrillin 2 
169  1451332_at  1511.71  48.01  1.43  1.79  BC021376  225207  Zfp521  zinc finger protein 
521 
170  1416200_at  1524.31  48.78  1.20  1.36  NM_133775  77125  9230117N10Rik 
RIKEN cDNA 
9230117N10 
gene 
171  1429504_at  1538.85  49.65  1.36  1.65  BE134108  67225  Rnpc3 
RNA-binding 
region (RNP1, 
RRM) containing 
3 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
General Information 
Experiment   VK1mouse4302 
Normalisation   rma across replicates 
Chip   one chip only 
Comparison   Treatment samples: K14D6 + CCL3 vs Baseline samples: WT + CCL3 
RP comparison   not paired 
Direction   Positive 
 
0  Probe-set ID  RPscore  FDR  FC_rma FC_nom "SOURCE" "EntrezGene" Gene Symbol  Title 
1  1422111_at  1.28  0.00  35.02  340.86  BE631540  59289  Ccbp2  chemokine binding 
protein 2 
2  1426438_at  186.44  12.00  3.97  9.59  AA210261  26900  Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
3, Y-linked 
3  1417210_at  190.60  9.00  3.73  8.67  NM_012011  26908  Eif2s3y 
eukaryotic translation 
initiation factor 2, 
subunit 3, structural 
gene Y-linked 
4  1452077_at  280.18  21.25  2.31  3.95  AA210261  26900  Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
3, Y-linked 
5  1420504_at  335.66  27.20  1.55  2.05  AF320226  56774  Slc6a14 
solute carrier family 6 
(neurotransmitter 
transporter), member 
14 
6  1426598_at  396.73  33.67  1.58  2.12  BB742957 
22290 
546404 
546411 
Uty /// 
LOC546404 
/// 
LOC546411 
ubiquitously 
transcribed 
tetratricopeptide 
repeat gene, Y 
chromosome /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb 
7  1424903_at  407.62  31.86  1.92  2.92  AF127244  20592  Jarid1d 
jumonji, AT rich 
interactive domain 
1D (Rbp2 like) 
8  1417022_at  423.42  32.00  1.52  1.99  NM_007515  11989  Slc7a3 
solute carrier family 7 
(cationic amino acid 
transporter, y+ 
system), member 3 
9  1426439_at  612.17  NA  1.80  2.62  AA210261  26900  Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
3, Y-linked 
10  1423522_at  627.90  NA  1.50  1.95  BB811478  18150  Npm3  nucleoplasmin 3 
11  1449484_at  698.90  NA  1.44  1.82  AF031035  20856  Stc2  stanniocalcin 2 
12  1437935_at  710.40  NA  1.46  1.85  BB821151  75033  4930486G11
Rik 
RIKEN cDNA 
4930486G11 gene 
13  1415862_at  729.26  NA  1.36  1.66  BB762957  22178  Tyrp1  tyrosinase-related 
protein 1 342 
 
14  1420503_at  789.24  NA  1.38  1.69  AF320226  56774  Slc6a14 
solute carrier family 6 
(neurotransmitter 
transporter), member 
14 
15  1421003_at  826.18  NA  1.38  1.69  AA024025  56809  Gmeb1 
glucocorticoid 
modulatory element 
binding protein 1 
16  1455626_at  917.50  NA  1.14  1.24  AA987181  15405  Hoxa9  homeo box A9 
17  1420901_a_at  948.05  NA  1.36  1.65  NM_010438  15275  Hk1  hexokinase 1 
18  1418666_at  956.11  NA  1.22  1.38  NM_008987  19288  Ptx3  pentraxin related 
gene 
19  1422523_at  973.05  NA  1.30  1.54  NM_021882  20431  Si  silver 
20  1422481_at  977.84  NA  1.28  1.50  NM_008473  16678  Krt2-1  keratin complex 2, 
basic, gene 1 
21  1437445_at  1076.16  NA  1.23  1.41  BB770967  17364  Trpm1 
transient receptor 
potential cation 
channel, subfamily 
M, member 1 
22  1452315_at  1120.02  NA  1.36  1.66  BB827235  16551  Kif11  kinesin family 
member 11 
23  1417649_at  1128.63  NA  1.23  1.41  NM_009876  12577  Cdkn1c 
cyclin-dependent 
kinase inhibitor 1C 
(P57) 
24  1415861_at  1141.68  NA  1.24  1.43  BB762957  22178  Tyrp1  tyrosinase-related 
protein 1 
25  1456095_at  1150.01  NA  1.19  1.33  BB769772  22173  Tyr  tyrosinase 
26  1418028_at  1186.33  NA  1.26  1.46  NM_010024  13190  Dct  dopachrome 
tautomerase 
27  1426065_a_at  1196.86  NA  1.36  1.65  BC012955  228775  Trib3  tribbles homolog 3 
(Drosophila) 
28  1421830_at  1228.50  NA  1.33  1.60  NM_009647  11639  Ak3l1  adenylate kinase 3 
alpha-like 1 
29  1456225_x_at  1241.53  NA  1.35  1.64  BB508622  228775  Trib3  tribbles homolog 3 
(Drosophila) 
30  1439409_x_at  1294.88  NA  1.23  1.40  BB006219  22178  Tyrp1  tyrosinase-related 
protein 1 
31  1448397_at  1302.50  NA  1.25  1.44  BC016507  14623  Gjb6 
gap junction 
membrane channel 
protein beta 6 
32  1453252_at  1304.65  NA  1.33  1.59  AK010138  71916  Dus4l 
dihydrouridine 
synthase 4-like (S. 
cerevisiae) 
33  1452514_a_at  1305.71  NA  1.27  1.49  X65997  16590  Kit  kit oncogene 
34  1421487_a_at  1318.38  NA  1.34  1.62  NM_010878  17973  Nck1 
non-catalytic region 
of tyrosine kinase 
adaptor protein 1 
35  1417717_a_at  1323.95  NA  1.24  1.41  NM_011661  22173  Tyr  tyrosinase 
36  1425415_a_at  1375.67  NA  1.32  1.58  U75214  20510  Slc1a1 
solute carrier family 1 
(neuronal/epithelial 
high affinity 
glutamate 
transporter, system 
Xag), member 1 
37  1448152_at  1414.85  NA  1.34  1.61  NM_010514  16002  Igf2  insulin-like growth 
factor 2 
38  1450618_a_at  1420.44  NA  1.28  1.50  NM_011468  20755  Sprr2a  small proline-rich 
protein 2A 
39  1426634_at  1471.30  NA  1.33  1.59  BB010989  230612  Slc5a9 
solute carrier family 5 
(sodium/glucose 
cotransporter), 
member 9 
40  1419906_at  1473.87  NA  1.32  1.58  AV026552  15446  Hpgd 
Hydroxyprostaglandi
n dehydrogenase 15 
(NAD), mRNA (cDNA 
clone MGC:14001 
IMAGE:4208980) 
41  1442153_at  1480.86  NA  1.47  1.87  BB206087  Mm.385427  --- 
0 day neonate 
thymus cDNA, 
RIKEN full-length 
enriched library, 343 
 
clone:A430072F05 
product:unclassifiable
, full insert sequence 
42  1437125_at  1503.50  NA  1.30  1.54  BB476448  12322  Camk2a 
calcium/calmodulin-
dependent protein 
kinase II alpha 
43  1448235_s_at  1517.76  NA  1.32  1.58  BF166000 
114675 
15289 
213440 
432959 
433238 
434174 
544824 
545506 
545555 
546331 
Hmgb1 /// 
4932431P20R
ik /// Hmgb1l 
/// 
LOC432959 
/// 
LOC433238 
/// 
LOC434174 
/// 
LOC544824 
/// 
LOC545506 
/// 
LOC545555 
/// 
LOC546331 
high mobility group 
box 1 /// RIKEN 
cDNA 4932431P20 
gene /// high mobility 
group box 1-like /// 
similar to High 
mobility group protein 
1 (HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to Ac2-008 /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) 
44  1448745_s_at  1519.00  NA  1.13  1.22  NM_008508  16939  Lor  loricrin 
45  1446990_at  1553.36  NA  1.30  1.53  AW556192  18027  Nfia  nuclear factor I/A 
46  1430635_at  1563.59  NA  1.21  1.37  BB774399  77836  Mlana  melan-A 
47  1415998_at  1574.94  NA  1.32  1.57  NM_011694  22333  Vdac1  voltage-dependent 
anion channel 1 
48  1429460_at  1583.55  NA  1.24  1.41  AK019508  78249  Gpr115  G protein-coupled 
receptor 115 
49  1451718_at  1591.23  NA  1.13  1.23  BB768495  18823  Plp1  proteolipid protein 
(myelin) 1 
50  1447625_at  1594.11  NA  1.26  1.47  BB286270  13559  E2f5  E2F transcription 
factor 5 
51  1429565_s_at  1598.37  NA  1.02  1.03  AK004318  66203  Lce5a  late cornified 
envelope 5A 
52  1449347_a_at  1603.63  NA  1.28  1.50  NM_021365  27083 
434794  Xlr4b /// Xlr4a 
X-linked lymphocyte-
regulated 4B /// X-
linked lymphocyte-
regulated 4A 
53  1429067_at  1612.21  NA  1.29  1.52  AK009171  69543  Capns2  calpain, small subunit 
2 
54  1449540_at  1628.21  NA  1.30  1.55  NM_023894  104384  Rhox9 
reproductive 
homeobox on X 
chromosome, 9 344 
 
55  1450976_at  1633.42  NA  1.28  1.50  AI987929  17988  Ndrg1  N-myc downstream 
regulated gene 1 
56  1450079_at  1633.77  NA  1.09  1.15  AK012873  27206  Nrk  Nik related kinase 
57  1448107_x_at  1655.08  NA  1.29  1.51  BC010754  16612  Klk6  kallikrein 6 
58  1451613_at  1672.90  NA  1.10  1.17  AY027660  68723  Hrnr  hornerin 
59  1419409_at  1700.51  NA  1.15  1.26  NM_026822  68720  Sprrl5  small proline rich-like 
5 
60  1417516_at  1703.92  NA  1.30  1.53  NM_007837  13198  Ddit3  DNA-damage 
inducible transcript 3 
61  1427663_a_at  1708.03  NA  1.30  1.55  BG921314  12750  Clk4  CDC like kinase 4 
62  1448185_at  1724.45  NA  1.30  1.53  NM_022331  64209  Herpud1 
homocysteine-
inducible, 
endoplasmic 
reticulum stress-
inducible, ubiquitin-
like domain member 
1 
63  1452138_a_at  1747.88  NA  1.29  1.52  BB497528  70008  Ace2 
angiotensin I 
converting enzyme 
(peptidyl-dipeptidase 
A) 2 
64  1419905_s_at  1792.82  NA  1.07  1.11  AV026552  15446  Hpgd 
hydroxyprostaglandin 
dehydrogenase 15 
(NAD) 
65  1420676_at  1794.82  NA  1.05  1.08  NM_025984  67127  Sprrl3  small proline rich-like 
3 
66  1448612_at  1809.06  NA  1.31  1.55  NM_018754  55948  Sfn  stratifin 
67  1416778_at  1837.15  NA  1.22  1.39  BE197945  20324  Sdpr  serum deprivation 
response 
68  1416691_at  1841.81  NA  1.29  1.52  NM_019581  56055  Gtpbp2  GTP binding protein 
2 
69  1453218_at  1888.02  NA  1.01  1.01  AK003705  73719  1110014K05R
ik 
RIKEN cDNA 
1110014K05 gene 
70  1420867_at  1891.78  NA  1.28  1.50  BB609648  56334  Tmed2 
transmembrane 
emp24 domain 
trafficking protein 2 
71  1451064_a_at  1893.43  NA  1.28  1.49  BC004827  107272  Psat1  phosphoserine 
aminotransferase 1 
72  1432032_a_at  1895.53  NA  1.29  1.52  AK015393  11876  Artn  artemin 
73  1423271_at  1932.34  NA  1.15  1.26  AV239646  14619  Gjb2 
gap junction 
membrane channel 
protein beta 2 
74  1422989_a_at  1941.79  NA  1.28  1.50  NM_032418  13400  Dmpk 
dystrophia 
myotonica-protein 
kinase 
75  1450387_s_at  1943.45  NA  1.24  1.43  NM_009647  11639  Ak3l1  adenylate kinase 3 
alpha-like 1 
76  1420431_at  1953.13  NA  0.99  0.98  NM_009100  20129  Rptn  repetin 
77  1420332_x_at  1953.24  NA  1.02  1.03  NM_027137  69611  Sprrl7  small proline rich-like 
7 
78  1422639_at  1963.56  NA  1.13  1.23  NM_054084  116903  Calcb  calcitonin-related 
polypeptide, beta 
79  1419591_at  1971.27  NA  1.21  1.36  NM_031378  83492  Mlze 
melanoma-derived 
leucine zipper, extra-
nuclear factor 
80  1418283_at  1979.65  NA  1.29  1.51  NM_009903  12740  Cldn4  claudin 4 
81  1448364_at  1979.87  NA  1.21  1.36  U95826  12452  Ccng2  cyclin G2 
82  1416934_at  1988.26  NA  1.27  1.49  NM_019926  17772  Mtm1  X-linked myotubular 
myopathy gene 1 
83  1457449_at  1991.14  NA  1.29  1.52  AW550676  241447  Lass6 
Longevity assurance 
homolog 6 (S. 
cerevisiae), mRNA 
(cDNA clone 
MGC:67674 
IMAGE:4224547) 
84  1419254_at  1991.99  NA  1.29  1.51  BG076333  17768  Mthfd2 
methylenetetrahydrof
olate dehydrogenase 
(NAD+ dependent), 
methenyltetrahydrofol345 
 
ate cyclohydrolase 
85  1437703_at  1997.64  NA  1.26  1.47  BM229128  382156  LOC382156 
similar to F-box- and 
WD40-repeat-
containing protein 
86  1444515_at  1999.14  NA  1.28  1.49  BM247709  338367  Myo1d  Myosin ID (Myo1d), 
mRNA 
87  1429602_at  2011.21  NA  1.26  1.47  AK009888  69655  Cd164l2  D164 sialomucin-like 
2 
88  1437306_at  2022.54  NA  1.17  1.30  BG071013  232035  C130092O11
Rik 
RIKEN cDNA 
C130092O11 gene 
89  1457040_at  2026.45  NA  1.21  1.38  BE947711  246316  Lgi2  leucine-rich repeat 
LGI family, member 2 
90  1436058_at  2041.03  NA  1.28  1.49  BB132493  58185  Rsad2 
radical S-adenosyl 
methionine domain 
containing 2 
91  1437809_x_at  2045.19  NA  1.26  1.46  AV296703  23872  Ets2 
E26 avian leukemia 
oncogene 2, 3' 
domain 
92  1430112_at  2045.22  NA  1.30  1.54  AK016965  269701 
545804 
Wdr66 /// 
LOC545804 
WD repeat domain 
66 /// similar to 
hypothetical protein 
MGC33630 
93  1444000_at  2052.19  NA  1.28  1.49  BB448693  319786  B930059L03R
ik 
RIKEN cDNA 
B930059L03 gene 
94  1424332_at  2054.71  NA  1.28  1.49  AF422144  224624  Rab40c  Rab40c, member 
RAS oncogene family 
95  1436055_at  2071.43  NA  1.19  1.32  AI506528  74488  Lrrc15  leucine rich repeat 
containing 15 
96  1418599_at  2077.45  NA  1.10  1.16  NM_007729  12814  Col11a1  procollagen, type XI, 
alpha 1 
97  1422247_a_at  2095.05  NA  1.09  1.15  NM_009484  22290 
546404 
Uty /// 
LOC546404 
ubiquitously 
transcribed 
tetratricopeptide 
repeat gene, Y 
chromosome /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb 
98  1425880_x_at  2096.27  NA  1.26  1.46  AF290196  236537  Zfp352  zinc finger protein 
352 
99  1449033_at  2098.87  NA  1.12  1.20  AB013898  18383  Tnfrsf11b 
tumor necrosis factor 
receptor superfamily, 
member 11b 
(osteoprotegerin) 
100  1429297_at  2107.08  NA  1.17  1.29  AK009018  71869  Serpinb12 
serine (or cysteine) 
peptidase inhibitor, 
clade B (ovalbumin), 
member 12 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
General Information 
Experiment   VK1mouse4302 
Normalisation   rma across replicates 
Chip   one chip only 
Comparison   Treatment samples: K14D6 Control vs Baseline samples: WT Control 
RP comparison   not paired 
Direction   Negative 
 
0  Probe-set ID  RPscore  FDR  FC_rma FC_nom "SOURCE" "EntrezGene"  Gene Symbol  Title 
1  1436996_x_at  80.91  0.00  -2.92  -5.79  AV066625  17110  Lzp-s  P lysozyme 
structural 
2  1448591_at  99.49  0.50  -2.81  -5.44  NM_021281  13040  Ctss  cathepsin S 
3  1439426_x_at  119.46  1.67  -2.73  -5.20  AV058500  17110  Lzp-s  P lysozyme 
structural 
4  1419627_s_at  204.14  5.75  -2.04  -3.22  NM_020001  56620  Clec4n 
C-type lectin 
domain family 4, 
member n 
5  1436905_x_at  241.21  8.20  -2.02  -3.18  BB218107  16792  Laptm5 
lysosomal-
associated 
protein 
transmembrane 5 
6  1420804_s_at  288.72  11.17  -1.84  -2.73  NM_010819  17474  Clec4d 
C-type lectin 
domain family 4, 
member d 
7  1453218_at  314.02  13.14  -1.94  -2.97  AK003705  73719  1110014K05Rik 
RIKEN cDNA 
1110014K05 
gene 
8  1448620_at  349.82  16.00  -1.84  -2.71  NM_010188  14131  Fcgr3  Fc receptor, IgG, 
low affinity III 
9  1444061_at  391.54  19.33  -1.96  -3.01  BB150166  109314  A030004J04Rik 
RIKEN cDNA 
A030004J04 
gene 
10  1423547_at  395.41  17.70  -1.88  -2.81  AW208566  17105  Lyzs  lysozyme 
11  1419599_s_at  395.62  16.09  -1.74  -2.49  NM_026835  64382  Ms4a11 
membrane-
spanning 4-
domains, 
subfamily A, 
member 11 
12  1432466_a_at  412.07  17.00  -1.79  -2.60  AK019319  11816  Apoe  apolipoprotein E 
13  1424903_at  436.82  18.77  -1.76  -2.53  AF127244  20592  Jarid1d 
jumonji, AT rich 
interactive 
domain 1D (Rbp2 
like) 
14  1452141_a_at  458.61  20.36  -1.75  -2.50  BC001991  20363  Sepp1  selenoprotein P, 
plasma, 1 
15  1456248_at  463.19  19.87  -1.87  -2.79  AV076385  69520  2310002A05Rik 
RIKEN cDNA 
2310002A05 
gene 
16  1420394_s_at  464.93  19.06  -1.73  -2.45  U05264  14727 14728  Gp49a /// Lilrb4 
glycoprotein 49 A 
/// leukocyte 
immunoglobulin-
like receptor, 
subfamily B, 347 
 
member 4 
17  1419409_at  529.00  26.29  -1.75  -2.50  NM_026822  68720  Sprrl5  small proline rich-
like 5 
18  1429565_s_at  530.23  24.89  -1.86  -2.76  AK004318  66203  Lce5a  late cornified 
envelope 5A 
19  1420332_x_at  533.51  23.89  -1.78  -2.57  NM_027137  69611  Sprrl7  small proline rich-
like 7 
20  1420550_at  577.80  28.95  -1.73  -2.46  AV014636  67828  1110055J05Rik 
RIKEN cDNA 
1110055J05 
gene 
21  1428980_at  601.17  30.43  -1.73  -2.46  AK003253  73731  1110001M24Rik 
RIKEN cDNA 
1110001M24 
gene 
22  1452077_at  626.85  32.00  -1.60  -2.15  AA210261  26900  Ddx3y 
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 3, Y-
linked 
23  1448995_at  639.19  32.13  -1.32  -1.58  NM_019932  56744  Cxcl4  chemokine (C-X-
C motif) ligand 4 
24  1438069_a_at  646.43  31.58  -1.56  -2.07  BE446879  83486  Rbm5  RNA binding 
motif protein 5 
25  1420350_at  648.49  30.68  -1.72  -2.44  NM_028625  73722  Sprrl2  small proline rich-
like 2 
26  1420676_at  662.44  31.35  -1.70  -2.38  NM_025984  67127  Sprrl3  small proline rich-
like 3 
27  1438558_x_at  665.94  30.52  -1.63  -2.22  AV009267  15220  Foxq1  Forkhead box Q1 
(Foxq1), mRNA 
28  1417808_at  667.50  29.68  -1.67  -2.31  NM_025621  66533  2310050C09Rik 
RIKEN cDNA 
2310050C09 
gene 
29  1423505_at  674.00  29.52  -1.49  -1.93  BB114067  21345  Tagln  transgelin 
30  1417936_at  686.95  30.53  -1.61  -2.19  AF128196  20308  Ccl9  chemokine (C-C 
motif) ligand 9 
31  1449265_at  718.21  34.00  -1.54  -2.03  BC008152  12362  Casp1  caspase 1 
32  1420431_at  719.47  33.00  -1.59  -2.14  NM_009100  20129  Rptn  repetin 
33  1423522_at  723.58  32.58  -1.57  -2.09  BB811478  18150  Npm3  nucleoplasmin 3 
34  1417275_at  731.55  32.50  -1.31  -1.55  NM_010762  17153  Mal 
myelin and 
lymphocyte 
protein, T-cell 
differentiation 
protein 
35  1432828_at  737.75  32.57  -1.52  -1.98  BF607489  ---  ---  --- 
36  1426438_at  764.20  35.17  -1.54  -2.04  AA210261  26900  Ddx3y 
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 3, Y-
linked 
37  1420741_x_at  791.06  37.41  -1.65  -2.28  NM_029667  76585  2310069N01Rik 
RIKEN cDNA 
2310069N01 
gene 
38  1427735_a_at  805.16  38.18  -1.53  -2.00  M12233  11459  Acta1  actin, alpha 1, 
skeletal muscle 
39  1431554_a_at  806.43  37.38  -1.60  -2.15  AK003395  71790  Anxa9  annexin A9 
40  1422963_at  808.90  36.98  -1.61  -2.19  NM_011475  20763  Sprr2i  small proline-rich 
protein 2I 
41  1425951_a_at  814.54  36.80  -1.51  -1.97  AF240358  56620  Clec4n 
C-type lectin 
domain family 4, 
member n 
42  1457777_at  817.53  36.43  -1.58  -2.11  AV240142  57911  Gsdm1  gasdermin 1 
43  1449833_at  833.07  37.70  -1.59  -2.14  NM_011472  20760  Sprr2f  small proline-rich 
protein 2F 
44  1435477_s_at  834.99  37.02  -1.58  -2.11  BM224327  14130  Fcgr2b  Fc receptor, IgG, 
low affinity IIb 
45  1423634_at  852.30  38.13  -1.58  -2.12  AI506986  57911  Gsdm1  gasdermin 1 
46  1449071_at  854.10  37.59  -1.50  -1.95  NM_022879  17898  Myl7 
myosin, light 
polypeptide 7, 
regulatory 
47  1456001_at  854.64  36.83  -1.60  -2.17  AV071932  Mm.387664  ---  CDNA clone 
MGC:118457 348 
 
IMAGE:30288561 
48  1426598_at  863.01  37.17  -1.48  -1.90  BB742957 
22290 
546404 
546411 
Uty /// 
LOC546404 /// 
LOC546411 
ubiquitously 
transcribed 
tetratricopeptide 
repeat gene, Y 
chromosome /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb 
49  1423542_at  869.86  37.16  -1.56  -2.08  BB283507  23993  Klk7 
kallikrein 7 
(chymotryptic, 
stratum corneum) 
50  1417210_at  874.20  36.80  -1.48  -1.91  NM_012011  26908  Eif2s3y 
eukaryotic 
translation 
initiation factor 2, 
subunit 3, 
structural gene Y-
linked 
51  1453092_at  875.77  36.14  -1.66  -2.29  AK009010  74175  2300002G24Rik 
RIKEN cDNA 
2300002G24 
gene 
52  1418188_a_at  879.22  36.19  -1.50  -1.95  AF146523  72289  Malat1 
metastasis 
associated lung 
adenocarcinoma 
transcript 1 (non-
coding RNA) 
53  1416468_at  881.14  35.64  -1.40  -1.75  NM_013467  11668  Aldh1a1 
aldehyde 
dehydrogenase 
family 1, 
subfamily A1 
54  1440966_at  882.57  35.20  -1.43  -1.79  BB248730  57438  March7 
membrane-
associated ring 
finger (C3HC4) 7 
55  1448291_at  890.87  35.47  -1.40  -1.74  NM_013599  17395  Mmp9 
matrix 
metallopeptidase 
9 
56  1427910_at  890.93  34.84  -1.61  -2.18  AK003744  73720  Cst6  cystatin E/M 
57  1418601_at  896.13  34.77  -1.04  -1.06  NM_011921  26358  Aldh1a7 
aldehyde 
dehydrogenase 
family 1, 
subfamily A7 
58  1420677_x_at  931.87  38.52  -1.57  -2.10  NM_025984  67127  Sprrl3  small proline rich-
like 3 
59  1460569_x_at  933.90  38.10  -1.47  -1.87  AW611462  12739  Cldn3  claudin 3 
60  1438403_s_at  944.91  38.80  -1.46  -1.86  BF537798  80291  BC003324 
CDNA sequence 
BC003324, 
mRNA (cDNA 
clone MGC:7036 
IMAGE:3156139) 
61  1455900_x_at  948.87  38.64  -1.59  -2.14  BB041811  21817  Tgm2  transglutaminase 
2, C polypeptide 
62  1437277_x_at  957.49  38.84  -1.49  -1.92  BB550124  21817  Tgm2  transglutaminase 
2, C polypeptide 
63  1449902_at  961.33  38.57  -1.50  -1.95  AV014636  66195  1110058A15Rik 
RIKEN cDNA 
1110058A15 
gene 
64  1417266_at  967.76  38.66  -1.72  -2.43  BC002073  20305  Ccl6  chemokine (C-C 
motif) ligand 6 
65  1435934_at  984.76  39.83  -1.43  -1.80  AI643884  70316  Ndufab1 
NADH 
dehydrogenase 
(ubiquinone) 1, 
alpha/beta 
subcomplex, 1 
66  1450430_at  1019.27  43.24  -1.50  -1.95  NM_008625  17533  Mrc1  mannose 
receptor, C type 1 
67  1432558_a_at  1032.55  44.00  -1.22  -1.39  AK019046  17153  Mal 
myelin and 
lymphocyte 
protein, T-cell 349 
 
differentiation 
protein 
68  1457254_x_at  1041.76  44.28  -1.63  -2.22  BB302103  432460  LOC432460 
similar to RIKEN 
cDNA 
6330442E10 
gene 
69  1456211_at  1061.10  45.87  -1.48  -1.90  BB003937  ---  ---  --- 
70  1447807_s_at  1066.37  45.89  -1.44  -1.82  AV336001  211945  Plekhh1 
pleckstrin 
homology domain 
containing, family 
H (with MyTH4 
domain) member 
1 
71  1419549_at  1071.67  45.93  -1.35  -1.63  NM_007482  11846  Arg1  arginase 1, liver 
72  1420377_at  1074.00  45.62  -1.27  -1.48  BG071333  20450  St8sia2 
ST8 alpha-N-
acetyl-
neuraminide 
alpha-2,8-
sialyltransferase 
2 
73  1417061_at  1090.52  46.88  -1.46  -1.86  AF226613  53945  Slc40a1 
solute carrier 
family 40 (iron-
regulated 
transporter), 
member 1 
74  1427268_at  1091.98  46.50  -1.55  -2.04  J03458  433621 
545581 
LOC433621 /// 
LOC545581 
similar to Acidic 
ribosomal 
phosphoprotein 
P0 /// similar to 
Acidic ribosomal 
phosphoprotein 
P0 
75  1435906_x_at  1103.69  47.03  -1.46  -1.85  BE197524  14469  Gbp2 
guanylate 
nucleotide 
binding protein 2 
76  1454849_x_at  1104.74  46.59  -1.38  -1.69  BB433678  12759  Clu  clusterin 
77  1452378_at  1116.67  47.32  -1.47  -1.88  AW012617  72289  Malat1 
metastasis 
associated lung 
adenocarcinoma 
transcript 1 (non-
coding RNA) 
78  1451601_a_at  1121.06  47.27  -1.54  -2.02  BC025823  216892  BC011467  cDNA sequence 
BC011467 
79  1426439_at  1135.14  48.33  -1.50  -1.95  AA210261  26900  Ddx3y 
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 3, Y-
linked 
80  1451613_at  1142.37  48.46  -1.48  -1.89  AY027660  68723  Hrnr  hornerin 
81  1448982_at  1158.63  49.88  -1.50  -1.94  NM_011177  19144  Prss18  protease, serine, 
18 
82  1448169_at  1202.81  NA  -1.31  -1.56  NM_010664  16668  Krt1-18  keratin complex 
1, acidic, gene 18 
83  1449959_x_at  1203.90  NA  -1.50  -1.95  NM_026335  67718  Sprrl9  small proline rich-
like 9 
84  1435462_at  1214.16  NA  -1.46  -1.86  BQ176176  433022  LOC433022  hypothetical 
LOC433022 
85  1437458_x_at  1221.73  NA  -1.37  -1.67  AV075715  12759  Clu  clusterin 
86  1419605_at  1240.04  NA  -1.44  -1.81  NM_010796  17312  Mgl1 
macrophage 
galactose N-
acetyl-
galactosamine 
specific lectin 1 
87  1450633_at  1243.32  NA  -1.48  -1.91  NM_020036  80796  Calm4  calmodulin 4 
88  1427963_s_at  1246.05  NA  -1.47  -1.88  BE979765  103142  Rdh9  retinol 
dehydrogenase 9 
89  1429540_at  1247.88  NA  -1.49  -1.92  AK008979  72383  Cnfn  cornifelin 
90  1422837_at  1249.20  NA  -1.43  -1.80  NM_022886  64929  Scel  sciellin 
91  1429060_at  1255.39  NA  -1.42  -1.77  AK020483  72289  Malat1 
metastasis 
associated lung 
adenocarcinoma 
transcript 1 (non-350 
 
coding RNA) 
92  1429230_at  1256.39  NA  -1.46  -1.87  AK003996  68668  1110030O19Rik 
RIKEN cDNA 
1110030O19 
gene 
93  1421398_at  1264.34  NA  -1.37  -1.67  NM_053166  94089  Trim7  tripartite motif 
protein 7 
94  1450792_at  1273.33  NA  -1.38  -1.69  NM_011662  22177  Tyrobp 
TYRO protein 
tyrosine kinase 
binding protein 
95  1418283_at  1274.46  NA  -1.34  -1.62  NM_009903  12740  Cldn4  claudin 4 
96  1418626_a_at  1277.22  NA  -1.34  -1.61  NM_013492  12759  Clu  clusterin 
97  1436917_s_at  1289.32  NA  -1.34  -1.62  BB491018  67839  Gpsm1 
G-protein 
signalling 
modulator 1 
(AGS3-like, C. 
elegans) 
98  1417917_at  1307.06  NA  -1.38  -1.69  NM_009922  12797  Cnn1  calponin 1 
99  1436329_at  1314.80  NA  -1.42  -1.79  AV346607  13655  Egr3  early growth 
response 3 
100  1429537_at  1315.93  NA  -1.34  -1.61  BG277020  66625  5730406M06Rik 
RIKEN cDNA 
5730406M06 
gene 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
 
General Information 
Experiment   VK1mouse4302 
Normalisation   rma across replicates 
Chip   one chip only 
Comparison   Treatment samples: WT + CCL3 vs Baseline samples: WT Control 
RP comparison   not paired 
Direction   Negative   
 
 
 
0  Probe-set ID  RPscore  FDR  FC_rma  FC_nom "SOURCE" "EntrezGene"  Gene 
Symbol  Title 
1  1426438_at  228.87  45.00  -4.27  -10.81  AA210261  26900  Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 3, 
Y-linked 
2  1453218_at  263.41  32.50  -1.59  -2.15  AK003705  73719  1110014K0
5Rik 
RIKEN cDNA 
1110014K05 gene 
3  1451613_at  265.52  22.00  -1.70  -2.39  AY027660  68723  Hrnr  Hornerin 
4  1452077_at  302.93  23.50  -2.63  -4.88  AA210261  26900  Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 3, 
Y-linked 
5  1417210_at  319.33  21.20  -3.57  -8.06  NM_01201
1  26908  Eif2s3y 
eukaryotic translation 
initiation factor 2, 
subunit 3, structural 
gene Y-linked 
6  1419409_at  332.57  19.83  -1.63  -2.22  NM_02682
2  68720  Sprrl5  small proline rich-like 5 
7  1429565_s_at  387.48  28.00  -1.55  -2.05  AK004318  66203  Lce5a  late cornified envelope 
5A 
8  1420431_at  415.16  30.12  -1.58  -2.11  NM_00910
0  20129  Rptn  Repetin 
9  1424903_at  443.01  32.11  -2.14  -3.49  AF127244  20592  Jarid1d 
jumonji, AT rich 
interactive domain 1D 
(Rbp2 like) 
10  1420332_x_at  453.86  30.90  -1.49  -1.92  NM_02713
7  69611  Sprrl7  small proline rich-like 7 
11  1452292_at  494.01  36.36  -1.51  -1.97  AV271093  ---  ---  --- 
12  1426598_at  506.99  35.75  -1.84  -2.72  BB742957 
22290 
546404 
546411 
Uty /// 
LOC54640
4 /// 
LOC54641
1 
ubiquitously transcribed 
tetratricopeptide repeat 
gene, Y chromosome /// 
similar to male-specific 
histocompatibility 
antigen H-YDb /// 
similar to male-specific 
histocompatibility 
antigen H-YDb 
13  1427268_at  508.76  33.62  -1.53  -2.00  J03458  433621 
545581 
LOC43362
1 /// 
LOC54558
1 
similar to Acidic 
ribosomal 
phosphoprotein P0 /// 
similar to Acidic 
ribosomal 
phosphoprotein P0 
14  1426439_at  544.39  36.79  -1.98  -3.07  AA210261  26900  Ddx3y  DEAD (Asp-Glu-Ala-352 
 
Asp) box polypeptide 3, 
Y-linked 
15  1428980_at  574.12  38.80  -1.47  -1.87  AK003253  73731  1110001M
24Rik 
RIKEN cDNA 
1110001M24 gene 
16  1448745_s_at  646.92  NA  -1.45  -1.84  NM_00850
8  16939  Lor  Loricrin 
17  1420350_at  652.06  NA  -1.42  -1.78  NM_02862
5  73722  Sprrl2  small proline rich-like 2 
18  1417275_at  698.11  NA  -1.44  -1.82  NM_01076
2  17153  Mal 
myelin and lymphocyte 
protein, T-cell 
differentiation protein 
19  1419906_at  708.68  NA  -1.46  -1.86  AV026552  15446  Hpgd 
Hydroxyprostaglandin 
dehydrogenase 15 
(NAD), mRNA (cDNA 
clone MGC:14001 
IMAGE:4208980) 
20  1429996_at  786.08  NA  -1.42  -1.77  BB207765  70760  6330417A1
6Rik 
RIKEN cDNA 
6330417A16 gene 
21  1459635_at  854.52  NA  -1.41  -1.76  BG144294  13383  Dlgh1 
Discs, large homolog 1 
(Drosophila) (Dlgh1), 
mRNA 
22  1417808_at  911.39  NA  -1.45  -1.84  NM_02562
1  66533  2310050C
09Rik 
RIKEN cDNA 
2310050C09 gene 
23  1420677_x_at  949.26  NA  -1.38  -1.69  NM_02598
4  67127  Sprrl3  small proline rich-like 3 
24  1444472_at  961.17  NA  -1.39  -1.72  BB154631  235344  Sik2  SNF1-like kinase 2 
(Snf1lk2), mRNA 
25  1442153_at  962.32  NA  -1.57  -2.10  BB206087  Mm.385427  --- 
0 day neonate thymus 
cDNA, RIKEN full-
length enriched library, 
clone:A430072F05 
product:unclassifiable, 
full insert sequence 
26  1420550_at  1016.33  NA  -1.34  -1.61  AV014636  67828  1110055J0
5Rik 
RIKEN cDNA 
1110055J05 gene 
27  1420183_at  1037.45  NA  -1.37  -1.67  AI036317  16939  Lor  Loricrin (Lor), mRNA 
28  1432558_a_a
t  1074.86  NA  -1.36  -1.65  AK019046  17153  Mal 
myelin and lymphocyte 
protein, T-cell 
differentiation protein 
29  1452315_at  1119.09  NA  -1.31  -1.56  BB827235  16551  Kif11  kinesin family member 
11 
30  1429772_at  1124.63  NA  -1.35  -1.64  BB085537  18845  Plxna2  plexin A2 
31  1453405_at  1164.96  NA  -1.38  -1.70  AK019180  78390  2610311B0
1Rik 
RIKEN cDNA 
2610311B01 gene 
32  1457065_at  1166.06  NA  -1.49  -1.93  BB530943  22268  Upk1b  uroplakin 1B 
33  1423952_a_a
t  1173.29  NA  -1.45  -1.84  BC010337  110310  Krt2-7  keratin complex 2, 
basic, gene 7 
34  1441100_at  1188.84  NA  -1.37  -1.68  BB496952  103537  Mbtd1  mbt domain containing 
1 
35  1420377_at  1217.31  NA  -1.22  -1.39  BG071333  20450  St8sia2 
ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 2 
36  1419905_s_at  1217.46  NA  -1.31  -1.55  AV026552  15446  Hpgd 
hydroxyprostaglandin 
dehydrogenase 15 
(NAD) 
37  1437782_at  1225.80  NA  -1.36  -1.67  BE651445  66797  Cntnap2  contactin associated 
protein-like 2 
38  1423320_at  1241.37  NA  -1.41  -1.76  AI507229  66705  Dnase1l2  deoxyribonuclease 1-
like 2 
39  1419549_at  1252.27  NA  -1.44  -1.82  NM_00748
2  11846  Arg1  arginase 1, liver 
40  1420676_at  1258.55  NA  -1.28  -1.51  NM_02598
4  67127  Sprrl3  small proline rich-like 3 
41  1449451_at  1259.55  NA  -1.34  -1.62  NM_02586
7  66957  Serpinb11 
serine (or cysteine) 
peptidase inhibitor, 
clade B (ovalbumin), 
member 11 
42  1421316_at  1264.83  NA  -1.38  -1.69  NM_02541
3  66195  1110058A1
5Rik 
RIKEN cDNA 
1110058A15 gene 353 
 
43  1420741_x_at  1275.58  NA  -1.30  -1.53  NM_02966
7  76585  2310069N
01Rik 
RIKEN cDNA 
2310069N01 gene 
44  1418855_at  1285.55  NA  -1.37  -1.68  NM_02862
8  73730  1110008K0
4Rik 
RIKEN cDNA 
1110008K04 gene 
45  1449902_at  1286.42  NA  -1.32  -1.57  AV014636  66195  1110058A1
5Rik 
RIKEN cDNA 
1110058A15 gene 
46  1424927_at  1315.09  NA  -1.35  -1.63  BC025083  73690  Glipr1  GLI pathogenesis-
related 1 (glioma) 
47  1440789_at  1329.47  NA  -1.35  -1.64  BB243938  18007  Neo1  Neogenin 
48  1440966_at  1338.11  NA  -1.37  -1.67  BB248730  57438  March7  membrane-associated 
ring finger (C3HC4) 7 
49  1456248_at  1352.60  NA  -1.29  -1.52  AV076385  69520  2310002A0
5Rik 
RIKEN cDNA 
2310002A05 gene 
50  1448393_at  1356.41  NA  -1.42  -1.78  BC008104  53624  Cldn7  claudin 7 
51  1416613_at  1364.07  NA  -1.10  -1.17  BI251808  13078  Cyp1b1 
cytochrome P450, 
family 1, subfamily b, 
polypeptide 1 
52  1430440_at  1368.33  NA  -1.34  -1.61  AK015363  74660  4930442J1
9Rik 
RIKEN cDNA 
4930442J19 gene 
53  1455464_x_at  1377.32  NA  -1.41  -1.76  BB427704  ---  ---  --- 
54  1422760_at  1398.06  NA  -1.28  -1.49  NM_01106
1  18602  Padi4  peptidyl arginine 
deiminase, type IV 
55  1420413_at  1405.23  NA  -1.34  -1.62  NM_01199
0  26570  Slc7a11 
solute carrier family 7 
(cationic amino acid 
transporter, y+ system), 
member 11 
56  1447625_at  1406.24  NA  -1.30  -1.54  BB286270  13559  E2f5  E2F transcription factor 
5 
57  1456001_at  1416.63  NA  -1.34  -1.61  AV071932  Mm.387664  --- 
CDNA clone 
MGC:118457 
IMAGE:30288561 
58  1460569_x_at  1420.12  NA  -1.37  -1.68  AW611462  12739  Cldn3  claudin 3 
59  1444192_at  1434.52  NA  -1.32  -1.58  BB460651  ---  ---  --- 
60  1450633_at  1435.50  NA  -1.34  -1.62  NM_02003
6  80796  Calm4  calmodulin 4 
61  1418283_at  1436.80  NA  -1.31  -1.57  NM_00990
3  12740  Cldn4  claudin 4 
62  1439845_at  1440.73  NA  -1.33  -1.60  BQ174438  Mm.348429  ---  Transcribed locus 
63  1419529_at  1441.16  NA  -1.20  -1.34  NM_03125
2  83430  Il23a  interleukin 23, alpha 
subunit p19 
64  1457077_at  1456.56  NA  -1.34  -1.61  BB306048  245683  --- 
PREDICTED: similar to 
hypothetical protein 
FLJ34960 [Mus 
musculus], mRNA 
sequence 
65  1453252_at  1459.43  NA  -1.27  -1.48  AK010138  71916  Dus4l  dihydrouridine synthase 
4-like (S. cerevisiae) 
66  1438558_x_at  1519.98  NA  -1.31  -1.55  AV009267  15220  Foxq1  Forkhead box Q1 
(Foxq1), mRNA 
67  1454299_at  1522.69  NA  -1.31  -1.55  AV250295  74587  4833422B0
7Rik 
RIKEN cDNA 
4833422B07 gene 
68  1454632_at  1530.52  NA  -1.32  -1.58  AV328515  268567  6330442E1
0Rik 
RIKEN cDNA 
6330442E10 gene 
69  1449071_at  1534.40  NA  -1.37  -1.68  NM_02287
9  17898  Myl7 
myosin, light 
polypeptide 7, 
regulatory 
70  1445916_at  1537.46  NA  -1.34  -1.62  BG070994  11964  Atp6v1a1 
ATPase, H+ 
transporting, V1 subunit 
A1, mRNA (cDNA clone 
MGC:6531 
IMAGE:2651677) 
71  1418496_at  1549.18  NA  -1.36  -1.65  NM_00825
9  15375  Foxa1  forkhead box A1 
72  1451601_a_a
t  1553.22  NA  -1.30  -1.53  BC025823  216892  BC011467  cDNA sequence 
BC011467 
73  1416368_at  1580.84  NA  -1.23  -1.40  NM_01035
7  14860  Gsta4  glutathione S-
transferase, alpha 4 
74  1459415_at  1594.42  NA  -1.31  -1.56  BB204258  ---  ---  --- 354 
 
75  1458871_at  1611.25  NA  -1.34  -1.62  BB148290  243084  Tmprss11e  transmembrane 
protease, serine 11e 
76  1427593_at  1632.56  NA  -1.31  -1.55  BB620112  93679  Trim8  tripartite motif protein 8 
77  1418423_s_at  1637.78  NA  -1.30  -1.53  AF425083 
20709 20710 
544923 
93806 
Serpinb9f 
/// 
Serpinb9e 
/// 
Serpinb9g 
/// 
LOC54492
3 
serine (or cysteine) 
peptidase inhibitor, 
clade B, member 9f /// 
serine (or cysteine) 
peptidase inhibitor, 
clade B, member 9e /// 
serine (or cysteine) 
peptidase inhibitor, 
clade B, member 9g /// 
similar to 
OTTMUSP0000000064
1 
78  1442750_at  1639.79  NA  -1.30  -1.54  BG067768  97884  D230016N
13Rik 
UDP-
GalNAc:betaGlcNAc 
beta 1,3-
galactosaminyltransfera
se, polypeptide 2, 
mRNA (cDNA clone 
MGC:103263 
IMAGE:30735904) 
79  1425671_at  1644.06  NA  -1.31  -1.56  AF093257  26556  Homer1  homer homolog 1 
(Drosophila) 
80  1444562_at  1655.13  NA  -1.32  -1.58  BE690666  100763  Ube3c 
Ubiquitin protein ligase 
E3C, mRNA (cDNA 
clone IMAGE:5353408) 
81  1419619_at  1661.35  NA  -1.32  -1.57  NM_02877
0  74127  1200016G
03Rik 
RIKEN cDNA 
1200016G03 gene 
82  1444349_at  1661.40  NA  -1.24  -1.42  BG071091  ---  ---  --- 
83  1422639_at  1680.58  NA  -1.32  -1.57  NM_05408
4  116903  Calcb  calcitonin-related 
polypeptide, beta 
84  1420647_a_a
t  1681.19  NA  -1.25  -1.44  NM_03117
0 
16691 
434261 
Krt2-8 /// 
LOC43426
1 
keratin complex 2, 
basic, gene 8 /// similar 
to cytokeratin EndoA – 
mouse 
85  1422247_a_a
t  1685.22  NA  -1.28  -1.50  NM_00948
4 
22290 
546404 
Uty /// 
LOC54640
4 
ubiquitously transcribed 
tetratricopeptide repeat 
gene, Y chromosome /// 
similar to male-specific 
histocompatibility 
antigen H-YDb 
86  1447807_s_at  1688.22  NA  -1.34  -1.62  AV336001  211945  Plekhh1 
pleckstrin homology 
domain containing, 
family H (with MyTH4 
domain) member 1 
87  1446570_at  1692.91  NA  -1.31  -1.56  BB469236  ---  ---  --- 
88  1448169_at  1698.16  NA  -1.23  -1.40  NM_01066
4  16668  Krt1-18  keratin complex 1, 
acidic, gene 18 
89  1415861_at  1699.74  NA  -1.22  -1.39  BB762957  22178  Tyrp1  tyrosinase-related 
protein 1 
90  1445477_at  1711.48  NA  -1.31  -1.55  BE952410  Mm.26390  ---  Retrotransposon ETn 
insertion in p53 mRNA 
91  1435831_at  1713.42  NA  -1.42  -1.79  BB427704  22268  Upk1b  uroplakin 1B 
92  1435321_at  1719.91  NA  -1.34  -1.61  BM117827  77569  3732412D
22Rik 
RIKEN cDNA 
3732412D22 gene 
93  1444202_at  1743.05  NA  -1.30  -1.54  BI965268  546051  LOC54605
1 
similar to hypothetical 
protein LOC80139 
94  1455679_at  1748.59  NA  -1.29  -1.51  BE457727  109019  5830411E1
0Rik 
RIKEN cDNA 
5830411E10 gene 
95  1438216_at  1751.69  NA  -1.27  -1.48  BG143502  68750  1110037N
09Rik 
PREDICTED: 
hypothetical protein 
LOC68750 [Mus 
musculus], mRNA 
sequence 
96  1435154_at  1760.27  NA  -1.24  -1.43  AV099404  245128  LOC24512
8 
similar to solute carrier 
family 7 (cationic amino 
acid transporter, y+ 
system), member 3 
97  1426941_at  1764.77  NA  -1.26  -1.47  BC020027  ---  ---  --- 355 
 
98  1420371_at  1787.33  NA  -1.29  -1.52  BI646094  20650  Sntb2  syntrophin, basic 2 
99  1443915_at  1788.56  NA  -1.30  -1.55  BE957160  74600  Mrpl47  mitochondrial ribosomal 
protein L47 
100  1436686_at  1789.49  NA  -1.31  -1.55  AA165749  68036  Zfp706  zinc finger protein 706 
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The Rank Product (RP) differential expression analysis report 
  
 
 
 
General Information 
Experiment   VK1mouse4302 
Normalisation   rma across replicates 
Chip   one chip only 
Comparison   Treatment samples: K14D6 + CCL3 vs Baseline samples: K14D6 Control 
RP comparison   not paired 
Direction   Negative 
 
 
0  Probe-set ID  RPscore  FDR  FC_rma FC_nom "SOURCE" "EntrezGene"  Gene Symbol  Title 
1  1452292_at  123.91  2.00  -1.85  -2.74  AV271093  ---  ---  --- 
2  1436319_at  264.52  29.00  -1.62  -2.21  BB751459  240725  Sulf1  sulfatase 1 
3  1435831_at  294.66  26.67  -1.60  -2.17  BB427704  22268  Upk1b  uroplakin 1B 
4  1434172_at  360.64  34.00  -1.44  -1.81  BQ177934  ---  ---  --- 
5  1450377_at  538.35  NA  -1.55  -2.04  AI385532  21825  Thbs1  thrombospondin 1 
6  1446481_at  543.55  NA  -1.49  -1.93  BB534411  11787  Apbb2 
Amyloid beta (A4) 
precursor protein-
binding, family B, 
member 2, mRNA 
(cDNA clone 
MGC:100042 
IMAGE:30550087) 
7  1435989_x_at  576.03  NA  -1.52  -1.99  AW322280  434261  LOC434261 
similar to 
cytokeratin EndoA 
- mouse 
8  1457479_at  603.21  NA  -1.44  -1.81  AW536823  22596  Xrcc5 
X-ray repair 
complementing 
defective repair in 
Chinese hamster 
cells 5, mRNA 
(cDNA clone 
IMAGE:2647262) 
9  1427262_at  649.58  NA  -1.42  -1.77  L04961  213742  Xist  inactive X specific 
transcripts 
10  1456661_at  657.15  NA  -1.50  -1.94  BM293452  16468  Jarid2 
Jumonji, AT rich 
interactive domain 
2, mRNA (cDNA 
clone 
IMAGE:3589616) 
11  1427610_at  674.96  NA  -1.47  -1.88  BC026631  109620  Dsp  desmoplakin 
12  1417275_at  680.37  NA  -1.46  -1.85  NM_010762  17153  Mal 
myelin and 
lymphocyte 
protein, T-cell 
differentiation 
protein 
13  1424598_at  683.47  NA  -1.44  -1.81  BC021452  13209  Ddx6 
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 6 
14  1455464_x_at  694.70  NA  -1.47  -1.88  BB427704  ---  ---  --- 
15  1445641_at  703.61  NA  -1.47  -1.88  BB727879  ---  ---  --- 
16  1427263_at  741.08  NA  -1.32  -1.58  L04961  213742  Xist  inactive X specific 
transcripts 357 
 
17  1440722_at  771.22  NA  -1.39  -1.72  BB284387  52013  D19Ertd386e 
DNA segment, Chr 
19, ERATO Doi 
386, expressed 
(D19Ertd386e), 
mRNA 
18  1420377_at  813.18  NA  -1.24  -1.41  BG071333  20450  St8sia2 
ST8 alpha-N-
acetyl-neuraminide 
alpha-2,8-
sialyltransferase 2 
19  1433902_at  819.15  NA  -1.36  -1.66  BB469300  243574  Kbtbd8 
kelch repeat and 
BTB (POZ) domain 
containing 8 
20  1460302_at  852.47  NA  -1.42  -1.77  AI385532  21825  Thbs1  thrombospondin 1 
21  1420647_a_at  861.38  NA  -1.45  -1.83  NM_031170  16691 
434261 
Krt2-8 /// 
LOC434261 
keratin complex 2, 
basic, gene 8 /// 
similar to 
cytokeratin EndoA 
- mouse 
22  1438200_at  874.34  NA  -1.42  -1.78  BB065799  240725  Sulf1  sulfatase 1 
23  1443393_at  878.47  NA  -1.44  -1.81  BB201890  75788  Smurf1 
SMAD specific E3 
ubiquitin protein 
ligase 1, mRNA 
(cDNA clone 
MGC:28022 
IMAGE:3660965) 
24  1440014_at  917.67  NA  -1.41  -1.76  AW553510  107975  Pacs1 
Phosphofurin 
acidic cluster 
sorting protein 1 
(Pacs1), mRNA 
25  1425092_at  920.21  NA  -1.27  -1.49  AF183946  320873  Cdh10  cadherin 10 
26  1454904_at  923.49  NA  -1.34  -1.61  BG976607  17772  Mtm1 
X-linked 
myotubular 
myopathy gene 1 
27  1423691_x_at  923.68  NA  -1.44  -1.82  M21836  16691  Krt2-8  keratin complex 2, 
basic, gene 8 
28  1437219_at  951.33  NA  -1.42  -1.77  AW553541  16001  Igf1r 
Insulin-like growth 
factor I receptor 
(Igf1r), mRNA 
29  1439760_x_at  963.24  NA  -1.37  -1.68  BB219662  22268  Upk1b  uroplakin 1B 
30  1442961_at  969.72  NA  -1.37  -1.67  BG071782  ---  ---  --- 
31  1456712_at  981.56  NA  -1.34  -1.62  AV231984  209707  A830039H10Rik  RIKEN cDNA 
A830039H10 gene 
32  1436039_at  1012.68  NA  -1.32  -1.58  BM245957  Mm.85165  --- 
Transcribed locus, 
moderately similar 
to XP_488601.1 
PREDICTED: 
hypothetical 
protein 
XP_488601 [Mus 
musculus] 
33  1454544_at  1035.15  NA  -1.38  -1.70  AK020650  78850  9530078B04Rik  RIKEN cDNA 
9530078B04 gene 
34  1421811_at  1059.53  NA  -1.37  -1.68  AI385532  21825  Thbs1  thrombospondin 1 
35  1447408_at  1082.37  NA  -1.42  -1.79  BM201377  71175  4933421G18Rik 
Nipped-B homolog 
(Drosophila) 
(Nipbl), transcript 
variant B, mRNA 
36  1445642_at  1088.29  NA  -1.36  -1.65  AV156411  213409  Lemd1  LEM domain 
containing 1 
37  1439843_at  1107.13  NA  -1.34  -1.62  AI840829  12326  Camk4 
calcium/calmodulin
-dependent protein 
kinase IV 
38  1457429_s_at  1114.50  NA  -1.33  -1.59  BB549174  226866  Gm106  gene model 106, 
(NCBI) 
39  1442535_at  1123.07  NA  -1.38  -1.70  BB533591  Mm.216110  --- 
Adult male 
hypothalamus 
cDNA, RIKEN full-
length enriched 
library, 
clone:A230075A13 
product:unclassifia
ble, full insert 358 
 
sequence 
40  1438148_at  1133.18  NA  -1.18  -1.30  BB829808  330122  Gm1960  gene model 1960, 
(NCBI) 
41  1455134_at  1137.25  NA  -1.34  -1.62  AF031164  242474  D730040F13Rik 
RIKEN cDNA 
D730040F13 gene 
(D730040F13Rik), 
mRNA 
42  1436982_at  1143.42  NA  -1.35  -1.63  BB788270  213988  Tnrc6b  trinucleotide repeat 
containing 6b 
43  1427072_at  1147.74  NA  -1.38  -1.69  BM119481  236920  Stard8  START domain 
containing 8 
44  1427056_at  1173.34  NA  -1.35  -1.64  AV228731  235130  Adamts15 
a disintegrin-like 
and 
metallopeptidase 
(reprolysin type) 
with 
thrombospondin 
type 1 motif, 15 
45  1441629_at  1191.73  NA  -1.31  -1.55  BB451601  ---  ---  --- 
46  1416368_at  1195.00  NA  -1.31  -1.56  NM_010357  14860  Gsta4 
glutathione S-
transferase, alpha 
4 
47  1445786_at  1208.94  NA  -1.34  -1.61  BB539247  109880  Braf  Braf transforming 
gene 
48  1454672_at  1232.33  NA  -1.36  -1.65  BE952212  ---  ---  --- 
49  1427537_at  1236.24  NA  -1.37  -1.67  BC026387  223650  Eppk1  epiplakin 1 
50  1450988_at  1265.15  NA  -1.30  -1.54  BB751088  14160  Lgr5 
leucine rich repeat 
containing G 
protein coupled 
receptor 5 
51  1441501_at  1268.76  NA  -1.32  -1.58  AV382262  66870  Serbp1  Serpine1 mRNA 
binding protein 1 
52  1459443_at  1273.18  NA  -1.31  -1.56  BM248133  16535  Kcnq1 
KCNQ1b mRNA 
for Q1-type 
potassium channel 
spliced variant 
53  1455059_at  1297.80  NA  -1.31  -1.55  BB104941  109278  9430093I07Rik  RIKEN cDNA 
9430093I07 gene 
54  1421038_a_at  1306.61  NA  -1.38  -1.70  NM_008433  16534  Kcnn4 
potassium 
intermediate/small 
conductance 
calcium-activated 
channel, subfamily 
N, member 4 
55  1427982_s_at  1313.46  NA  -1.34  -1.61  BF582734  ---  ---  --- 
56  1446196_at  1314.47  NA  -1.29  -1.52  BB105328  15364  Hmga2  high mobility group 
AT-hook 2 
57  1437534_at  1318.78  NA  -1.34  -1.63  AU019880  106529  Gpsn2 
ES cells cDNA, 
RIKEN full-length 
enriched library, 
clone:2410016D23 
product:SC2 
homolog [Rattus 
sp], full insert 
sequence 
58  1435945_a_at  1339.40  NA  -1.36  -1.67  BG865910  16534  Kcnn4 
potassium 
intermediate/small 
conductance 
calcium-activated 
channel, subfamily 
N, member 4 
59  1458068_at  1355.02  NA  -1.33  -1.60  BB374785  74370  4932417H02Rik 
Raptor mRNA for 
p150 target of 
rapamycin (TOR)-
scaffold protein 
containing WD-
repeats 
60  1446616_at  1357.47  NA  -1.30  -1.55  AW551961  ---  ---  --- 
61  1430425_at  1368.44  NA  -1.34  -1.61  AW493494  237979  Sdk2  sidekick homolog 2 
(chicken) 
62  1431528_at  1375.82  NA  -1.34  -1.61  BE225800  76042  5830427D02Rik  RIKEN cDNA 359 
 
5830427D02 gene 
63  1440343_at  1385.12  NA  -1.31  -1.55  BQ174267  73086  Rps6ka5 
ribosomal protein 
S6 kinase, 
polypeptide 5 
64  1418480_at  1432.73  NA  -1.29  -1.52  NM_023785  57349  Cxcl7  chemokine (C-X-C 
motif) ligand 7 
65  1424112_at  1435.45  NA  -1.33  -1.60  BG092290  16004  Igf2r  insulin-like growth 
factor 2 receptor 
66  1439129_at  1466.83  NA  -1.31  -1.55  AW495734  68813  1110060D06Rik  RIKEN cDNA 
1110060D06 gene 
67  1447294_at  1470.87  NA  -1.34  -1.61  BB730861  103583  Fbxw11  F-box and WD-40 
domain protein 11 
68  1439545_at  1478.26  NA  -1.31  -1.55  BM240227  18181  Nrf1 
Nuclear respiratory 
factor 1, mRNA 
(cDNA clone 
MGC:5646 
IMAGE:3496661) 
69  1457262_at  1479.82  NA  -1.34  -1.62  BB024162  233789  2610207I05Rik  RIKEN cDNA 
2610207I05 gene 
70  1441652_at  1489.70  NA  -1.27  -1.48  BB185152  12168  Bmpr2 
bone morphogenic 
protein receptor, 
type II 
(serine/threonine 
kinase) 
71  1453125_at  1492.31  NA  -1.25  -1.44  BM508495  20666  Sox11  SRY-box 
containing gene 11 
72  1432358_at  1495.44  NA  -1.30  -1.54  AK003577  73732  1110008I14Rik  RIKEN cDNA 
1110008I14 gene 
73  1458663_at  1502.50  NA  -1.35  -1.64  AI552833  16795  Large 
Like-
glycosyltransferas
e (Large), mRNA 
74  1448169_at  1520.27  NA  -1.38  -1.69  NM_010664  16668  Krt1-18  keratin complex 1, 
acidic, gene 18 
75  1455965_at  1521.30  NA  -1.21  -1.37  BG064671  ---  ---  --- 
76  1418547_at  1532.31  NA  -0.89  -0.82  NM_009364  21789  Tfpi2  tissue factor 
pathway inhibitor 2 
77  1439571_at  1535.73  NA  -1.30  -1.53  BB820889  319683  E230008J23Rik  RIKEN cDNA 
E230008J23 gene 
78  1438575_a_at  1538.08  NA  -1.32  -1.58  BG143413  Mm.254833  ---  Transcribed locus 
79  1455377_at  1542.74  NA  -1.28  -1.49  BB795572  70892  4921517B04Rik  RIKEN cDNA 
4921517B04 gene 
80  1424927_at  1546.63  NA  -1.27  -1.49  BC025083  73690  Glipr1  GLI pathogenesis-
related 1 (glioma) 
81  1444218_at  1549.04  NA  -1.29  -1.52  AI117684  76539  D19Ertd737e 
DNA segment, Chr 
19, ERATO Doi 
737, expressed 
82  1428719_at  1549.16  NA  -1.28  -1.50  AK008551 
207685 
547243 
70018 
2010309G21Rik 
/// LOC207685 
/// LOC547243 
RIKEN cDNA 
2010309G21 gene 
/// hypothetical 
protein 
LOC207685 /// 
similar to Ig 
lambda-2 chain 
83  1423071_x_at  1585.19  NA  -1.28  -1.50  AW549928 
270335 
434328 
544983 
545175 
545584 
546326 
LOC270335 /// 
LOC434328 /// 
LOC544983 /// 
LOC545175 /// 
LOC545584 /// 
LOC546326 
hypothetical gene 
supported by 
BC019681; 
BC027236 /// 
hypothetical 
LOC434328 /// 
similar to RIKEN 
cDNA 
2610524H06 gene 
/// similar to 
LOC381508 
protein /// similar to 
LOC381508 
protein /// similar to 
LOC381508 
protein 
84  1450923_at  1592.44  NA  -1.30  -1.53  BF144658  21808  Tgfb2 
transforming 
growth factor, beta 
2 360 
 
85  1436790_a_at  1598.23  NA  -1.27  -1.48  BG072739  20666  Sox11  SRY-box 
containing gene 11 
86  1433201_at  1599.52  NA  -1.26  -1.45  AK010214  70290  2310079F09Rik  RIKEN cDNA 
2310079F09 gene 
87  1416612_at  1605.67  NA  -1.21  -1.37  BI251808  13078  Cyp1b1 
cytochrome P450, 
family 1, subfamily 
b, polypeptide 1 
88  1422324_a_at  1615.75  NA  -1.17  -1.29  NM_008970  19227  Pthlh 
parathyroid 
hormone-like 
peptide 
89  1445943_at  1617.75  NA  -1.28  -1.49  BG071766  ---  ---  --- 
90  1460571_at  1618.37  NA  -1.27  -1.48  BM208197  192119  Dicer1 
Double-strand-
specific 
ribonuclease 
MDCR 
91  1428944_at  1625.90  NA  -1.23  -1.41  BB417360  231380  5730469D23Rik  RIKEN cDNA 
5730469D23 gene 
92  1416613_at  1628.60  NA  -1.17  -1.29  BI251808  13078  Cyp1b1 
cytochrome P450, 
family 1, subfamily 
b, polypeptide 1 
93  1459646_at  1631.73  NA  -1.16  -1.27  BM899994  328779  Hs3st6 
heparan sulfate 
(glucosamine) 3-
O-sulfotransferase 
6 
94  1457065_at  1646.08  NA  -1.30  -1.53  BB530943  22268  Upk1b  uroplakin 1B 
95  1435154_at  1648.01  NA  -1.26  -1.46  AV099404  245128  LOC245128 
similar to solute 
carrier family 7 
(cationic amino 
acid transporter, 
y+ system), 
member 3 
96  1458657_at  1648.43  NA  -1.29  -1.52  AA822260  69538  Antxr1 
Tumor endothelial 
marker 8 precursor 
(Tem8) 
97  1437554_at  1666.56  NA  -1.30  -1.54  BM232239  18810  Plec1  plectin 1 
98  1441688_at  1671.69  NA  -1.29  -1.52  AV343428  319654  6430537I21Rik  RIKEN cDNA 
6430537I21 gene 
99  1447143_at  1683.35  NA  -1.35  -1.64  BM115076  ---  ---  --- 
100  1458021_at  1684.30  NA  -1.29  -1.51  BB550531  69024  Snx15 
Sorting nexin 15, 
mRNA (cDNA 
clone MGC:27611 
IMAGE:4503873) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 361 
 
The Rank Product (RP) differential expression analysis report 
 
 
 
 
 
0  Probe-set ID  RPscore  FDR  FC_rma FC_nom "SOURCE" "EntrezGene"  Gene Symbol  Title 
1  1436905_x_at  145.03  10.00  -2.01  -3.15  BB218107  16792  Laptm5 
lysosomal-
associated protein 
transmembrane 5 
2  1436996_x_at  154.19  5.50  -1.96  -3.01  AV066625  17110  Lzp-s  P lysozyme 
structural 
3  1439426_x_at  163.17  3.67  -2.04  -3.21  AV058500  17110  Lzp-s  P lysozyme 
structural 
4  1420804_s_at  186.83  4.50  -2.12  -3.43  NM_010819  17474  Clec4d 
C-type lectin 
domain family 4, 
member d 
5  1448591_at  204.23  4.60  -1.93  -2.95  NM_021281  13040  Ctss  cathepsin S 
6  1448748_at  236.28  6.33  -1.96  -3.01  AF181829  56193  Plek  pleckstrin 
7  1424754_at  377.58  22.14  -1.93  -2.93  BC024402  109225  Ms4a7 
membrane-
spanning 4-
domains, subfamily 
A, member 7 
8  1448995_at  378.78  19.62  -1.69  -2.36  NM_019932  56744  Cxcl4  chemokine (C-X-C 
motif) ligand 4 
9  1418547_at  381.87  17.89  -1.70  -2.39  NM_009364  21789  Tfpi2  tissue factor 
pathway inhibitor 2 
10  1448929_at  407.64  20.70  -1.82  -2.68  NM_028784  74145  F13a1  coagulation factor 
XIII, A1 subunit 
11  1419599_s_at  418.00  20.82  -1.74  -2.49  NM_026835  64382  Ms4a11 
membrane-
spanning 4-
domains, subfamily 
A, member 11 
12  1450430_at  418.30  19.08  -1.77  -2.55  NM_008625  17533  Mrc1  mannose receptor, 
C type 1 
13  1417266_at  421.12  17.92  -1.73  -2.46  BC002073  20305  Ccl6  chemokine (C-C 
motif) ligand 6 
14  1438989_s_at  421.60  16.86  -1.56  -2.08  BB386167  320860  B130021B11Rik  RIKEN cDNA 
B130021B11 gene 
15  1425951_a_at  427.86  16.67  -2.06  -3.28  AF240358  56620  Clec4n 
C-type lectin 
domain family 4, 
member n 
16  1435477_s_at  462.57  19.31  -1.86  -2.77  BM224327  14130  Fcgr2b  Fc receptor, IgG, 
low affinity IIb 
17  1419598_at  502.33  23.24  -1.83  -2.69  NM_026835  68774  Ms4a6d 
membrane-
spanning 4-
domains, subfamily 
A, member 6D 
18  1423547_at  562.57  31.33  -1.66  -2.30  AW208566  17105  Lyzs  lysozyme 
19  1417381_at  565.86  30.11  -1.82  -2.68  NM_007572  12259  C1qa  complement 
component 1, q 
General Information 
Experiment   VK1mouse4302 
Normalisation   rma across replicates 
Chip   one chip only 
Comparison   Treatment samples: K14D6 + CCL3 vs Baseline samples: WT + CCL3 
RP comparison   not paired 
Direction   Negative 362 
 
subcomponent, 
alpha polypeptide 
20  1419627_s_at  572.64  29.65  -1.78  -2.57  NM_020001  56620  Clec4n 
C-type lectin 
domain family 4, 
member n 
21  1449254_at  640.21  37.48  -1.75  -2.50  NM_009263  20750  Spp1  secreted 
phosphoprotein 1 
22  1449368_at  646.39  36.95  -1.39  -1.71  NM_007833  13179  Dcn  decorin 
23  1442082_at  694.46  43.87  -1.75  -2.51  BB333624  12267  C3ar1 
complement 
component 3a 
receptor 1 
24  1419473_a_at  698.40  42.71  -1.63  -2.23  NM_031161  12424  Cck  cholecystokinin 
25  1448620_at  730.34  46.00  -1.64  -2.25  NM_010188  14131  Fcgr3  Fc receptor, IgG, 
low affinity III 
26  1419728_at  740.66  45.88  -1.53  -2.02  NM_009141  20311  Cxcl5  chemokine (C-X-C 
motif) ligand 5 
27  1427262_at  754.73  46.93  -1.47  -1.88  L04961  213742  Xist  inactive X specific 
transcripts 
28  1417936_at  783.45  NA  -1.41  -1.75  AF128196  20308  Ccl9  chemokine (C-C 
motif) ligand 9 
29  1434172_at  791.18  NA  -1.58  -2.12  BQ177934  ---  ---  --- 
30  1437558_at  793.08  NA  -1.45  -1.84  BM119919  320860  B130021B11Rik  RIKEN cDNA 
B130021B11 gene 
31  1420394_s_at  840.89  NA  -1.58  -2.11  U05264  14727 14728  Gp49a /// Lilrb4 
glycoprotein 49 A 
/// leukocyte 
immunoglobulin-
like receptor, 
subfamily B, 
member 4 
32  1444176_at  840.89  NA  -1.71  -2.41  AV204216  242341  Atp6v0d2 
ATPase, H+ 
transporting, V0 
subunit D, isoform 
2 
33  1443673_x_at  888.70  NA  -1.38  -1.70  BB710847  ---  ---  --- 
34  1456858_at  912.26  NA  -1.42  -1.77  BB075339  229357  Gpr149  G protein-coupled 
receptor 149 
35  1440969_at  918.41  NA  -1.40  -1.74  BE944957  407797  BC030308  cDNA sequence 
BC030308 
36  1438672_at  929.31  NA  -1.42  -1.77  BI134721  170736  Parvb  Parvin, beta 
(Parvb), mRNA 
37  1436568_at  929.37  NA  -1.62  -2.20  AU016127  67374  Jam2  junction adhesion 
molecule 2 
38  1427263_at  952.72  NA  -1.37  -1.67  L04961  213742  Xist  inactive X specific 
transcripts 
39  1452141_a_at  985.76  NA  -1.48  -1.90  BC001991  20363  Sepp1  selenoprotein P, 
plasma, 1 
40  1415983_at  985.90  NA  -1.49  -1.92  NM_008879  18826  Lcp1  lymphocyte 
cytosolic protein 1 
41  1443775_x_at  995.49  NA  -1.39  -1.71  AV165539  380993  Zfp406  zinc finger protein 
406 
42  1434877_at  1003.29  NA  -1.31  -1.56  AI152800  18164  Nptx1  neuronal pentraxin 
1 
43  1418511_at  1011.43  NA  -1.49  -1.92  NM_019759  56429  Dpt  dermatopontin 
44  1441688_at  1032.11  NA  -1.37  -1.68  AV343428  319654  6430537I21Rik  RIKEN cDNA 
6430537I21 gene 
45  1420249_s_at  1057.30  NA  -1.60  -2.16  AV084904  20305  Ccl6  chemokine (C-C 
motif) ligand 6 
46  1427268_at  1059.33  NA  -1.15  -1.26  J03458  433621 
545581 
LOC433621 /// 
LOC545581 
similar to Acidic 
ribosomal 
phosphoprotein P0 
/// similar to Acidic 
ribosomal 
phosphoprotein P0 
47  1425575_at  1062.51  NA  -1.50  -1.95  M68513  13837  Epha3  Eph receptor A3 
48  1448169_at  1089.52  NA  -1.47  -1.88  NM_010664  16668  Krt1-18  keratin complex 1, 
acidic, gene 18 
49  1451289_at  1091.74  NA  -1.44  -1.82  AW105916  13175  Dcamkl1  double cortin and 
calcium/calmodulin-363 
 
dependent protein 
kinase-like 1 
50  1423477_at  1107.54  NA  -1.45  -1.85  BB361162  22771  Zic1  zinc finger protein 
of the cerebellum 1 
51  1422340_a_at  1114.62  NA  -1.45  -1.83  NM_009610  11468  Actg2 
actin, gamma 2, 
smooth muscle, 
enteric 
52  1416811_s_at  1118.89  NA  -1.33  -1.59  NM_007796  13024 13025  Ctla2a /// Ctla2b 
cytotoxic T 
lymphocyte-
associated protein 
2 alpha /// cytotoxic 
T lymphocyte-
associated protein 
2 beta 
53  1422135_at  1132.40  NA  -1.36  -1.65  NM_011980  26465  Zfp146  zinc finger protein 
146 
54  1419872_at  1139.33  NA  -1.50  -1.94  AI323359  12978  Csf1r  colony stimulating 
factor 1 receptor 
55  1442257_at  1142.86  NA  -1.38  -1.70  BI134319  Mm.204306  --- 
12 days embryo 
female mullerian 
duct includes 
surrounding region 
cDNA, RIKEN full-
length enriched 
library, 
clone:6820438B06 
product:unclassifia
ble, full insert 
sequence 
56  1418826_at  1150.73  NA  -1.56  -2.07  NM_027209  69774  Ms4a6b 
membrane-
spanning 4-
domains, subfamily 
A, member 6B 
57  1448471_a_at  1190.30  NA  -1.33  -1.59  NM_007796  13024  Ctla2a 
cytotoxic T 
lymphocyte-
associated protein 
2 alpha 
58  1450652_at  1201.01  NA  -1.36  -1.66  NM_007802  13038  Ctsk  cathepsin K 
59  1422124_a_at  1203.52  NA  -1.40  -1.74  NM_011210  19264  Ptprc 
protein tyrosine 
phosphatase, 
receptor type, C 
60  1418157_at  1236.99  NA  -1.31  -1.56  NM_010151  13865  Nr2f1 
nuclear receptor 
subfamily 2, group 
F, member 1 
61  1435943_at  1256.04  NA  -1.22  -1.38  AI647687  13479  Dpep1  dipeptidase 1 
(renal) 
62  1427115_at  1268.28  NA  -1.32  -1.58  M74753  17883  Myh3 
myosin, heavy 
polypeptide 3, 
skeletal muscle, 
embryonic 
63  1419609_at  1270.76  NA  -1.43  -1.79  AV231648  12768  Ccr1  chemokine (C-C 
motif) receptor 1 
64  1427076_at  1270.97  NA  -1.59  -2.14  L20315  17476  Mpeg1  macrophage 
expressed gene 1 
65  1423505_at  1271.94  NA  -1.37  -1.67  BB114067  21345  Tagln  transgelin 
66  1416613_at  1274.71  NA  -1.18  -1.31  BI251808  13078  Cyp1b1 
cytochrome P450, 
family 1, subfamily 
b, polypeptide 1 
67  1440145_at  1317.38  NA  -1.38  -1.70  BB831986  15101  H60 
PREDICTED: 
histocompatibility 
60 [Mus musculus], 
mRNA sequence 
68  1423691_x_at  1322.52  NA  -1.43  -1.79  M21836  16691  Krt2-8  keratin complex 2, 
basic, gene 8 
69  1440295_at  1329.05  NA  -1.36  -1.65  BB130189  68832  1110057K04Rik  RIKEN cDNA 
1110057K04 gene 
70  1434129_s_at  1340.14  NA  -1.50  -1.95  BG917242  218454  Lhfpl2  lipoma HMGIC 
fusion partner-like 2 
71  1456046_at  1342.16  NA  -1.53  -2.00  AV319144  17064  C1qr1 
complement 
component 1, q 
subcomponent, 
receptor 1 364 
 
72  1429693_at  1354.44  NA  -1.44  -1.82  AK017619  13132  Dab2  disabled homolog 2 
(Drosophila) 
73  1439364_a_at  1380.07  NA  -1.18  -1.32  BF147716  17390  Mmp2  matrix 
metallopeptidase 2 
74  1435989_x_at  1384.32  NA  -1.42  -1.77  AW322280  434261  LOC434261 
similar to 
cytokeratin EndoA - 
mouse 
75  1416136_at  1387.90  NA  -1.20  -1.34  NM_008610  17390  Mmp2  matrix 
metallopeptidase 2 
76  1454656_at  1389.76  NA  -1.38  -1.69  AV271736  219140  Spata13  spermatogenesis 
associated 13 
77  1433525_at  1395.56  NA  -1.44  -1.82  AW558570  13617  Ednra  endothelin receptor 
type A 
78  1451161_a_at  1448.52  NA  -1.41  -1.75  U66888  13733  Emr1 
EGF-like module 
containing, mucin-
like, hormone 
receptor-like 
sequence 1 
79  1456014_s_at  1456.21  NA  -1.53  -2.02  BB113173  108101  BC032204  cDNA sequence 
BC032204 
80  1458299_s_at  1458.03  NA  -1.40  -1.75  BB820441  18037  Nfkbie 
nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor, epsilon 
81  1420498_a_at  1458.52  NA  -1.35  -1.63  NM_023118  13132  Dab2  disabled homolog 2 
(Drosophila) 
82  1436970_a_at  1465.52  NA  -1.39  -1.72  AA499047  18596  Pdgfrb 
platelet derived 
growth factor 
receptor, beta 
polypeptide 
83  1426236_a_at  1466.34  NA  -1.40  -1.74  AI391218  14645  Glul 
glutamate-
ammonia ligase 
(glutamine 
synthetase) 
84  1452382_at  1471.67  NA  -1.34  -1.62  BB542096  ---  ---  --- 
85  1456475_s_at  1475.79  NA  -1.41  -1.76  BB216074  19088  Prkar2b 
protein kinase, 
cAMP dependent 
regulatory, type II 
beta 
86  1424443_at  1476.00  NA  -1.43  -1.79  AV378394  107769 
29877 
Hdgfrp3 /// 
Tm6sf1 
hepatoma-derived 
growth factor, 
related protein 3 /// 
transmembrane 6 
superfamily 
member 1 
87  1444061_at  1484.12  NA  -1.18  -1.32  BB150166  109314  A030004J04Rik  RIKEN cDNA 
A030004J04 gene 
88  1435343_at  1488.16  NA  -1.41  -1.77  BF715043  210293  Dock10  dedicator of 
cytokinesis 10 
89  1420431_at  1495.23  NA  -1.01  -1.02  NM_009100  20129  Rptn  repetin 
90  1429210_at  1498.92  NA  -1.44  -1.83  BE290548  237759  Col23a1  procollagen, type 
XXIII, alpha 1 
91  1437726_x_at  1518.53  NA  -1.39  -1.71  BB111335  12260  C1qb 
complement 
component 1, q 
subcomponent, 
beta polypeptide 
92  1427883_a_at  1520.30  NA  -1.33  -1.60  AW550625  12825  Col3a1  procollagen, type 
III, alpha 1 
93  1432466_a_at  1521.93  NA  -1.37  -1.69  AK019319  11816  Apoe  apolipoprotein E 
94  1451867_x_at  1535.31  NA  -1.57  -2.09  AF177664  11856  Arhgap6  Rho GTPase 
activating protein 6 
95  1438975_x_at  1543.90  NA  -1.32  -1.59  AV361868  224454  Zdhhc14 
zinc finger, DHHC 
domain containing 
14 
96  1419090_x_at  1558.48  NA  -1.31  -1.55  NM_010644  16618  Klk26  kallikrein 26 
97  1449038_at  1558.98  NA  -1.31  -1.56  NM_008288  15483  Hsd11b1 
hydroxysteroid 11-
beta 
dehydrogenase 1 
98  1448061_at  1560.02  NA  -1.43  -1.80  AA183642  ---  ---  --- 365 
 
99  1427484_at  1561.14  NA  -1.31  -1.55  BB650819  319670  Eml5 
echinoderm 
microtubule 
associated protein 
like 5 
100  1455660_at  1567.23  NA  -1.61  -2.19  BB769628  12983  Csf2rb1 
colony stimulating 
factor 2 receptor, 
beta 1, low-affinity 
(granulocyte-
macrophage) 
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Appendix Three 
Iterative  Group  Analysis  (iGA)  report  on  the  differentially 
expressed functional gene classes 
 
 
 
General Information 
Mode  Representative 
Number of genes on chip   23155 
Number of annotated genes   15986 
Number of groups   8092 
Number of singletons   2867 
Significance threshold   1.2e-04 
File name   K14D6 Control v WT Control positive 
 
Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
5581 - collagen  34  5  1.9e-07  14.71 
7169 - transmembrane receptor protein tyrosine kinase 
signaling pathway  76  6  4.3e-06  7.89 
30020 - extracellular matrix structural constituent 
conferring tensile strength  29  4  4.5e-06  13.79 
IPR008160 - Collagen triple helix repeat  65  5  5.1e-06  7.69 
IPR000233 - Cadherin cytoplasmic region  12  3  7.8e-06  25.00 
6817 - phosphate transport  84  5  1.8e-05  5.95 
1516 - prostaglandin biosynthesis  9  2  2.9e-05  22.22 
5201 - extracellular matrix structural constituent  47  4  3.2e-05  8.51 
5229 - intracellular calcium activated chloride channel 
activity  3  3  1.0e-04  100.00 
 
Changed group breakdown: 
Group  P-value   Probe-set ID  Rank  Gene ID   Gene 
Symbol   Title  
5581 - collagen  6.6e-02  1448590_at  32  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  3.8e-03  1450857_a_at  43  BF227507  Col1a2  procollagen, type I, alpha 
2 
  2.1e-04  1452250_a_at  55  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
  6.7e-06  1430676_at  58  AK019854  Col19a1  procollagen, type XIX, 
alpha 1 
show the whole group  1.9e-07  1427883_a_at  62  AW550625  Col3a1  procollagen, type III, 
alpha 1 
7169 - transmembrane 
receptor protein tyrosine 
kinase signaling pathway 
1.6e-01  1421917_at  36  AW537708  Pdgfra 
platelet derived growth 
factor receptor, alpha 
polypeptide 
  1.5e-02  1416121_at  40  M65143  Lox  lysyl oxidase 
  1.1e-03  1450857_a_at  43  BF227507  Col1a2  procollagen, type I, alpha 
2 
  3.2e-04  1437219_at  69  AW553541  Igf1r  Insulin-like growth factor I 
receptor (Igf1r), mRNA 367 
 
  3.0e-05  1436970_a_at  76  AA499047  Pdgfrb 
platelet derived growth 
factor receptor, beta 
polypeptide 
show the whole group  4.3e-06  1419248_at  90  AF215668  Rgs2  regulator of G-protein 
signaling 2 
30020 - extracellular matrix 
structural constituent 
conferring tensile strength 
5.7e-02  1448590_at  32  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  2.7e-03  1450857_a_at  43  BF227507  Col1a2  procollagen, type I, alpha 
2 
  1.3e-04  1452250_a_at  55  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
show the whole group  4.5e-06  1427883_a_at  62  AW550625  Col3a1  procollagen, type III, 
alpha 1 
IPR008160 - Collagen triple 
helix repeat  1.2e-01  1448590_at  32  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  1.3e-02  1450857_a_at  43  BF227507  Col1a2  procollagen, type I, alpha 
2 
  1.4e-03  1452250_a_at  55  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
  9.0e-05  1430676_at  58  AK019854  Col19a1  procollagen, type XIX, 
alpha 1 
show the whole group  5.1e-06  1427883_a_at  62  AW550625  Col3a1  procollagen, type III, 
alpha 1 
IPR000233 - Cadherin 
cytoplasmic region  1.0e-02  1418815_at  14  BC022107  Cdh2  cadherin 2 
  4.2e-04  1450757_at  41  NM_009866  Cdh11  cadherin 11 
show the whole group  7.8e-06  1425092_at  54  AF183946  Cdh10  cadherin 10 
6817 - phosphate transport  1.6e-01  1448590_at  32  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  2.1e-02  1450857_a_at  43  BF227507  Col1a2  procollagen, type I, alpha 
2 
  3.0e-03  1452250_a_at  55  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
  2.4e-04  1430676_at  58  AK019854  Col19a1  procollagen, type XIX, 
alpha 1 
show the whole group  1.8e-05  1427883_a_at  62  AW550625  Col3a1  procollagen, type III, 
alpha 1 
1516 - prostaglandin 
biosynthesis  4.5e-03  1448816_at  8  NM_008968  Ptgis  prostaglandin I2 
(prostacyclin) synthase 
show the whole group  2.9e-05  1436448_a_at  15  AA833146  Ptgs1  prostaglandin-
endoperoxide synthase 1 
5201 - extracellular matrix 
structural constituent  9.0e-02  1448590_at  32  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  7.1e-03  1450857_a_at  43  BF227507  Col1a2  procollagen, type I, alpha 
2 
  5.6e-04  1452250_a_at  55  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
show the whole group  3.2e-05  1427883_a_at  62  AW550625  Col3a1  procollagen, type III, 
alpha 1 
5229 - intracellular calcium 
activated chloride channel 
activity 
2.7e-02  1460259_s_at  144  AF108501  Clca1 /// 
Clca2 
chloride channel calcium 
activated 1 /// chloride 
channel calcium activated 
2 
  4.0e-04  1419463_at  164  AF108501  Clca2  chloride channel calcium 
activated 2 
  1.0e-04  1417853_at  343  AF047838  Clca1  chloride channel calcium 
activated 1 
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General Information 
Mode  Representative 
Number of genes on chip   23155 
Number of annotated genes   16003 
Number of groups   8107 
Number of singletons   2867 
Significance threshold   1.2e-04 
File name   WT +CCL3 V WT Control Positive 
 
Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
IPR008160 - Collagen triple helix repeat  71  8  7.6e-11  11.27 
6817 - phosphate transport  84  7  1.3e-10  8.33 
5201 - extracellular matrix structural constituent  48  8  4.3e-10  16.67 
30020 - extracellular matrix structural constituent 
conferring tensile strength  29  5  1.1e-09  17.24 
5581 - collagen  35  5  2.9e-09  14.29 
IPR000885 - Fibrillar collagen, C-terminal  11  5  3.2e-09  45.45 
IPR001811 - Small chemokine, interleukin-8 like  31  6  1.8e-08  19.35 
8009 - chemokine activity  38  6  6.4e-08  15.79 
7169 - transmembrane receptor protein tyrosine kinase 
signaling pathway  76  6  4.7e-07  7.89 
IPR007237 - CD20/IgE Fc receptor beta subunit  15  4  5.5e-07  26.67 
IPR000372 - Cysteine-rich flanking region, N-terminal  39  5  2.2e-06  12.82 
1527 - microfibril  6  3  3.8e-06  50.00 
30023 - extracellular matrix constituent conferring 
elasticity  2  2  4.9e-06  100.00 
6935 - chemotaxis  87  6  9.4e-06  6.90 
8201 - heparin binding  57  5  2.3e-05  8.77 
Inflammatory_Response_Pathway - GenMAPP  40  3  4.1e-05  7.50 
Eicosanoid_Synthesis - GenMAPP  21  3  4.6e-05  14.29 
IPR001007 - von Willebrand factor, type C  22  2  5.0e-05  9.09 
IPR001695 - Lysyl oxidase  4  2  7.2e-05  50.00 
5229 - intracellular calcium activated chloride channel 
activity  3  3  9.8e-05  100.00 
50766 - positive regulation of phagocytosis  21  3  1.1e-04  14.29 
5588 - collagen type V  3  3  1.2e-04  100.00 
 
Changed group breakdown: 
Group  P-value   Probe-set ID  Rank  Gene ID   Gene 
Symbol   Title  
IPR008160 - Collagen triple helix 
repeat  1.8e-02  1427883_a_at  4  AW550625  Col3a1  procollagen, type III, 
alpha 1 
  1.0e-03  1448590_at  11  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  2.3e-05  1452250_a_at  13  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
  3.4e-07  1417381_at  14  NM_007572  C1qa 
complement 
component 1, q 
subcomponent, 
alpha polypeptide 
  8.9e-09  1449154_at  17  NM_007729  Col11a1  procollagen, type XI, 369 
 
alpha 1 
  1.1e-09  1416414_at  25  NM_133918  Emilin1  elastin microfibril 
interfacer 1 
  1.0e-10  1450857_a_at  27  BF227507  Col1a2  procollagen, type I, 
alpha 2 
show the whole group  7.6e-11  1423110_at  34  BF227507  ---  --- 
6817 - phosphate transport  2.1e-02  1427883_a_at  4  AW550625  Col3a1  procollagen, type III, 
alpha 1 
  1.5e-03  1448590_at  11  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  3.8e-05  1452250_a_at  13  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
  6.8e-07  1417381_at  14  NM_007572  C1qa 
complement 
component 1, q 
subcomponent, 
alpha polypeptide 
  2.1e-08  1449154_at  17  NM_007729  Col11a1  procollagen, type XI, 
alpha 1 
  2.9e-09  1416414_at  25  NM_133918  Emilin1  elastin microfibril 
interfacer 1 
show the whole group  1.3e-10  1450857_a_at  27  BF227507  Col1a2  procollagen, type I, 
alpha 2 
5201 - extracellular matrix structural 
constituent  1.2e-02  1427883_a_at  4  AW550625  Col3a1  procollagen, type III, 
alpha 1 
  4.8e-04  1448590_at  11  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  7.1e-06  1452250_a_at  13  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
  1.6e-07  1449154_at  17  NM_007729  Col11a1  procollagen, type XI, 
alpha 1 
  1.5e-08  1450857_a_at  27  BF227507  Col1a2  procollagen, type I, 
alpha 2 
  2.2e-07  1460208_at  87  NM_007993  Fbn1  fibrillin 1 
  1.1e-08  1454830_at  93  AV010392  Fbn2  fibrillin 2 
show the whole group  4.3e-10  1416740_at  96  AW744319  Col5a1  procollagen, type V, 
alpha 1 
30020 - extracellular matrix 
structural constituent conferring 
tensile strength 
7.2e-03  1427883_a_at  4  AW550625  Col3a1  procollagen, type III, 
alpha 1 
  1.7e-04  1448590_at  11  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  1.5e-06  1452250_a_at  13  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
  2.0e-08  1449154_at  17  NM_007729  Col11a1  procollagen, type XI, 
alpha 1 
show the whole group  1.1e-09  1450857_a_at  27  BF227507  Col1a2  procollagen, type I, 
alpha 2 
5581 - collagen  8.7e-03  1427883_a_at  4  AW550625  Col3a1  procollagen, type III, 
alpha 1 
  2.5e-04  1448590_at  11  NM_009933  Col6a1  procollagen, type VI, 
alpha 1 
  2.7e-06  1452250_a_at  13  BI455189  Col6a2  procollagen, type VI, 
alpha 2 
  4.5e-08  1449154_at  17  NM_007729  Col11a1  procollagen, type XI, 
alpha 1 
show the whole group  2.9e-09  1450857_a_at  27  BF227507  Col1a2  procollagen, type I, 
alpha 2 
IPR000885 - Fibrillar collagen, C-
terminal  2.7e-03  1427883_a_at  4  AW550625  Col3a1  procollagen, type III, 
alpha 1 
  5.8e-05  1449154_at  17  NM_007729  Col11a1  procollagen, type XI, 
alpha 1 
  7.0e-07  1450857_a_at  27  BF227507  Col1a2  procollagen, type I, 
alpha 2 
  5.6e-09  1423110_at  34  BF227507  ---  --- 
show the whole group  3.2e-09  1416740_at  96  AW744319  Col5a1  procollagen, type V, 
alpha 1 
IPR001811 - Small chemokine,  3.9e-03  1448995_at  2  NM_019932  Cxcl4  chemokine (C-X-C 370 
 
interleukin-8 like  motif) ligand 4 
  2.1e-03  1419728_at  35  NM_009141  Cxcl5  chemokine (C-X-C 
motif) ligand 5 
  8.8e-05  1420380_at  45  AF065933  Ccl2  chemokine (C-C 
motif) ligand 2 
  7.6e-06  1417266_at  66  BC002073  Ccl6  chemokine (C-C 
motif) ligand 6 
  4.5e-07  1417936_at  81  AF128196  Ccl9  chemokine (C-C 
motif) ligand 9 
show the whole group  1.8e-08  1449984_at  90  NM_009140  Cxcl2  chemokine (C-X-C 
motif) ligand 2 
8009 - chemokine activity  4.7e-03  1448995_at  2  NM_019932  Cxcl4  chemokine (C-X-C 
motif) ligand 4 
  3.1e-03  1419728_at  35  NM_009141  Cxcl5  chemokine (C-X-C 
motif) ligand 5 
  1.6e-04  1420380_at  45  AF065933  Ccl2  chemokine (C-C 
motif) ligand 2 
  1.8e-05  1417266_at  66  BC002073  Ccl6  chemokine (C-C 
motif) ligand 6 
  1.3e-06  1417936_at  81  AF128196  Ccl9  chemokine (C-C 
motif) ligand 9 
show the whole group  6.4e-08  1449984_at  90  NM_009140  Cxcl2  chemokine (C-X-C 
motif) ligand 2 
7169 - transmembrane receptor 
protein tyrosine kinase signaling 
pathway 
4.7e-02  1436970_a_at  10  AA499047  Pdgfrb 
platelet derived 
growth factor 
receptor, beta 
polypeptide 
  7.2e-03  1450857_a_at  27  BF227507  Col1a2  procollagen, type I, 
alpha 2 
  3.1e-04  1416121_at  28  M65143  Lox  lysyl oxidase 
  3.8e-05  1421917_at  40  AW537708  Pdgfra 
platelet derived 
growth factor 
receptor, alpha 
polypeptide 
  2.0e-06  1419248_at  44  AF215668  Rgs2  regulator of G-
protein signaling 2 
show the whole group  4.7e-07  1425575_at  62  M68513  Epha3  Eph receptor A3 
IPR007237 - CD20/IgE Fc receptor 
beta subunit  9.4e-04  1424754_at  1  BC024402  Ms4a7 
membrane-spanning 
4-domains, subfamily 
A, member 7 
  1.2e-04  1419598_at  18  NM_026835  Ms4a6d 
membrane-spanning 
4-domains, subfamily 
A, member 6D 
  2.7e-05  1418990_at  64  NM_025658  Ms4a4d 
membrane-spanning 
4-domains, subfamily 
A, member 4D 
show the whole group  5.5e-07  1419599_s_at  74  NM_026835  Ms4a11 
membrane-spanning 
4-domains, subfamily 
A, member 11 
IPR000372 - Cysteine-rich flanking 
region, N-terminal  1.7e-02  1423607_at  7  AK014312  Lum  lumican 
  1.8e-03  1449368_at  26  NM_007833  Dcn  decorin 
  6.3e-05  1416405_at  32  BC019502  Bgn  biglycan 
  4.8e-05  1423311_s_at  83  BQ177165  Tpbg  trophoblast 
glycoprotein 
show the whole group  2.2e-06  1452296_at  88  BM570006  Slit3  slit homolog 3 
(Drosophila) 
1527 - microfibril  1.3e-02  1418454_at  36  NM_015776  Mfap5  microfibrillar 
associated protein 5 
  4.3e-04  1460208_at  87  NM_007993  Fbn1  fibrillin 1 
show the whole group  3.8e-06  1454830_at  93  AV010392  Fbn2  fibrillin 2 
30023 - extracellular matrix 
constituent conferring elasticity  3.1e-03  1416414_at  25  NM_133918  Emilin1  elastin microfibril 
interfacer 1 
  4.9e-06  1418454_at  36  NM_015776  Mfap5  microfibrillar 
associated protein 5 
6935 - chemotaxis  1.1e-02  1448995_at  2  NM_019932  Cxcl4  chemokine (C-X-C 
motif) ligand 4 371 
 
  1.5e-02  1419728_at  35  NM_009141  Cxcl5  chemokine (C-X-C 
motif) ligand 5 
  1.9e-03  1420380_at  45  AF065933  Ccl2  chemokine (C-C 
motif) ligand 2 
  4.5e-04  1417266_at  66  BC002073  Ccl6  chemokine (C-C 
motif) ligand 6 
  7.8e-05  1417936_at  81  AF128196  Ccl9  chemokine (C-C 
motif) ligand 9 
show the whole group  9.4e-06  1449984_at  90  NM_009140  Cxcl2  chemokine (C-X-C 
motif) ligand 2 
8201 - heparin binding  7.1e-03  1448995_at  2  NM_019932  Cxcl4  chemokine (C-X-C 
motif) ligand 4 
  3.4e-04  1450663_at  8  NM_011581  Thbs2  thrombospondin 2 
  4.7e-05  1423606_at  20  BI110565  Postn  periostin, osteoblast 
specific factor 
  2.3e-05  1416221_at  47  BI452727  Fstl1  follistatin-like 1 
show the whole group  2.3e-05  1416740_at  96  AW744319  Col5a1  procollagen, type V, 
alpha 1 
Inflammatory_Response_Pathway - 
GenMAPP  1.0e-02  1427883_a_at  4  AW550625  Col3a1  procollagen, type III, 
alpha 1 
  2.2e-04  1416136_at  9  NM_008610  Mmp2  matrix 
metallopeptidase 2 
show the whole group  4.1e-05  1450857_a_at  27  BF227507  Col1a2  procollagen, type I, 
alpha 2 
Eicosanoid_Synthesis - GenMAPP  2.1e-02  1435943_at  16  AI647687  Dpep1  dipeptidase 1 (renal) 
  1.8e-03  1448816_at  48  NM_008968  Ptgis 
prostaglandin I2 
(prostacyclin) 
synthase 
show the whole group  4.6e-05  1436448_a_at  54  AA833146  Ptgs1 
prostaglandin-
endoperoxide 
synthase 1 
IPR001007 - von Willebrand factor, 
type C  5.5e-03  1427883_a_at  4  AW550625  Col3a1  procollagen, type III, 
alpha 1 
show the whole group  5.0e-05  1450663_at  8  NM_011581  Thbs2  thrombospondin 2 
IPR001695 - Lysyl oxidase  7.0e-03  1416121_at  28  M65143  Lox  lysyl oxidase 
show the whole group  7.2e-05  1451978_at  56  AF357006  Loxl1  lysyl oxidase-like 1 
5229 - intracellular calcium activated 
chloride channel activity  3.2e-02  1419463_at  172  AF108501  Clca2  chloride channel 
calcium activated 2 
  7.0e-04  1417852_x_at  230  AF047838  Clca1  chloride channel 
calcium activated 1 
  9.8e-05  1460259_s_at  262  AF108501  Clca1 /// 
Clca2 
chloride channel 
calcium activated 1 
/// chloride channel 
calcium activated 2 
50766 - positive regulation of 
phagocytosis  4.0e-02  1435477_s_at  31  BM224327  Fcgr2b  Fc receptor, IgG, low 
affinity IIb 
  8.5e-04  1418666_at  33  NM_008987  Ptx3  pentraxin related 
gene 
show the whole group  1.1e-04  1448620_at  73  NM_010188  Fcgr3  Fc receptor, IgG, low 
affinity III 
5588 - collagen type V  1.8e-02  1416740_at  96  AW744319  Col5a1  procollagen, type V, 
alpha 1 
  6.3e-04  1422437_at  215  AV229424  Col5a2  procollagen, type V, 
alpha 2 
  1.2e-04  1419703_at  492  NM_016919  Col5a3  procollagen, type V, 
alpha 3 
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General Information 
Mode  Representative 
Number of genes on chip   23155 
Number of annotated genes   15988 
Number of groups   8102 
Number of singletons   2879 
Significance threshold   1.2e-04 
File name   K14D6 + CCL3 v K14D6 control positive 
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Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
30020 - extracellular matrix structural constituent 
conferring tensile strength  29  7  1.9e-10  24.14 
5581 - collagen  35  7  6.9e-10  20.00 
8201 - heparin binding  57  8  1.7e-09  14.04 
5201 - extracellular matrix structural constituent  48  7  6.8e-09  14.58 
IPR000885 - Fibrillar collagen, C-terminal  10  4  2.4e-08  40.00 
IPR008160 - Collagen triple helix repeat  72  6  1.5e-07  8.33 
6817 - phosphate transport  85  7  3.9e-07  8.24 
6935 - chemotaxis  87  7  3.9e-07  8.05 
IPR001811 - Small chemokine, interleukin-8 like  31  5  5.7e-07  16.13 
8009 - chemokine activity  38  5  1.6e-06  13.16 
50766 - positive regulation of phagocytosis  21  3  3.9e-06  14.29 
19864 - IgG binding  5  2  2.2e-05  40.00 
IPR001614 - Myelin proteolipid protein PLP  3  2  3.1e-05  66.67 
IPR007237 - CD20/IgE Fc receptor beta subunit  14  3  3.8e-05  21.43 
IPR001916 - Glycoside hydrolase, family 22  8  2  5.0e-05  25.00 
IPR002086 - Aldehyde dehydrogenase  26  2  5.3e-05  7.69 
45576 - mast cell activation  9  2  7.7e-05  22.22 
3796 - lysozyme activity  10  2  8.1e-05  20.00 
IPR001751 - Calcium-binding protein, S-100/ICaBP type  15  3  9.3e-05  20.00 
5229 - intracellular calcium activated chloride channel 
activity  3  3  9.4e-05  100.00 
IPR002227 - Tyrosinase  3  3  9.8e-05  100.00 
IPR002035 - von Willebrand factor, type A  44  4  1.1e-04  9.09 
 
Changed group breakdown: 
Group  P-value   Probe-set ID  Rank  Gene ID   Gene 
Symbol   Title  
30020 - extracellular matrix 
structural constituent 
conferring tensile strength 
1.8e-02  1427883_a_at  10  AW550625  Col3a1  procollagen, type III, alpha 1 
  6.5e-04  1455494_at  21  BI794771  Col1a1  procollagen, type I, alpha 1 
  9.3e-06  1452250_a_at  23  BI455189  Col6a2  procollagen, type VI, alpha 2 
  1.5e-07  1448590_at  27  NM_009933  Col6a1  procollagen, type VI, alpha 1 
  4.3e-09  1449154_at  35  NM_007729  Col11a1  procollagen, type XI, alpha 1 
  5.2e-10  1450857_a_at  54  BF227507  Col1a2  procollagen, type I, alpha 2 
show the whole group  1.9e-10  1434479_at  87  AV246911  Col5a1  Procollagen, type V, alpha 1 
(Col5a1), mRNA 
5581 - collagen  2.2e-02  1427883_a_at  10  AW550625  Col3a1  procollagen, type III, alpha 1 
  9.5e-04  1455494_at  21  BI794771  Col1a1  procollagen, type I, alpha 1 
  1.7e-05  1452250_a_at  23  BI455189  Col6a2  procollagen, type VI, alpha 2 
  3.3e-07  1448590_at  27  NM_009933  Col6a1  procollagen, type VI, alpha 1 
  1.2e-08  1449154_at  35  NM_007729  Col11a1  procollagen, type XI, alpha 1 
  1.7e-09  1450857_a_at  54  BF227507  Col1a2  procollagen, type I, alpha 2 
show the whole group  6.9e-10  1434479_at  87  AV246911  Col5a1  Procollagen, type V, alpha 1 
(Col5a1), mRNA 
8201 - heparin binding  4.9e-02  1432466_a_at  14  AK019319  Apoe  apolipoprotein E 
  6.1e-03  1448259_at  33  BI452727  Fstl1  follistatin-like 1 
  7.9e-04  1448995_at  51  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  2.0e-04  1423606_at  81  BI110565  Postn  periostin, osteoblast specific 
factor 
  1.3e-05  1421228_at  85  AF128193  Ccl7  chemokine (C-C motif) ligand 
7 
  6.3e-07  1434479_at  87  AV246911  Col5a1  Procollagen, type V, alpha 1 
(Col5a1), mRNA 
  4.3e-08  1448303_at  95  NM_053110  Gpnmb  glycoprotein 
(transmembrane) nmb 
show the whole group  1.7e-09  1422571_at  96  NM_011581  Thbs2  thrombospondin 2 374 
 
5201 - extracellular matrix 
structural constituent  3.0e-02  1427883_a_at  10  AW550625  Col3a1  procollagen, type III, alpha 1 
  1.8e-03  1455494_at  21  BI794771  Col1a1  procollagen, type I, alpha 1 
  4.3e-05  1452250_a_at  23  BI455189  Col6a2  procollagen, type VI, alpha 2 
  1.2e-06  1448590_at  27  NM_009933  Col6a1  procollagen, type VI, alpha 1 
  6.0e-08  1449154_at  35  NM_007729  Col11a1  procollagen, type XI, alpha 1 
  1.2e-08  1450857_a_at  54  BF227507  Col1a2  procollagen, type I, alpha 2 
show the whole group  6.8e-09  1434479_at  87  AV246911  Col5a1  Procollagen, type V, alpha 1 
(Col5a1), mRNA 
IPR000885 - Fibrillar 
collagen, C-terminal  6.2e-03  1427883_a_at  10  AW550625  Col3a1  procollagen, type III, alpha 1 
  2.1e-04  1449154_at  35  NM_007729  Col11a1  procollagen, type XI, alpha 1 
  2.5e-06  1423110_at  45  BF227507  ---  --- 
show the whole group  2.4e-08  1450857_a_at  54  BF227507  Col1a2  procollagen, type I, alpha 2 
IPR008160 - Collagen triple 
helix repeat  4.4e-02  1427883_a_at  10  AW550625  Col3a1  procollagen, type III, alpha 1 
  4.8e-03  1452250_a_at  23  BI455189  Col6a2  procollagen, type VI, alpha 2 
  2.4e-04  1448590_at  27  NM_009933  Col6a1  procollagen, type VI, alpha 1 
  1.8e-05  1449154_at  35  NM_007729  Col11a1  procollagen, type XI, alpha 1 
  1.7e-06  1423110_at  45  BF227507  ---  --- 
show the whole group  1.5e-07  1450857_a_at  54  BF227507  Col1a2  procollagen, type I, alpha 2 
6817 - phosphate transport  5.2e-02  1427883_a_at  10  AW550625  Col3a1  procollagen, type III, alpha 1 
  5.5e-03  1455494_at  21  BI794771  Col1a1  procollagen, type I, alpha 1 
  2.4e-04  1452250_a_at  23  BI455189  Col6a2  procollagen, type VI, alpha 2 
  1.2e-05  1448590_at  27  NM_009933  Col6a1  procollagen, type VI, alpha 1 
  1.1e-06  1449154_at  35  NM_007729  Col11a1  procollagen, type XI, alpha 1 
  4.0e-07  1450857_a_at  54  BF227507  Col1a2  procollagen, type I, alpha 2 
show the whole group  3.9e-07  1434479_at  87  AV246911  Col5a1  Procollagen, type V, alpha 1 
(Col5a1), mRNA 
6935 - chemotaxis  7.9e-02  1417936_at  15  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
  4.7e-03  1417266_at  19  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 
  2.4e-03  1419394_s_at  49  NM_013650  S100a8  S100 calcium binding protein 
A8 (calgranulin A) 
  1.7e-04  1448995_at  51  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  1.3e-05  1449984_at  56  NM_009140  Cxcl2  chemokine (C-X-C motif) 
ligand 2 
  2.6e-06  1419483_at  72  NM_009779  C3ar1  complement component 3a 
receptor 1 
show the whole group  3.9e-07  1421228_at  85  AF128193  Ccl7  chemokine (C-C motif) ligand 
7 
IPR001811 - Small 
chemokine, interleukin-8 
like 
2.9e-02  1417936_at  15  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
  6.1e-04  1417266_at  19  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 
  1.3e-04  1448995_at  51  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  4.0e-06  1449984_at  56  NM_009140  Cxcl2  chemokine (C-X-C motif) 
ligand 2 
show the whole group  5.7e-07  1421228_at  85  AF128193  Ccl7  chemokine (C-C motif) ligand 
7 
8009 - chemokine activity  3.5e-02  1417936_at  15  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
  9.2e-04  1417266_at  19  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 
  2.4e-04  1448995_at  51  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  9.1e-06  1449984_at  56  NM_009140  Cxcl2  chemokine (C-X-C motif) 
ligand 2 
show the whole group  1.6e-06  1421228_at  85  AF128193  Ccl7  chemokine (C-C motif) ligand 
7 375 
 
50766 - positive regulation 
of phagocytosis  7.9e-03  1418666_at  6  NM_008987  Ptx3  pentraxin related gene 
  5.9e-05  1448620_at  9  NM_010188  Fcgr3  Fc receptor, IgG, low affinity 
III 
show the whole group  3.9e-06  1435477_s_at  24  BM224327  Fcgr2b  Fc receptor, IgG, low affinity 
IIb 
19864 - IgG binding  2.8e-03  1448620_at  9  NM_010188  Fcgr3  Fc receptor, IgG, low affinity 
III 
show the whole group  2.2e-05  1435477_s_at  24  BM224327  Fcgr2b  Fc receptor, IgG, low affinity 
IIb 
IPR001614 - Myelin 
proteolipid protein PLP  3.0e-03  1423091_a_at  16  AK016567  Gpm6b  glycoprotein m6b 
show the whole group  3.1e-05  1451718_at  52  BB768495  Plp1  proteolipid protein (myelin) 1 
IPR007237 - CD20/IgE Fc 
receptor beta subunit  2.8e-02  1424754_at  32  BC024402  Ms4a7 
membrane-spanning 4-
domains, subfamily A, 
member 7 
  1.2e-03  1419599_s_at  60  NM_026835  Ms4a11 
membrane-spanning 4-
domains, subfamily A, 
member 11 
show the whole group  3.8e-05  1419598_at  77  NM_026835  Ms4a6d 
membrane-spanning 4-
domains, subfamily A, 
member 6D 
IPR001916 - Glycoside 
hydrolase, family 22  1.0e-03  1436996_x_at  2  AV066625  Lzp-s  P lysozyme structural 
show the whole group  5.0e-05  1423547_at  22  AW208566  Lyzs  lysozyme 
IPR002086 - Aldehyde 
dehydrogenase  1.6e-03  1418601_at  1  NM_011921  Aldh1a7  aldehyde dehydrogenase 
family 1, subfamily A7 
show the whole group  5.3e-05  1416468_at  7  NM_013467  Aldh1a1  aldehyde dehydrogenase 
family 1, subfamily A1 
45576 - mast cell activation  5.1e-03  1448620_at  9  NM_010188  Fcgr3  Fc receptor, IgG, low affinity 
III 
show the whole group  7.7e-05  1435477_s_at  24  BM224327  Fcgr2b  Fc receptor, IgG, low affinity 
IIb 
3796 - lysozyme activity  1.3e-03  1436996_x_at  2  AV066625  Lzp-s  P lysozyme structural 
show the whole group  8.1e-05  1423547_at  22  AW208566  Lyzs  lysozyme 
IPR001751 - Calcium-
binding protein, S-
100/ICaBP type 
3.5e-02  1448756_at  38  NM_009114  S100a9  S100 calcium binding protein 
A9 (calgranulin B) 
  9.4e-04  1419394_s_at  49  NM_013650  S100a8  S100 calcium binding protein 
A8 (calgranulin A) 
show the whole group  9.3e-05  1424542_at  97  D00208  S100a4  S100 calcium binding protein 
A4 
5229 - intracellular calcium 
activated chloride channel 
activity 
1.3e-02  1419463_at  70  AF108501  Clca2  chloride channel calcium 
activated 2 
  9.6e-05  1460259_s_at  91  AF108501  Clca1 /// 
Clca2 
chloride channel calcium 
activated 1 /// chloride 
channel calcium activated 2 
  9.4e-05  1417852_x_at  102  AF047838  Clca1  chloride channel calcium 
activated 1 
IPR002227 - Tyrosinase  2.8e-02  1415862_at  150  BB762957  Tyrp1  tyrosinase-related protein 1 
  6.2e-04  1417717_a_at  214  NM_011661  Tyr  tyrosinase 
  9.8e-05  1418028_at  257  NM_010024  Dct  dopachrome tautomerase 
IPR002035 - von Willebrand 
factor, type A  6.1e-02  1452250_a_at  23  BI455189  Col6a2  procollagen, type VI, alpha 2 
  2.5e-03  1448590_at  27  NM_009933  Col6a1  procollagen, type VI, alpha 1 
  9.4e-04  1419463_at  70  AF108501  Clca2  chloride channel calcium 
activated 2 
show the whole group  1.1e-04  1460259_s_at  91  AF108501  Clca1 /// 
Clca2 
chloride channel calcium 
activated 1 /// chloride 
channel calcium activated 2 
Iterative  Group  Analysis  (iGA)  report  on  the  differentially 
expressed functional gene classes 
 376 
 
 
 
 
 
 
 
 
 
 
 
 
Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed   Percent Changed 
6583 - melanin biosynthesis from tyrosine  6  4  3.4e-11  66.67 
1533 - cornified envelope  14  5  1.2e-08  35.71 
IPR003347 - Transcription factor jumonji, 
jmjC  21  3  3.9e-08  14.29 
42470 - melanosome  7  3  6.8e-08  42.86 
IPR002227 - Tyrosinase  2  2  1.6e-06  100.00 
15171 - amino acid transporter activity  18  2  2.5e-05  11.11 
31424 - keratinization  23  3  4.3e-05  13.04 
 
Changed group breakdown: 
Group  P-value   Probe-set ID  Rank  Gene ID   Gene Symbol   Title  
6583 - melanin 
biosynthesis 
from tyrosine 
3.8e-03  1415862_at  10  BB762957  Tyrp1  tyrosinase-related protein 1 
  1.2e-05  1422523_at  15  NM_021882  Si  silver 
  3.4e-08  1456095_at  20  BB769772  Tyr  tyrosinase 
show the whole 
group  3.4e-11  1418028_at  21  NM_010024  Dct  dopachrome tautomerase 
1533 - cornified 
envelope  2.6e-02  1450618_a_at  30  NM_011468  Sprr2a  small proline-rich protein 2A 
  4.2e-04  1448745_s_at  35  NM_008508  Lor  loricrin 
  9.1e-06  1451613_at  48  AY027660  Hrnr  hornerin 
  1.8e-07  1420431_at  60  NM_009100  Rptn  repetin 
show the whole 
group  1.2e-08  1422837_at  94  NM_022886  Scel  sciellin 
IPR003347 - 
Transcription 
factor jumonji, 
jmjC 
2.6e-03  1426438_at  2  AA210261  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked 
  1.6e-05  1426598_at  5  BB742957 
Uty /// 
LOC546404 /// 
LOC546411 
ubiquitously transcribed 
tetratricopeptide repeat gene, Y 
chromosome /// similar to male-
specific histocompatibility antigen H-
YDb /// similar to male-specific 
histocompatibility antigen H-YDb 
show the whole 
group  3.9e-08  1424903_at  6  AF127244  Jarid1d  jumonji, AT rich interactive domain 
1D (Rbp2 like) 
42470 - 
melanosome  4.4e-03  1415862_at  10  BB762957  Tyrp1  tyrosinase-related protein 1 
  3.1e-05  1456095_at  20  BB769772  Tyr  tyrosinase 
show the whole 
group  6.8e-08  1418028_at  21  NM_010024  Dct  dopachrome tautomerase 
General Information 
Mode  Representative 
Number of genes on chip   23155 
Number of annotated genes   15966 
Number of groups   8086 
Number of singletons   2867 
Significance threshold   1.2e-04 
File name   K14D6 + CCL3 v WT + CCL3 Positive 377 
 
IPR002227 - 
Tyrosinase  1.3e-03  1415862_at  10  BB762957  Tyrp1  tyrosinase-related protein 1 
  1.6e-06  1418028_at  21  NM_010024  Dct  dopachrome tautomerase 
15171 - amino 
acid transporter 
activity 
4.5e-03  1420504_at  4  AF320226  Slc6a14 
solute carrier family 6 
(neurotransmitter transporter), 
member 14 
show the whole 
group  2.5e-05  1417022_at  7  NM_007515  Slc7a3 
solute carrier family 7 (cationic 
amino acid transporter, y+ system), 
member 3 
31424 - 
keratinization  4.2e-02  1450618_a_at  30  NM_011468  Sprr2a  small proline-rich protein 2A 
  1.1e-03  1448745_s_at  35  NM_008508  Lor  loricrin 
show the whole 
group  4.3e-05  1451613_at  48  AY027660  Hrnr  hornerin 
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General Information 
Mode  Representative 
Number of genes on chip   23155 
Number of annotated genes   15976 378 
 
Number of groups   8057 
Number of singletons   2885 
Significance threshold   1.2e-04 
File name   K14D6 Control v WT Control Negative 
 
Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
1533 - cornified envelope  14  7  9.3e-13  50.00 
31424 - keratinization  23  4  4.1e-06  17.39 
IPR001916 - Glycoside hydrolase, family 22  8  2  4.6e-06  25.00 
3796 - lysozyme activity  10  2  7.4e-06  20.00 
16998 - cell wall catabolism  16  2  2.0e-05  12.50 
IPR001811 - Small chemokine, interleukin-8 
like  31  4  2.2e-05  12.90 
19835 - cytolysis  20  2  3.1e-05  10.00 
19864 - IgG binding  5  2  4.1e-05  40.00 
8009 - chemokine activity  38  4  5.0e-05  10.53 
6935 - chemotaxis  87  5  1.1e-04  5.75 
IPR002227 - Tyrosinase         
 
Changed group breakdown: 
Group  P-value   Probe-set ID  Rank  Gene ID   Gene Symbol   Title  
1533 - cornified 
envelope  2.1e-02  1420431_at  24  NM_009100  Rptn  repetin 
  6.0e-04  1427910_at  42  AK003744  Cst6  cystatin E/M 
  1.4e-05  1427268_at  55  J03458  LOC433621 /// 
LOC545581 
similar to Acidic ribosomal 
phosphoprotein P0 /// similar 
to Acidic ribosomal 
phosphoprotein P0 
  1.6e-07  1451613_at  59  AY027660  Hrnr  hornerin 
  2.0e-09  1429540_at  66  AK008979  Cnfn  cornifelin 
  9.5e-12  1422837_at  67  NM_022886  Scel  sciellin 
show the whole group  9.3e-13  1448745_s_at  77  NM_008508  Lor  loricrin 
31424 - 
keratinization  4.2e-02  1422963_at  30  NM_011475  Sprr2i  small proline-rich protein 2I 
  9.6e-04  1449833_at  32  NM_011472  Sprr2f  small proline-rich protein 2F 
  8.0e-05  1451613_at  59  AY027660  Hrnr  hornerin 
show the whole group  4.1e-06  1448745_s_at  77  NM_008508  Lor  loricrin 
IPR001916 - 
Glycoside 
hydrolase, family 22 
5.0e-04  1436996_x_at  1  AV066625  Lzp-s  P lysozyme structural 
show the whole group  4.6e-06  1423547_at  7  AW208566  Lyzs  lysozyme 
3796 - lysozyme 
activity  6.3e-04  1436996_x_at  1  AV066625  Lzp-s  P lysozyme structural 
show the whole group  7.4e-06  1423547_at  7  AW208566  Lyzs  lysozyme 
16998 - cell wall 
catabolism  1.0e-03  1436996_x_at  1  AV066625  Lzp-s  P lysozyme structural 
show the whole group  2.0e-05  1423547_at  7  AW208566  Lyzs  lysozyme 
IPR001811 - Small 
chemokine, 
interleukin-8 like 
3.2e-02  1448995_at  17  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  8.2e-04  1417936_at  22  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
  1.1e-04  1417266_at  48  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 
show the whole group  2.2e-05  1449984_at  86  NM_009140  Cxcl2  chemokine (C-X-C motif) 
ligand 2 
19835 - cytolysis  1.3e-03  1436996_x_at  1  AV066625  Lzp-s  P lysozyme structural 
show the whole group  3.1e-05  1423547_at  7  AW208566  Lyzs  lysozyme 
19864 - IgG binding  1.9e-03  1448620_at  6  NM_010188  Fcgr3  Fc receptor, IgG, low affinity 
III 
show the whole group  4.1e-05  1435477_s_at  33  BM224327  Fcgr2b  Fc receptor, IgG, low affinity 
IIb 379 
 
8009 - chemokine 
activity  4.0e-02  1448995_at  17  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  1.2e-03  1417936_at  22  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
  2.0e-04  1417266_at  48  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 
show the whole group  5.0e-05  1449984_at  86  NM_009140  Cxcl2  chemokine (C-X-C motif) 
ligand 2 
6935 - chemotaxis  8.9e-02  1448995_at  17  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  6.3e-03  1417936_at  22  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
  2.3e-03  1417266_at  48  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 
  8.6e-04  1419483_at  78  NM_009779  C3ar1  complement component 3a 
receptor 1 
show the whole group  1.1e-04  1449984_at  86  NM_009140  Cxcl2  chemokine (C-X-C motif) 
ligand 2 
IPR002227 - 
Tyrosinase  4.3e-02  1418028_at  233  NM_010024  Dct  dopachrome tautomerase 
  2.7e-03  1415861_at  474  BB762957  Tyrp1  tyrosinase-related protein 1 
  1.2e-04  1417717_a_at  477  NM_011661  Tyr  tyrosinase 
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General Information 
Mode  Representative 
Number of genes on chip   23155 
Number of annotated genes   15960 
Number of groups   8038 
Number of singletons   2867 
Significance threshold   1.2e-04 
File name   WT + CCL3 V WT Control Negative 
 
Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
1533 - cornified envelope  14  4  8.0e-11  28.57 
42470 - melanosome  7  4  4.6e-08  57.14 
IPR003347 - Transcription factor jumonji, jmjC  18  3  6.7e-08  16.67 
5882 - intermediate filament  93  8  9.3e-08  8.60 
IPR001664 - Intermediate filament protein  57  6  4.5e-07  10.53 
6583 - melanin biosynthesis from tyrosine  6  3  4.4e-06  50.00 
IPR001751 - Calcium-binding protein, S-
100/ICaBP type  14  2  7.1e-06  14.29 
IPR002227 - Tyrosinase  2  2  2.5e-05  100.00 
16338 - calcium-independent cell-cell adhesion  22  3  2.5e-05  13.64 
42383 - sarcolemma  14  3  4.6e-05  21.43 
42802 - identical protein binding  81  4  6.0e-05  4.94 
IPR004031 - PMP-22/EMP/MP20 and claudin 
family  30  3  6.5e-05  10.00 
31424 - keratinization  23  2  8.9e-05  8.70 
5200 - structural constituent of cytoskeleton  91  5  1.0e-04  5.49 
 
Changed group breakdown: 
Group  P-value   Probe-set ID  Rank  Gene ID   Gene Symbol   Title  
1533 - cornified 
envelope  1.8e-03  1451613_at  2  AY027660  Hrnr  hornerin 
  7.1e-06  1420431_at  5  NM_009100  Rptn  repetin 
  4.5e-08  1427268_at  9  J03458  LOC433621 /// 
LOC545581 
similar to Acidic ribosomal 
phosphoprotein P0 /// similar 
to Acidic ribosomal 
phosphoprotein P0 
show the whole 
group  8.0e-11  1448745_s_at  10  NM_008508  Lor  loricrin 
42470 - 
melanosome  2.7e-02  1415861_at  63  BB762957  Tyrp1  tyrosinase-related protein 1 
  5.1e-04  1418028_at  80  NM_010024  Dct  dopachrome tautomerase 
  5.0e-06  1449896_at  85  NM_053015  Mlph  melanophilin 
show the whole 
group  4.6e-08  1456095_at  98  BB769772  Tyr  tyrosinase 
IPR003347 - 
Transcription 
factor jumonji, 
jmjC 
1.1e-03  1426438_at  1  AA210261  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked 
  1.8e-05  1424903_at  6  AF127244  Jarid1d  jumonji, AT rich interactive 
domain 1D (Rbp2 like) 
show the whole 
group  6.7e-08  1426598_at  8  BB742957  Uty /// 
LOC546404 /// 
ubiquitously transcribed 
tetratricopeptide repeat gene, 381 
 
LOC546411  Y chromosome /// similar to 
male-specific histocompatibility 
antigen H-YDb /// similar to 
male-specific histocompatibility 
antigen H-YDb 
5882 - 
intermediate 
filament 
2.3e-02  1429565_s_at  4  AK004318  Lce5a  late cornified envelope 5A 
  6.6e-03  1423952_a_at  21  BC010337  Krt2-7  keratin complex 2, basic, gene 
7 
  4.5e-03  1419619_at  57  NM_028770  1200016G03Rik  RIKEN cDNA 1200016G03 
gene 
  3.8e-04  1420647_a_at  59  NM_031170  Krt2-8 /// 
LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
  3.0e-05  1448169_at  62  NM_010664  Krt1-18  keratin complex 1, acidic, gene 
18 
  6.1e-06  1435989_x_at  78  AW322280  LOC434261  similar to cytokeratin EndoA - 
mouse 
  4.8e-07  1423691_x_at  82  M21836  Krt2-8  keratin complex 2, basic, gene 
8 
show the whole 
group  9.3e-08  1438849_at  97  BB144669  2310030B04Rik  RIKEN cDNA 2310030B04 
gene 
IPR001664 - 
Intermediate 
filament protein 
7.2e-02  1423952_a_at  21  BC010337  Krt2-7  keratin complex 2, basic, gene 
7 
  1.8e-02  1419619_at  57  NM_028770  1200016G03Rik  RIKEN cDNA 1200016G03 
gene 
  1.2e-03  1420647_a_at  59  NM_031170  Krt2-8 /// 
LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
  7.0e-05  1448169_at  62  NM_010664  Krt1-18  keratin complex 1, acidic, gene 
18 
  8.4e-06  1435989_x_at  78  AW322280  LOC434261  similar to cytokeratin EndoA - 
mouse 
show the whole 
group  4.5e-07  1423691_x_at  82  M21836  Krt2-8  keratin complex 2, basic, gene 
8 
6583 - melanin 
biosynthesis 
from tyrosine 
2.3e-02  1415861_at  63  BB762957  Tyrp1  tyrosinase-related protein 1 
  3.7e-04  1418028_at  80  NM_010024  Dct  dopachrome tautomerase 
show the whole 
group  4.4e-06  1456095_at  98  BB769772  Tyr  tyrosinase 
IPR001751 - 
Calcium-binding 
protein, S-
100/ICaBP type 
1.8e-03  1451613_at  2  AY027660  Hrnr  hornerin 
show the whole 
group  7.1e-06  1420431_at  5  NM_009100  Rptn  repetin 
IPR002227 - 
Tyrosinase  7.9e-03  1415861_at  63  BB762957  Tyrp1  tyrosinase-related protein 1 
  2.5e-05  1418028_at  80  NM_010024  Dct  dopachrome tautomerase 
16338 - calcium-
independent cell-
cell adhesion 
4.7e-02  1448393_at  35  BC008104  Cldn7  claudin 7 
  1.4e-03  1460569_x_at  40  AW611462  Cldn3  claudin 3 
show the whole 
group  2.5e-05  1418283_at  42  NM_009903  Cldn4  claudin 4 
42383 - 
sarcolemma  5.1e-02  1420647_a_at  59  NM_031170  Krt2-8 /// 
LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
  2.1e-03  1435989_x_at  78  AW322280  LOC434261  similar to cytokeratin EndoA - 
mouse 
show the whole 
group  4.6e-05  1423691_x_at  82  M21836  Krt2-8  keratin complex 2, basic, gene 
8 
42802 - identical 
protein binding  5.4e-02  1420350_at  11  NM_028625  Sprrl2  small proline rich-like 2 
  1.4e-02  1448393_at  35  BC008104  Cldn7  claudin 7 
  1.1e-03  1460569_x_at  40  AW611462  Cldn3  claudin 3 382 
 
show the whole 
group  6.0e-05  1418283_at  42  NM_009903  Cldn4  claudin 4 
IPR004031 - 
PMP-
22/EMP/MP20 
and claudin 
family 
6.4e-02  1448393_at  35  BC008104  Cldn7  claudin 7 
  2.5e-03  1460569_x_at  40  AW611462  Cldn3  claudin 3 
show the whole 
group  6.5e-05  1418283_at  42  NM_009903  Cldn4  claudin 4 
31424 - 
keratinization  2.9e-03  1451613_at  2  AY027660  Hrnr  hornerin 
show the whole 
group  8.9e-05  1448745_s_at  10  NM_008508  Lor  loricrin 
5200 - structural 
constituent of 
cytoskeleton 
5.6e-02  1448745_s_at  10  NM_008508  Lor  loricrin 
  6.3e-03  1423952_a_at  21  BC010337  Krt2-7  keratin complex 2, basic, gene 
7 
  4.6e-03  1420647_a_at  59  NM_031170  Krt2-8 /// 
LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
  4.3e-04  1448169_at  62  NM_010664  Krt1-18  keratin complex 1, acidic, gene 
18 
show the whole 
group  1.0e-04  1423691_x_at  82  M21836  Krt2-8  keratin complex 2, basic, gene 
8 
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General Information 
Mode  Representative 
Number of genes on chip   23155 
Number of annotated genes   15969 
Number of groups   8045 
Number of singletons   2869 
Significance threshold   1.2e-04 
File name   K14D6 +CCL3 vs K14D6 Control negative 
 
Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
IPR001101 - Plectin repeat  8  4  3.8e-08  50.00 
42383 - sarcolemma  14  3  6.1e-07  21.43 
30018 - Z disc  27  3  4.8e-06  11.11 
9613 - response to pest, pathogen or 
parasite  31  3  7.4e-06  9.68 
IPR001664 - Intermediate filament protein  59  4  3.7e-05  6.78 
46716 - muscle maintenance  4  2  5.7e-05  50.00 
IPR002017 - Spectrin repeat  19  3  1.1e-04  15.79 
 
Changed group breakdown: 
Group  P-value   Probe-set ID  Rank  Gene ID   Gene Symbol  Title  
IPR001101 - Plectin 
repeat  5.0e-03  1427610_at  10  BC026631  Dsp  desmoplakin 
  1.1e-04  1427537_at  32  BC026387  Eppk1  epiplakin 1 
  3.4e-06  1437554_at  64  BM232239  Plec1  plectin 1 
show the whole group  3.8e-08  1428847_a_at  79  BM248206  Macf1  microtubule-actin crosslinking 
factor 1 
42383 - sarcolemma  5.2e-03  1435989_x_at  6  AW322280  LOC434261  similar to cytokeratin EndoA - 
mouse 
  7.4e-05  1420647_a_at  15  NM_031170  Krt2-8 /// 
LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
show the whole group  6.1e-07  1423691_x_at  20  M21836  Krt2-8  keratin complex 2, basic, gene 
8 
30018 - Z disc  1.0e-02  1435989_x_at  6  AW322280  LOC434261  similar to cytokeratin EndoA - 
mouse 
  2.9e-04  1420647_a_at  15  NM_031170  Krt2-8 ///  keratin complex 2, basic, gene 384 
 
LOC434261  8 /// similar to cytokeratin 
EndoA - mouse 
show the whole group  4.8e-06  1423691_x_at  20  M21836  Krt2-8  keratin complex 2, basic, gene 
8 
9613 - response to 
pest, pathogen or 
parasite 
1.2e-02  1435989_x_at  6  AW322280  LOC434261  similar to cytokeratin EndoA - 
mouse 
  3.8e-04  1420647_a_at  15  NM_031170  Krt2-8 /// 
LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
show the whole group  7.4e-06  1423691_x_at  20  M21836  Krt2-8  keratin complex 2, basic, gene 
8 
IPR001664 - 
Intermediate filament 
protein 
2.2e-02  1435989_x_at  6  AW322280  LOC434261  similar to cytokeratin EndoA - 
mouse 
  1.4e-03  1420647_a_at  15  NM_031170  Krt2-8 /// 
LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
  5.2e-05  1423691_x_at  20  M21836  Krt2-8  keratin complex 2, basic, gene 
8 
show the whole group  3.7e-05  1448169_at  51  NM_010664  Krt1-18  keratin complex 1, acidic, 
gene 18 
46716 - muscle 
maintenance  4.8e-03  1454904_at  19  BG976607  Mtm1  X-linked myotubular myopathy 
gene 1 
show the whole group  5.7e-05  1458663_at  50  AI552833  Large  Like-glycosyltransferase 
(Large), mRNA 
IPR002017 - Spectrin 
repeat  1.2e-02  1427610_at  10  BC026631  Dsp  desmoplakin 
  2.6e-03  1437554_at  64  BM232239  Plec1  plectin 1 
show the whole group  1.1e-04  1428847_a_at  79  BM248206  Macf1  microtubule-actin crosslinking 
factor 1 
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General Information 
Mode  Representative 
Number of genes on chip   23155 
Number of annotated genes   15985 
Number of groups   8056 
Number of singletons   2858 
Significance threshold   1.2e-04 
File name   K14D6 + CCL3 v WT + CCL3 negative 
 
Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
IPR007237 - CD20/IgE Fc receptor beta 
subunit  15  4  8.0e-08  26.67 
IPR001811 - Small chemokine, interleukin-8 
like  31  4  1.4e-07  12.90 
6935 - chemotaxis  87  5  2.1e-07  5.75 
8009 - chemokine activity  38  4  3.3e-07  10.53 
30595 - immune cell chemotaxis  5  3  3.4e-07  60.00 
19864 - IgG binding  5  2  1.8e-05  40.00 
IPR001916 - Glycoside hydrolase, family 22  8  2  2.6e-05  25.00 
3796 - lysozyme activity  10  2  4.2e-05  20.00 
42383 - sarcolemma  14  3  5.4e-05  21.43 
IPR001304 - C-type lectin  99  3  6.3e-05  3.03 
45576 - mast cell activation  9  2  6.5e-05  22.22 
16998 - cell wall catabolism  16  2  1.1e-04  12.50 
 
Changed group breakdown: 
Group  P-value   Probe-set ID  Rank  Gene ID   Gene Symbol   Title  
IPR007237 - CD20/IgE 
Fc receptor beta 
subunit 
5.6e-03  1424754_at  6  BC024402  Ms4a7 
membrane-spanning 4-
domains, subfamily A, 
member 7 
  3.7e-05  1419599_s_at  10  NM_026835  Ms4a11 
membrane-spanning 4-
domains, subfamily A, 
member 11 
  3.0e-07  1419598_at  15  NM_026835  Ms4a6d 
membrane-spanning 4-
domains, subfamily A, 
member 6D 
show the whole group  8.0e-08  1418826_at  46  NM_027209  Ms4a6b 
membrane-spanning 4-
domains, subfamily A, 
member 6B 
IPR001811 - Small 
chemokine, 
interleukin-8 like 
1.3e-02  1448995_at  7  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  2.4e-04  1417266_at  12  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 
  1.1e-05  1419728_at  23  NM_009141  Cxcl5  chemokine (C-X-C motif) 
ligand 5 
show the whole group  1.4e-07  1417936_at  25  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
6935 - chemotaxis  3.7e-02  1448995_at  7  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  1.9e-03  1417266_at  12  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 386 
 
  1.7e-04  1442082_at  20  BB333624  C3ar1  complement component 3a 
receptor 1 
  6.7e-06  1419728_at  23  NM_009141  Cxcl5  chemokine (C-X-C motif) 
ligand 5 
show the whole group  2.1e-07  1417936_at  25  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
8009 - chemokine 
activity  1.7e-02  1448995_at  7  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  3.6e-04  1417266_at  12  BC002073  Ccl6  chemokine (C-C motif) ligand 
6 
  2.1e-05  1419728_at  23  NM_009141  Cxcl5  chemokine (C-X-C motif) 
ligand 5 
show the whole group  3.3e-07  1417936_at  25  AF128196  Ccl9  chemokine (C-C motif) ligand 
9 
30595 - immune cell 
chemotaxis  2.2e-03  1448995_at  7  NM_019932  Cxcl4  chemokine (C-X-C motif) 
ligand 4 
  1.2e-05  1449254_at  18  NM_009263  Spp1  secreted phosphoprotein 1 
show the whole group  3.4e-07  1419609_at  53  AV231648  Ccr1  chemokine (C-C motif) 
receptor 1 
19864 - IgG binding  4.4e-03  1435477_s_at  14  BM224327  Fcgr2b  Fc receptor, IgG, low affinity 
IIb 
show the whole group  1.8e-05  1448620_at  22  NM_010188  Fcgr3  Fc receptor, IgG, low affinity 
III 
IPR001916 - 
Glycoside hydrolase, 
family 22 
1.0e-03  1436996_x_at  2  AV066625  Lzp-s  P lysozyme structural 
show the whole group  2.6e-05  1423547_at  16  AW208566  Lyzs  lysozyme 
3796 - lysozyme 
activity  1.3e-03  1436996_x_at  2  AV066625  Lzp-s  P lysozyme structural 
show the whole group  4.2e-05  1423547_at  16  AW208566  Lyzs  lysozyme 
42383 - sarcolemma  5.0e-02  1423691_x_at  58  M21836  Krt2-8  keratin complex 2, basic, 
gene 8 
  1.4e-03  1435989_x_at  64  AW322280  LOC434261  similar to cytokeratin EndoA 
- mouse 
show the whole group  5.4e-05  1420647_a_at  87  NM_031170  Krt2-8 /// 
LOC434261 
keratin complex 2, basic, 
gene 8 /// similar to 
cytokeratin EndoA - mouse 
IPR001304 - C-type 
lectin  1.8e-02  1420804_s_at  3  NM_010819  Clec4d  C-type lectin domain family 
4, member d 
  2.0e-03  1450430_at  11  NM_008625  Mrc1  mannose receptor, C type 1 
show the whole group  6.3e-05  1425951_a_at  13  AF240358  Clec4n  C-type lectin domain family 
4, member n 
45576 - mast cell 
activation  7.9e-03  1435477_s_at  14  BM224327  Fcgr2b  Fc receptor, IgG, low affinity 
IIb 
show the whole group  6.5e-05  1448620_at  22  NM_010188  Fcgr3  Fc receptor, IgG, low affinity 
III 
16998 - cell wall 
catabolism  2.0e-03  1436996_x_at  2  AV066625  Lzp-s  P lysozyme structural 
show the whole group  1.1e-04  1423547_at  16  AW208566  Lyzs  lysozyme 
 
 
 
 
 